ketamine has been researched along with Depressive Disorder, Major in 627 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The benefits of low-dose ketamine for patients with treatment-resistant depression (TRD) and prominent suicidal ideation require further investigation." | 9.69 | A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation. ( Bai, YM; Chen, LF; Chen, MH; Li, CT; Li, WC; Lin, WC; Mao, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2023) |
| "Whether pretreatment working memory and response inhibition function are associated with the rapid and sustained antisuicidal effect of low-dose ketamine among patients with treatment-resistant depression (TRD) and strong suicidal ideation is unclear." | 9.69 | Baseline cognitive function predicts full remission of suicidal symptoms among patients with treatment-resistant depression and strong suicidal ideation after low-dose ketamine infusion. ( Bai, YM; Chen, MH; Li, CT; Lin, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2023) |
| " However, whether low-dose ketamine infusion alters klotho levels among patients with treatment-resistant depression (TRD) remains unknown." | 9.69 | Role of klotho on antidepressant and antisuicidal effects of low-dose ketamine infusion among patients with treatment-resistant depression and suicidal ideation. ( Bai, YM; Chen, MH; Li, CT; Lin, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2023) |
| " This trial will provide efficacy, safety and health economic data on serial ketamine infusions and thus help inform clinical practice on the potential role of this treatment in the management of depression." | 9.69 | Study protocol for Ketamine as an adjunctive therapy for major depression (2): a randomised controlled trial (KARMA-Dep [2]). ( Igoe, A; Jelovac, A; Loughran, O; McCaffrey, C; McDonagh, K; McDonogh, S; McLoughlin, DM; Mohamed, E; O'Neill, C; Shackleton, E; Shanahan, E; Terao, M; Whooley, E, 2023) |
| "Exploratory, post hoc analysis of data from a randomized clinical trial of ketamine vs midazolam in patients with major depressive disorder (MDD) and clinically significant suicidal ideation examined changes in factor analysis-derived symptom clusters from standard measures of depression (Hamilton Depression Rating Scale, HDRS; Beck Depression Inventory, BDI) and mood disturbance (Profile of Mood States, POMS), and their relationship to severity of suicidal ideation (Beck Scale for Suicidal Ideation; SSI)." | 9.51 | Ketamine vs midazolam: Mood improvement reduces suicidal ideation in depression. ( Burke, AK; Grunebaum, MF; Hochschild, A; Keilp, JG; Madden, SP; Mann, JJ, 2022) |
| " Ketamine has demonstrated rapid and robust improvements in suicidal ideation (SI)." | 9.51 | mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression. ( Abdallah, CG; Ahn, KH; Averill, CL; Averill, LA; D'Souza, DC; Duman, RS; Fouda, S; Gueorguieva, R; Krystal, JH; Ranganathan, M; Sanacora, G; Sherif, M; Southwick, SM, 2022) |
| "Using data from a randomized, double-blind (DB), placebo-controlled trial of esketamine (ESK) in patients with treatment-resistant depression (TRD), we conducted exploratory analyses." | 9.51 | Different symptomatic improvement pattern revealed by factor analysis between placebo response and response to Esketamine in treatment resistant depression. ( Kobayashi, H; Ohnishi, T; Wakamatsu, A, 2022) |
| "This study examined magnetoencephalographic (MEG) correlates of suicidal ideation (SI) and suicide attempt history in patients with treatment-resistant major depression (TRD) at baseline and following subanesthetic-dose ketamine infusion." | 9.51 | Magnetoencephalography biomarkers of suicide attempt history and antidepressant response to ketamine in treatment-resistant major depression. ( Ballard, ED; Burton, CR; Gerner, JL; Gilbert, JR; Nugent, AC; Zarate, CA, 2022) |
| " The present study applies free-water imaging to investigate the relationship between altered peripheral inflammation and WM microstructure and their predictive value in determining response to ketamine treatment in MDD." | 9.51 | Association between peripheral inflammation and free-water imaging in Major Depressive Disorder before and after ketamine treatment - A pilot study. ( Cetin-Karayumak, S; Chunga, N; Espinoza, RT; Kubicki, A; Kubicki, M; Langhein, M; Lyall, AE; Mulert, C; Narr, KL; Pasternak, O; Seitz-Holland, J, 2022) |
| "This posthoc analysis compared the antidepressant and antisuicidal effects of low-dose ketamine infusion with those of repetitive transcranial magnetic stimulation (rTMS) on treatment-resistant depression (TRD)." | 9.51 | Comparative study of low-dose ketamine infusion and repetitive transcranial magnetic stimulation in treatment-resistant depression: A posthoc pooled analysis of two randomized, double-blind, placebo-controlled studies. ( Bai, YM; Chen, MH; Cheng, CM; Li, CT; Lin, WC; Su, TP; Tsai, SJ, 2022) |
| " Intravenous ketamine has been shown to have a rapid but transient antidepressant effect, but there is still lack evidence on the efficacy and safety of intravenous esketamine in reducing suicidal ideation and depressive symptoms in MDD patients with suicidal ideation." | 9.51 | The efficacy and safety of esketamine in the treatment of major depressive disorder with suicidal ideation: study protocol for a randomized controlled trial. ( Chao, Z; Fu, L; Hu, Z; Lan, X; Li, W; Liu, H; Ning, Y; Wang, C; Ye, Y; Zhang, F; Zhou, Y, 2022) |
| "Esketamine nasal spray (Spravato) in conjunction with oral antidepressants (ADs) is approved in the European Union, United States, and other markets for treatment-resistant depression (TRD)." | 9.41 | Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study. ( Goto, R; Shimizu, H; Shiraishi, A; Takahashi, N; Tominaga, Y; Yamada, A, 2021) |
| " Previous study showed that ketamine could reduce suicidal ideation (SI), potentially by improving the impaired working memory (WM)." | 9.41 | Working memory associated with anti-suicidal ideation effect of repeated-dose intravenous ketamine in depressed patients. ( Chen, X; Hu, Y; Lan, X; Li, H; Liu, W; Ning, Y; Wang, C; Wang, M; Zhan, Y; Zhang, B; Zheng, W; Zhong, X; Zhou, Y, 2021) |
| "In a randomized, double-blind, placebo-controlled, proof-of-concept trial, 18 depressed subjects with acute suicidal ideation, who required hospitalization, were randomized to either an intravenous ketamine 0." | 9.34 | Ketamine for acute suicidal ideation. An emergency department intervention: A randomized, double-blind, placebo-controlled, proof-of-concept trial. ( Domany, Y; McCullumsmith, CB; Shelton, RC, 2020) |
| "To compare esketamine to placebo, each in addition to standard-of-care treatment, for rapidly reducing major depressive disorder symptoms, including suicidal ideation." | 9.34 | Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I). ( Canuso, CM; Drevets, WC; Fu, DJ; Hough, D; Ionescu, DF; Lane, R; Li, X; Lim, P; Manji, H; Sanacora, G, 2020) |
| "Twenty-six medicated outpatients with severe major depressive disorder with current, chronic suicidal ideation were randomized in a double-blind fashion to six ketamine infusions (0." | 9.30 | Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial. ( Akeju, O; Alpert, JE; Baer, L; Bentley, KH; Brown, EN; Cusin, C; Dording, C; Eikermann, M; Fava, M; Ionescu, DF; Mischoulon, D; Nock, MK; Pavone, KJ; Petrie, SR; Swee, MB; Taylor, N, 2019) |
| "Compared to placebo, ketamine significantly improved fatigue (p = ." | 9.30 | Disentangling the association of depression on the anti-fatigue effects of ketamine. ( Ballard, ED; Farmer, C; Kadriu, B; Saligan, LN; Zarate, CA, 2019) |
| "Ketamine induces rapid and robust antidepressant effects, and many patients also describe dissociation, which is associated with antidepressant response." | 9.27 | Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression. ( Ballard, ED; Brutsche, NE; Farmer, C; Jaso, BA; Luckenbaugh, DA; Niciu, MJ; Park, LT; Shovestul, BJ; Zarate, CA, 2018) |
| " We tested our hypothesis that ketamine-based anesthesia for ECT results in superior improvement in treatment-resistant MDD outcomes compared with propofol-based anesthesia." | 9.27 | Ketamine-based anesthesia improves electroconvulsive therapy outcomes: a randomized-controlled study. ( Balbuena, L; Bi, H; Bowen, R; Gamble, JJ; Prasad, R; Sanjanwala, R; Weisgerber, G, 2018) |
| "Ketamine is known to rapidly reduce depressive symptoms and suicidal ideation (SI) in patients with major depressive disorder (MDD), but evidence is limited for its acceptability and effectiveness in "real-world" settings." | 9.27 | Ketamine augmentation for major depressive disorder and suicidal ideation: Preliminary experience in an inpatient psychiatry setting. ( Belo, S; Castel, S; Levitt, AJ; Mah, L; Orser, B; Schaffer, A; Sinyor, M; Vincent, M; Williams, M; Zarate, C, 2018) |
| "The N-methyl-D-aspartate receptor antagonist ketamine has rapid onset activity in treatment-resistant depression, post-traumatic stress disorder and obsessive compulsive disorder." | 9.24 | Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. ( Anderson-Fahey, B; Glue, P; Gray, A; Harland, S; Le Nedelec, M; McNaughton, N; Medlicott, NJ; Neehoff, S, 2017) |
| " Anhedonia occurs across psychiatric diagnoses and has been associated with specific neural circuits in response to rapid-acting treatments, such as ketamine." | 9.24 | Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials. ( Ameli, R; Ballard, ED; Brutsche, NE; Lally, N; Luckenbaugh, DA; Niciu, MJ; Park, L; Richards, EM; Walls, T; Wills, K; Zarate, CA, 2017) |
| "This narrative review describes the evolution of ketamine to treat mood disorders and suicidality." | 9.22 | Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress. ( Kritzer, MD; Lai, CS; Masand, PS; Mathew, SJ; Mischel, NA; Szabo, ST; Young, JR, 2022) |
| " Ketamine, a racemic mixture of the two enantiomers, (R)-ketamine and (S)-ketamine, is an N-methyl-d-aspartate receptor (NMDAR) antagonist and has been shown to have rapid-acting antidepressant properties in patients with treatment-resistant depression (TRD)." | 9.22 | Is (R)-ketamine a potential therapeutic agent for treatment-resistant depression with less detrimental side effects? A review of molecular mechanisms underlying ketamine and its enantiomers. ( Antqueviezc, B; Colombo, R; Dalpiaz, G; Ferraz Goularte, J; Paul Géa, L; Ribeiro Rosa, A; Scotton, E; Vasconcelos, MF, 2022) |
| " Ketamine, a N-methyl-d-aspartate glutamate receptor antagonist, and its enantiomer esketamine rapidly reduce depressive symptoms in depressed patients with current suicidal ideation." | 9.22 | Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how? ( Courtet, P; Lengvenyte, A; Olié, E; Strumila, R, 2022) |
| "We conducted a PRISMA-guided review for relevant randomized controlled trials of racemic or esketamine for unipolar or bipolar major depression from database inception through 2021." | 9.22 | Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. ( Bahji, A; Vazquez, GH; Zarate, CA, 2022) |
| "Despite a burgeoning body of literature demonstrating that inflammation is linked to TRD, there is still a lack of comprehensive research on the relationship between proinflammatory biomarkers and ketamine's antidepressant effect on TRD patients." | 9.22 | Antidepressant Effect of Ketamine on Inflammation-Mediated Cytokine Dysregulation in Adults with Treatment-Resistant Depression: Rapid Systematic Review. ( Gu, J; Sukhram, SD; Yilmaz, G, 2022) |
| " We have previously shown that a single dose of ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, is associated with a rapid reduction in depressive symptom severity and SI in patients with treatment-resistant depression." | 9.20 | Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. ( Brallier, JW; Charney, DS; Collins, KA; DeWilde, KE; Goodman, WK; Iacoviello, BM; Iosifescu, DV; Kautz, M; Kim, J; Lapidus, KA; Lener, M; Murrough, JW; Perez, AM; Price, RB; Rodriguez, GJ; Soleimani, L; Stern, JB, 2015) |
| "To assess the effects - and review the acceptability and tolerability - of ketamine and other glutamate receptor modulators in alleviating the acute symptoms of depression in people with unipolar major depressive disorder." | 9.12 | Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. ( Barnes, A; Cipriani, A; Cowen, PJ; Dean, RL; Hawton, K; Hollingsworth, S; Hurducas, C; Marquardt, T; McShane, R; Smith, R; Spyridi, S; Turner, EH, 2021) |
| "Ketamine appears to have a therapeutic role in certain mental disorders, most notably depression." | 9.12 | Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. ( Bahji, A; Vazquez, GH; Zarate, CA, 2021) |
| "The efficacy of ketamine in reducing suicidal ideation (SI) has been previously reported." | 9.12 | The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis. ( Carvalho, I; Chen-Li, D; Gill, H; Lee, Y; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Narsi, F; Rodrigues, NB; Rosenblat, JD; Xiong, J, 2021) |
| "The approval of intranasal esketamine for treatment-resistant depression marks the next step in our understanding of and ability to treat treatment-resistant depression." | 9.12 | Intranasal esketamine: From origins to future implications in treatment-resistant depression. ( Brula, AQ; Sanders, B, 2021) |
| " Esketamine (ESK), an NMDA receptor antagonist able to modulate glutamatergic neurotransmission has been recently developed as an intranasal formulation for treatment-resistant depression (TRD) and for rapid reduction of depressive symptomatology, including suicidal ideation in MDD patients at imminent risk for suicide." | 9.05 | An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine. ( De Berardis, D; Di Giannantonio, M; Fornaro, M; Fraticelli, S; Kim, YK; Martinotti, G; Orsolini, L; Perna, G; Pompili, M; Serafini, G; Tomasetti, C; Valchera, A; Vellante, F; Volpe, U, 2020) |
| " Studies of oral ketamine for depression, from case series to randomized clinical trials, were eligible." | 9.05 | An Update on the Efficacy and Tolerability of Oral Ketamine for Major Depression: A Systematic Review and Meta-Analysis. ( Frye, MA; Joseph, B; Kung, S; Nuñez, NA; Pahwa, M; Prokop, LJ; Schak, KM; Seshadri, A; Singh, B; Vande Voort, JL, 2020) |
| "Discovering that the anesthetic drug ketamine has rapidly acting antidepressant effects in many individuals with major depression is one of the most important findings in clinical psychopharmacology in recent decades." | 9.01 | Rodent ketamine depression-related research: Finding patterns in a literature of variability. ( Fitzgerald, PJ; Hale, PJ; Polis, AJ; Watson, BO, 2019) |
| " The primary outcome measures were the suicide items from clinician-administered (the Montgomery-Åsberg Depression Rating Scale [MADRS] or the Hamilton Depression Rating Scale [HAM-D]) and self-report scales (the Quick Inventory of Depressive Symptomatology-Self Report [QIDS-SR] or the Beck Depression Inventory [BDI]), obtained for up to 1 week after ketamine administration." | 8.98 | The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. ( Ballard, ED; Bloch, MH; Feder, A; Mathew, SJ; Murrough, JW; Sanacora, G; Sos, P; Wang, G; Wilkinson, ST; Zarate, CA, 2018) |
| "Anhedonia as measured by the MADRS appeared to not be positively related to suicidal ideation after serial ketamine infusions." | 8.31 | Association of anhedonia and suicidal ideation in patients with treatment-refractory depression after intravenous ketamine infusions. ( Gu, LM; Lan, XF; Ning, YP; Wang, CY; Yang, XH; Zhang, B; Zheng, W; Zhou, YL, 2023) |
| "Most research describing ketamine as a treatment for depression has relied on intravenous dosing." | 8.31 | Intranasal racemic ketamine for patients hospitalized with treatment-resistant depression: A retrospective analysis. ( Cheveldae, I; Halpape, K; Peters, EM; Wanson, A, 2023) |
| "Hippocampal functional connectivity (FC) alterations, which may happen following ketamine treatment, play a key role in major depression remission." | 8.31 | Ketamine-induced hippocampal functional connectivity alterations associated with clinical remission in major depression. ( Hu, Z; Lan, X; Li, W; Liu, H; Ning, Y; Wang, C; Ye, Y; You, Z; Zhang, F; Zhou, Y, 2023) |
| "Esketamine, the S-enantiomer of ketamine, has recently emerged as a therapy for treatment-resistant depression (TRD), showing both rapid antidepressant action and good efficacy and high safety." | 8.31 | Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study. ( Andriola, I; Barlati, S; Bassetti, R; Chiappini, S; Clerici, M; d'Andrea, G; De Filippis, S; Dell'Osso, B; Di Nicola, M; Martinotti, G; Pettorruso, M; Sensi, S; Vita, A, 2023) |
| "This study aims to investigate the differences in safety and antidepressant effects of multi-infusion ketamine treatment between elderly and young adults with depression." | 8.31 | A comparative analysis of antidepressant and anti-suicidal effects of repeated ketamine infusions in elderly and younger adults with depression. ( Lan, XF; Ning, YP; Wang, CY; Zheng, W; Zhou, YL, 2023) |
| " We have previously used the chronic mild stress (CMS) model of depression in male rats to show that CMS induces morphological, functional, and molecular changes in the hippocampus of vulnerable animals, the majority of which were recovered using acute subanesthetic ketamine in just 24 h." | 8.31 | Functional and Molecular Changes in the Prefrontal Cortex of the Chronic Mild Stress Rat Model of Depression and Modulation by Acute Ketamine. ( Barbon, A; Bertoli, M; Bonanno, G; Bonifacino, T; La Via, L; Milanese, M; Mingardi, J; Misztak, P; Musazzi, L; Ndoj, E; Popoli, M; Russo, I; Torazza, C, 2023) |
| " Ketamine, known as an anesthetic, is a new treatment option that can be effective in patients with treatment-resistant depression." | 8.31 | [Consider (es)ketamine for treatment-resistant depression]. ( Kramers, CK; Ruhé, HG; Stuiver, S; van Verseveld, M; van Waarde, JA; Vos, CF, 2023) |
| "This Viewpoint examines key issues stemming from several recent reports of electroconvulsive therapy (ECT) vs ketamine for improving depressive symptoms in treatment-resistant depression (TRD)." | 8.31 | Choosing Between Ketamine and Electroconvulsive Therapy for Outpatients With Treatment-Resistant Depression-Advantage Ketamine? ( Anand, A; Jha, MK; Mathew, SJ, 2023) |
| " We report the case of a 57-year-old woman diagnosed with treatment-resistant depression (TRD) and comorbid FMD treated with weekly intranasal administrations of esketamine over a six-month follow-up period." | 8.12 | Remission of functional motor symptoms following esketamine administration in a patient with treatment-resistant depression: a single-case report. ( Bentivoglio, AR; Calabresi, P; Camardese, G; Di Nicola, M; Janiri, D; Lanzotti, P; Moccia, L; Palumbo, L; Pepe, M; Sani, G, 2022) |
| "This preliminary study found that repeated ketamine infusions appeared to be effective at rapidly ameliorating anhedonia, with similar efficacy in MDD and BD." | 8.12 | Comparative effectiveness of repeated ketamine infusions in treating anhedonia in bipolar and unipolar depression. ( Gu, LM; Lan, XF; Ning, YP; Sun, CH; Wang, CY; Zhang, B; Zheng, W; Zhou, YL, 2022) |
| "Outcomes of ketamine intravenous therapy (KIT) for depression in real-world care settings have been minimally evaluated." | 8.12 | A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings. ( DeBattista, C; Gargeya, RS; Heifets, BD; McInnes, LA; Qian, JJ, 2022) |
| "Ketamine can be used for depression and suicidal ideation due to its effectiveness and low complication rates; moreover, allergic reactions are rare." | 8.12 | Allergic reaction induced by subcutaneous administration of ketamine: a case report. ( Anzolin, AP; Belmonte-de-Abreu, PS; Cordova, VHS; Lacerda, A; Sant'Ana, MK, 2022) |
| "Interest in the use of parenteral ketamine has been increasing over the last 2 decades for the management of treatment-resistant depression (TRD)." | 8.12 | Repeated subcutaneous racemic ketamine in treatment-resistant depression: case series. ( Budd, GP; Do, A; Fridfinnson, J; Lam, RW; Rafizadeh, R; Siu, JTP; Tham, JCW, 2022) |
| "One hundred thirty-five Chinese individuals with anxious depression (n = 92) and nonanxious depression (n = 43) received six intravenous infusions of ketamine (0." | 8.12 | Antianhedonic effects of serial intravenous subanaesthetic ketamine in anxious versus nonanxious depression. ( Gu, LM; Ning, YP; Tan, JQ; Wang, CY; Yang, XH; Zheng, W; Zhou, YL, 2022) |
| "A short course of repeated ketamine infusions did not impair neurocognitive function in patients with treatment-resistant depression." | 8.12 | Assessment of Objective and Subjective Cognitive Function in Patients With Treatment-Resistant Depression Undergoing Repeated Ketamine Infusions. ( Batten, LA; Blier, P; Burhunduli, P; Norris, S; Ortiz, A; Owoeye, O; Phillips, JL; Talbot, J; Van Geel, A; Vasudev, D, 2022) |
| " These findings may help explain the more modest findings in clinical IV ketamine trials for suicidal ideation than overall depression." | 8.12 | A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Nonsuicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine. ( Ballard, ED; Bloomfield-Clagett, B; Fava, M; Greenstein, DK; Grunebaum, MF; Mathew, SJ; Murrough, JW; Phillips, JL; Sanacora, G; Wilkinson, ST; Zarate, CA, 2022) |
| "Clinical research has shown that persistent negative beliefs maintain depression and that subanesthetic ketamine infusions induce rapid antidepressant responses." | 8.12 | Evaluation of Early Ketamine Effects on Belief-Updating Biases in Patients With Treatment-Resistant Depression. ( Bottemanne, H; Claret, A; Fossati, P; Morlaas, O; Schmidt, L; Sharot, T, 2022) |
| "Ketamine has emerged as a promising pharmacotherapy for depression and other mental illnesses, and the intramuscular (IM) administration of ketamine is now offered at many North American outpatient psychiatric clinics." | 8.12 | Real-world depression, anxiety and safety outcomes of intramuscular ketamine treatment: a retrospective descriptive cohort study. ( Ahuja, S; Brendle, M; Moore, C; Robison, R; Smart, L; Thielking, P, 2022) |
| "Esketamine is the S-enantiomer of racemic ketamine and has been approved by the Food and Drug Administration for the management of treatment resistant depression, demonstrating effective and long-lasting benefits." | 8.12 | Association of intranasal esketamine, a novel 'standard of care' treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice. ( Do, A; Giacobbe, P; Gutierrez, G; Hawken, E; Karthikeyan, G; Lam, RW; Milev, R; Ravindran, N; Rosenblat, J; Schaffer, A; Swainson, J; Vazquez, G, 2022) |
| "Treatment-resistant depression (TRD) may be responsive to interventions beyond antidepressants including brain stimulation such as electroconvulsive therapy (ECT) or to ketamine or esketamine, the latter of which is approved for TRD in an intranasal form." | 8.02 | Commentary: Treatment-resistant Depression: Considerations Related to ECT and Ketamine. ( Garakani, A, 2021) |
| "Patients with TRD and prominent anxiety receiving IV ketamine exhibited a significant reduction in depressive, SI and anxiety symptoms." | 8.02 | The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence. ( Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lipsitz, O; Lui, LM; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, K, 2021) |
| "We evaluated the effects of repeated subanesthetic ketamine infusions on suicidal ideation (SI) in patients with major depression." | 8.02 | Subanesthetic ketamine infusions for suicide ideation in patients with bipolar and unipolar treatment refractory depression. ( Anjum, MR; Chandrasena, R; Fairbairn, J; Hawken, ER; Kang, MJY; Kulcar, E; Vazquez, GH, 2021) |
| "The aim of this study was to examine the effect on depressive symptoms of repeated subanesthetic doses of SC esketamine in unipolar and bipolar treatment-resistant depression (TRD) and clinical predictors of response." | 8.02 | Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity. ( Abdo, G; B Andreoli, S; B Puertas, C; Barbosa, M; Cohrs, FM; Del Porto, JA; Del Sant, LC; Delfino, R; Fava, VA; Lacerda, AL; Liberatori, A; Lucchese, AC; Magalhães, EJM; Nakahira, C; Sarin, LM; Steiglich, MS; Surjan, J; Tuena, MA, 2021) |
| "This study suggests the possible clinical utility of resting-state functional magnetic resonance imaging for predicting the antidepressant effects of ketamine in treatment-resistant depression patients and implicated resting-state functional connectivity alterations to determine the trait-like pathophysiology underlying treatment response heterogeneity in treatment-resistant depression." | 8.02 | Functional connectivity between the amygdala and subgenual cingulate gyrus predicts the antidepressant effects of ketamine in patients with treatment-resistant depression. ( Abe, T; Hiraki, T; Horikawa, N; Ishibashi, M; Nakamura, T; Tomita, M; Uchimura, N; Uematsu, K, 2021) |
| "Adults with treatment-resistant depression (TRD) receiving intravenous (IV) ketamine had depressive symptoms measured with the 16-Item Quick Inventory Depressive Symptoms Self-Report (QIDS-SR-16) and MARRRS at baseline and as a repeated measure across an acute course of four infusions." | 8.02 | Validation of the McIntyre And Rosenblat Rapid Response Scale (MARRRS) in Adults with Treatment-Resistant Depression Receiving Intravenous Ketamine Treatment. ( Cha, DS; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M, 2021) |
| " Herein, we investigated whether pre-treatment functioning in outpatients with treatment-resistant depression (TRD) moderates response to intravenous (IV) ketamine." | 8.02 | Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression? ( Cha, DS; Gill, H; Ho, RC; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2021) |
| "Herein we evaluate the impact of COVID-19 restrictions on antidepressant effectiveness of intravenous (IV) ketamine in adults with treatment-resistant depression (TRD)." | 8.02 | Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic. ( Abrishami, A; Arekapudi, AK; Chau, EH; Di Vincenzo, JD; Kratiuk, K; Lee, Y; Lipsitz, O; Mansur, RB; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Szpejda, W; Wong, L, 2021) |
| "To identify a meaningful change threshold (MCT) in depression outcomes in adults with treatment-resistant major depressive disorder (MDD) or bipolar disorder (BD) receiving intravenous ketamine treatment at a community-based mood disorders center." | 8.02 | The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine. ( Gill, H; Ho, RC; Jones, BDM; Kratiuk, K; Lee, Y; Ling, R; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2021) |
| "Some patients with refractory depression who fail to respond to rapid injection of standard-dose ketamine are injected with high doses, but the safety and efficacy of this practice are unclear." | 7.96 | Repeated ketamine injections in synergy with antidepressants for treating refractory depression: A case showing 6-month improvement. ( Fang, J; Li, Z; Su, B; Wang, L; Wang, M; Xiong, Z; Yang, Y, 2020) |
| "Concerns about ketamine for treating depression include abuse potential and the occurrence of psychotomimetic effects." | 7.96 | Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. ( Acevedo-Diaz, EE; Cavanaugh, GW; Greenstein, D; Kadriu, B; Kraus, C; Park, LT; Zarate, CA, 2020) |
| "To determine the effectiveness of intravenous (IV) ketamine on anxiety, irritability, agitation, and suicidality, in adults with treatment-resistant major depressive disorder (MDD) or bipolar disorder (BD)." | 7.96 | The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder. ( Cha, DS; Fagiolini, A; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Malhi, GS; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Suppes, T; Vinberg, M, 2020) |
| "The effectiveness, tolerability, and safety of intravenous (IV) ketamine in adults with treatment resistant depression (TRD) receiving care in real-word settings is insufficiently characterized." | 7.96 | The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence. ( Abrishami, A; Arekapudi, AK; Brietzke, E; Carvalho, IP; Chau, EH; Gill, H; Kratiuk, K; Lee, Y; Lipsitz, O; Lui, LMW; Majeed, A; Mansur, RB; McIntyre, RS; Nasri, F; Phan, L; Rodrigues, NB; Rosenblat, JD; Senyk, O; Siegel, A; Subramaniapillai, M; Szpejda, W, 2020) |
| "Subanesthetic ketamine is found to induce fast-acting and pronounced antidepressant effects, even in treatment resistant depression (TRD)." | 7.96 | Modulation of inhibitory control networks relate to clinical response following ketamine therapy in major depression. ( Congdon, E; Espinoza, R; Joshi, SH; Kubicki, A; Loureiro, JR; Narr, KL; Sahib, AK; Vasavada, MM; Wade, B; Woods, RP, 2020) |
| "After adjusting for age, sex, primary diagnosis, concomitant medication, body mass index, and baseline depression severity, there was a statistically significant reduction in symptoms of anhedonia with IV ketamine treatment (F (2, 235." | 7.96 | Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence. ( Cha, DS; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Majeed, A; Mansur, RB; McIntyre, RS; Nasri, F; Phan, L; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M, 2020) |
| "The glutamatergic modulator ketamine has been shown to result in rapid reductions in both suicidal ideation (SI) and depressive symptoms in clinical trials." | 7.96 | Predicting therapeutic response to oral ketamine for chronic suicidal ideation: a Bayesian network for clinical decision support. ( Beaudequin, D; Can, AT; Dutton, M; Forsyth, G; Gallay, C; Hermens, DF; Jones, M; Lagopoulos, J; Schwenn, P; Simcock, G; Yang, C, 2020) |
| " There is a rising promise in a N-methyl-D-aspartate (NMDA) receptor antagonist, ketamine, which may be used in the treatment of resistant depression." | 7.91 | Short-term ketamine administration in treatment-resistant depression patients: focus on adverse effects on the central nervous system. ( Cubała, WJ; Małyszko, A; Szarmach, J; Wiglusz, MS; Włodarczyk, A, 2019) |
| " Previous studies found that ketamine intervention could rapidly reduce suicidal ideation in depression." | 7.91 | A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation. ( Chen, L; Li, H; Li, M; Li, MD; Liu, W; Ning, Y; Walter, M; Wang, C; Yu, L; Zhan, Y; Zhang, B; Zheng, W; Zhou, Y, 2019) |
| "Data were obtained from 110 individuals with mood disorders (predominantly major depressive disorder) who underwent intravenous ketamine infusion." | 7.88 | Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale. ( Davidson, L; Sanacora, G; Silverman, WK; van Schalkwyk, GI; Wilkinson, ST, 2018) |
| "No pharmacological treatments exist for active suicidal ideation (SI), but the glutamatergic modulator ketamine elicits rapid changes in SI." | 7.88 | Characterizing the course of suicidal ideation response to ketamine. ( Ballard, ED; Farmer, CA; Kadriu, B; Machado-Vieira, R; Niciu, MJ; Park, L; Richards, E; Yarrington, JS; Yuan, P; Zarate, CA, 2018) |
| " The current case report describes a patient suffering from severe depression and dementia who received electroconvulsive therapy with S-ketamine anesthesia at our psychiatric intensive care unit for the treatment of her therapy-resistant catatonic stupor." | 7.85 | Electroconvulsive therapy with S-ketamine anesthesia for catatonia in coexisting depression and dementia. ( Bauer, M; Frey, R; Kasper, S; Litvan, Z, 2017) |
| "In this preliminary study, repeated doses of open-label ketamine rapidly and robustly decreased suicidal ideation in pharmacologically treated outpatients with treatment-resistant depression with stable suicidal thoughts; this decrease was maintained for at least 3 months following the final ketamine infusion in 2 patients." | 7.83 | Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study. ( Akeju, O; Alpert, JE; Baer, L; Brown, EN; Cassano, P; Cusin, C; Fava, M; Ionescu, DF; Mischoulon, D; Nock, MK; Nyer, M; Pavone, KJ; Swee, MB; Taylor, N, 2016) |
| "SC ketamine was safe and well tolerated, and most adverse events were mild and transient." | 7.01 | Potential advantages of ketamine over electroconvulsive therapy in the treatment of nonrefractory severe depression in older patients with multiple medical comorbidities. ( Cunha, UGV; Duarte, DB; Hara, C; Rocha, FL, 2023) |
| "Norketamine concentration was not associated with antidepressant response." | 6.94 | Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression. ( Adeojo, L; Farmer, CA; George, J; Gilbert, JR; Gould, TD; Kadriu, B; Lovett, J; Moaddel, R; Nugent, AC; Park, LT; Yuan, P; Zarate, CA, 2020) |
| "About 20 to 30 percent of patients with Major Depressive Disorder (MDD) do not respond to standard treatment and are considered treatment-resistant." | 6.90 | Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder. ( Aust, S; Bajbouj, M; Basso, L; Chae, WR; Cosma, NC; Gärtner, M; Grimm, S; Heuser-Collier, I; Otte, C; Regen, F; van Hall, F; Wingenfeld, K, 2019) |
| "Ketamine is a fast-acting anesthetic with hypnotic properties." | 6.82 | Ketamine for resistant depression: a scoping review. ( Andrés, VC; Angel, RO; Angela, A; David, C; Eduardo, TQ; Estefania, C; Juan, G; Juan, P; Mateo, L; Melanie, LZ; Natalia, RS; Valentina, PF, 2022) |
| "The therapy of depression is prevalently based on monoamine reuptake blockers; consequently, investigations aimed to clarify the aetiology of depression have mostly looked at brain areas innervated by monamines and brain circuitry involved in inputs and outputs of these areas." | 6.82 | BDNF Alterations in Brain Areas and the Neurocircuitry Involved in the Antidepressant Effects of Ketamine in Animal Models, Suggest the Existence of a Primary Circuit of Depression. ( Carboni, E; Carta, AR, 2022) |
| "Ketamine is a novel rapid-acting antidepressant with neuroplastic potential." | 6.82 | The Downstaging Concept in Treatment-Resistant Depression: Spotlight on Ketamine. ( Cubała, WJ; Wilkowska, A, 2022) |
| "Anhedonia is a cardinal symptom of major depression and is often refractory to standard treatment, yet no approved medication for this specific symptom exists." | 6.80 | Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. ( Lally, N; Luckenbaugh, DA; Niciu, MJ; Nugent, AC; Roiser, JP; Zarate, CA, 2015) |
| "Sevoflurane was initiated in both groups at 8% for anesthesia induction until loss of consciousness was achieved, at which point it was discontinued." | 6.80 | Effect of the Addition of Ketamine to Sevoflurane Anesthesia on Seizure Duration in Electroconvulsive Therapy. ( Çolak, C; Cumurcu, B; Durmus, M; Erdil, F; Ozgul, U, 2015) |
| " Further research is warranted into: optimal dosing strategy, including number and frequency; and long-term efficacy and safety." | 6.72 | The rapid anti-suicidal ideation effect of ketamine: A systematic review. ( Grunebaum, MF; Hochschild, A; Mann, JJ, 2021) |
| "Psychotic depression is a subtype of major depressive disorder characterized by mood congruent hallucinations and/or delusions." | 6.72 | Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effects. ( Cao, B; Cha, DS; Di Vincenzo, JD; Gill, H; Ho, RC; Le, TT; Lee, Y; Lin, K; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2021) |
| "Patients with major depressive disorder often have limited response to first-line and second-line medications; hence, novel pharmacological treatments are needed for treatment-resistant depression (TRD)." | 6.72 | The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et ( Beaulieu, S; Blier, J; Blier, P; Brietzke, E; Frey, BN; Kennedy, SH; Lam, RW; McGirr, A; McIntyre, RS; Milev, RV; Parikh, SV; Ravindran, AV; Ravindran, N; Richard-Devantoy, S; Schaffer, A; Swainson, J; Taylor, VH; Tourjman, V; van Ameringen, M; Yatham, LN, 2021) |
| "Ketamine is a novel rapid-acting antidepressant with high efficacy in treatment-resistant patients." | 6.72 | Ketamine's effect on inflammation and kynurenine pathway in depression: A systematic review. ( Kopra, E; Mondelli, V; Nikkheslat, N; Pariante, C, 2021) |
| "Esketamine and ketamine have been shown to decrease inflammation in numerous ways principally through reducing pro-inflammatory cytokines (e." | 5.91 | The Glutamatergic System in Treatment-Resistant Depression and Comparative Effectiveness of Ketamine and Esketamine: Role of Inflammation? ( Cook, J; Halaris, A, 2023) |
| "Major depressive disorder is frequently characterized by disinhibition of rapid eye movement (REM) sleep and disruption of non-REM (NREM) sleep." | 5.91 | (S)-Ketamine but Not (R)-Ketamine Shows Acute Effects on Depression-Like Behavior and Sleep-Wake Architecture in Rats. ( Bagdy, G; Koncz, S; Papp, N; Pothorszki, D, 2023) |
| "Ketamine was also efficacious in decreasing the level of inflammation with an evident reduction in microglial activation and pro-inflammatory cytokines in the studied regions, following CUMS exposure." | 5.72 | Ketamine abrogates sensorimotor deficits and cytokine dysregulation in a chronic unpredictable mild stress model of depression. ( Akinluyi, ET; Anyanwu, CC; Edem, EE; Enye, LA; Fafure, AA; Ishola, AO; Nebo, KE, 2022) |
| "Depression is a serious physical and mental disease, with major depressive disorder (MDD) being a hard-to-treat, life-threatening form of the condition." | 5.72 | Autophagy: A New Mechanism for Esketamine as a Depression Therapeutic. ( Gu, T; Jiang, G; Liu, Q; Liu, S; Wang, Y; Yin, A; Zhang, L, 2022) |
| "Ketamine is a potentially life-saving option." | 5.72 | The effect of IV ketamine in patients with major depressive disorder and elevated features of borderline personality disorder. ( Chen, KS; Dwivedi, Y; Shelton, RC, 2022) |
| "Evidence has shown that brain-derived neurotrophic factor (BDNF) is associated with anhedonia symptoms in major depressive disorder (MDD) patients, while the rapid antianhedonic effects of ketamine may occur independently of depressive symptoms." | 5.69 | Baseline Plasma BDNF Levelsare Associated with Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Major Depressive Disorder. ( Gu, L; Lan, X; Li, Z; Ning, Y; Wang, C; Zhang, B; Zheng, W; Zhou, Y, 2023) |
| "The benefits of low-dose ketamine for patients with treatment-resistant depression (TRD) and prominent suicidal ideation require further investigation." | 5.69 | A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation. ( Bai, YM; Chen, LF; Chen, MH; Li, CT; Li, WC; Lin, WC; Mao, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2023) |
| "Whether pretreatment working memory and response inhibition function are associated with the rapid and sustained antisuicidal effect of low-dose ketamine among patients with treatment-resistant depression (TRD) and strong suicidal ideation is unclear." | 5.69 | Baseline cognitive function predicts full remission of suicidal symptoms among patients with treatment-resistant depression and strong suicidal ideation after low-dose ketamine infusion. ( Bai, YM; Chen, MH; Li, CT; Lin, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2023) |
| " However, whether low-dose ketamine infusion alters klotho levels among patients with treatment-resistant depression (TRD) remains unknown." | 5.69 | Role of klotho on antidepressant and antisuicidal effects of low-dose ketamine infusion among patients with treatment-resistant depression and suicidal ideation. ( Bai, YM; Chen, MH; Li, CT; Lin, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2023) |
| " This trial will provide efficacy, safety and health economic data on serial ketamine infusions and thus help inform clinical practice on the potential role of this treatment in the management of depression." | 5.69 | Study protocol for Ketamine as an adjunctive therapy for major depression (2): a randomised controlled trial (KARMA-Dep [2]). ( Igoe, A; Jelovac, A; Loughran, O; McCaffrey, C; McDonagh, K; McDonogh, S; McLoughlin, DM; Mohamed, E; O'Neill, C; Shackleton, E; Shanahan, E; Terao, M; Whooley, E, 2023) |
| "Ketamine has been shown to provide rapid and significant efficacy in treating patients with TRD." | 5.62 | Ketamine monotherapy versus adjunctive ketamine in adults with treatment-resistant depression: Results from the Canadian Rapid Treatment Centre of Excellence. ( Di Vincenzo, JD; Gill, H; Kratiuk, K; Lee, Y; Lipsitz, O; Mansur, R; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M, 2021) |
| "Patients with major depressive disorder (MDD) exhibit impaired control of cognitive and emotional systems, including deficient response selection and inhibition." | 5.62 | Ketamine's modulation of cerebro-cerebellar circuitry during response inhibition in major depression. ( Congdon, E; Espinoza, R; Hellemann, G; Joshi, S; Kubicki, A; Leaver, A; Loureiro, JRA; Narr, KL; Sahib, AK; Vasavada, M; Wade, B; Woods, RP, 2021) |
| "Ketamine has rapid and robust antidepressant effects in depression, while its effects on cognitive measures are less clearly understood." | 5.62 | The potential pro-cognitive effects with intravenous subanesthetic ketamine in adults with treatment-resistant major depressive or bipolar disorders and suicidality. ( Chao, Z; Lan, X; Li, H; McIntyre, RS; Ning, Y; Wang, C; Wu, K; Zheng, W; Zhou, Y, 2021) |
| "Ketamine is a highly effective antidepressant for patients with treatment-resistant major depressive disorder (MDD)." | 5.62 | Effects of Serial Ketamine Infusions on Corticolimbic Functional Connectivity in Major Depression. ( Congdon, E; Espinoza, RT; Hellemann, G; Kubicki, A; Leaver, AM; Loureiro, J; Narr, KL; Sahib, A; Vasavada, MM; Wade, B, 2021) |
| "Ketamine has demonstrated rapid and robust efficacy in adults with TRD." | 5.62 | Intravenous ketamine for postmenopausal women with treatment-resistant depression: Results from the Canadian Rapid Treatment Center of Excellence. ( Cha, DS; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Mansur, RB; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M, 2021) |
| "Esketamine nasal spray is a novel, fast-acting agent that provides an additional treatment option for patients with TRD who have previously failed several therapies." | 5.62 | Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance. ( Cubała, WJ; Fagiolini, A; Kasper, S; Ramos-Quiroga, JA; Souery, D; Young, AH, 2021) |
| "Ketamine was associated with transient treatment-emergent hypertension." | 5.62 | Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case Series. ( Cao, B; Cha, DS; Di Vincenzo, JD; Flint, AJ; Greenberg, D; Ho, RC; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2021) |
| "About 16% of the world's population has major depressive disorder." | 5.56 | Low-Dose Ketamine Improves LPS-Induced Depression-like Behavior in Rats by Activating Cholinergic Anti-inflammatory Pathways. ( Chang, D; Du, X; Gao, L; Lian, H; Liu, X; Zhang, X; Zhao, J, 2020) |
| "Ketamine was well-tolerated, with less than 5% of patients withdrawing due to tolerability concerns." | 5.56 | Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence. ( Cha, DS; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M, 2020) |
| "Ketamine has rapid-acting antidepressant properties but also potentially concerning transient dissociative side effects (SEs)." | 5.56 | Can 'floating' predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression. ( Acevedo-Diaz, EE; Cavanaugh, GW; Greenstein, D; Kadriu, B; Kraus, C; Park, L; Zarate, CA, 2020) |
| "Exploratory, post hoc analysis of data from a randomized clinical trial of ketamine vs midazolam in patients with major depressive disorder (MDD) and clinically significant suicidal ideation examined changes in factor analysis-derived symptom clusters from standard measures of depression (Hamilton Depression Rating Scale, HDRS; Beck Depression Inventory, BDI) and mood disturbance (Profile of Mood States, POMS), and their relationship to severity of suicidal ideation (Beck Scale for Suicidal Ideation; SSI)." | 5.51 | Ketamine vs midazolam: Mood improvement reduces suicidal ideation in depression. ( Burke, AK; Grunebaum, MF; Hochschild, A; Keilp, JG; Madden, SP; Mann, JJ, 2022) |
| " Ketamine has demonstrated rapid and robust improvements in suicidal ideation (SI)." | 5.51 | mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression. ( Abdallah, CG; Ahn, KH; Averill, CL; Averill, LA; D'Souza, DC; Duman, RS; Fouda, S; Gueorguieva, R; Krystal, JH; Ranganathan, M; Sanacora, G; Sherif, M; Southwick, SM, 2022) |
| "Using data from a randomized, double-blind (DB), placebo-controlled trial of esketamine (ESK) in patients with treatment-resistant depression (TRD), we conducted exploratory analyses." | 5.51 | Different symptomatic improvement pattern revealed by factor analysis between placebo response and response to Esketamine in treatment resistant depression. ( Kobayashi, H; Ohnishi, T; Wakamatsu, A, 2022) |
| "This study examined magnetoencephalographic (MEG) correlates of suicidal ideation (SI) and suicide attempt history in patients with treatment-resistant major depression (TRD) at baseline and following subanesthetic-dose ketamine infusion." | 5.51 | Magnetoencephalography biomarkers of suicide attempt history and antidepressant response to ketamine in treatment-resistant major depression. ( Ballard, ED; Burton, CR; Gerner, JL; Gilbert, JR; Nugent, AC; Zarate, CA, 2022) |
| " The present study applies free-water imaging to investigate the relationship between altered peripheral inflammation and WM microstructure and their predictive value in determining response to ketamine treatment in MDD." | 5.51 | Association between peripheral inflammation and free-water imaging in Major Depressive Disorder before and after ketamine treatment - A pilot study. ( Cetin-Karayumak, S; Chunga, N; Espinoza, RT; Kubicki, A; Kubicki, M; Langhein, M; Lyall, AE; Mulert, C; Narr, KL; Pasternak, O; Seitz-Holland, J, 2022) |
| "This posthoc analysis compared the antidepressant and antisuicidal effects of low-dose ketamine infusion with those of repetitive transcranial magnetic stimulation (rTMS) on treatment-resistant depression (TRD)." | 5.51 | Comparative study of low-dose ketamine infusion and repetitive transcranial magnetic stimulation in treatment-resistant depression: A posthoc pooled analysis of two randomized, double-blind, placebo-controlled studies. ( Bai, YM; Chen, MH; Cheng, CM; Li, CT; Lin, WC; Su, TP; Tsai, SJ, 2022) |
| " Intravenous ketamine has been shown to have a rapid but transient antidepressant effect, but there is still lack evidence on the efficacy and safety of intravenous esketamine in reducing suicidal ideation and depressive symptoms in MDD patients with suicidal ideation." | 5.51 | The efficacy and safety of esketamine in the treatment of major depressive disorder with suicidal ideation: study protocol for a randomized controlled trial. ( Chao, Z; Fu, L; Hu, Z; Lan, X; Li, W; Liu, H; Ning, Y; Wang, C; Ye, Y; Zhang, F; Zhou, Y, 2022) |
| "Major depression is one of the most frequent psychiatric conditions." | 5.51 | The immunomodulatory effect of ketamine in depression. ( Cubała, WJ; Gałuszko-Węgielnik, M; Górska, N; Jakuszkowiak-Wojten, K; Lisowska, KA; Szarmach, J; Szałach, ŁP; Słupski, J; Wiglusz, MS; Wilkowska, A; Włodarczyk, A, 2019) |
| "Patients with major depressive disorder (MDD) often have structural and functional deficits in the ventromedial prefrontal cortex (vmPFC), but the underlying molecular pathways are incompletely understood." | 5.51 | VGF and its C-terminal peptide TLQP-62 in ventromedial prefrontal cortex regulate depression-related behaviors and the response to ketamine. ( Jiang, C; Labonté, B; Lin, WJ; Nestler, EJ; Russo, SJ; Salton, SR; Tamminga, CA; Turecki, G, 2019) |
| "Esketamine nasal spray (Spravato) in conjunction with oral antidepressants (ADs) is approved in the European Union, United States, and other markets for treatment-resistant depression (TRD)." | 5.41 | Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study. ( Goto, R; Shimizu, H; Shiraishi, A; Takahashi, N; Tominaga, Y; Yamada, A, 2021) |
| "Triggered by the ground-breaking finding that ketamine exerts robust and rapid-acting antidepressant effects in patients with treatment-resistant depression, glutamatergic systems have attracted attention as targets for the development of novel antidepressants." | 5.41 | mGlu2/3 receptor antagonists for depression: overview of underlying mechanisms and clinical development. ( Chaki, S; Watanabe, M, 2023) |
| "Ketamine and esketamine, the S-enantiomer of the racemic mixture, have recently generated considerable interest as potential therapeutic agents for Treatment-Resistant Depression (TRD), a complex disorder that includes various psychopathological dimensions and distinct clinical profiles (e." | 5.41 | Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties? ( d'Andrea, G; Lorenzo, GD; Mancusi, G; Martinotti, G; McIntyre, RS; Pettorruso, M, 2023) |
| "This double-blind study (ASPIRE II) randomized adults (aged 18-64 years) with MDD having active suicidal ideation with intent to esketamine 84 mg or placebo nasal spray twice weekly for 4 weeks, given with comprehensive standard of care (hospitalization ≥5 days and newly initiated or optimized oral antidepressant[s])." | 5.41 | Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II). ( Canuso, CM; Drevets, WC; Fu, DJ; Hough, D; Ionescu, DF; Kasper, S; Lane, R; Lim, P; Manji, H; Qiu, X, 2021) |
| " Previous study showed that ketamine could reduce suicidal ideation (SI), potentially by improving the impaired working memory (WM)." | 5.41 | Working memory associated with anti-suicidal ideation effect of repeated-dose intravenous ketamine in depressed patients. ( Chen, X; Hu, Y; Lan, X; Li, H; Liu, W; Ning, Y; Wang, C; Wang, M; Zhan, Y; Zhang, B; Zheng, W; Zhong, X; Zhou, Y, 2021) |
| "This study included 127 patients with major depressive disorder or bipolar disorder who received ketamine treatments during a 12-day period." | 5.41 | Sleep improvement is associated with the antidepressant efficacy of repeated-dose ketamine and serum BDNF levels: a post-hoc analysis. ( Lan, X; Liu, W; Ning, Y; Wang, C; Wang, M; Zhan, Y; Zhang, B; Zheng, W; Zhou, Y, 2021) |
| "Dissociation is a treatment-emergent adverse event commonly associated with IV ketamine, often measured using the 23-item Clinician-Administered Dissociative States Scale (CADSS)." | 5.41 | A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions. ( Cha, DS; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Mansur, RB; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Shekotikhina, M; Subramaniapillai, M; Vinberg, M, 2021) |
| "Ketamine is a non-competitive N-methyl-D-aspartate receptor antagonist that is Food and Drug Administration-approved in the United States for anesthesia due to its sedative effects with low risk of severe respiratory depression." | 5.39 | Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder. ( Bloch, MH; Corlett, PR; Grunschel, BD; Niciu, MJ; Pittenger, C, 2013) |
| "Pain was also improved, although for a shorter duration." | 5.38 | Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. ( Glue, P; Perez, D; Zanicotti, CG, 2012) |
| "In a randomized, double-blind, placebo-controlled, proof-of-concept trial, 18 depressed subjects with acute suicidal ideation, who required hospitalization, were randomized to either an intravenous ketamine 0." | 5.34 | Ketamine for acute suicidal ideation. An emergency department intervention: A randomized, double-blind, placebo-controlled, proof-of-concept trial. ( Domany, Y; McCullumsmith, CB; Shelton, RC, 2020) |
| "Clinically, patients showed significantly reduced SI and depression after ketamine administration." | 5.34 | Magnetoencephalographic Correlates of Suicidal Ideation in Major Depression. ( Ballard, ED; Galiano, CS; Gilbert, JR; Nugent, AC; Zarate, CA, 2020) |
| "To compare esketamine to placebo, each in addition to standard-of-care treatment, for rapidly reducing major depressive disorder symptoms, including suicidal ideation." | 5.34 | Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I). ( Canuso, CM; Drevets, WC; Fu, DJ; Hough, D; Ionescu, DF; Lane, R; Li, X; Lim, P; Manji, H; Sanacora, G, 2020) |
| "Ketamine's effects on different dimensions of depressive symptomatology, including typical/melancholic and atypical depression, remain largely unknown." | 5.34 | The effects of ketamine on typical and atypical depressive symptoms. ( Ballard, ED; Henter, ID; Hopkins, MA; Kadriu, B; Lener, MS; Luckenbaugh, DA; Park, LT; Pennybaker, SJ; Zarate, CA, 2020) |
| "Ketamine shows promise as a rapidly-acting treatment for depression and suicidal ideation, but side effects and abuse potential limit its use." | 5.30 | Ketamine metabolite pilot study in a suicidal depression trial. ( Burke, AK; Choo, TH; Cooper, TB; Galfalvy, HC; Grunebaum, MF; Mann, JJ; Parris, MS; Suckow, RF, 2019) |
| "Twenty-six medicated outpatients with severe major depressive disorder with current, chronic suicidal ideation were randomized in a double-blind fashion to six ketamine infusions (0." | 5.30 | Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial. ( Akeju, O; Alpert, JE; Baer, L; Bentley, KH; Brown, EN; Cusin, C; Dording, C; Eikermann, M; Fava, M; Ionescu, DF; Mischoulon, D; Nock, MK; Pavone, KJ; Petrie, SR; Swee, MB; Taylor, N, 2019) |
| "Compared to placebo, ketamine significantly improved fatigue (p = ." | 5.30 | Disentangling the association of depression on the anti-fatigue effects of ketamine. ( Ballard, ED; Farmer, C; Kadriu, B; Saligan, LN; Zarate, CA, 2019) |
| "To examine the effect of high baseline anxiety on response to ketamine versus midazolam (active placebo) in treatment-resistant depression (TRD)." | 5.30 | Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. ( Cusin, C; Debattista, C; Fava, M; Flynn, M; Freeman, MP; Hock, RS; Hoeppner, B; Ionescu, DF; Iosifescu, DV; Mathew, SJ; Papakostas, GI; Salloum, NC; Sanacora, G; Trivedi, MH, 2019) |
| "In a randomized clinical trial, adults (N=80) with current major depressive disorder and a score ≥4 on the Scale for Suicidal Ideation (SSI), of whom 54% (N=43) were taking antidepressant medication, were randomly assigned to receive ketamine or midazolam infusion." | 5.27 | Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial. ( Burke, AK; Choo, TH; Galfalvy, HC; Grunebaum, MF; Keilp, JG; Mann, JJ; Marver, JE; Milak, MS; Moitra, VK; Oquendo, MA; Parris, MS; Sublette, ME, 2018) |
| "Ketamine induces rapid and robust antidepressant effects, and many patients also describe dissociation, which is associated with antidepressant response." | 5.27 | Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression. ( Ballard, ED; Brutsche, NE; Farmer, C; Jaso, BA; Luckenbaugh, DA; Niciu, MJ; Park, LT; Shovestul, BJ; Zarate, CA, 2018) |
| " We tested our hypothesis that ketamine-based anesthesia for ECT results in superior improvement in treatment-resistant MDD outcomes compared with propofol-based anesthesia." | 5.27 | Ketamine-based anesthesia improves electroconvulsive therapy outcomes: a randomized-controlled study. ( Balbuena, L; Bi, H; Bowen, R; Gamble, JJ; Prasad, R; Sanjanwala, R; Weisgerber, G, 2018) |
| "Ketamine is known to rapidly reduce depressive symptoms and suicidal ideation (SI) in patients with major depressive disorder (MDD), but evidence is limited for its acceptability and effectiveness in "real-world" settings." | 5.27 | Ketamine augmentation for major depressive disorder and suicidal ideation: Preliminary experience in an inpatient psychiatry setting. ( Belo, S; Castel, S; Levitt, AJ; Mah, L; Orser, B; Schaffer, A; Sinyor, M; Vincent, M; Williams, M; Zarate, C, 2018) |
| "The N-methyl-D-aspartate receptor antagonist ketamine has rapid onset activity in treatment-resistant depression, post-traumatic stress disorder and obsessive compulsive disorder." | 5.24 | Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. ( Anderson-Fahey, B; Glue, P; Gray, A; Harland, S; Le Nedelec, M; McNaughton, N; Medlicott, NJ; Neehoff, S, 2017) |
| " Anhedonia occurs across psychiatric diagnoses and has been associated with specific neural circuits in response to rapid-acting treatments, such as ketamine." | 5.24 | Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials. ( Ameli, R; Ballard, ED; Brutsche, NE; Lally, N; Luckenbaugh, DA; Niciu, MJ; Park, L; Richards, EM; Walls, T; Wills, K; Zarate, CA, 2017) |
| "3 mg/kg ketamine and then underwent ECT under propofol anesthesia, and a control group, which received isovolumetric placebo (normal saline) and then underwent ECT under propofol anesthesia." | 5.24 | Effect of Low Dose of Ketamine on Learning Memory Function in Patients Undergoing Electroconvulsive Therapy-A Randomized, Double-Blind, Controlled Clinical Study. ( Chen, J; Chen, Q; Hao, X; Li, X; Luo, Q; Meng, H; Min, S; Peng, L, 2017) |
| "This narrative review describes the evolution of ketamine to treat mood disorders and suicidality." | 5.22 | Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress. ( Kritzer, MD; Lai, CS; Masand, PS; Mathew, SJ; Mischel, NA; Szabo, ST; Young, JR, 2022) |
| " A statistically significant reduction of depressive symptoms and suicidal ideation after S-ketamine treatment was found." | 5.22 | [Practical aspects of ketamine treatment-Safety, combination treatment and comorbidities]. ( Bauer, M; Findeis, H; Graff, J; Ludwig, V; Mikolas, P; Ritter, P, 2022) |
| " Ketamine, a racemic mixture of the two enantiomers, (R)-ketamine and (S)-ketamine, is an N-methyl-d-aspartate receptor (NMDAR) antagonist and has been shown to have rapid-acting antidepressant properties in patients with treatment-resistant depression (TRD)." | 5.22 | Is (R)-ketamine a potential therapeutic agent for treatment-resistant depression with less detrimental side effects? A review of molecular mechanisms underlying ketamine and its enantiomers. ( Antqueviezc, B; Colombo, R; Dalpiaz, G; Ferraz Goularte, J; Paul Géa, L; Ribeiro Rosa, A; Scotton, E; Vasconcelos, MF, 2022) |
| " Ketamine, a N-methyl-d-aspartate glutamate receptor antagonist, and its enantiomer esketamine rapidly reduce depressive symptoms in depressed patients with current suicidal ideation." | 5.22 | Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how? ( Courtet, P; Lengvenyte, A; Olié, E; Strumila, R, 2022) |
| "We conducted a PRISMA-guided review for relevant randomized controlled trials of racemic or esketamine for unipolar or bipolar major depression from database inception through 2021." | 5.22 | Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. ( Bahji, A; Vazquez, GH; Zarate, CA, 2022) |
| "Despite a burgeoning body of literature demonstrating that inflammation is linked to TRD, there is still a lack of comprehensive research on the relationship between proinflammatory biomarkers and ketamine's antidepressant effect on TRD patients." | 5.22 | Antidepressant Effect of Ketamine on Inflammation-Mediated Cytokine Dysregulation in Adults with Treatment-Resistant Depression: Rapid Systematic Review. ( Gu, J; Sukhram, SD; Yilmaz, G, 2022) |
| "Little is known about the antidepressive effects of repeated intravenous ketamine infusions beyond the acute phase of treatment in patients with refractory depression." | 5.22 | Continuation phase intravenous ketamine in adults with treatment-resistant depression. ( Bobo, WV; Frye, MA; Kung, S; Morgan, RJ; Palmer, BA; Rasmussen, KG; Rico, J; Ritter, MJ; Schak, KM; Tye, SJ; Vande Voort, JL, 2016) |
| " Data were examined from 58 patients with major depressive disorder or bipolar disorder enrolled in double-blind, placebo-controlled, crossover studies who received a single infusion of ketamine (0." | 5.20 | Rating depression over brief time intervals with the Hamilton Depression Rating Scale: standard vs. abbreviated scales. ( Ameli, R; Brutsche, NE; Luckenbaugh, DA; Zarate, CA, 2015) |
| " We have previously shown that a single dose of ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, is associated with a rapid reduction in depressive symptom severity and SI in patients with treatment-resistant depression." | 5.20 | Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. ( Brallier, JW; Charney, DS; Collins, KA; DeWilde, KE; Goodman, WK; Iacoviello, BM; Iosifescu, DV; Kautz, M; Kim, J; Lapidus, KA; Lener, M; Murrough, JW; Perez, AM; Price, RB; Rodriguez, GJ; Soleimani, L; Stern, JB, 2015) |
| "Recently, ketamine has attracted attention for induction of anesthesia during electroconvulsive therapy (ECT)." | 5.19 | Comparing effects of ketamine and thiopental administration during electroconvulsive therapy in patients with major depressive disorder: a randomized, double-blind study. ( Akhondzadeh, S; Alimadadi, A; Ghaeli, P; Kargar, M; Rafei, A; Sadeghi, M; Sepehri, AS; Yoosefi, A, 2014) |
| "Ketamine in electroconvulsive therapy (ECT) anesthesia has been reported to be associated with better seizure quality and longer duration compared with methohexital anesthesia." | 5.17 | Effects of S-ketamine as an anesthetic adjuvant to propofol on treatment response to electroconvulsive therapy in treatment-resistant depression: a randomized pilot study. ( Björkqvist, M; Chrapek, W; Häkkinen, H; Järventausta, K; Kampman, O; Leinonen, E; Tuohimaa, K; Yli-Hankala, A, 2013) |
| "Subjects with major depressive disorder or bipolar disorder referred for ECT treatment of a major depressive episode were randomized to receive thiopental alone or thiopental plus ketamine (0." | 5.16 | Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting. ( Abdallah, CG; Fasula, M; Kelmendi, B; Ostroff, R; Sanacora, G, 2012) |
| "Suicidal ideation in the context of MDD improved within 40 minutes of a ketamine infusion and remained improved for up to 4 hours postinfusion." | 5.14 | Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. ( Ameli, R; Brutsche, NE; DiazGranados, N; Henter, ID; Ibrahim, LA; Luckenbaugh, DA; Machado-Vieira, R; Zarate, CA, 2010) |
| "To assess the effects - and review the acceptability and tolerability - of ketamine and other glutamate receptor modulators in alleviating the acute symptoms of depression in people with unipolar major depressive disorder." | 5.12 | Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. ( Barnes, A; Cipriani, A; Cowen, PJ; Dean, RL; Hawton, K; Hollingsworth, S; Hurducas, C; Marquardt, T; McShane, R; Smith, R; Spyridi, S; Turner, EH, 2021) |
| "Ketamine appears to have a therapeutic role in certain mental disorders, most notably depression." | 5.12 | Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. ( Bahji, A; Vazquez, GH; Zarate, CA, 2021) |
| "The efficacy of ketamine in reducing suicidal ideation (SI) has been previously reported." | 5.12 | The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis. ( Carvalho, I; Chen-Li, D; Gill, H; Lee, Y; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Narsi, F; Rodrigues, NB; Rosenblat, JD; Xiong, J, 2021) |
| "The approval of intranasal esketamine for treatment-resistant depression marks the next step in our understanding of and ability to treat treatment-resistant depression." | 5.12 | Intranasal esketamine: From origins to future implications in treatment-resistant depression. ( Brula, AQ; Sanders, B, 2021) |
| " Previous research has shown that intranasal esketamine and intravenous ketamine can rapidly decrease the severity of depressive symptoms and suicidal ideation." | 5.12 | Antisuicidal and antidepressant effects of ketamine and esketamine in patients with baseline suicidality: A systematic review. ( Brietzke, E; Di Vincenzo, JD; Gill, H; Ho, R; Lui, LMW; McIntyre, RS; Ng, J; Rodrigues, NB; Rosenblat, JD; Siegel, AN; Teopiz, KM, 2021) |
| " Esketamine (ESK), an NMDA receptor antagonist able to modulate glutamatergic neurotransmission has been recently developed as an intranasal formulation for treatment-resistant depression (TRD) and for rapid reduction of depressive symptomatology, including suicidal ideation in MDD patients at imminent risk for suicide." | 5.05 | An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine. ( De Berardis, D; Di Giannantonio, M; Fornaro, M; Fraticelli, S; Kim, YK; Martinotti, G; Orsolini, L; Perna, G; Pompili, M; Serafini, G; Tomasetti, C; Valchera, A; Vellante, F; Volpe, U, 2020) |
| " Studies of oral ketamine for depression, from case series to randomized clinical trials, were eligible." | 5.05 | An Update on the Efficacy and Tolerability of Oral Ketamine for Major Depression: A Systematic Review and Meta-Analysis. ( Frye, MA; Joseph, B; Kung, S; Nuñez, NA; Pahwa, M; Prokop, LJ; Schak, KM; Seshadri, A; Singh, B; Vande Voort, JL, 2020) |
| "Discovering that the anesthetic drug ketamine has rapidly acting antidepressant effects in many individuals with major depression is one of the most important findings in clinical psychopharmacology in recent decades." | 5.01 | Rodent ketamine depression-related research: Finding patterns in a literature of variability. ( Fitzgerald, PJ; Hale, PJ; Polis, AJ; Watson, BO, 2019) |
| " The primary outcome measures were the suicide items from clinician-administered (the Montgomery-Åsberg Depression Rating Scale [MADRS] or the Hamilton Depression Rating Scale [HAM-D]) and self-report scales (the Quick Inventory of Depressive Symptomatology-Self Report [QIDS-SR] or the Beck Depression Inventory [BDI]), obtained for up to 1 week after ketamine administration." | 4.98 | The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. ( Ballard, ED; Bloch, MH; Feder, A; Mathew, SJ; Murrough, JW; Sanacora, G; Sos, P; Wang, G; Wilkinson, ST; Zarate, CA, 2018) |
| "The current meta-analysis examines the effects of ketamine infusion on depressive symptoms over time in major depressive disorder (MDD) and bipolar disorder (BD)." | 4.91 | The use of ketamine as an antidepressant: a systematic review and meta-analysis. ( Coyle, CM; Laws, KR, 2015) |
| "The electronic database Pubmed, Web of Science and sciencedirect were searched using the keywords: ketamine, N-methyl-d-aspartate receptor antagonist, rapid-acting antidepressant, depression, treatment-resistant depression, bipolar depression, suicidal ideation, electroconvulsive therapy, mechanism of action." | 4.90 | A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. ( Clarke, G; Cryan, JF; Dinan, TG; Naughton, M; O'Leary, OF, 2014) |
| "Anhedonia as measured by the MADRS appeared to not be positively related to suicidal ideation after serial ketamine infusions." | 4.31 | Association of anhedonia and suicidal ideation in patients with treatment-refractory depression after intravenous ketamine infusions. ( Gu, LM; Lan, XF; Ning, YP; Wang, CY; Yang, XH; Zhang, B; Zheng, W; Zhou, YL, 2023) |
| "Most research describing ketamine as a treatment for depression has relied on intravenous dosing." | 4.31 | Intranasal racemic ketamine for patients hospitalized with treatment-resistant depression: A retrospective analysis. ( Cheveldae, I; Halpape, K; Peters, EM; Wanson, A, 2023) |
| "Ketamine is an anesthetic drug that has recently been approved for the treatment of treatment-resistant depression." | 4.31 | The Effects of Acute and Repeated Administration of Ketamine on Memory, Behavior, and Plasma Corticosterone Levels in Female Mice. ( Acevedo, J; Johnson, EM; Mugarura, NE; Siegel, JA; Welter, AL, 2023) |
| "Hippocampal functional connectivity (FC) alterations, which may happen following ketamine treatment, play a key role in major depression remission." | 4.31 | Ketamine-induced hippocampal functional connectivity alterations associated with clinical remission in major depression. ( Hu, Z; Lan, X; Li, W; Liu, H; Ning, Y; Wang, C; Ye, Y; You, Z; Zhang, F; Zhou, Y, 2023) |
| "Esketamine, the S-enantiomer of ketamine, has recently emerged as a therapy for treatment-resistant depression (TRD), showing both rapid antidepressant action and good efficacy and high safety." | 4.31 | Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study. ( Andriola, I; Barlati, S; Bassetti, R; Chiappini, S; Clerici, M; d'Andrea, G; De Filippis, S; Dell'Osso, B; Di Nicola, M; Martinotti, G; Pettorruso, M; Sensi, S; Vita, A, 2023) |
| "This study aims to investigate the differences in safety and antidepressant effects of multi-infusion ketamine treatment between elderly and young adults with depression." | 4.31 | A comparative analysis of antidepressant and anti-suicidal effects of repeated ketamine infusions in elderly and younger adults with depression. ( Lan, XF; Ning, YP; Wang, CY; Zheng, W; Zhou, YL, 2023) |
| " We have previously used the chronic mild stress (CMS) model of depression in male rats to show that CMS induces morphological, functional, and molecular changes in the hippocampus of vulnerable animals, the majority of which were recovered using acute subanesthetic ketamine in just 24 h." | 4.31 | Functional and Molecular Changes in the Prefrontal Cortex of the Chronic Mild Stress Rat Model of Depression and Modulation by Acute Ketamine. ( Barbon, A; Bertoli, M; Bonanno, G; Bonifacino, T; La Via, L; Milanese, M; Mingardi, J; Misztak, P; Musazzi, L; Ndoj, E; Popoli, M; Russo, I; Torazza, C, 2023) |
| " Ketamine, known as an anesthetic, is a new treatment option that can be effective in patients with treatment-resistant depression." | 4.31 | [Consider (es)ketamine for treatment-resistant depression]. ( Kramers, CK; Ruhé, HG; Stuiver, S; van Verseveld, M; van Waarde, JA; Vos, CF, 2023) |
| "This Viewpoint examines key issues stemming from several recent reports of electroconvulsive therapy (ECT) vs ketamine for improving depressive symptoms in treatment-resistant depression (TRD)." | 4.31 | Choosing Between Ketamine and Electroconvulsive Therapy for Outpatients With Treatment-Resistant Depression-Advantage Ketamine? ( Anand, A; Jha, MK; Mathew, SJ, 2023) |
| " We report the case of a 57-year-old woman diagnosed with treatment-resistant depression (TRD) and comorbid FMD treated with weekly intranasal administrations of esketamine over a six-month follow-up period." | 4.12 | Remission of functional motor symptoms following esketamine administration in a patient with treatment-resistant depression: a single-case report. ( Bentivoglio, AR; Calabresi, P; Camardese, G; Di Nicola, M; Janiri, D; Lanzotti, P; Moccia, L; Palumbo, L; Pepe, M; Sani, G, 2022) |
| "This preliminary study found that repeated ketamine infusions appeared to be effective at rapidly ameliorating anhedonia, with similar efficacy in MDD and BD." | 4.12 | Comparative effectiveness of repeated ketamine infusions in treating anhedonia in bipolar and unipolar depression. ( Gu, LM; Lan, XF; Ning, YP; Sun, CH; Wang, CY; Zhang, B; Zheng, W; Zhou, YL, 2022) |
| "Outcomes of ketamine intravenous therapy (KIT) for depression in real-world care settings have been minimally evaluated." | 4.12 | A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings. ( DeBattista, C; Gargeya, RS; Heifets, BD; McInnes, LA; Qian, JJ, 2022) |
| "Psychological pain and hopelessness were not associated with the re-emergence of SI post-ketamine." | 4.12 | Prospective association of psychological pain and hopelessness with suicidal thoughts. ( Ballard, ED; Bloomfield-Clagett, B; Farmer, CA; Gerner, J; Park, LT; Zarate, CA, 2022) |
| "Ketamine can be used for depression and suicidal ideation due to its effectiveness and low complication rates; moreover, allergic reactions are rare." | 4.12 | Allergic reaction induced by subcutaneous administration of ketamine: a case report. ( Anzolin, AP; Belmonte-de-Abreu, PS; Cordova, VHS; Lacerda, A; Sant'Ana, MK, 2022) |
| "Interest in the use of parenteral ketamine has been increasing over the last 2 decades for the management of treatment-resistant depression (TRD)." | 4.12 | Repeated subcutaneous racemic ketamine in treatment-resistant depression: case series. ( Budd, GP; Do, A; Fridfinnson, J; Lam, RW; Rafizadeh, R; Siu, JTP; Tham, JCW, 2022) |
| "One hundred thirty-five Chinese individuals with anxious depression (n = 92) and nonanxious depression (n = 43) received six intravenous infusions of ketamine (0." | 4.12 | Antianhedonic effects of serial intravenous subanaesthetic ketamine in anxious versus nonanxious depression. ( Gu, LM; Ning, YP; Tan, JQ; Wang, CY; Yang, XH; Zheng, W; Zhou, YL, 2022) |
| "A short course of repeated ketamine infusions did not impair neurocognitive function in patients with treatment-resistant depression." | 4.12 | Assessment of Objective and Subjective Cognitive Function in Patients With Treatment-Resistant Depression Undergoing Repeated Ketamine Infusions. ( Batten, LA; Blier, P; Burhunduli, P; Norris, S; Ortiz, A; Owoeye, O; Phillips, JL; Talbot, J; Van Geel, A; Vasudev, D, 2022) |
| " These findings may help explain the more modest findings in clinical IV ketamine trials for suicidal ideation than overall depression." | 4.12 | A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Nonsuicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine. ( Ballard, ED; Bloomfield-Clagett, B; Fava, M; Greenstein, DK; Grunebaum, MF; Mathew, SJ; Murrough, JW; Phillips, JL; Sanacora, G; Wilkinson, ST; Zarate, CA, 2022) |
| "Clinical research has shown that persistent negative beliefs maintain depression and that subanesthetic ketamine infusions induce rapid antidepressant responses." | 4.12 | Evaluation of Early Ketamine Effects on Belief-Updating Biases in Patients With Treatment-Resistant Depression. ( Bottemanne, H; Claret, A; Fossati, P; Morlaas, O; Schmidt, L; Sharot, T, 2022) |
| "Ketamine has emerged as a promising pharmacotherapy for depression and other mental illnesses, and the intramuscular (IM) administration of ketamine is now offered at many North American outpatient psychiatric clinics." | 4.12 | Real-world depression, anxiety and safety outcomes of intramuscular ketamine treatment: a retrospective descriptive cohort study. ( Ahuja, S; Brendle, M; Moore, C; Robison, R; Smart, L; Thielking, P, 2022) |
| "Esketamine is the S-enantiomer of racemic ketamine and has been approved by the Food and Drug Administration for the management of treatment resistant depression, demonstrating effective and long-lasting benefits." | 4.12 | Association of intranasal esketamine, a novel 'standard of care' treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice. ( Do, A; Giacobbe, P; Gutierrez, G; Hawken, E; Karthikeyan, G; Lam, RW; Milev, R; Ravindran, N; Rosenblat, J; Schaffer, A; Swainson, J; Vazquez, G, 2022) |
| "IV ketamine was effective in reducing symptoms of depression, SI, anxiety, and anhedonia in both cohorts in this large, well-characterized community-based sample of adults with TRD." | 4.12 | Effectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulation. ( Cha, DS; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Shekotikhina, M; Siegel, A; Simonson, K; Subramaniapillai, M, 2022) |
| "Treatment-resistant depression (TRD) may be responsive to interventions beyond antidepressants including brain stimulation such as electroconvulsive therapy (ECT) or to ketamine or esketamine, the latter of which is approved for TRD in an intranasal form." | 4.02 | Commentary: Treatment-resistant Depression: Considerations Related to ECT and Ketamine. ( Garakani, A, 2021) |
| "Patients with treatment-resistant depression (TRD) treated with esketamine nasal spray commonly experience transient symptoms of dissociation." | 4.02 | Managing dissociative symptoms following the use of esketamine nasal spray: a case report. ( Brennan, E; Liebowitz, MR; Moran, M; Patel, A; Pereira, S; Wallier, J, 2021) |
| "Patients with TRD and prominent anxiety receiving IV ketamine exhibited a significant reduction in depressive, SI and anxiety symptoms." | 4.02 | The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence. ( Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lipsitz, O; Lui, LM; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, K, 2021) |
| "We evaluated the effects of repeated subanesthetic ketamine infusions on suicidal ideation (SI) in patients with major depression." | 4.02 | Subanesthetic ketamine infusions for suicide ideation in patients with bipolar and unipolar treatment refractory depression. ( Anjum, MR; Chandrasena, R; Fairbairn, J; Hawken, ER; Kang, MJY; Kulcar, E; Vazquez, GH, 2021) |
| "The aim of this study was to examine the effect on depressive symptoms of repeated subanesthetic doses of SC esketamine in unipolar and bipolar treatment-resistant depression (TRD) and clinical predictors of response." | 4.02 | Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity. ( Abdo, G; B Andreoli, S; B Puertas, C; Barbosa, M; Cohrs, FM; Del Porto, JA; Del Sant, LC; Delfino, R; Fava, VA; Lacerda, AL; Liberatori, A; Lucchese, AC; Magalhães, EJM; Nakahira, C; Sarin, LM; Steiglich, MS; Surjan, J; Tuena, MA, 2021) |
| "This study suggests the possible clinical utility of resting-state functional magnetic resonance imaging for predicting the antidepressant effects of ketamine in treatment-resistant depression patients and implicated resting-state functional connectivity alterations to determine the trait-like pathophysiology underlying treatment response heterogeneity in treatment-resistant depression." | 4.02 | Functional connectivity between the amygdala and subgenual cingulate gyrus predicts the antidepressant effects of ketamine in patients with treatment-resistant depression. ( Abe, T; Hiraki, T; Horikawa, N; Ishibashi, M; Nakamura, T; Tomita, M; Uchimura, N; Uematsu, K, 2021) |
| "Adults with treatment-resistant depression (TRD) receiving intravenous (IV) ketamine had depressive symptoms measured with the 16-Item Quick Inventory Depressive Symptoms Self-Report (QIDS-SR-16) and MARRRS at baseline and as a repeated measure across an acute course of four infusions." | 4.02 | Validation of the McIntyre And Rosenblat Rapid Response Scale (MARRRS) in Adults with Treatment-Resistant Depression Receiving Intravenous Ketamine Treatment. ( Cha, DS; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M, 2021) |
| " Herein, we investigated whether pre-treatment functioning in outpatients with treatment-resistant depression (TRD) moderates response to intravenous (IV) ketamine." | 4.02 | Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression? ( Cha, DS; Gill, H; Ho, RC; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2021) |
| "Herein we evaluate the impact of COVID-19 restrictions on antidepressant effectiveness of intravenous (IV) ketamine in adults with treatment-resistant depression (TRD)." | 4.02 | Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic. ( Abrishami, A; Arekapudi, AK; Chau, EH; Di Vincenzo, JD; Kratiuk, K; Lee, Y; Lipsitz, O; Mansur, RB; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Szpejda, W; Wong, L, 2021) |
| "To identify a meaningful change threshold (MCT) in depression outcomes in adults with treatment-resistant major depressive disorder (MDD) or bipolar disorder (BD) receiving intravenous ketamine treatment at a community-based mood disorders center." | 4.02 | The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine. ( Gill, H; Ho, RC; Jones, BDM; Kratiuk, K; Lee, Y; Ling, R; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2021) |
| "Some patients with refractory depression who fail to respond to rapid injection of standard-dose ketamine are injected with high doses, but the safety and efficacy of this practice are unclear." | 3.96 | Repeated ketamine injections in synergy with antidepressants for treating refractory depression: A case showing 6-month improvement. ( Fang, J; Li, Z; Su, B; Wang, L; Wang, M; Xiong, Z; Yang, Y, 2020) |
| "Concerns about ketamine for treating depression include abuse potential and the occurrence of psychotomimetic effects." | 3.96 | Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. ( Acevedo-Diaz, EE; Cavanaugh, GW; Greenstein, D; Kadriu, B; Kraus, C; Park, LT; Zarate, CA, 2020) |
| "To determine the effectiveness of intravenous (IV) ketamine on anxiety, irritability, agitation, and suicidality, in adults with treatment-resistant major depressive disorder (MDD) or bipolar disorder (BD)." | 3.96 | The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder. ( Cha, DS; Fagiolini, A; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Malhi, GS; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Suppes, T; Vinberg, M, 2020) |
| "The effectiveness, tolerability, and safety of intravenous (IV) ketamine in adults with treatment resistant depression (TRD) receiving care in real-word settings is insufficiently characterized." | 3.96 | The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence. ( Abrishami, A; Arekapudi, AK; Brietzke, E; Carvalho, IP; Chau, EH; Gill, H; Kratiuk, K; Lee, Y; Lipsitz, O; Lui, LMW; Majeed, A; Mansur, RB; McIntyre, RS; Nasri, F; Phan, L; Rodrigues, NB; Rosenblat, JD; Senyk, O; Siegel, A; Subramaniapillai, M; Szpejda, W, 2020) |
| "Subanesthetic ketamine is found to induce fast-acting and pronounced antidepressant effects, even in treatment resistant depression (TRD)." | 3.96 | Modulation of inhibitory control networks relate to clinical response following ketamine therapy in major depression. ( Congdon, E; Espinoza, R; Joshi, SH; Kubicki, A; Loureiro, JR; Narr, KL; Sahib, AK; Vasavada, MM; Wade, B; Woods, RP, 2020) |
| "After adjusting for age, sex, primary diagnosis, concomitant medication, body mass index, and baseline depression severity, there was a statistically significant reduction in symptoms of anhedonia with IV ketamine treatment (F (2, 235." | 3.96 | Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence. ( Cha, DS; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Majeed, A; Mansur, RB; McIntyre, RS; Nasri, F; Phan, L; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M, 2020) |
| "The glutamatergic modulator ketamine has been shown to result in rapid reductions in both suicidal ideation (SI) and depressive symptoms in clinical trials." | 3.96 | Predicting therapeutic response to oral ketamine for chronic suicidal ideation: a Bayesian network for clinical decision support. ( Beaudequin, D; Can, AT; Dutton, M; Forsyth, G; Gallay, C; Hermens, DF; Jones, M; Lagopoulos, J; Schwenn, P; Simcock, G; Yang, C, 2020) |
| " There is a rising promise in a N-methyl-D-aspartate (NMDA) receptor antagonist, ketamine, which may be used in the treatment of resistant depression." | 3.91 | Short-term ketamine administration in treatment-resistant depression patients: focus on adverse effects on the central nervous system. ( Cubała, WJ; Małyszko, A; Szarmach, J; Wiglusz, MS; Włodarczyk, A, 2019) |
| " Previous studies found that ketamine intervention could rapidly reduce suicidal ideation in depression." | 3.91 | A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation. ( Chen, L; Li, H; Li, M; Li, MD; Liu, W; Ning, Y; Walter, M; Wang, C; Yu, L; Zhan, Y; Zhang, B; Zheng, W; Zhou, Y, 2019) |
| "Ketamine produces a rapid-onset antidepressant effect in patients with treatment-resistant depression (TRD), although it concurrently causes undesirable psychotomimetic side effects." | 3.91 | TAK-137, an AMPA receptor potentiator with little agonistic effect, produces antidepressant-like effect without causing psychotomimetic effects in rats. ( Hara, H; Kimura, H; Kunugi, A; Murakami, K; Suzuki, A; Tajima, Y, 2019) |
| " These behavioral effects are associated with i/ a reversal of anxiety and reduced self-care, ii/ a decrease in parenchymal cytokine production, iii/ a modulation of the microglial reactivity and iv/ a decrease in microglial quinolinic acid production that is correlated with plasmatic peripheral production." | 3.91 | Microglial production of quinolinic acid as a target and a biomarker of the antidepressant effect of ketamine. ( Abdel-Ahad, P; Blatzer, M; Callebert, J; Chrétien, F; Danckaert, A; de Maricourt, P; De Medeiros, GF; Gaillard, R; Jouvion, G; Langeron, O; Launay, JM; Maignan, A; Petit, AC; Sharshar, T; Van Steenwinckel, J; Verdonk, F; Vinckier, F, 2019) |
| "Data were obtained from 110 individuals with mood disorders (predominantly major depressive disorder) who underwent intravenous ketamine infusion." | 3.88 | Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale. ( Davidson, L; Sanacora, G; Silverman, WK; van Schalkwyk, GI; Wilkinson, ST, 2018) |
| "No pharmacological treatments exist for active suicidal ideation (SI), but the glutamatergic modulator ketamine elicits rapid changes in SI." | 3.88 | Characterizing the course of suicidal ideation response to ketamine. ( Ballard, ED; Farmer, CA; Kadriu, B; Machado-Vieira, R; Niciu, MJ; Park, L; Richards, E; Yarrington, JS; Yuan, P; Zarate, CA, 2018) |
| " The current case report describes a patient suffering from severe depression and dementia who received electroconvulsive therapy with S-ketamine anesthesia at our psychiatric intensive care unit for the treatment of her therapy-resistant catatonic stupor." | 3.85 | Electroconvulsive therapy with S-ketamine anesthesia for catatonia in coexisting depression and dementia. ( Bauer, M; Frey, R; Kasper, S; Litvan, Z, 2017) |
| "In this preliminary study, repeated doses of open-label ketamine rapidly and robustly decreased suicidal ideation in pharmacologically treated outpatients with treatment-resistant depression with stable suicidal thoughts; this decrease was maintained for at least 3 months following the final ketamine infusion in 2 patients." | 3.83 | Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study. ( Akeju, O; Alpert, JE; Baer, L; Brown, EN; Cassano, P; Cusin, C; Fava, M; Ionescu, DF; Mischoulon, D; Nock, MK; Nyer, M; Pavone, KJ; Swee, MB; Taylor, N, 2016) |
| "Data from 108 treatment-resistant inpatients meeting criteria for major depressive disorder and bipolar disorder who received a single subanesthetic ketamine infusion were analyzed." | 3.80 | Do the dissociative side effects of ketamine mediate its antidepressant effects? ( Brutsche, NE; Guevara, S; Ionescu, DF; Luckenbaugh, DA; Niciu, MJ; Nolan, NM; Richards, EM; Zarate, CA, 2014) |
| " Ketamine anesthesia does not possess pronounced anticonvulsive properties like propofol, etomidate, thiopental, or methohexital." | 3.78 | Rethinking restimulation: a case report. ( Hoyer, C; Janke, C; Kranaster, L; Lederbogen, F; Lewien, A; Sartorius, A, 2012) |
| "Ketamine has considerable therapeutic potential in alleviating major depressive disorder and chronic suicidality." | 3.30 | Spectral Changes of EEG Following a 6-Week Low-Dose Oral Ketamine Treatment in Adults With Major Depressive Disorder and Chronic Suicidality. ( Anijärv, TE; Can, AT; Dutton, M; Forsyth, GA; Gallay, CC; Hermens, DF; Lagopoulos, J; Mitchell, JS, 2023) |
| "Ketamine was noninferior to ECT as therapy for treatment-resistant major depression without psychosis." | 3.30 | Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. ( Aloysi, AS; Altinay, M; Anand, A; Asghar-Ali, AA; Barnett, BS; Chang, LC; Collins, KA; Costi, S; Goes, FS; Hu, B; Iqbal, S; Jha, MK; Krishnan, K; Malone, DA; Mathew, SJ; Murrough, JW; Nikayin, S; Nissen, SE; Ostroff, RB; Reti, IM; Sanacora, G; Wilkinson, ST; Wolski, K, 2023) |
| "Seventy-one patients with major depressive disorder and sleep disturbance were randomly divided into 2 groups, namely, the ECT without ketamine group (group ES), receiving routine ECT and saline (3 mL) at each ECT session, and the ECT-assisted ketamine group (group KS), which received ECT and ketamine (3 mL) at each ECT session." | 3.30 | Subanesthetic Dose of Ketamine Administered Before Each Electroconvulsive Therapy Session Improves Antidepressant and Sleep Quality Outcomes: A Randomized, Controlled Trial. ( Chen, Q; Dong, J; Min, S; Qiu, H; Ren, L, 2023) |
| "Esketamine is an NMDA receptor antagonist inducing antidepressant effects within hours." | 3.30 | The effects of esketamine and treatment expectation in acute major depressive disorder (Expect): study protocol for a pharmacological fMRI study using a balanced placebo design. ( Bitsch, F; Falkenberg, I; Kircher, T; Liu, W; Matsingos, A; Noor, L; Vogelbacher, C; Yildiz, C, 2023) |
| "Ketamine has emerged as a fast-acting and powerful antidepressant, but no head to head trial has been performed, Here, ketamine is compared with electroconvulsive therapy (ECT), the most effective therapy for depression." | 3.11 | Racemic Ketamine as an Alternative to Electroconvulsive Therapy for Unipolar Depression: A Randomized, Open-Label, Non-Inferiority Trial (KetECT). ( Åkeson, J; Cheng, T; Ekstrand, J; Fattah, C; Lindström, MB; Movahed Rad, P; Nordanskog, P; Nordenskjöld, A; Persson, M; Tingström, A, 2022) |
| "SC ketamine was safe and well tolerated, and most adverse events were mild and transient." | 3.01 | Potential advantages of ketamine over electroconvulsive therapy in the treatment of nonrefractory severe depression in older patients with multiple medical comorbidities. ( Cunha, UGV; Duarte, DB; Hara, C; Rocha, FL, 2023) |
| "Ketamine has shown antidepressant effects in patients with major depressive disorder (MDD) resistant to first-line treatments and approved for use in this patient population." | 3.01 | Translational control by ketamine and its implications for comorbid cognitive deficits in depressive disorders. ( Aguilar-Valles, A; Arsenault, E; Lewis, V; Matta-Camacho, E; Myers, M; Rodrigue, B; Silva, WCC; Taghavi-Abkuh, FF; Zhang, M, 2023) |
| "Major depressive disorder is a prevalent and heterogeneous disorder with treatment resistance in at least 50% of individuals." | 3.01 | Imaging synaptic density in depression. ( Abdallah, C; Esterlis, I; Holmes, SE, 2023) |
| " Notwithstanding, ketamine is a drug of abuse, and this liability may pose limitations for long term use as an antidepressant." | 3.01 | Role of the mesolimbic dopamine pathway in the antidepressant effects of ketamine. ( Bolaños-Guzmán, CA; Cardona-Acosta, AM, 2023) |
| "Ketamine is a NMDA receptor antagonist that has a rapid acting antidepressant effect with high efficacy in treatment-resistant patients." | 3.01 | Biomarkers of ketamine's antidepressant effect: An umbrella review. ( Cao, B; Ceban, F; Di Vincenzo, JD; Ho, RC; Jawad, MY; McIntyre, RS; Meshkat, S; Rhee, TG; Rosenblat, JD; Teopiz, KM, 2023) |
| "Major depressive disorder is a highly prevalent psychiatric disorder." | 3.01 | Neuroimaging-Derived Biomarkers of the Antidepressant Effects of Ketamine. ( Al-Sharif, NB; Espinoza, RT; Leaver, AM; Narr, KL; Sahib, AK; Taraku, B; Zavaliangos-Petropulu, A, 2023) |
| "Arketamine has been found to have more potent antidepressant-like actions than esketamine in rodents." | 3.01 | Arketamine for cognitive impairment in psychiatric disorders. ( Hashimoto, K, 2023) |
| "Ketamine seems to be an attractive alternative due to its rapid-onset antidepressant effects and impact on suicidal thoughts." | 3.01 | Efficacy and adverse effects of ketamine versus electroconvulsive therapy for major depressive disorder: A systematic review and meta-analysis. ( Cavalcanti, S; de A Simoes Moreira, D; Fonseca da Silva, AC; Gauer, LE; Quevedo, J; Teixeira, G, 2023) |
| "Arketamine might produce fast-onset and sustained antidepressant effects in humans with favorable safety profile, like previously reported with animals; further controlled-trials are needed." | 3.01 | Intravenous arketamine for treatment-resistant depression: open-label pilot study. ( Bandeira, ID; Bezerra, MLO; Caliman-Fontes, AT; Correia-Melo, FS; Dias-Neto, AL; Guerreiro-Costa, LNF; Jesus-Nunes, AP; Lacerda, ALT; Leal, GC; Lima, CS; Loo, C; Marback, RF; Marques, BLS; Mello, RP; Quarantini, LC; Sampaio, AS; Sanacora, G; Silva, SS; Telles, M; Turecki, G; Vieira, F, 2021) |
| " Older age, hypertension, large ketamine dosage and dissociative symptoms may predict increased ketamine-induced cardiovascular effects." | 3.01 | Cardiovascular effects of repeated subanaesthetic ketamine infusion in depression. ( Lan, XF; Liu, WJ; Ning, YP; Wang, CY; Weng, SY; Zheng, W; Zhou, YL, 2021) |
| "Patients with major depressive disorder who do not respond to ≥2 different pharmacological treatments within the current depressive episode are considered to have treatment resistant depression (TRD)." | 3.01 | Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Tr ( Blackowicz, M; Cooper, K; Drevets, WC; Fedgchin, M; Floden, L; Hudgens, S; Jamieson, C; Lane, R; Popova, V; Singh, J, 2021) |
| "Ketamine was associated with transient, self-limited dissociative symptoms that affected participant blinding, but there were no serious adverse events." | 3.01 | Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. ( Bloch, MH; Couloures, K; Dwyer, JB; Flores, JM; Johnson, JA; Landeros-Weisenberger, A; Londono Tobon, A; Nasir, M; Sanacora, G, 2021) |
| "Ketamine has been shown to be effective in treatment of episodes of major depressive disorder (MDD)." | 3.01 | Predictive value of heart rate in treatment of major depression with ketamine in two controlled trials. ( Andrashko, V; Brunovsky, M; Horacek, J; Meyer, T; Novak, T; Olbrich, S; Seifritz, E, 2021) |
| "Norketamine concentration was not associated with antidepressant response." | 2.94 | Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression. ( Adeojo, L; Farmer, CA; George, J; Gilbert, JR; Gould, TD; Kadriu, B; Lovett, J; Moaddel, R; Nugent, AC; Park, LT; Yuan, P; Zarate, CA, 2020) |
| "Esketamine nasal spray was recently approved for treatment-resistant depression." | 2.94 | Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data. ( Aluisio, L; Borentain, S; Daly, E; DiBernardo, A; Janik, A; Nijs, M; Singh, JB; Turkoz, I; Wajs, E; Wiegand, F, 2020) |
| "Patients diagnosed with Major Depressive Disorder (MDD) (n = 134) were randomized into 3 groups: routine ECT group (group E, n = 45); repeated ketamine-assisted ECT group (group RK, n = 43), and intermittent ketamine-assisted ECT group (group IK, n = 46)." | 2.90 | Intermittent administration of low dose ketamine can shorten the course of electroconvulsive therapy for depression and reduce complications: A randomized controlled trial. ( Chen, Q; Dong, J; Min, S; Qiu, H; Ren, L, 2019) |
| "Ketamine has a robust antidepressant effect, but there are no reported studies of ketamine for depression relapse prevention." | 2.90 | Ketamine Versus Midazolam for Depression Relapse Prevention Following Successful Electroconvulsive Therapy: A Randomized Controlled Pilot Trial. ( Daly, L; Finnegan, M; Galligan, T; Harkin, A; McLoughlin, DM; Ryan, K; Shanahan, E, 2019) |
| "Ketamine has demonstrated a rapid antidepressant and antisuicidal effect in patients with major depressive disorder (MDD), but the neurocognitive effects of ketamine are relatively unknown." | 2.90 | Neurocognitive performance and repeated-dose intravenous ketamine in major depressive disorder. ( Chen, LJ; Li, HQ; Li, MD; Liu, WJ; Ning, YP; Wang, CY; Zhan, YN; Zheng, W; Zhou, YL, 2019) |
| "About 20 to 30 percent of patients with Major Depressive Disorder (MDD) do not respond to standard treatment and are considered treatment-resistant." | 2.90 | Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder. ( Aust, S; Bajbouj, M; Basso, L; Chae, WR; Cosma, NC; Gärtner, M; Grimm, S; Heuser-Collier, I; Otte, C; Regen, F; van Hall, F; Wingenfeld, K, 2019) |
| "Seventy-seven patients with major depressive disorder were eligible to receive augmentation with six ketamine infusions (0." | 2.90 | Investigation of medical effect of multiple ketamine infusions on patients with major depressive disorder. ( Chen, LJ; Li, HQ; Li, MD; Liu, WJ; Ning, YP; Wang, CY; Zhan, YN; Zheng, W; Zhou, YL, 2019) |
| " The five most common adverse events (dissociation, nausea, vertigo, dysgeusia, and dizziness) all were observed more frequently in the esketamine plus antidepressant arm than in the antidepressant plus placebo arm; 7% and 0." | 2.90 | Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. ( Bajbouj, M; Cooper, K; Daly, EJ; Drevets, WC; Hough, D; Lane, R; Lim, P; Manji, H; Mazzucco, C; Molero, P; Popova, V; Shelton, RC; Singh, JB; Thase, ME; Trivedi, M; Vieta, E, 2019) |
| "Patients with major depressive disorder (MDD) have clinically relevant, significant decreases in bone mineral density (BMD)." | 2.87 | Acute ketamine administration corrects abnormal inflammatory bone markers in major depressive disorder. ( Ballard, ED; De Sousa, RT; Gold, PW; Henter, ID; Kadriu, B; Lener, MS; Luckenbaugh, DA; Machado-Vieira, R; Niciu, MJ; Park, LT; Yuan, P; Zarate, CA, 2018) |
| " Three of 56 (5%) esketamine-treated participants during the double-blind phase vs none receiving placebo and 1 of 57 participants (2%) during the open-label phase had adverse events that led to study discontinuation (1 event each of syncope, headache, dissociative syndrome, and ectopic pregnancy)." | 2.87 | Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial. ( Cooper, K; Daly, EJ; Drevets, WC; Fedgchin, M; Lim, P; Manji, H; Shelton, RC; Singh, JB; Thase, ME; Van Nueten, L; Winokur, A, 2018) |
| "The symptoms of major depressive disorder (MDD) are rapidly alleviated by administration of a single dose of the glutamatergic modulator ketamine." | 2.87 | Default Mode Connectivity in Major Depressive Disorder Measured Up to 10 Days After Ketamine Administration. ( Brutsché, N; Evans, JW; Nugent, AC; Park, LT; Szczepanik, J; Zarate, CA, 2018) |
| " The most common adverse events among participants in the esketamine group were nausea, dizziness, dissociation, unpleasant taste, and headache." | 2.87 | Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. ( Alphs, L; Canuso, CM; Drevets, WC; Fedgchin, M; Hough, D; Lane, R; Lim, P; Manji, H; Pinter, C; Sanacora, G; Singh, JB, 2018) |
| "Both major depressive disorder and healthy subjects showed ketamine-mediated NMDA-blockade sensitization, with major depressive disorder subjects showing enhanced NMDA connectivity estimates in backward connections and controls showing enhanced NMDA connectivity estimates in forward connections in our model." | 2.87 | Glutamatergic Signaling Drives Ketamine-Mediated Response in Depression: Evidence from Dynamic Causal Modeling. ( Gilbert, JR; Nugent, AC; Wills, KE; Yarrington, JS; Zarate, CA, 2018) |
| "Ketamine treatment resulted in a general increase in circulating sphingomyelins, levels which were not correlated with response." | 2.87 | Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects. ( Ferrucci, L; Gould, TD; Kadriu, B; Khadeer, M; Lovett, J; Moaddel, R; Morris, PJ; Ravichandran, S; Shardell, M; Thomas, CJ; Yuan, P; Zarate, CA, 2018) |
| "Ketamine has proven to have rapid, robust antidepressant effects on treatment-resistant depression." | 2.87 | Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression. ( Chen, L; Li, H; Li, M; Liu, W; Ning, Y; Wang, C; Zhan, Y; Zheng, W; Zhou, Y, 2018) |
| "Ketamine has been documented for its rapid antidepressant effects." | 2.87 | Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression: An Open 4-Week Longitudinal Study. ( Aubry, JM; Bancila, V; Dayer, A; Gex-Fabry, M; Jermann, F; Khan, N; Kosel, M; Michalopoulos, G; Schwartz, S; Sterpenich, V; Vidal, S; Vutskits, L; Warrot, D, 2018) |
| "Ketamine has shown rapid though short-lived antidepressant effects." | 2.84 | Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression. ( Fasula, MK; Fenton, L; Griepp, M; Ostroff, RB; Sanacora, G; Wilkinson, ST; Wright, D, 2017) |
| "Current first-line treatments for major depressive disorder (MDD), i." | 2.82 | Rapid treatments for depression: Endocannabinoid system as a therapeutic target. ( Ahmadalipour, A; Fakhari, A; Khajehnasiri, N; Pakkhesal, S; Sharafi, A, 2022) |
| "After pooling data from seven randomized controlled trials, treatment with adjunctive IN esketamine vs IN placebo was safe overall, and more effective at decreasing depressive symptoms (d = -0." | 2.82 | The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: a systematic review and meta-analysis. ( Alnafeesi, Y; Ceban, F; Di Vincenzo, JD; Gillissie, ES; Jaberi, S; Jawad, MY; Lui, LMW; McIntyre, RS; Rosenblat, JD, 2022) |
| "Esketamine was approved for adults with treatment-resistant depression (TRD) in conjunction with an oral antidepressant, and for treating depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior." | 2.82 | Craving and addictive potential of esketamine as side effects? ( Orsolini, L; Salvi, V; Volpe, U, 2022) |
| "Intravenous, subcutaneous, and possibly oral esketamine may offer an effective and safe addition to the depression treatment armamentarium." | 2.82 | The antidepressant effect and safety of non-intranasal esketamine: A systematic review. ( Aan Het Rot, M; Kamphuis, J; Schoevers, RA; Smith-Apeldoorn, SY; Veraart, JK; Vischjager, M, 2022) |
| "Ketamine is a fast-acting anesthetic with hypnotic properties." | 2.82 | Ketamine for resistant depression: a scoping review. ( Andrés, VC; Angel, RO; Angela, A; David, C; Eduardo, TQ; Estefania, C; Juan, G; Juan, P; Mateo, L; Melanie, LZ; Natalia, RS; Valentina, PF, 2022) |
| "Pharmacotherapy of depression is characterized by the delayed onset of action, chronic treatment requirements, and insufficient effectiveness." | 2.82 | New investigational agents for the treatment of major depressive disorder. ( Krupa, AJ; Pochwat, B; Siwek, M; Szewczyk, B, 2022) |
| "The therapy of depression is prevalently based on monoamine reuptake blockers; consequently, investigations aimed to clarify the aetiology of depression have mostly looked at brain areas innervated by monamines and brain circuitry involved in inputs and outputs of these areas." | 2.82 | BDNF Alterations in Brain Areas and the Neurocircuitry Involved in the Antidepressant Effects of Ketamine in Animal Models, Suggest the Existence of a Primary Circuit of Depression. ( Carboni, E; Carta, AR, 2022) |
| " Safety outcomes included serious adverse events (eg, suicide attempts and deaths) and other adverse events." | 2.82 | Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode: A Systematic Review and Meta-analysis. ( Forester, BP; Krystal, JH; McIntyre, RS; Nierenberg, AA; Papakostas, GI; Rhee, TG; Sanacora, G; Shim, SR; Wilkinson, ST, 2022) |
| "Ketamine is a novel rapid-acting antidepressant with neuroplastic potential." | 2.82 | The Downstaging Concept in Treatment-Resistant Depression: Spotlight on Ketamine. ( Cubała, WJ; Wilkowska, A, 2022) |
| "We gave 16 medication-free, major depressive disorder (MDD) patients a single, sub-anesthetic dose infusion of ketamine (0." | 2.80 | Hippocampal volume and the rapid antidepressant effect of ketamine. ( Abdallah, CG; Baldwin, P; Jackowski, A; Mathew, SJ; Salas, R; Sato, JR, 2015) |
| "Anhedonia is a cardinal symptom of major depression and is often refractory to standard treatment, yet no approved medication for this specific symptom exists." | 2.80 | Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. ( Lally, N; Luckenbaugh, DA; Niciu, MJ; Nugent, AC; Roiser, JP; Zarate, CA, 2015) |
| "Sevoflurane was initiated in both groups at 8% for anesthesia induction until loss of consciousness was achieved, at which point it was discontinued." | 2.80 | Effect of the Addition of Ketamine to Sevoflurane Anesthesia on Seizure Duration in Electroconvulsive Therapy. ( Çolak, C; Cumurcu, B; Durmus, M; Erdil, F; Ozgul, U, 2015) |
| "The ketamine ECT study is a multi-site randomised, placebo-controlled, double blind trial." | 2.80 | Study protocol for the randomised controlled trial: Ketamine augmentation of ECT to improve outcomes in depression (Ketamine-ECT study). ( Anderson, IM; Blamire, A; Branton, T; Clark, R; Downey, D; Dunn, G; Easton, A; Elliott, R; Ellwell, C; Hayden, K; Holland, F; Karim, S; Loo, C; Lowe, J; McAllister-Williams, RH; Nair, R; Oakley, T; Prakash, A; Sharma, PK; Trevithick, L; Williams, SR, 2015) |
| "Twenty-six inpatients with treatment-resistant major depressive disorder (MDD) (DSM-IV criteria) received a single infusion of ketamine (0." | 2.79 | Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. ( Brutsche, NE; Ionescu, DF; Luckenbaugh, DA; Niciu, MJ; Richards, EM; Slonena, EE; Vande Voort, JL; Zarate, CA, 2014) |
| "Ketamine was superior to placebo in all visits (day 1, 4, and 7) assessed by MADRS with effect size (Cohen´s d) of 0." | 2.78 | Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression. ( Horacek, J; Klirova, M; Kohutova, B; Novak, T; Palenicek, T; Sos, P, 2013) |
| "Twenty drug-free major depressive disorder patients received a single, open-label intravenous infusion of ketamine hydrochloride (." | 2.77 | Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. ( Brutsche, NE; Cornwell, BR; Furey, M; Grillon, C; Marquardt, CA; Salvadore, G; Zarate, CA, 2012) |
| " Psychotomimetic effects and adverse events were recorded repeatedly." | 2.75 | Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. ( aan het Rot, M; Charney, DS; Collins, KA; Mathew, SJ; Murrough, JW; Perez, AM; Reich, DL, 2010) |
| "Subjects with a family history of alcohol dependence showed significantly greater improvement in MADRS scores compared with subjects who had no family history of alcohol dependence." | 2.74 | Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. ( Brutsche, N; Luckenbaugh, DA; Manji, HK; Moral, JR; Phelps, LE; Zarate, CA, 2009) |
| "Esketamine (ESK) has been approved as a rapid-acting intranasal treatment for treatment-resistant depression (TRD)." | 2.72 | Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review. ( Buoli, M; Caldiroli, A; Capellazzi, M; Capuzzi, E; Clerici, M; Colmegna, F; Dakanalis, A; Marcatili, M; Tagliabue, I, 2021) |
| " Further research is warranted into: optimal dosing strategy, including number and frequency; and long-term efficacy and safety." | 2.72 | The rapid anti-suicidal ideation effect of ketamine: A systematic review. ( Grunebaum, MF; Hochschild, A; Mann, JJ, 2021) |
| "Psychotic depression is a subtype of major depressive disorder characterized by mood congruent hallucinations and/or delusions." | 2.72 | Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effects. ( Cao, B; Cha, DS; Di Vincenzo, JD; Gill, H; Ho, RC; Le, TT; Lee, Y; Lin, K; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2021) |
| "Patients with major depressive disorder often have limited response to first-line and second-line medications; hence, novel pharmacological treatments are needed for treatment-resistant depression (TRD)." | 2.72 | The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et ( Beaulieu, S; Blier, J; Blier, P; Brietzke, E; Frey, BN; Kennedy, SH; Lam, RW; McGirr, A; McIntyre, RS; Milev, RV; Parikh, SV; Ravindran, AV; Ravindran, N; Richard-Devantoy, S; Schaffer, A; Swainson, J; Taylor, VH; Tourjman, V; van Ameringen, M; Yatham, LN, 2021) |
| "Ketamine is a potential rapid-acting treatment for depression." | 2.72 | The time course of psychotic symptom side effects of ketamine in the treatment of depressive disorders: a systematic review and meta-analysis. ( Dragovic, M; Ford, A; Gabriel, L; Tashakkori, M; Waters, F, 2021) |
| "Major depression is a frequent and disabling disorder." | 2.72 | [A review of the antidepressant properties of ketamine]. ( Blier, P; Desfossés, CY, 2021) |
| "Ketamine is a demonstrated treatment for major depressive episodes, as relief from depressive symptoms can occur rapidly following treatment." | 2.72 | Efficacy of ketamine for major depressive episodes at 2, 4, and 6-weeks post-treatment: A meta-analysis. ( Barber, KE; Conley, AA; Griffith, JD; Hatvany, TC; Norwood, AEQ, 2021) |
| "Ketamine is a N-methyl-D-Aspartate receptor antagonist, historically used in anesthesia, but also affects other neurotransmitters systems, synaptic plasticity, neurogenesis, and neural connectivity." | 2.72 | Therapeutic potential of ketamine for alcohol use disorder. ( Gould, TJ; Worrell, SD, 2021) |
| "Ketamine is a novel rapid-acting antidepressant with high efficacy in treatment-resistant patients." | 2.72 | Ketamine's effect on inflammation and kynurenine pathway in depression: A systematic review. ( Kopra, E; Mondelli, V; Nikkheslat, N; Pariante, C, 2021) |
| "Most trials of adding lithium involved older, mainly tricyclic, antidepressants, and the dosing of adjunctive treatments were not optimized." | 2.72 | Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium. ( Bahji, A; Baldessarini, RJ; Tondo, L; Undurraga, J; Vázquez, GH, 2021) |
| " The literature shows that treatment with ketamine is efficacious and safe, and the majority of adverse drug reactions are mild and tend to mostly disappear within 30 min to 2 h of ketamine administration." | 2.66 | Safety and Tolerability of Ketamine Use in Treatment-Resistant Bipolar Depression Patients with Regard to Central Nervous System Symptomatology: Literature Review and Analysis. ( Cubała, WJ; Włodarczyk, A, 2020) |
| " We excluded studies with bipolar depression or with repeated dosing and no single-dose phase." | 2.66 | The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review. ( Kosten, TR; Mathai, DS; Meyer, MJ; Storch, EA, 2020) |
| "20 (depending on the dosing regimen used); p ≤ 0." | 2.66 | Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials. ( Brzostek, T; Kawalec, P; Kryst, J; Lasoń, W; Mitoraj, AM; Pilc, A, 2020) |
| "Esketamine was recently licensed by the US Food and Drug Administration (FDA) and European Drug Agency (EDA) for use in treatment resistant depression (TRD), and further research indicates ketamine as a possible treatment in other mental health conditions." | 2.66 | Ketamine as a mental health treatment: Are acute psychoactive effects associated with outcomes? A systematic review. ( Borissova, A; Curran, HV; Grabski, M; Marsh, B; Morgan, CJA, 2020) |
| "Despite the growing burden of major depressive disorder (MDD) on the society, therapeutic management that is mostly based on the conventional monoaminergic mechanisms, is significantly delimited especially from low response rate and time lag for treatment response; thus, often prolonging the distress for patients." | 2.66 | Rapid acting antidepressants in the mTOR pathway: Current evidence. ( Chakravarty, S; K V, A; Mohan, AS, 2020) |
| "Ketamine is an effective treatment option for patients with MDD with undesirable effects when administered via oral, IV and IN routes." | 2.66 | Effectiveness and Safety of Ketamine for Unipolar Depression: a Systematic Review. ( Abbas, N; Chaudhary, AMD; Faquih, AE; Fida, A; Memon, RI; Naveed, S; Qayyum, Z, 2020) |
| "Major depressive disorder is one of the most important psychiatric issues worldwide, with important prevalence of treatment-resistant depression (TRD)." | 2.61 | Role of copper and ketamine in major depressive disorder - an update. ( Cubała, WJ; Gałuszko-Węgielnik, M; Górska, N; Jakuszkowiak-Wojten, K; Szarmach, J; Szałach, ŁP; Słupska, A; Słupski, J; Wiglusz, MS; Wilkowska, A; Włodarczyk, A, 2019) |
| "Ketamine alone was not more efficacious in treating depressive symptoms than other anesthetic drugs at early study, post-ECT and end of study time points." | 2.61 | Adjunctive ketamine and electroconvulsive therapy for major depressive disorder: A meta-analysis of randomized controlled trials. ( Cai, DB; He, SH; Hu, YD; Li, XH; Ng, CH; Ning, YP; Ungvari, GS; Wang, G; Xiang, YT; Yang, XH; Zheng, W; Zhu, XM, 2019) |
| "Ketamine is a racemic mixture comprising equal parts of (R)-ketamine (or arketamine) and (S)-ketamine (or esketamine)." | 2.61 | Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective. ( Hashimoto, K, 2019) |
| "Major depressive disorder is a frequent and devastating psychological condition with tremendous public health impact." | 2.58 | General Anesthetics to Treat Major Depressive Disorder: Clinical Relevance and Underlying Mechanisms. ( Vutskits, L, 2018) |
| "Ketamine treatment showed acute effectiveness in another 7 cases, especially in terms of reduction of suicidal ideation, albeit without significant long-term antidepressant effect." | 2.58 | Is Ketamine the Future Clozapine for Depression? A Case Series and Literature Review on Maintenance Ketamine in Treatment-resistant Depression With Suicidal Behavior. ( Chan, LF; Chong, BTW; Eu, CL; Kahn, DA; Loo, JL; Loo, TH; Maniam, T; Ng, YP; Shahidii Kadir, Z; Sharip, S; Soh, SY; Wong, VCW, 2018) |
| "Major depressive disorder is a severe and complex mental disorder." | 2.55 | New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity. ( Huang, YJ; Lane, HY; Lin, CH, 2017) |
| " When so extended, the ideal frequency is perhaps best individualized wherein ketamine is dosed a little before the effect of the previous session is expected to wear off." | 2.55 | Ketamine for Depression, 4: In What Dose, at What Rate, by What Route, for How Long, and at What Frequency? ( Andrade, C, 2017) |
| " This article explores potential pharmacokinetic and pharmacodynamic drug interactions of relevance to the use of ketamine in depression." | 2.55 | Ketamine for Depression, 5: Potential Pharmacokinetic and Pharmacodynamic Drug Interactions. ( Andrade, C, 2017) |
| " Results Potential avenues investigated to minimise psychotomimetic effects associated with ketamine administration include the following: (1) altering dosing and infusion rates; (2) route of administration; (3) enantiomer choice; (4) co-administration with mood stabilisers of antipsychotics; and (5) use of alternative N-methyl-d-aspartate (NMDA)-modulating agents." | 2.55 | Strategies to mitigate dissociative and psychotomimetic effects of ketamine in the treatment of major depressive episodes: a narrative review. ( Cha, DS; Cooper, MD; Kakar, R; Lee, Y; McIntyre, RS; Rosenblat, JD, 2017) |
| "In patients with major depressive disorder or bipolar disorder, abnormalities in excitatory and/or inhibitory neurotransmission and neuronal plasticity may lead to aberrant functional connectivity patterns within large brain networks." | 2.55 | Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine. ( Ballard, ED; Lener, MS; Niciu, MJ; Nugent, AC; Park, LT; Park, M; Zarate, CA, 2017) |
| "Subjects were diagnosed with either major depressive disorder (MDD) or bipolar depression." | 2.55 | Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion. ( Luckenbaugh, DA; Niciu, MJ; Pennybaker, SJ; Zarate, CA, 2017) |
| " Fundamental questions remain regarding the future prospects of this line of drug development, including questions concerning safety and tolerability, efficacy, dose-response relationships and therapeutic mechanisms." | 2.55 | Targeting glutamate signalling in depression: progress and prospects. ( Abdallah, CG; Mathew, SJ; Murrough, JW, 2017) |
| "Major depression is a chronic and debilitating illness that effects approximately 1 in 5 people, but currently available treatments are limited by low rates of efficacy, therapeutic time lag, and undesirable side effects." | 2.53 | Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity. ( Duman, RS; Gerhard, DM; Wohleb, ES, 2016) |
| " Secondary outcomes included response, remission, all-cause discontinuation and adverse effects." | 2.53 | Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. ( Bauer, M; Chawla, JM; Correll, CU; Hagi, K; Kane, JM; Kishimoto, T; Zarate, CA, 2016) |
| "R-ketamine has greater antidepressant actions than S-ketamine, without ketamine-related side-effects." | 2.53 | Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant. ( Ding, Z; Hashimoto, K; Lu, L; Shi, J; Zhang, Y; Zhu, W, 2016) |
| "Ketamine was associated with higher rates of clinical remission relative to comparator (saline or midazolam) at 24 h [OR 7." | 2.52 | A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. ( Berlim, MT; Bond, DJ; Fleck, MP; Lam, RW; McGirr, A; Yatham, LN, 2015) |
| "Ketamine has demonstrated rapid antidepressant effects in patients with treatment-resistant depression (TRD); however, the safety and tolerability of ketamine in this population have not been fully described." | 2.52 | Ketamine safety and tolerability in clinical trials for treatment-resistant depression. ( Brallier, JW; Chang, LC; Charney, DS; Foulkes, A; Iosifescu, DV; Levitch, CF; Mathew, SJ; Murrough, JW; Perez, AM; Wan, LB, 2015) |
| "Ketamine's efficacy was confirmed in MDD (resistant to previous pharmacological treatments or not) (SMD = -0." | 2.50 | Ketamine administration in depressive disorders: a systematic review and meta-analysis. ( Abbar, M; Boyer, L; Brittner, M; Courtet, P; Fond, G; Lançon, C; Leboyer, M; Loundou, A; Macgregor, A; Micoulaud-Franchi, JA; Rabu, C; Richieri, R; Roger, M, 2014) |
| " After long-term use as a dissociative anesthetic, it has re-emerged as a useful agent for ameliorating pain, asthmaticus, and depression." | 2.50 | Ketamine-an update on its clinical uses and abuses. ( Lei, H; Xu, J, 2014) |
| "Major depressive disorder is an extremely debilitating condition affecting millions of people worldwide." | 2.49 | Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties. ( Cattaneo, A; Horowitz, MA; Lupi, MM; Pariante, CM; Zunszain, PA, 2013) |
| "Major depressive disorder is among the most prevalent forms of mental illness." | 2.49 | mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants. ( Ago, Y; Chaki, S; Matrisciano, F; Palucha-Paniewiera, A; Pilc, A, 2013) |
| "Ketamine for treatment-resistant MDD requires further evaluation before it can be considered a viable treatment option." | 2.48 | Intravenous ketamine for treatment-resistant major depressive disorder. ( Covvey, JR; Crawford, AN; Lowe, DK, 2012) |
| "Existing treatments for major depressive disorder (MDD) usually take weeks to months to achieve their antidepressant effects, and a significant number of patients do not have adequate improvement even after months of treatment." | 2.45 | Ketamine and the next generation of antidepressants with a rapid onset of action. ( Diazgranados, N; Machado-Vieira, R; Salvadore, G; Zarate, CA, 2009) |
| " In rats, compound 7k had better pharmacokinetic properties and oral bioavailability (F = 67." | 1.91 | 3,4-Dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide analogs act as potential AMPA receptor potentiators with antidepressant activity. ( Deng, W; Guo, W; Hu, X; Li, T; Luo, X; Ma, X; Ni, P; Qi, X; Wang, Q; Wei, L; Wei, Y; Yu, X; Zhao, L; Zheng, Y, 2023) |
| "Esketamine and ketamine have been shown to decrease inflammation in numerous ways principally through reducing pro-inflammatory cytokines (e." | 1.91 | The Glutamatergic System in Treatment-Resistant Depression and Comparative Effectiveness of Ketamine and Esketamine: Role of Inflammation? ( Cook, J; Halaris, A, 2023) |
| "Rapid onset and the ability to impact treatment-resistant depression, raises the question of the best first-line medicines for patients." | 1.91 | Clinical pharmacological innovation in the treatment of depression. ( Golani, LK; Smith, JL; Witkin, JM, 2023) |
| "Major depressive disorder is frequently characterized by disinhibition of rapid eye movement (REM) sleep and disruption of non-REM (NREM) sleep." | 1.91 | (S)-Ketamine but Not (R)-Ketamine Shows Acute Effects on Depression-Like Behavior and Sleep-Wake Architecture in Rats. ( Bagdy, G; Koncz, S; Papp, N; Pothorszki, D, 2023) |
| "Among the greatest unmet needs in major depressive disorder (MDD) is a lack of effective pharmacotherapies for patients who do not respond to first- and second-line antidepressant medications." | 1.91 | Have Effective Antidepressants Finally Arrived? Developments in Major Depressive Disorder Therapy. ( Thase, ME, 2023) |
| "Major Depressive Disorder is the leading cause of disability worldwide." | 1.91 | A HOPEFUL ALTERNATIVE “THERAPY WITH INTRA- NASAL ESKETAMINE IN A PATIENT WITH RESISTANT DEPRESSION”. A CASE REPORT. ( Galán-Armenteros, RM; González-González, C; Marco-Feced, MA; Moreno-Campos, AJ; Romero-Mohedano, MC, 2023) |
| "Ketamine was also efficacious in decreasing the level of inflammation with an evident reduction in microglial activation and pro-inflammatory cytokines in the studied regions, following CUMS exposure." | 1.72 | Ketamine abrogates sensorimotor deficits and cytokine dysregulation in a chronic unpredictable mild stress model of depression. ( Akinluyi, ET; Anyanwu, CC; Edem, EE; Enye, LA; Fafure, AA; Ishola, AO; Nebo, KE, 2022) |
| "Ketamine is a promising treatment option for patients with Major Depressive Disorder (MDD) and has become an important research tool to investigate antidepressant mechanisms of action." | 1.72 | Increase in thalamic cerebral blood flow is associated with antidepressant effects of ketamine in major depressive disorder. ( de Rover, M; Gärtner, M; Grimm, S; Scheidegger, M; Václavů, L; van Osch, MJP, 2022) |
| " The current study investigated 1) changes in neurocognitive performance after a repeated ketamine dosing regimen and 2) baseline neurocognitive performance as a predictor of ketamine treatment effect." | 1.72 | Neurocognitive effects of repeated ketamine infusions in comorbid posttraumatic stress disorder and major depressive disorder. ( Albott, CS; Erbes, C; Lim, KO; Shiroma, PR; Thuras, P; Tye, SJ; Wels, J, 2022) |
| "Multiple illicit substance users were more likely to use methamphetamine (p = 0." | 1.72 | Survey of substance use among adolescent drug offenders referred from juvenile courts in Taiwan: Clinical epidemiology of single versus multiple illicit substance use. ( Chen, LY; Chen, MH; Chen, YH; Wei, HT, 2022) |
| "Ketamine is a rapidly-acting antidepressant treatment with robust response rates." | 1.72 | Anterior default mode network and posterior insular connectivity is predictive of depressive symptom reduction following serial ketamine infusion. ( Congdon, E; Espinoza, RT; Hellemann, G; Joshi, SH; Kubicki, A; Loureiro, J; Narr, KL; Sahib, A; Wade, BSC; Woods, RP, 2022) |
| "Depression is a serious physical and mental disease, with major depressive disorder (MDD) being a hard-to-treat, life-threatening form of the condition." | 1.72 | Autophagy: A New Mechanism for Esketamine as a Depression Therapeutic. ( Gu, T; Jiang, G; Liu, Q; Liu, S; Wang, Y; Yin, A; Zhang, L, 2022) |
| "Ketamine is a potentially life-saving option." | 1.72 | The effect of IV ketamine in patients with major depressive disorder and elevated features of borderline personality disorder. ( Chen, KS; Dwivedi, Y; Shelton, RC, 2022) |
| "Esketamine was safe and well tolerated." | 1.72 | Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression. ( Abdo, GL; Barbosa, MG; de Oliveira Cerqueira, R; Del Porto, JA; Del Sant, LC; Delfino, RS; Fava, VAR; Grossi, JD; Lacerda, ALT; Lucchese, AC; Magalhães, E; Nakahira, C; Sarin, LM; Steglich, MS; Surjan, J; Tuena, MA, 2022) |
| "Ketamine has also been applied to establish animal models of mania." | 1.72 | Chronic lithium treatment ameliorates ketamine-induced mania-like behavior via the PI3K-AKT signaling pathway. ( Gao, TH; Li, T; Ma, XH; Ni, PY; Ni, RJ; Tian, Y; Wang, YY; Wei, JX; Zhao, LS, 2022) |
| "Ketamine-treated CRS rats showed a significant improvement in habenular nuclear neuroplasticity." | 1.72 | Ketamine May Exert Rapid Antidepressant Effects Through Modulation of Neuroplasticity, Autophagy, and Ferroptosis in the Habenular Nucleus. ( Chen, S; Hong, W; Huang, H; Lyu, D; Shi, S; Wang, F; Wang, M; Wei, Z; Xu, Y; Yang, W; Zhang, M, 2022) |
| "Ketamine has been shown to provide rapid and significant efficacy in treating patients with TRD." | 1.62 | Ketamine monotherapy versus adjunctive ketamine in adults with treatment-resistant depression: Results from the Canadian Rapid Treatment Centre of Excellence. ( Di Vincenzo, JD; Gill, H; Kratiuk, K; Lee, Y; Lipsitz, O; Mansur, R; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M, 2021) |
| "Patients with major depressive disorder (MDD) exhibit impaired control of cognitive and emotional systems, including deficient response selection and inhibition." | 1.62 | Ketamine's modulation of cerebro-cerebellar circuitry during response inhibition in major depression. ( Congdon, E; Espinoza, R; Hellemann, G; Joshi, S; Kubicki, A; Leaver, A; Loureiro, JRA; Narr, KL; Sahib, AK; Vasavada, M; Wade, B; Woods, RP, 2021) |
| "Ketamine has rapid and robust antidepressant effects in depression, while its effects on cognitive measures are less clearly understood." | 1.62 | The potential pro-cognitive effects with intravenous subanesthetic ketamine in adults with treatment-resistant major depressive or bipolar disorders and suicidality. ( Chao, Z; Lan, X; Li, H; McIntyre, RS; Ning, Y; Wang, C; Wu, K; Zheng, W; Zhou, Y, 2021) |
| "Ketamine is a highly effective antidepressant for patients with treatment-resistant major depressive disorder (MDD)." | 1.62 | Effects of Serial Ketamine Infusions on Corticolimbic Functional Connectivity in Major Depression. ( Congdon, E; Espinoza, RT; Hellemann, G; Kubicki, A; Leaver, AM; Loureiro, J; Narr, KL; Sahib, A; Vasavada, MM; Wade, B, 2021) |
| "Ketamine has demonstrated rapid and robust efficacy in adults with TRD." | 1.62 | Intravenous ketamine for postmenopausal women with treatment-resistant depression: Results from the Canadian Rapid Treatment Center of Excellence. ( Cha, DS; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Mansur, RB; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M, 2021) |
| "Esketamine nasal spray is a novel, fast-acting agent that provides an additional treatment option for patients with TRD who have previously failed several therapies." | 1.62 | Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance. ( Cubała, WJ; Fagiolini, A; Kasper, S; Ramos-Quiroga, JA; Souery, D; Young, AH, 2021) |
| "Ketamine was associated with transient treatment-emergent hypertension." | 1.62 | Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case Series. ( Cao, B; Cha, DS; Di Vincenzo, JD; Flint, AJ; Greenberg, D; Ho, RC; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2021) |
| "Ketamine has been safely used as an anesthetic for over 50 years." | 1.62 | Compounded intranasal racemic ketamine for major depressive disorder: A case report. ( Halpape, K; Peters, E; Wanson, A; Ziegler, L, 2021) |
| "Psychiatric (n = 29; 15 PTSD, 14 MDD) and sex- age- and IQ matched HC (n = 29) groups were recruited from the community." | 1.62 | Acute cognitive effects of single-dose intravenous ketamine in major depressive and posttraumatic stress disorder. ( Davis, MT; DellaGiogia, N; Esterlis, I; Maruff, P; Pietrzak, RH, 2021) |
| "Major depressive disorder is prevalent in children and adolescents and is associated with a high degree of morbidity throughout life, with potentially devastating personal consequences and public health impact." | 1.62 | The Resilient Phenotype Induced by Prophylactic Ketamine Exposure During Adolescence Is Mediated by the Ventral Tegmental Area-Nucleus Accumbens Pathway. ( Bolaños-Guzmán, CA; Cardona-Acosta, AM; Chaudhury, D; Gyles, TM; Han, MH; Juarez, B; Nestler, EJ; Parise, EM; Parise, LF; Sial, OK, 2021) |
| "Major depressive disorder is a common, recurrent illness." | 1.62 | Fluoroethylnormemantine, a Novel NMDA Receptor Antagonist, for the Prevention and Treatment of Stress-Induced Maladaptive Behavior. ( Chen, BK; Denny, CA; Hunsberger, HC; Luna, VM; Mastrodonato, A; McGowan, JC; Rubinstenn, G; Shannon, ME; Stackmann, M, 2021) |
| " The dose-response relationship calls for caution with higher doses of tranylcypromine." | 1.62 | Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study. ( Bauer, M; Findeis, H; Ludwig, VM; Ritter, P; Rucker, J; Sauer, C; Young, AH, 2021) |
| "The safety psychometrics assessed dissociation and psychomimetic symptomatology with the Clinician-Administered Dissociative States Scale (CADSS) the Brief Psychiatric Rating Scale (BPRS)." | 1.62 | Dissociative symptoms with intravenous ketamine in treatment-resistant depression exploratory observational study. ( Cubała, WJ; Gałuszko-Węgielnik, M; Szarmach, J; Włodarczyk, A, 2021) |
| "Ketamine has demonstrated a fast and robust antidepressant effect in subanesthetic doses." | 1.56 | Ketamine as augmentation for the treatment of major depression and suicidal risk in advanced cancer: Case report. ( Allende-Pérez, S; Domínguez-Ocadio, G; Pérez-Esparza, R; Rodríguez-Mayoral, O, 2020) |
| " A numerical dose-response relationship was observed, with remitters/responders on ketamine 1." | 1.56 | Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. ( Cusin, C; Debattista, C; Fava, M; Flynn, M; Freeman, MP; Hock, RS; Hoeppner, B; Ionescu, DF; Iosifescu, DV; Mathew, SJ; Papakostas, GI; Salloum, NC; Sanacora, G; Trivedi, MH, 2020) |
| "About 16% of the world's population has major depressive disorder." | 1.56 | Low-Dose Ketamine Improves LPS-Induced Depression-like Behavior in Rats by Activating Cholinergic Anti-inflammatory Pathways. ( Chang, D; Du, X; Gao, L; Lian, H; Liu, X; Zhang, X; Zhao, J, 2020) |
| "S-ketamine has been proposed as a rapid acting antidepressant and, indeed, the FDA recently approved it for treatment of resistant MDD." | 1.56 | S-ketamine induces acute changes in the proteome of the mouse amygdala. ( Al Shweiki, MR; Barschke, P; Dorner-Ciossek, C; Hengerer, B; Oeckl, P; Otto, M; Pryce, C; Schönfeldt-Lecuona, C; Steinacker, P, 2020) |
| "Ketamine has been demonstrated to have robust and rapid antidepressant effects, and few studies have focused on the relationship between insomnia and the efficacy of ketamine." | 1.56 | Baseline insomnia as a predictor of antidepressant efficacy to repeated intravenous ketamine for unipolar and bipolar depression: A preliminary study. ( Chen, L; Lan, X; Li, H; Li, M; Liu, W; Ning, Y; Wang, C; Zhan, Y; Zhang, B; Zheng, W; Zhou, Y, 2020) |
| "The treatment of major depressive disorder (MDD) is still a challenge." | 1.56 | Guanosine fast onset antidepressant-like effects in the olfactory bulbectomy mice model. ( de Almeida, RF; Elisabetsky, E; Pocharski, CB; Rodrigues, ALS; Souza, DO, 2020) |
| "Ketamine was well-tolerated, with less than 5% of patients withdrawing due to tolerability concerns." | 1.56 | Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence. ( Cha, DS; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M, 2020) |
| "Ketamine has rapid-acting antidepressant properties but also potentially concerning transient dissociative side effects (SEs)." | 1.56 | Can 'floating' predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression. ( Acevedo-Diaz, EE; Cavanaugh, GW; Greenstein, D; Kadriu, B; Kraus, C; Park, L; Zarate, CA, 2020) |
| "Forty-four patients with major depressive disorder received six intravenous ketamine (0." | 1.56 | Relationship between hippocampal volume and inflammatory markers following six infusions of ketamine in major depressive disorder. ( Deng, XR; Lan, XF; Ning, YP; Wang, CY; Wu, FC; Zheng, W; Zhou, YL, 2020) |
| "Major depression is one of the most frequent psychiatric conditions." | 1.51 | The immunomodulatory effect of ketamine in depression. ( Cubała, WJ; Gałuszko-Węgielnik, M; Górska, N; Jakuszkowiak-Wojten, K; Lisowska, KA; Szarmach, J; Szałach, ŁP; Słupski, J; Wiglusz, MS; Wilkowska, A; Włodarczyk, A, 2019) |
| "Ketamine treatment elevates extracellular glutamate in the prefrontal cortex." | 1.51 | Ketamine-Induced Glutamatergic Mechanisms of Sleep and Wakefulness: Insights for Developing Novel Treatments for Disturbed Sleep and Mood. ( Ballard, ED; Duncan, WC; Zarate, CA, 2019) |
| "Major depressive disorder is a common and debilitating condition with substantial economic impact." | 1.51 | The novel antidepressant ketamine enhances dentate gyrus proliferation with no effects on synaptic plasticity or hippocampal function in depressive-like rats. ( Andersson, M; Bergström, N; Culley, G; Ehn, J; Engström, A; Hanse, E; Karlsson, L; Kuhn, HG; Michaëlsson, H; Savvidi, P; Seth, H; Svensson, J, 2019) |
| "Patients with major depressive disorder (MDD) often have structural and functional deficits in the ventromedial prefrontal cortex (vmPFC), but the underlying molecular pathways are incompletely understood." | 1.51 | VGF and its C-terminal peptide TLQP-62 in ventromedial prefrontal cortex regulate depression-related behaviors and the response to ketamine. ( Jiang, C; Labonté, B; Lin, WJ; Nestler, EJ; Russo, SJ; Salton, SR; Tamminga, CA; Turecki, G, 2019) |
| "Ketamine is an antidepressant with rapid therapeutic onset and long-lasting effect, although the underlying mechanism(s) remain unknown." | 1.51 | Astrocyte Specific Remodeling of Plasmalemmal Cholesterol Composition by Ketamine Indicates a New Mechanism of Antidepressant Action. ( Anderluh, G; Božić, M; Horvat, A; Jorgačevski, J; Lasič, E; Lisjak, M; Šakanović, A; Stenovec, M; Vardjan, N; Verkhratsky, A; Zorec, R, 2019) |
| "An effective rapid-onset treatment for major depressive disorder could save lives." | 1.48 | The rapid-onset antidepressant effect of ketamine: More surprises? ( Pergolizzi, JV; Raffa, RB; Taylor, R, 2018) |
| "Treatment with ketamine, minocycline and amitriptyline were able to exert antidepressant effects in the forced swimming test." | 1.48 | Acute treatment with ketamine and chronic treatment with minocycline exert antidepressant-like effects and antioxidant properties in rats subjected different stressful events. ( Abelaira, HM; de Moura, AB; de Souza, TG; Fileti, ME; Garbossa, L; Goldim, MP; Maciel, AL; Mathias, K; Matos, D; Petronilho, F; Quevedo, J; Réus, GZ; Rosa, T; Strassi, AP; Tuon, T, 2018) |
| " Further research and large clinical trials are needed on the optimum KIT protocol, including dose, dosing interval, total number of treatments and when to stop." | 1.48 | Intravenous ketamine infusion for a patient with treatment-resistant major depression: a 10-month follow-up. ( Hong, JP; Kwon, JH; Lee, JY; Sim, WS; Song, IS, 2018) |
| "Inpatients with major depressive disorder (n = 76) or bipolar depression (n = 43) were participating in clinical ketamine trials." | 1.48 | Parsing the heterogeneity of depression: An exploratory factor analysis across commonly used depression rating scales. ( Ballard, ED; Farmer, CA; Kadriu, B; Lally, N; Lener, MS; Machado-Vieira, R; Niciu, MJ; Park, L; Williams, D; Yarrington, JS; Zarate, CA, 2018) |
| "Current alternatives for the treatment of major depressive disorder lack efficacy and have a delayed onset of action." | 1.48 | Ketamine for Treatment-Resistant Depression: a New Advocate. ( Pérez-Esparza, R, 2018) |
| "Six ketamine infusions were safe and effective in patients with unipolar and bipolar depression." | 1.48 | Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression. ( Chen, LJ; Li, HQ; Li, MD; Liu, WJ; Ning, YP; Wang, CY; Zhan, YN; Zheng, W; Zhou, YL, 2018) |
| "The ketamine-treated sample included 157 unrelated European subjects with major depressive disorder (MDD) or bipolar disorder (BD)." | 1.48 | Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. ( Akula, N; Charney, DS; Drevets, W; Furey, M; Grunebaum, M; Guo, W; Henter, I; Kadriu, B; Machado-Vieira, R; Mann, JJ; Mathew, S; McMahon, FJ; Merikangas, K; Murrough, JW; Oquendo, MA; Shugart, YY; Yuan, P; Zarate, CA, 2018) |
| " Etomidate, mean dosage (SD) = 0." | 1.46 | S -ketamine compared to etomidate during electroconvulsive therapy in major depression. ( Ahrens, K; Dannlowski, U; Dietsche, P; Kircher, T; Kluge, I; Köhnlein, B; Konrad, C; Wohltmann, T; Zavorotnyy, M, 2017) |
| "Ketamine infusions were well tolerated with occasional nausea or anxiety and mild hemodynamic effects during the infusion." | 1.46 | Low-dose ketamine for treatment resistant depression in an academic clinical practice setting. ( Boggie, D; Feifel, D; Lee, K; Malcolm, B, 2017) |
| "Major depression is one of the most common affective disorders caused by schizophrenia." | 1.46 | Agonist E-6837 and antagonist SB-271046 of 5-HT6 receptors both reverse the depressive-like effect induced in mice by subchronic ketamine administration. ( Briones-Aranda, A; Espinosa-Raya, J; Picazo, O; Suárez-Santiago, JE, 2017) |
| "Major depressive disorder is increasingly recognized to involve functional deficits in both gamma-aminobutyric acid (GABA)ergic and glutamatergic synaptic transmission." | 1.43 | Bidirectional Homeostatic Regulation of a Depression-Related Brain State by Gamma-Aminobutyric Acidergic Deficits and Ketamine Treatment. ( Fuchs, T; Jefferson, SJ; Luscher, B; Pribiag, H; Ren, Z; Shorey, M; Stellwagen, D, 2016) |
| " Important questions are as follows: is it specific or coincidental to other effects; is there a dose-response relationship; and is the mechanism related to that of current antidepressants." | 1.42 | Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression. ( Drewniany, E; Han, J; Hancock, C; Jones, RL; Lim, J; Nemat Gorgani, N; Raffa, RB; Sperry, JK; Yu, HJ, 2015) |
| " Side effects and risk of abuse limit the chronic use of ketamine." | 1.42 | Ketamine modulates TRH and TRH-like peptide turnover in brain and peripheral tissues of male rats. ( Lloyd, RL; Pekary, AE; Sattin, A, 2015) |
| "Current treatments for major depressive disorder (MDD) have a time lag and are ineffective for a large number of patients." | 1.42 | Ribosomal protein S6 kinase 1 signaling in prefrontal cortex controls depressive behavior. ( DiLeone, RJ; Duman, RS; Dwyer, JM; Lepack, AE; Maldonado-Avilés, JG, 2015) |
| "Ketamine is an anesthetic with antidepressant properties." | 1.42 | The positive effect on ketamine as a priming adjuvant in antidepressant treatment. ( Dalla, C; Ferreira, C; Kokras, N; Melo, A; Pêgo, JM; Sousa, N; Ventura-Silva, AP, 2015) |
| "Medication-free patients (n=19) with treatment-resistant major depressive disorder underwent positron emission tomography imaging at baseline and 230 minutes after an open-label ketamine infusion (0." | 1.40 | Neural correlates of suicidal ideation and its reduction in depression. ( Ballard, ED; Furey, ML; Lally, N; Luckenbaugh, DA; Nugent, AC; Zarate, CA, 2014) |
| "Ketamine (Ketalar®) is an anesthetic agent derived from the hallucinogenic drug phencyclidine (PCP)." | 1.39 | Ketamine for the treatment of depression. ( Howland, RH, 2013) |
| "Ketamine is a non-competitive N-methyl-D-aspartate receptor antagonist that is Food and Drug Administration-approved in the United States for anesthesia due to its sedative effects with low risk of severe respiratory depression." | 1.39 | Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder. ( Bloch, MH; Corlett, PR; Grunschel, BD; Niciu, MJ; Pittenger, C, 2013) |
| "Ketamine has been used in anesthesia for many years and in various environments with an acceptable safety margin." | 1.39 | Effects of ketamine on major depressive disorder in a patient with posttraumatic stress disorder. ( Womble, AL, 2013) |
| "Ketamine is a N-methyl-D-aspartic acid (NMDA) antagonist that has been associated with temporary clinical improvement in patients with depression." | 1.38 | Lack of effect of ketamine on cortical glutamate and glutamine in healthy volunteers: a proton magnetic resonance spectroscopy study. ( Cowen, PJ; Mhuircheartaigh, RN; Taylor, MJ; Tiangga, ER, 2012) |
| "Pain was also improved, although for a shorter duration." | 1.38 | Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. ( Glue, P; Perez, D; Zanicotti, CG, 2012) |
| "Ketamine has rapid antidepressant effects lasting as long as 1 week in patients with major depressive disorder (MDD) and bipolar depression (BD)." | 1.38 | Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. ( Brutsche, N; Laje, G; Luckenbaugh, DA; Moaddel, R; Ramamoorthy, A; Venkata, SL; Wainer, IW; Zarate, CA, 2012) |
| "Ten subjects with major depressive disorder (MDD) received saline, then ketamine in a fixed order, one week apart, under single-blind conditions." | 1.37 | The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. ( Fasula, M; Gomez, R; Krystal, JH; Mason, GF; Pittman, B; Sanacora, G; Valentine, GW; Watzl, J, 2011) |
| " We analysed the number of sessions until completion of ECT treatment (used as a surrogate parameter for outcome), psychopathology as assessed by pre- and post-ECT Mini-Mental State Examination (MMSE) and Hamilton Rating Scale for Depression (HAM-D) scores as well as ECT and seizure parameters (stimulation dose, seizure duration and concordance, urapidil dosage for post-seizure blood pressure management)." | 1.37 | Clinically favourable effects of ketamine as an anaesthetic for electroconvulsive therapy: a retrospective study. ( Hoyer, C; Kammerer-Ciernioch, J; Kranaster, L; Sartorius, A, 2011) |
| "Most patients with major depressive disorder (MDD) experience a period of lengthy trial and error when trying to find optimal antidepressant treatment; identifying biomarkers that could predict response to antidepressant treatment would be of enormous benefit." | 1.35 | Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. ( Colon-Rosario, V; Coppola, R; Cornwell, BR; Grillon, C; Manji, HK; Salvadore, G; Zarate, CA, 2009) |
| " We conclude that a well-designed, randomized study of IV ketamine "bursts" in cancer patients suffering from depression is needed to further establish the role and appropriate dosing of ketamine in this patient population." | 1.35 | Intravenous ketamine "burst" for refractory depression in a patient with advanced cancer. ( Demas, M; Oneschuk, D; Stefanczyk-Sapieha, L, 2008) |
| "Ketamine is a racemic mixture consisting of two enantiomers, R- and S-ketamine." | 1.35 | Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases. ( Frodl, T; Möller, HJ; Padberg, F; Paul, R; Schaaff, N, 2009) |
| "Major depressive disorder is a difficult-to-treat and recurrent debilitating disorder." | 1.34 | Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy. ( Goforth, HW; Holsinger, T, 2007) |
| "Ketamine was well tolerated and prolonged seizure duration overall, but particularly in those who had a seizure duration shorter than 25 seconds with methohexital at the maximum available stimulus intensity." | 1.32 | Comparison of seizure duration, ictal EEG, and cognitive effects of ketamine and methohexital anesthesia with ECT. ( Coffey, CE; Dean, MD; Falcone, G; Krystal, AD; Lindahl, VH; Tramontozzi, LA; Weiner, RD, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (2.71) | 29.6817 |
| 2010's | 285 (45.45) | 24.3611 |
| 2020's | 325 (51.83) | 2.80 |
| Authors | Studies |
|---|---|
| Das, J | 1 |
| Nikayin, S | 2 |
| Sanacora, G | 27 |
| Capuzzi, E | 1 |
| Caldiroli, A | 1 |
| Capellazzi, M | 1 |
| Tagliabue, I | 1 |
| Marcatili, M | 1 |
| Colmegna, F | 1 |
| Clerici, M | 2 |
| Buoli, M | 1 |
| Dakanalis, A | 1 |
| Di Vincenzo, JD | 9 |
| Lipsitz, O | 22 |
| Rodrigues, NB | 23 |
| Lee, Y | 25 |
| Gill, H | 22 |
| Kratiuk, K | 19 |
| Subramaniapillai, M | 21 |
| Mansur, R | 2 |
| McIntyre, RS | 35 |
| Rosenblat, JD | 31 |
| Dean, RL | 1 |
| Hurducas, C | 1 |
| Hawton, K | 1 |
| Spyridi, S | 1 |
| Cowen, PJ | 3 |
| Hollingsworth, S | 1 |
| Marquardt, T | 1 |
| Barnes, A | 1 |
| Smith, R | 1 |
| McShane, R | 1 |
| Turner, EH | 1 |
| Cipriani, A | 1 |
| Hochschild, A | 2 |
| Grunebaum, MF | 7 |
| Mann, JJ | 7 |
| Beaudequin, D | 2 |
| Can, AT | 4 |
| Jones, M | 3 |
| Yang, C | 5 |
| Scherman, JK | 1 |
| Dutton, M | 4 |
| Schwenn, P | 2 |
| Forsyth, CGG | 1 |
| Jensen, E | 2 |
| Hermens, DF | 5 |
| Lagopoulos, J | 5 |
| Loureiro, JRA | 3 |
| Sahib, AK | 5 |
| Vasavada, M | 2 |
| Leaver, A | 2 |
| Kubicki, A | 7 |
| Wade, B | 4 |
| Joshi, S | 2 |
| Hellemann, G | 3 |
| Congdon, E | 6 |
| Woods, RP | 6 |
| Espinoza, R | 4 |
| Narr, KL | 9 |
| Gee, SH | 1 |
| Wratten, C | 1 |
| Cairns, R | 1 |
| Santhouse, A | 1 |
| Taylor, D | 1 |
| Skiteva, O | 2 |
| Yao, N | 2 |
| Chergui, K | 2 |
| Hara, H | 2 |
| Suzuki, A | 2 |
| Kunugi, A | 2 |
| Tajima, Y | 2 |
| Yamada, R | 1 |
| Kimura, H | 2 |
| Mathai, DS | 2 |
| McCathern, AG | 1 |
| Guzick, AG | 1 |
| Schneider, SC | 1 |
| Weinzimmer, SA | 1 |
| Cepeda, SL | 1 |
| Garcia-Romeu, A | 1 |
| Storch, EA | 2 |
| Takahashi, N | 1 |
| Yamada, A | 1 |
| Shiraishi, A | 1 |
| Shimizu, H | 1 |
| Goto, R | 1 |
| Tominaga, Y | 1 |
| Zhou, Y | 15 |
| Wang, C | 13 |
| Lan, X | 10 |
| Zheng, W | 23 |
| Li, H | 7 |
| Chao, Z | 4 |
| Wu, K | 1 |
| Ning, Y | 15 |
| Garakani, A | 1 |
| Edem, EE | 1 |
| Anyanwu, CC | 1 |
| Nebo, KE | 1 |
| Akinluyi, ET | 1 |
| Fafure, AA | 1 |
| Ishola, AO | 1 |
| Enye, LA | 1 |
| Le, TT | 1 |
| Teopiz, KM | 9 |
| Cha, DS | 12 |
| Lui, LMW | 14 |
| Ho, RC | 6 |
| Cao, B | 5 |
| Lin, K | 11 |
| Nasri, F | 15 |
| Mansur, RB | 20 |
| Mouwen, A | 1 |
| Walsh, S | 1 |
| Andrade, C | 8 |
| Moccia, L | 1 |
| Lanzotti, P | 1 |
| Pepe, M | 1 |
| Palumbo, L | 1 |
| Janiri, D | 1 |
| Camardese, G | 1 |
| Bentivoglio, AR | 1 |
| Di Nicola, M | 2 |
| Calabresi, P | 1 |
| Sani, G | 1 |
| Jones, BDM | 2 |
| Ho, R | 15 |
| Ponton, E | 1 |
| Turecki, G | 5 |
| Nagy, C | 1 |
| Keilp, JG | 4 |
| Madden, SP | 1 |
| Burke, AK | 3 |
| Gu, LM | 3 |
| Sun, CH | 1 |
| Zhou, YL | 10 |
| Wang, CY | 10 |
| Lan, XF | 6 |
| Zhang, B | 9 |
| Ning, YP | 13 |
| Özgen, MH | 1 |
| van den Brink, W | 2 |
| Gärtner, M | 5 |
| de Rover, M | 1 |
| Václavů, L | 1 |
| Scheidegger, M | 4 |
| van Osch, MJP | 1 |
| Grimm, S | 6 |
| Vaccarino, SR | 1 |
| Adamsahib, F | 1 |
| Milev, RV | 2 |
| Parikh, SV | 3 |
| Lam, RW | 7 |
| Blier, P | 9 |
| Kennedy, SH | 3 |
| Ladha, KS | 1 |
| Bhat, V | 2 |
| Ekstrand, J | 2 |
| Fattah, C | 1 |
| Persson, M | 1 |
| Cheng, T | 1 |
| Nordanskog, P | 1 |
| Åkeson, J | 1 |
| Tingström, A | 1 |
| Lindström, MB | 1 |
| Nordenskjöld, A | 2 |
| Movahed Rad, P | 1 |
| McInnes, LA | 1 |
| Qian, JJ | 1 |
| Gargeya, RS | 1 |
| DeBattista, C | 6 |
| Heifets, BD | 1 |
| Vanicek, T | 1 |
| Unterholzner, J | 1 |
| Lanzenberger, R | 1 |
| Naderi-Heiden, A | 1 |
| Kasper, S | 7 |
| Praschak-Rieder, N | 1 |
| Voelker, J | 1 |
| Sheehan, JJ | 1 |
| Le, HH | 1 |
| Toro-Diaz, H | 1 |
| Li, S | 2 |
| Joshi, K | 1 |
| Zhu, X | 1 |
| Zhang, F | 6 |
| You, Y | 1 |
| Wang, H | 1 |
| Yuan, S | 1 |
| Wu, B | 1 |
| Zhu, R | 1 |
| Liu, D | 1 |
| Yan, F | 1 |
| Wang, Z | 2 |
| Averill, LA | 6 |
| Averill, CL | 2 |
| Gueorguieva, R | 5 |
| Fouda, S | 3 |
| Sherif, M | 2 |
| Ahn, KH | 3 |
| Ranganathan, M | 3 |
| D'Souza, DC | 3 |
| Southwick, SM | 2 |
| Duman, RS | 10 |
| Krystal, JH | 14 |
| Abdallah, CG | 14 |
| Zhang, NN | 1 |
| Zhang, Y | 4 |
| Wang, ZZ | 1 |
| Chen, NH | 1 |
| Holmes, SE | 3 |
| Finnema, SJ | 1 |
| Naganawa, M | 1 |
| DellaGioia, N | 2 |
| Holden, D | 1 |
| Fowles, K | 1 |
| Davis, M | 1 |
| Ropchan, J | 1 |
| Emory, P | 1 |
| Ye, Y | 5 |
| Nabulsi, N | 2 |
| Matuskey, D | 2 |
| Angarita, GA | 1 |
| Pietrzak, RH | 3 |
| Carson, RE | 2 |
| Esterlis, I | 6 |
| Kritzer, MD | 1 |
| Mischel, NA | 1 |
| Young, JR | 1 |
| Lai, CS | 1 |
| Masand, PS | 2 |
| Szabo, ST | 2 |
| Mathew, SJ | 28 |
| Findeis, H | 3 |
| Ludwig, V | 1 |
| Mikolas, P | 1 |
| Graff, J | 1 |
| Bauer, M | 5 |
| Ritter, P | 3 |
| Jesus-Nunes, AP | 2 |
| Leal, GC | 4 |
| Correia-Melo, FS | 3 |
| Vieira, F | 4 |
| Mello, RP | 4 |
| Caliman-Fontes, AT | 3 |
| Echegaray, MVF | 1 |
| Marback, RF | 2 |
| Guerreiro-Costa, LNF | 2 |
| Souza-Marques, B | 3 |
| Santos-Lima, C | 1 |
| Souza, LS | 2 |
| Bandeira, ID | 4 |
| Kapczinski, F | 3 |
| Lacerda, ALT | 9 |
| Quarantini, LC | 4 |
| Scotton, E | 2 |
| Antqueviezc, B | 1 |
| Vasconcelos, MF | 1 |
| Dalpiaz, G | 1 |
| Paul Géa, L | 1 |
| Ferraz Goularte, J | 1 |
| Colombo, R | 2 |
| Ribeiro Rosa, A | 1 |
| Dijkstra, FM | 1 |
| van de Loo, AJ | 1 |
| Abdulahad, S | 1 |
| Bosma, ER | 1 |
| Hartog, M | 1 |
| Huls, H | 1 |
| Kuijper, DC | 1 |
| de Vries, E | 1 |
| Solanki, B | 1 |
| Singh, J | 4 |
| Aluisio, L | 2 |
| Zannikos, P | 1 |
| Stuurman, FE | 1 |
| Jacobs, GE | 1 |
| Verster, JC | 1 |
| Lengvenyte, A | 2 |
| Strumila, R | 1 |
| Olié, E | 3 |
| Courtet, P | 4 |
| Bahji, A | 3 |
| Zarate, CA | 74 |
| Vazquez, GH | 5 |
| Becker, B | 1 |
| Breen, E | 1 |
| Sharafi, A | 1 |
| Pakkhesal, S | 1 |
| Fakhari, A | 1 |
| Khajehnasiri, N | 1 |
| Ahmadalipour, A | 1 |
| Jawad, MY | 3 |
| Ceban, F | 3 |
| Jaberi, S | 1 |
| Gillissie, ES | 1 |
| Alnafeesi, Y | 1 |
| Ballard, ED | 22 |
| Farmer, CA | 5 |
| Gerner, J | 1 |
| Bloomfield-Clagett, B | 2 |
| Park, LT | 10 |
| Albott, CS | 1 |
| Lim, KO | 1 |
| Erbes, C | 1 |
| Thuras, P | 1 |
| Wels, J | 1 |
| Tye, SJ | 3 |
| Shiroma, PR | 2 |
| Wulf, HA | 1 |
| Browne, CA | 1 |
| Lucki, I | 1 |
| Terao, I | 1 |
| Honyashiki, M | 1 |
| Inoue, T | 1 |
| Chen, YH | 1 |
| Chen, MH | 8 |
| Wei, HT | 1 |
| Chen, LY | 2 |
| Rocha, FL | 1 |
| Cunha, UGV | 1 |
| Duarte, DB | 1 |
| Hara, C | 1 |
| Moaddel, R | 5 |
| Zanos, P | 4 |
| Kadriu, B | 13 |
| Morris, PJ | 2 |
| Lovett, J | 3 |
| Acevedo-Diaz, EE | 3 |
| Cavanaugh, GW | 3 |
| Yuan, P | 11 |
| Yavi, M | 1 |
| Thomas, CJ | 2 |
| Ferrucci, L | 2 |
| Gould, TD | 6 |
| Cordova, VHS | 1 |
| Anzolin, AP | 1 |
| Sant'Ana, MK | 1 |
| Lacerda, A | 1 |
| Belmonte-de-Abreu, PS | 1 |
| Klein, ME | 1 |
| Grice, AB | 1 |
| Sheth, S | 1 |
| Go, M | 1 |
| Murrough, JW | 28 |
| Orsolini, L | 3 |
| Salvi, V | 1 |
| Volpe, U | 2 |
| Smith-Apeldoorn, SY | 2 |
| Vischjager, M | 1 |
| Veraart, JK | 1 |
| Kamphuis, J | 2 |
| Aan Het Rot, M | 3 |
| Schoevers, RA | 3 |
| Wade, BSC | 1 |
| Loureiro, J | 2 |
| Sahib, A | 2 |
| Joshi, SH | 4 |
| Espinoza, RT | 5 |
| Ohnishi, T | 1 |
| Wakamatsu, A | 1 |
| Kobayashi, H | 1 |
| Jiang, G | 1 |
| Wang, Y | 1 |
| Liu, Q | 1 |
| Gu, T | 1 |
| Liu, S | 2 |
| Yin, A | 1 |
| Zhang, L | 1 |
| Eduardo, TQ | 1 |
| Angela, A | 1 |
| Mateo, L | 1 |
| Melanie, LZ | 1 |
| Valentina, PF | 1 |
| David, C | 1 |
| Estefania, C | 1 |
| Natalia, RS | 1 |
| Andrés, VC | 1 |
| Angel, RO | 1 |
| Juan, G | 1 |
| Juan, P | 1 |
| Velit-Salazar, MR | 1 |
| Vorobyov, Y | 1 |
| Lewis, V | 1 |
| Rodrigue, B | 1 |
| Arsenault, E | 1 |
| Zhang, M | 5 |
| Taghavi-Abkuh, FF | 1 |
| Silva, WCC | 1 |
| Myers, M | 1 |
| Matta-Camacho, E | 3 |
| Aguilar-Valles, A | 3 |
| Tham, JCW | 1 |
| Do, A | 2 |
| Fridfinnson, J | 1 |
| Rafizadeh, R | 1 |
| Siu, JTP | 1 |
| Budd, GP | 1 |
| Faria-Guimarães, D | 2 |
| Silva, SS | 3 |
| Alves-Pereira, R | 1 |
| Fontes, M | 1 |
| Cardoso, TA | 1 |
| Sampaio, AS | 2 |
| Gilbert, JR | 7 |
| Gerner, JL | 1 |
| Burton, CR | 1 |
| Nugent, AC | 19 |
| Abdallah, C | 1 |
| Yang, XH | 3 |
| Tan, JQ | 1 |
| Lamanna, J | 1 |
| Isotti, F | 1 |
| Ferro, M | 1 |
| Spadini, S | 1 |
| Racchetti, G | 1 |
| Musazzi, L | 3 |
| Malgaroli, A | 1 |
| Langhein, M | 1 |
| Seitz-Holland, J | 1 |
| Lyall, AE | 1 |
| Pasternak, O | 1 |
| Chunga, N | 1 |
| Cetin-Karayumak, S | 1 |
| Mulert, C | 1 |
| Kubicki, M | 1 |
| Scott, F | 1 |
| Hampsey, E | 1 |
| Gnanapragasam, S | 1 |
| Carter, B | 1 |
| Marwood, L | 1 |
| Taylor, RW | 1 |
| Emre, C | 1 |
| Korotkova, L | 1 |
| Martín-Dombrowski, J | 1 |
| Cleare, AJ | 1 |
| Young, AH | 5 |
| Strawbridge, R | 1 |
| van der Zee, YY | 1 |
| Eijssen, LMT | 1 |
| Mews, P | 1 |
| Ramakrishnan, A | 1 |
| Alvarez, K | 1 |
| Lardner, CK | 1 |
| Cates, HM | 1 |
| Walker, DM | 1 |
| Torres-Berrío, A | 2 |
| Browne, CJ | 1 |
| Cunningham, A | 1 |
| Cathomas, F | 1 |
| Kronman, H | 1 |
| Parise, EM | 3 |
| de Nijs, L | 1 |
| Shen, L | 1 |
| Rutten, BPF | 1 |
| Nestler, EJ | 3 |
| Issler, O | 1 |
| Chen, KS | 1 |
| Dwivedi, Y | 1 |
| Shelton, RC | 5 |
| Lyu, D | 2 |
| Wang, F | 2 |
| Yang, W | 2 |
| Huang, H | 2 |
| Huang, Q | 1 |
| Wu, C | 1 |
| Qian, N | 1 |
| Wang, M | 5 |
| Zhang, H | 1 |
| Zheng, S | 1 |
| Chen, J | 4 |
| Fu, Y | 1 |
| Zhang, C | 2 |
| Li, Z | 4 |
| Hong, W | 2 |
| Phillips, JL | 4 |
| Van Geel, A | 1 |
| Burhunduli, P | 1 |
| Vasudev, D | 1 |
| Batten, LA | 2 |
| Norris, S | 2 |
| Talbot, J | 2 |
| Ortiz, A | 2 |
| Owoeye, O | 2 |
| Pilc, A | 6 |
| Machaczka, A | 1 |
| Kawalec, P | 3 |
| Smith, JL | 2 |
| Witkin, JM | 2 |
| Cheng, CM | 3 |
| Li, CT | 7 |
| Tsai, SJ | 5 |
| Lin, WC | 7 |
| Bai, YM | 6 |
| Su, TP | 7 |
| Weigand, A | 1 |
| Wyss, PO | 1 |
| Henning, A | 2 |
| Seifritz, E | 3 |
| Stippl, A | 2 |
| Herrera-Melendez, A | 1 |
| Bajbouj, M | 4 |
| Aust, S | 3 |
| Pochwat, B | 4 |
| Krupa, AJ | 1 |
| Siwek, M | 1 |
| Szewczyk, B | 4 |
| Zhang, JC | 2 |
| Yao, W | 1 |
| Hashimoto, K | 10 |
| Greenstein, DK | 1 |
| Wilkinson, ST | 9 |
| Fava, M | 11 |
| Surjan, J | 5 |
| Grossi, JD | 4 |
| Del Porto, JA | 5 |
| Delfino, RS | 4 |
| de Oliveira Cerqueira, R | 1 |
| Lucchese, AC | 2 |
| Magalhães, E | 1 |
| Del Sant, LC | 2 |
| Tuena, MA | 2 |
| Nakahira, C | 2 |
| Fava, VAR | 1 |
| Steglich, MS | 1 |
| Abdo, GL | 1 |
| Barbosa, MG | 1 |
| Sarin, LM | 2 |
| Oliver, PA | 1 |
| Snyder, AD | 1 |
| Feinn, R | 1 |
| Malov, S | 1 |
| McDiarmid, G | 1 |
| Arias, AJ | 1 |
| Carboni, E | 1 |
| Carta, AR | 1 |
| Williamson, DJ | 1 |
| Gogate, JP | 1 |
| Kern Sliwa, JK | 1 |
| Manera, LS | 1 |
| Preskorn, SH | 1 |
| Winokur, A | 3 |
| Starr, HL | 1 |
| Daly, EJ | 5 |
| Sukhram, SD | 1 |
| Yilmaz, G | 1 |
| Gu, J | 1 |
| Bottemanne, H | 2 |
| Morlaas, O | 1 |
| Claret, A | 1 |
| Sharot, T | 1 |
| Fossati, P | 4 |
| Schmidt, L | 2 |
| Gu, L | 1 |
| Carlessi, AS | 1 |
| Botelho, MEM | 2 |
| Manosso, LM | 1 |
| Borba, LA | 2 |
| Maciel, LR | 1 |
| Andrade, NM | 1 |
| Martinello, NS | 1 |
| Padilha, APZ | 1 |
| Generoso, CM | 1 |
| Bencke, CV | 1 |
| de Moura, AB | 3 |
| Lodetti, BF | 1 |
| Collodel, A | 1 |
| Joaquim, L | 1 |
| Bonfante, S | 1 |
| Biehl, E | 1 |
| Generoso, JS | 1 |
| Arent, CO | 1 |
| Barichello, T | 1 |
| Petronilho, F | 3 |
| Quevedo, J | 5 |
| Réus, GZ | 4 |
| Ahuja, S | 1 |
| Brendle, M | 1 |
| Smart, L | 1 |
| Moore, C | 1 |
| Thielking, P | 1 |
| Robison, R | 1 |
| Ni, RJ | 2 |
| Gao, TH | 2 |
| Wang, YY | 1 |
| Tian, Y | 2 |
| Wei, JX | 1 |
| Zhao, LS | 1 |
| Ni, PY | 1 |
| Ma, XH | 1 |
| Li, T | 3 |
| Rhee, TG | 3 |
| Shim, SR | 1 |
| Forester, BP | 1 |
| Nierenberg, AA | 2 |
| Papakostas, GI | 11 |
| Shi, S | 1 |
| Wei, Z | 1 |
| Chen, S | 1 |
| Xu, Y | 4 |
| O'Brien, B | 2 |
| Lee, J | 3 |
| Kim, S | 1 |
| Nandra, GS | 1 |
| Pannu, P | 1 |
| Swann, AC | 2 |
| Murphy, N | 2 |
| Tamman, AJF | 1 |
| Amarneh, D | 1 |
| Lijffijt, M | 2 |
| Meiering, MS | 1 |
| Weigner, D | 1 |
| Schäfer, T | 1 |
| Wilkowska, A | 8 |
| Cubała, WJ | 14 |
| Feeney, A | 5 |
| Hoeppner, BB | 3 |
| Freeman, MP | 5 |
| Flynn, M | 5 |
| Iosifescu, DV | 20 |
| Trivedi, MH | 6 |
| Ionescu, DF | 16 |
| Cusin, C | 8 |
| Jha, MK | 8 |
| Liu, H | 5 |
| Fu, L | 3 |
| Li, W | 4 |
| Hu, Z | 4 |
| Schatzberg, AF | 6 |
| Peters, EM | 2 |
| Halpape, K | 3 |
| Cheveldae, I | 2 |
| Wanson, A | 3 |
| Acevedo, J | 2 |
| Mugarura, NE | 2 |
| Welter, AL | 2 |
| Johnson, EM | 2 |
| Siegel, JA | 2 |
| Hock, RS | 5 |
| Iovieno, N | 2 |
| Cardona-Acosta, AM | 3 |
| Bolaños-Guzmán, CA | 5 |
| Meshkat, S | 2 |
| Vazquez, G | 1 |
| Gutierrez, G | 1 |
| Rosenblat, J | 1 |
| Schaffer, A | 3 |
| Swainson, J | 2 |
| Karthikeyan, G | 1 |
| Ravindran, N | 2 |
| Giacobbe, P | 1 |
| Hawken, E | 1 |
| Milev, R | 2 |
| Pompili, M | 3 |
| Sarli, G | 1 |
| Erbuto, D | 1 |
| Manfredi, G | 1 |
| Comparelli, A | 1 |
| Huang, MC | 3 |
| Chen, CH | 1 |
| Liu, TH | 2 |
| Chung, AN | 2 |
| Liu, YL | 2 |
| Quednow, BB | 2 |
| Bavato, F | 2 |
| You, Z | 1 |
| Chaki, S | 3 |
| Watanabe, M | 1 |
| Casa, PL | 1 |
| de Abreu, FP | 1 |
| de Avila E Silva, S | 1 |
| Wilges, RLB | 1 |
| Rossetto, MV | 1 |
| Géa, LP | 1 |
| Rosa, AR | 1 |
| Zavaliangos-Petropulu, A | 1 |
| Al-Sharif, NB | 1 |
| Taraku, B | 1 |
| Leaver, AM | 3 |
| Anijärv, TE | 1 |
| Gallay, CC | 2 |
| Forsyth, GA | 1 |
| Mitchell, JS | 1 |
| Lineham, A | 1 |
| Avila-Quintero, VJ | 1 |
| Bloch, MH | 6 |
| Dwyer, J | 1 |
| Onisiforou, A | 1 |
| Georgiou, P | 1 |
| d'Andrea, G | 2 |
| Pettorruso, M | 2 |
| Lorenzo, GD | 1 |
| Mancusi, G | 1 |
| Martinotti, G | 4 |
| de A Simoes Moreira, D | 1 |
| Gauer, LE | 1 |
| Teixeira, G | 1 |
| Fonseca da Silva, AC | 1 |
| Cavalcanti, S | 1 |
| Wei, L | 1 |
| Qi, X | 1 |
| Yu, X | 1 |
| Zheng, Y | 1 |
| Luo, X | 1 |
| Wei, Y | 2 |
| Ni, P | 2 |
| Zhao, L | 3 |
| Wang, Q | 2 |
| Ma, X | 3 |
| Deng, W | 1 |
| Guo, W | 2 |
| Hu, X | 1 |
| Halaris, A | 1 |
| Cook, J | 1 |
| Wu, HJ | 3 |
| Mao, WC | 1 |
| Tu, PC | 6 |
| Chen, LF | 1 |
| Li, WC | 1 |
| Ibi, D | 1 |
| Golani, LK | 1 |
| Menon, V | 1 |
| Varadharajan, N | 1 |
| Faheem, A | 1 |
| Chiappini, S | 1 |
| De Filippis, S | 1 |
| Andriola, I | 1 |
| Bassetti, R | 1 |
| Barlati, S | 1 |
| Sensi, S | 1 |
| Dell'Osso, B | 1 |
| Vita, A | 1 |
| Barrutieta-Arberas, I | 1 |
| Ortuzar, N | 1 |
| Vaquero-Rodríguez, A | 1 |
| Picó-Gallardo, M | 1 |
| Bengoetxea, H | 1 |
| Guevara, MA | 1 |
| Gargiulo, PA | 1 |
| Lafuente, JV | 1 |
| Floriano, I | 1 |
| Silvinato, A | 1 |
| Bernardo, WM | 1 |
| Anand, A | 4 |
| Goes, FS | 1 |
| Altinay, M | 1 |
| Aloysi, AS | 1 |
| Asghar-Ali, AA | 1 |
| Barnett, BS | 1 |
| Chang, LC | 4 |
| Collins, KA | 6 |
| Costi, S | 4 |
| Iqbal, S | 2 |
| Krishnan, K | 1 |
| Malone, DA | 1 |
| Nissen, SE | 1 |
| Ostroff, RB | 3 |
| Reti, IM | 1 |
| Wolski, K | 1 |
| Hu, B | 2 |
| Adzic, M | 1 |
| Lukic, I | 1 |
| Mitic, M | 1 |
| Glavonic, E | 1 |
| Dragicevic, N | 1 |
| Ivkovic, S | 1 |
| Harris, E | 1 |
| Dong, J | 2 |
| Min, S | 3 |
| Chen, Q | 3 |
| Qiu, H | 2 |
| Ren, L | 2 |
| van Amsterdam, J | 1 |
| Kaur, S | 1 |
| Parmar, C | 1 |
| Gaur, V | 1 |
| Chauhan, A | 1 |
| Chen, T | 1 |
| Cheng, L | 1 |
| Ma, J | 1 |
| Yuan, J | 1 |
| Pi, C | 1 |
| Xiong, L | 1 |
| Tang, J | 1 |
| Zhong, Y | 1 |
| Zhang, X | 3 |
| Liu, Z | 1 |
| Zuo, Y | 1 |
| Shen, H | 1 |
| Lins-Silva, DH | 1 |
| Dorea-Bandeira, I | 1 |
| Carneiro, B | 1 |
| Miranda-Scippa, Â | 1 |
| Madjid, N | 1 |
| Lidell, V | 1 |
| Nordvall, G | 1 |
| Lindskog, M | 1 |
| Ögren, SO | 1 |
| Forsell, P | 1 |
| Sandin, J | 1 |
| Božić, M | 2 |
| Pirnat, S | 1 |
| Fink, K | 1 |
| Potokar, M | 1 |
| Kreft, M | 1 |
| Zorec, R | 2 |
| Stenovec, M | 2 |
| Mingardi, J | 2 |
| Ndoj, E | 1 |
| Bonifacino, T | 1 |
| Misztak, P | 2 |
| Bertoli, M | 1 |
| La Via, L | 1 |
| Torazza, C | 1 |
| Russo, I | 1 |
| Milanese, M | 1 |
| Bonanno, G | 1 |
| Popoli, M | 1 |
| Barbon, A | 1 |
| van Verseveld, M | 1 |
| Stuiver, S | 1 |
| Vos, CF | 1 |
| Ruhé, HG | 1 |
| van Waarde, JA | 1 |
| Kramers, CK | 1 |
| Chen, X | 2 |
| Falkenberg, I | 1 |
| Bitsch, F | 1 |
| Liu, W | 8 |
| Matsingos, A | 1 |
| Noor, L | 1 |
| Vogelbacher, C | 1 |
| Yildiz, C | 1 |
| Kircher, T | 2 |
| Koncz, S | 1 |
| Papp, N | 1 |
| Pothorszki, D | 1 |
| Bagdy, G | 1 |
| Shenasa, MA | 1 |
| Afshar, HT | 1 |
| Miller, EA | 1 |
| Ellerman-Tayag, E | 1 |
| Mishra, J | 1 |
| Ramanathan, D | 1 |
| Thase, ME | 5 |
| de Leon, VC | 1 |
| Kumar, A | 1 |
| Nagele, P | 1 |
| Palanca, BJ | 1 |
| Gott, B | 1 |
| Janski, A | 1 |
| Zorumski, CF | 1 |
| Conway, CR | 1 |
| Holsinger, T | 2 |
| Riordan, P | 1 |
| Souza, SA | 1 |
| Josino, TR | 1 |
| Bisol, LW | 1 |
| Silberbauer, LR | 1 |
| Spies, M | 1 |
| Movahed, P | 1 |
| Kellner, CH | 4 |
| Derosa, S | 1 |
| Mazzini, G | 1 |
| Müller, HK | 2 |
| Berkovitch, L | 1 |
| Gauld, C | 1 |
| Balcerac, A | 1 |
| Mouchabac, S | 1 |
| Galán-Armenteros, RM | 1 |
| Romero-Mohedano, MC | 1 |
| González-González, C | 1 |
| Marco-Feced, MA | 1 |
| Moreno-Campos, AJ | 1 |
| Chiang, CH | 3 |
| Hsia, YP | 1 |
| Schwartz, OS | 1 |
| Amminger, P | 1 |
| Baune, BT | 1 |
| Bedi, G | 1 |
| Berk, M | 2 |
| Cotton, SM | 1 |
| Daglas-Georgiou, R | 1 |
| Glozier, N | 2 |
| Harrison, B | 1 |
| Jennings, E | 1 |
| Loo, C | 8 |
| Mallawaarachchi, S | 1 |
| Martin, D | 1 |
| Phelan, B | 1 |
| Read, N | 1 |
| Rodgers, A | 3 |
| Schmaal, L | 1 |
| Somogyi, AA | 4 |
| Thurston, L | 1 |
| Weller, A | 1 |
| Davey, CG | 1 |
| Niciu, MJ | 19 |
| Meisner, RC | 1 |
| Carr, BR | 1 |
| Farooqui, AA | 1 |
| Feifel, D | 2 |
| Kaplin, A | 1 |
| Kendrick, EJ | 1 |
| Kim, PM | 1 |
| Schneck, CD | 1 |
| Vande Voort, JL | 10 |
| Brandão, AAC | 1 |
| Deus, DLS | 1 |
| Duarte-Filho, LAMS | 1 |
| Menezes, PMN | 1 |
| Massaranduba, ABR | 1 |
| Silva, FS | 1 |
| Ribeiro, LAA | 1 |
| Lee, W | 2 |
| Sheehan, C | 2 |
| Chye, R | 2 |
| Chang, S | 2 |
| Bayes, A | 1 |
| Draper, B | 2 |
| Agar, MR | 1 |
| Currow, DC | 2 |
| Jelovac, A | 1 |
| McCaffrey, C | 1 |
| Terao, M | 1 |
| Shanahan, E | 2 |
| Mohamed, E | 1 |
| Whooley, E | 1 |
| McDonagh, K | 1 |
| McDonogh, S | 1 |
| Igoe, A | 1 |
| Loughran, O | 1 |
| Shackleton, E | 1 |
| O'Neill, C | 1 |
| McLoughlin, DM | 3 |
| Guilloux, JP | 1 |
| Nguyen, TML | 1 |
| Gardier, AM | 1 |
| Hilal, F | 1 |
| Jeanblanc, J | 1 |
| Naassila, M | 1 |
| Rodríguez-Mayoral, O | 1 |
| Pérez-Esparza, R | 2 |
| Domínguez-Ocadio, G | 1 |
| Allende-Pérez, S | 1 |
| Galfalvy, HC | 2 |
| Choo, TH | 2 |
| Parris, MS | 2 |
| Suckow, RF | 3 |
| Cooper, TB | 3 |
| Polis, AJ | 1 |
| Fitzgerald, PJ | 2 |
| Hale, PJ | 1 |
| Watson, BO | 2 |
| Hong, CJ | 3 |
| Xiong, Z | 1 |
| Su, B | 1 |
| Wang, L | 1 |
| Yang, Y | 2 |
| Fang, J | 1 |
| Zhan, Y | 7 |
| Chen, L | 4 |
| Walter, M | 4 |
| Li, M | 6 |
| Li, MD | 6 |
| Szałach, ŁP | 3 |
| Lisowska, KA | 1 |
| Słupski, J | 4 |
| Włodarczyk, A | 6 |
| Górska, N | 4 |
| Szarmach, J | 5 |
| Jakuszkowiak-Wojten, K | 3 |
| Gałuszko-Węgielnik, M | 5 |
| Wiglusz, MS | 4 |
| Krysta, K | 1 |
| Słupska, A | 2 |
| Małyszko, A | 1 |
| Salloum, NC | 3 |
| Hoeppner, B | 2 |
| Sumner, RL | 3 |
| McMillan, R | 4 |
| Spriggs, MJ | 3 |
| Campbell, D | 3 |
| Malpas, G | 4 |
| Maxwell, E | 3 |
| Deng, C | 3 |
| Hay, J | 4 |
| Ponton, R | 4 |
| Kirk, IJ | 1 |
| Sundram, F | 4 |
| Muthukumaraswamy, SD | 3 |
| Zhuo, C | 1 |
| Tian, H | 1 |
| Li, G | 1 |
| Chen, M | 1 |
| Jiang, D | 1 |
| Lin, X | 3 |
| Wang, W | 1 |
| Kryst, J | 2 |
| Rashidian, H | 1 |
| Moretti, M | 2 |
| Werle, I | 1 |
| da Rosa, PB | 1 |
| Neis, VB | 2 |
| Platt, N | 1 |
| Souza, SVS | 1 |
| Rodrigues, ALS | 2 |
| Domany, Y | 1 |
| McCullumsmith, CB | 1 |
| Nowak, W | 1 |
| Grendas, LN | 1 |
| Sanmarco, LM | 1 |
| Estecho, IG | 1 |
| Arena, ÁR | 1 |
| Eberhardt, N | 1 |
| Rodante, DE | 1 |
| Aoki, MP | 1 |
| Daray, FM | 1 |
| Carrera Silva, EA | 1 |
| Errasti, AE | 1 |
| Kim, JW | 1 |
| Monteggia, LM | 3 |
| Veraart, JKE | 1 |
| van Asselt, ADI | 1 |
| Touw, DJ | 1 |
| Xu, L | 1 |
| Mao, R | 1 |
| Scheele, D | 1 |
| Zimbal, S | 1 |
| Feinstein, JS | 1 |
| Delis, A | 1 |
| Neumann, C | 1 |
| Mielacher, C | 1 |
| Philipsen, A | 1 |
| Hurlemann, R | 1 |
| Greenstein, D | 2 |
| Kraus, C | 4 |
| Bartoli, F | 2 |
| Wlkinson, ST | 1 |
| Sumner, R | 1 |
| Forsyth, A | 1 |
| Muthukumaraswamy, S | 1 |
| Zhang, K | 1 |
| Sakamoto, A | 1 |
| Chang, L | 1 |
| Qu, Y | 1 |
| Wang, S | 1 |
| Pu, Y | 1 |
| Tan, Y | 1 |
| Wang, X | 4 |
| Fujita, Y | 2 |
| Ishima, T | 1 |
| Hatano, M | 1 |
| Morris, LS | 1 |
| Tan, A | 1 |
| Stern, ER | 1 |
| Charney, DS | 15 |
| Galiano, CS | 1 |
| Cai, DB | 2 |
| Xiang, YQ | 1 |
| Jiang, WL | 1 |
| Sim, K | 2 |
| Ungvari, GS | 3 |
| Huang, X | 2 |
| Huang, XX | 1 |
| Xiang, YT | 4 |
| Mkrtchian, A | 2 |
| Evans, JW | 6 |
| De Berardis, D | 1 |
| Tomasetti, C | 2 |
| Serafini, G | 2 |
| Vellante, F | 2 |
| Fornaro, M | 2 |
| Valchera, A | 2 |
| Perna, G | 2 |
| Fraticelli, S | 1 |
| Di Giannantonio, M | 1 |
| Kim, YK | 2 |
| Zhao, J | 1 |
| Liu, X | 1 |
| Chang, D | 1 |
| Lian, H | 1 |
| Du, X | 1 |
| Gao, L | 1 |
| Sial, OK | 2 |
| Parise, LF | 2 |
| Gnecco, T | 1 |
| Carreno, FR | 1 |
| Lodge, DJ | 1 |
| Frazer, A | 1 |
| Al Shweiki, MR | 1 |
| Oeckl, P | 1 |
| Steinacker, P | 1 |
| Barschke, P | 1 |
| Pryce, C | 1 |
| Dorner-Ciossek, C | 1 |
| Schönfeldt-Lecuona, C | 1 |
| Hengerer, B | 1 |
| Otto, M | 1 |
| Meyer, MJ | 1 |
| Kosten, TR | 1 |
| Vasavada, MM | 4 |
| Wang, K | 1 |
| Wang, DJJ | 1 |
| Boucher, ML | 1 |
| Kokane, SS | 1 |
| Armant, RJ | 1 |
| Perrotti, LI | 1 |
| Telles, M | 1 |
| Lima, CS | 1 |
| Marques, BLS | 1 |
| Bezerra, MLO | 1 |
| Dias-Neto, AL | 1 |
| Goktas, S | 1 |
| Purohit, P | 1 |
| Formica, R | 1 |
| Anderson, IM | 2 |
| McAllister-Williams, RH | 2 |
| Downey, D | 3 |
| Elliott, R | 2 |
| George, J | 1 |
| Adeojo, L | 1 |
| Peng, FZ | 1 |
| Fan, J | 1 |
| Ge, TT | 1 |
| Liu, QQ | 1 |
| Li, BJ | 1 |
| Nijs, M | 1 |
| Wajs, E | 2 |
| Turkoz, I | 1 |
| Daly, E | 1 |
| Janik, A | 2 |
| Borentain, S | 2 |
| Singh, JB | 6 |
| DiBernardo, A | 1 |
| Wiegand, F | 1 |
| Mitoraj, AM | 1 |
| Lasoń, W | 1 |
| Brzostek, T | 1 |
| Peyrovian, B | 1 |
| Phan, L | 4 |
| Majeed, A | 5 |
| Chen-Li, D | 3 |
| Vinberg, M | 2 |
| Malhi, GS | 1 |
| Fagiolini, A | 3 |
| Suppes, T | 1 |
| Fu, DJ | 2 |
| Li, X | 3 |
| Lane, R | 7 |
| Lim, P | 6 |
| Hough, D | 5 |
| Manji, H | 6 |
| Drevets, WC | 12 |
| Canuso, CM | 4 |
| David, S | 1 |
| de Almeida, RF | 1 |
| Pocharski, CB | 1 |
| Elisabetsky, E | 1 |
| Souza, DO | 1 |
| Grabski, M | 1 |
| Borissova, A | 1 |
| Marsh, B | 1 |
| Morgan, CJA | 1 |
| Curran, HV | 1 |
| Jaworska, N | 1 |
| Kamler, E | 1 |
| Blier, J | 2 |
| Foster, JA | 1 |
| Hassel, S | 1 |
| Ho, K | 1 |
| McMurray, L | 1 |
| Moazamigoudarzi, Z | 1 |
| Placenza, FM | 1 |
| Richard-Devantoy, S | 2 |
| Rotzinger, S | 1 |
| Kavalali, ET | 2 |
| Perez-Caballero, L | 1 |
| Perez, V | 1 |
| Berrocoso, E | 1 |
| Elmer, GI | 1 |
| Tapocik, JD | 1 |
| Mayo, CL | 1 |
| Dold, M | 1 |
| Bartova, L | 1 |
| Davoudian, PA | 1 |
| Domin, H | 1 |
| Rafało-Ulińska, A | 1 |
| Nowak, G | 3 |
| Senyk, O | 1 |
| Carvalho, IP | 2 |
| Siegel, A | 2 |
| Brietzke, E | 4 |
| Arekapudi, AK | 2 |
| Abrishami, A | 2 |
| Chau, EH | 2 |
| Szpejda, W | 2 |
| Luckenbaugh, DA | 23 |
| Pennybaker, SJ | 2 |
| Hopkins, MA | 1 |
| Henter, ID | 5 |
| Lener, MS | 5 |
| Deng, X | 1 |
| Liu, WJ | 5 |
| Weng, SY | 1 |
| Li, QS | 1 |
| Ochs-Ross, R | 1 |
| Loureiro, JR | 1 |
| K V, A | 1 |
| Mohan, AS | 1 |
| Chakravarty, S | 1 |
| Wu, FC | 2 |
| Zhan, YN | 4 |
| Crisanti, C | 1 |
| Enrico, P | 1 |
| Fiorentini, A | 1 |
| Delvecchio, G | 1 |
| Brambilla, P | 1 |
| Milak, MS | 3 |
| Rashid, R | 1 |
| Dong, Z | 1 |
| Kegeles, LS | 2 |
| Ogden, RT | 2 |
| Mulhern, ST | 2 |
| Mao, X | 3 |
| Shungu, DC | 3 |
| Pereira, S | 1 |
| Brennan, E | 1 |
| Patel, A | 1 |
| Moran, M | 1 |
| Wallier, J | 1 |
| Liebowitz, MR | 1 |
| Memon, RI | 1 |
| Naveed, S | 1 |
| Faquih, AE | 1 |
| Fida, A | 1 |
| Abbas, N | 1 |
| Chaudhary, AMD | 1 |
| Qayyum, Z | 2 |
| Qiu, X | 1 |
| Park, L | 7 |
| Coles, AC | 1 |
| Tamura, JK | 1 |
| Iacobucci, M | 1 |
| Singhal, N | 1 |
| Wong, ER | 1 |
| Deng, XR | 1 |
| Roiser, JP | 3 |
| Nobile, B | 1 |
| Nemati, S | 1 |
| Morgan, PT | 1 |
| Mathalon, DH | 1 |
| Driesen, NR | 1 |
| Munkholm, K | 1 |
| Jørgensen, KJ | 1 |
| Choi, KH | 1 |
| Berman, RY | 1 |
| Spencer, HF | 1 |
| Radford, KD | 1 |
| Nuñez, NA | 1 |
| Joseph, B | 1 |
| Pahwa, M | 1 |
| Seshadri, A | 1 |
| Prokop, LJ | 1 |
| Kung, S | 6 |
| Schak, KM | 4 |
| Frye, MA | 6 |
| Singh, B | 2 |
| Lui, LM | 1 |
| Teopiz, K | 1 |
| Lundin, NB | 2 |
| Sepe-Forrest, L | 1 |
| Carver, FW | 1 |
| Furey, ML | 5 |
| Gallay, C | 1 |
| Forsyth, G | 1 |
| Simcock, G | 1 |
| Ramos-Quiroga, JA | 1 |
| Souery, D | 1 |
| McGirr, A | 5 |
| Beaulieu, S | 1 |
| Frey, BN | 1 |
| Taylor, VH | 1 |
| Tourjman, V | 1 |
| van Ameringen, M | 1 |
| Yatham, LN | 3 |
| Ravindran, AV | 1 |
| Tashakkori, M | 1 |
| Ford, A | 1 |
| Dragovic, M | 1 |
| Gabriel, L | 1 |
| Waters, F | 1 |
| Rivas-Grajales, AM | 1 |
| Salas, R | 3 |
| Robinson, ME | 1 |
| Qi, K | 1 |
| Hudgens, S | 1 |
| Floden, L | 1 |
| Blackowicz, M | 1 |
| Jamieson, C | 1 |
| Popova, V | 3 |
| Fedgchin, M | 3 |
| Cooper, K | 3 |
| Alshammari, TK | 1 |
| Simonson, K | 1 |
| Shekotikhina, M | 3 |
| De Gregorio, D | 2 |
| Eslamizade, MJ | 2 |
| Khlaifia, A | 1 |
| Skaleka, A | 1 |
| Lopez-Canul, M | 1 |
| Bermudez, S | 1 |
| Rurak, GM | 1 |
| Simard, S | 1 |
| Salmaso, N | 1 |
| Gobbi, G | 2 |
| Lacaille, JC | 2 |
| Sonenberg, N | 2 |
| Kang, MJY | 1 |
| Kulcar, E | 1 |
| Chandrasena, R | 1 |
| Anjum, MR | 1 |
| Fairbairn, J | 1 |
| Hawken, ER | 1 |
| Xiong, J | 1 |
| Carvalho, I | 1 |
| Narsi, F | 1 |
| Hu, Y | 2 |
| Zhong, X | 1 |
| Gonçalves, CL | 1 |
| Abelaira, HM | 3 |
| Rosa, T | 2 |
| Veron, DC | 1 |
| Goldim, MP | 2 |
| Garbossa, L | 2 |
| Fileti, ME | 2 |
| Ignácio, ZM | 1 |
| Magalhães, EJM | 1 |
| B Puertas, C | 1 |
| Fava, VA | 1 |
| Delfino, R | 1 |
| Steiglich, MS | 1 |
| Barbosa, M | 1 |
| Abdo, G | 1 |
| Cohrs, FM | 1 |
| Liberatori, A | 1 |
| Lacerda, AL | 1 |
| B Andreoli, S | 1 |
| Wei, J | 1 |
| Greenberg, D | 1 |
| Flint, AJ | 1 |
| Desfossés, CY | 1 |
| Kounelis-Wuillaume, SK | 1 |
| Gheidi, A | 1 |
| Morrow, JD | 1 |
| Spencer-Segal, JL | 1 |
| Scherman, J | 1 |
| Beaudequin, DA | 1 |
| Schwenn, PE | 1 |
| Shinohara, R | 2 |
| Aghajanian, GK | 2 |
| Cepeda, MS | 1 |
| Mathews, M | 1 |
| Manji, HK | 7 |
| Ozerdem, A | 1 |
| McDonald, WM | 2 |
| Riva-Posse, P | 1 |
| Nakamura, T | 1 |
| Tomita, M | 1 |
| Horikawa, N | 1 |
| Ishibashi, M | 1 |
| Uematsu, K | 1 |
| Hiraki, T | 1 |
| Abe, T | 1 |
| Uchimura, N | 1 |
| Sanders, B | 1 |
| Brula, AQ | 1 |
| Herrera, A | 1 |
| Dwyer, JB | 2 |
| Landeros-Weisenberger, A | 1 |
| Johnson, JA | 1 |
| Londono Tobon, A | 1 |
| Flores, JM | 1 |
| Nasir, M | 1 |
| Couloures, K | 1 |
| Ziegler, L | 1 |
| Peters, E | 1 |
| Kopf-Beck, J | 1 |
| Fietz, J | 1 |
| Nemeroff, CB | 4 |
| Dodd, S | 1 |
| Gorwood, P | 1 |
| Lopez Jaramillo, C | 1 |
| Lee, JG | 2 |
| Thase, M | 1 |
| Vieta, E | 2 |
| Stahl, S | 1 |
| Kim, YS | 1 |
| Wells, A | 1 |
| Ramakrishnan, N | 1 |
| Siegel, AN | 1 |
| Ng, J | 1 |
| Chacko, E | 1 |
| Anderson, C | 1 |
| French, A | 1 |
| Jung, S | 1 |
| Rajan, A | 1 |
| Chen, YL | 1 |
| Conley, AA | 1 |
| Norwood, AEQ | 1 |
| Hatvany, TC | 1 |
| Griffith, JD | 1 |
| Barber, KE | 1 |
| Stocker, K | 1 |
| Hasler, G | 2 |
| Hartmann, M | 1 |
| Davis, MT | 1 |
| DellaGiogia, N | 1 |
| Maruff, P | 1 |
| Bao, Z | 1 |
| Zhao, X | 1 |
| Li, J | 1 |
| Zhang, G | 1 |
| Wu, H | 1 |
| Yang, Z | 1 |
| Meyer, T | 1 |
| Brunovsky, M | 1 |
| Horacek, J | 2 |
| Novak, T | 2 |
| Andrashko, V | 1 |
| Olbrich, S | 1 |
| Alexander, L | 1 |
| Jelen, LA | 1 |
| Mehta, MA | 1 |
| Worrell, SD | 1 |
| Gould, TJ | 1 |
| Veldman, ER | 1 |
| Mamula, D | 1 |
| Jiang, H | 1 |
| Tiger, M | 2 |
| Ekman, CJ | 1 |
| Lundberg, J | 1 |
| Svenningsson, P | 3 |
| Wang, A | 1 |
| Fagerholm, ED | 1 |
| Leech, R | 1 |
| Williams, S | 2 |
| Moran, RJ | 1 |
| Zhou, JY | 1 |
| Hamilton, P | 1 |
| Macres, S | 1 |
| Peña, M | 1 |
| Tang, S | 1 |
| Pulcu, E | 1 |
| Guinea, C | 1 |
| Murphy, SE | 1 |
| Harmer, CJ | 2 |
| Dogra, S | 1 |
| Conn, PJ | 1 |
| Kopra, E | 1 |
| Mondelli, V | 1 |
| Pariante, C | 1 |
| Nikkheslat, N | 1 |
| Agar, M | 1 |
| Hillhouse, TM | 1 |
| Anderson, PM | 1 |
| Koppenhaver, PO | 1 |
| Kegen, TN | 1 |
| Manicka, SG | 1 |
| Lane, JT | 1 |
| Pottanat, E | 1 |
| Van Fossen, M | 1 |
| Rice, R | 1 |
| Porter, JH | 1 |
| Undurraga, J | 1 |
| Tondo, L | 1 |
| Baldessarini, RJ | 1 |
| Wong, L | 1 |
| Gyles, TM | 1 |
| Juarez, B | 1 |
| Chaudhury, D | 1 |
| Han, MH | 1 |
| Chen, BK | 1 |
| Luna, VM | 1 |
| Shannon, ME | 1 |
| Hunsberger, HC | 1 |
| Mastrodonato, A | 1 |
| Stackmann, M | 1 |
| McGowan, JC | 1 |
| Rubinstenn, G | 1 |
| Denny, CA | 1 |
| Ludwig, VM | 1 |
| Sauer, C | 1 |
| Rucker, J | 1 |
| Ling, R | 1 |
| Gärde, M | 1 |
| Tateno, A | 1 |
| Matheson, GJ | 1 |
| Sakayori, T | 1 |
| Nogami, T | 1 |
| Moriya, H | 1 |
| Varnäs, K | 1 |
| Arakawa, R | 1 |
| Okubo, Y | 1 |
| Lazarevic, V | 1 |
| Flais, I | 1 |
| Kiraly, DD | 1 |
| Horn, SR | 1 |
| Van Dam, NT | 1 |
| Schwartz, J | 4 |
| Kim-Schulze, S | 1 |
| Patel, M | 1 |
| Hodes, GE | 1 |
| Russo, SJ | 2 |
| Merad, M | 1 |
| Beyer, C | 1 |
| Berlim, MT | 3 |
| Bond, DJ | 2 |
| Chan, PY | 1 |
| Yang, J | 1 |
| Pittenger, C | 3 |
| Parsey, RV | 1 |
| DeLorenzo, C | 2 |
| Zavorotnyy, M | 1 |
| Kluge, I | 1 |
| Ahrens, K | 1 |
| Wohltmann, T | 1 |
| Köhnlein, B | 1 |
| Dietsche, P | 1 |
| Dannlowski, U | 1 |
| Konrad, C | 1 |
| Glue, P | 7 |
| Medlicott, NJ | 1 |
| Harland, S | 1 |
| Neehoff, S | 1 |
| Anderson-Fahey, B | 1 |
| Le Nedelec, M | 2 |
| Gray, A | 1 |
| McNaughton, N | 1 |
| Duncan, WC | 4 |
| Slonena, E | 1 |
| Hejazi, NS | 2 |
| Brutsche, N | 7 |
| Yu, KC | 1 |
| Wills, K | 1 |
| Lally, N | 5 |
| Richards, EM | 9 |
| Walls, T | 1 |
| Ameli, R | 5 |
| Brutsche, NE | 14 |
| Wright, D | 1 |
| Fasula, MK | 1 |
| Fenton, L | 1 |
| Griepp, M | 1 |
| Huang, YJ | 1 |
| Lane, HY | 1 |
| Lin, CH | 1 |
| Gold, PW | 3 |
| De Sousa, RT | 2 |
| Machado-Vieira, R | 15 |
| Malcolm, B | 1 |
| Boggie, D | 1 |
| Lee, K | 1 |
| Suárez-Santiago, JE | 1 |
| Briones-Aranda, A | 1 |
| Espinosa-Raya, J | 1 |
| Picazo, O | 1 |
| Ajub, E | 1 |
| Ma, M | 1 |
| Ren, Q | 2 |
| Dong, C | 1 |
| Ohgi, Y | 1 |
| Futamura, T | 1 |
| Fassauer, GM | 1 |
| Hofstetter, R | 1 |
| Hasan, M | 1 |
| Oswald, S | 1 |
| Modeß, C | 1 |
| Siegmund, W | 1 |
| Link, A | 1 |
| Feder, A | 3 |
| Sos, P | 3 |
| Wang, G | 4 |
| Iadarola, ND | 1 |
| Banerjee, D | 2 |
| Park, M | 3 |
| Lener, M | 2 |
| Akula, N | 2 |
| McMahon, FJ | 2 |
| van Schalkwyk, GI | 1 |
| Davidson, L | 1 |
| Silverman, WK | 1 |
| Gurnani, T | 1 |
| Khurshid, KA | 1 |
| Sharma, P | 1 |
| Hales, CA | 1 |
| Houghton, CJ | 1 |
| Robinson, ESJ | 1 |
| Vutskits, L | 3 |
| Rosenheck, R | 1 |
| Li, Q | 1 |
| Xiao, Y | 1 |
| Fan, N | 1 |
| He, H | 1 |
| Raffa, RB | 2 |
| Pergolizzi, JV | 1 |
| Taylor, R | 1 |
| Moitra, VK | 1 |
| Marver, JE | 1 |
| Sublette, ME | 1 |
| Oquendo, MA | 3 |
| Maciel, AL | 1 |
| de Souza, TG | 1 |
| Matos, D | 1 |
| Tuon, T | 1 |
| Strassi, AP | 1 |
| Mathias, K | 1 |
| Van Nueten, L | 1 |
| Kwon, JH | 1 |
| Sim, WS | 1 |
| Hong, JP | 1 |
| Song, IS | 1 |
| Lee, JY | 1 |
| Tang, H | 1 |
| Kukral, D | 1 |
| Li, YW | 1 |
| Fronheiser, M | 1 |
| Malone, H | 1 |
| Pena, A | 1 |
| Pieschl, R | 1 |
| Sidik, K | 1 |
| Tobon, G | 1 |
| Chow, PL | 1 |
| Bristow, LJ | 1 |
| Hayes, W | 1 |
| Luo, F | 1 |
| Pereira, VS | 1 |
| Hiroaki-Sato, VA | 1 |
| Mischel, N | 1 |
| Bjerre-Real, C | 1 |
| Komisar, J | 1 |
| Ginsberg, B | 1 |
| PreudʼHomme, X | 1 |
| Wojdacz, R | 1 |
| Święcicki, Ł | 1 |
| Antosik-Wójcińska, A | 1 |
| Yarrington, JS | 3 |
| Williams, D | 1 |
| Shovestul, BJ | 1 |
| Jaso, BA | 1 |
| Farmer, C | 4 |
| Szczepanik, J | 2 |
| Alphs, L | 1 |
| Pinter, C | 1 |
| Arabzadeh, S | 1 |
| Hakkikazazi, E | 1 |
| Shahmansouri, N | 1 |
| Tafakhori, A | 1 |
| Ghajar, A | 1 |
| Jafarinia, M | 1 |
| Akhondzadeh, S | 2 |
| Wills, KE | 2 |
| Gamble, JJ | 1 |
| Bi, H | 1 |
| Bowen, R | 1 |
| Weisgerber, G | 1 |
| Sanjanwala, R | 1 |
| Prasad, R | 1 |
| Balbuena, L | 1 |
| Morvai, S | 1 |
| Nagy, AI | 1 |
| Bálint-Szöllősi, A | 1 |
| Móré, EC | 1 |
| Berecz, R | 1 |
| Frecska, E | 1 |
| An, L | 1 |
| Li, N | 1 |
| Snider, SL | 1 |
| Shen, J | 2 |
| Haji, N | 1 |
| Popic, J | 1 |
| Sharma, V | 1 |
| Cao, R | 1 |
| Rummel, C | 1 |
| Tanti, A | 1 |
| Wiebe, S | 1 |
| Nuñez, N | 1 |
| Comai, S | 1 |
| Nadon, R | 1 |
| Luheshi, G | 1 |
| Mechawar, N | 1 |
| Vollmer, H | 1 |
| Reed, JL | 2 |
| Szczepanik, JE | 2 |
| Richards, E | 1 |
| Sinyor, M | 1 |
| Williams, M | 1 |
| Belo, S | 1 |
| Orser, B | 1 |
| Vincent, M | 1 |
| Mah, L | 1 |
| Zarate, C | 1 |
| Castel, S | 1 |
| Levitt, AJ | 1 |
| Shardell, M | 1 |
| Khadeer, M | 1 |
| Ravichandran, S | 1 |
| Furey, M | 3 |
| Ellis, J | 1 |
| Filip, M | 1 |
| Jasionowska, J | 1 |
| Gałecki, P | 1 |
| Li, HQ | 3 |
| Chen, LJ | 3 |
| Bentley, KH | 1 |
| Eikermann, M | 1 |
| Taylor, N | 2 |
| Akeju, O | 2 |
| Swee, MB | 2 |
| Pavone, KJ | 2 |
| Petrie, SR | 1 |
| Dording, C | 1 |
| Mischoulon, D | 2 |
| Alpert, JE | 2 |
| Brown, EN | 2 |
| Baer, L | 2 |
| Nock, MK | 2 |
| Saligan, LN | 1 |
| Vidal, S | 2 |
| Gex-Fabry, M | 1 |
| Bancila, V | 2 |
| Michalopoulos, G | 2 |
| Warrot, D | 2 |
| Jermann, F | 1 |
| Dayer, A | 2 |
| Sterpenich, V | 2 |
| Schwartz, S | 2 |
| Khan, N | 1 |
| Aubry, JM | 2 |
| Kosel, M | 2 |
| Michaëlsson, H | 1 |
| Andersson, M | 1 |
| Svensson, J | 1 |
| Karlsson, L | 1 |
| Ehn, J | 1 |
| Culley, G | 1 |
| Engström, A | 1 |
| Bergström, N | 1 |
| Savvidi, P | 1 |
| Kuhn, HG | 1 |
| Hanse, E | 1 |
| Seth, H | 1 |
| Chan, LF | 1 |
| Eu, CL | 1 |
| Soh, SY | 1 |
| Maniam, T | 1 |
| Shahidii Kadir, Z | 1 |
| Chong, BTW | 1 |
| Loo, JL | 1 |
| Sharip, S | 1 |
| Wong, VCW | 1 |
| Loo, TH | 1 |
| Ng, YP | 1 |
| Kahn, DA | 1 |
| Farber, NB | 1 |
| Jiang, C | 1 |
| Lin, WJ | 1 |
| Labonté, B | 1 |
| Tamminga, CA | 1 |
| Salton, SR | 1 |
| Finnegan, M | 1 |
| Galligan, T | 1 |
| Ryan, K | 1 |
| Harkin, A | 1 |
| Daly, L | 1 |
| Mathew, S | 1 |
| Grunebaum, M | 1 |
| Henter, I | 1 |
| Merikangas, K | 1 |
| Drevets, W | 1 |
| Shugart, YY | 1 |
| Yoon, G | 1 |
| Petrakis, IL | 1 |
| Crocamo, C | 1 |
| Carrà, G | 1 |
| Basso, L | 1 |
| Otte, C | 1 |
| Wingenfeld, K | 1 |
| Chae, WR | 1 |
| Heuser-Collier, I | 1 |
| Regen, F | 1 |
| Cosma, NC | 1 |
| van Hall, F | 1 |
| Herzog, DP | 1 |
| Wegener, G | 2 |
| Lieb, K | 1 |
| Müller, MB | 1 |
| Treccani, G | 1 |
| Li, XH | 1 |
| Zhu, XM | 1 |
| Ng, CH | 1 |
| Hu, YD | 2 |
| He, SH | 1 |
| Soleimani, L | 3 |
| Glasgow, A | 1 |
| Brallier, J | 1 |
| Spivack, J | 1 |
| Levitch, CF | 5 |
| Richards, S | 1 |
| Hoch, M | 1 |
| Stade, EC | 1 |
| Welch, A | 1 |
| Wang, XL | 1 |
| Yuan, K | 1 |
| Zhang, W | 2 |
| Li, SX | 1 |
| Gao, GF | 1 |
| Lu, L | 2 |
| Montemitro, C | 1 |
| Fiengo, ALC | 1 |
| Santone, C | 1 |
| Carano, A | 1 |
| Giannantonio, MD | 1 |
| Nicola, MD | 1 |
| Bellomo, A | 1 |
| Ventriglio, A | 1 |
| Berardis, DD | 1 |
| Fukumoto, K | 1 |
| Fogaça, MV | 1 |
| Hare, B | 1 |
| Birmingham, M | 1 |
| Hatchard, T | 1 |
| Yu, L | 1 |
| Carvalho, AF | 1 |
| Subramanieapillai, M | 1 |
| Hofmeister, J | 1 |
| Desseilles, M | 1 |
| Rantamäki, T | 1 |
| Yalcin, I | 1 |
| Trivedi, M | 1 |
| Mazzucco, C | 1 |
| Molero, P | 2 |
| Köhler-Forsberg, O | 1 |
| Zarrinnegar, P | 1 |
| Kothari, J | 1 |
| Cheng, K | 1 |
| Duca, AR | 1 |
| Zajecka, J | 1 |
| Divacka, I | 1 |
| Cubala, WJ | 1 |
| Bitter, I | 1 |
| Murakami, K | 1 |
| Sun, Q | 1 |
| Jia, L | 1 |
| Verdonk, F | 1 |
| Petit, AC | 1 |
| Abdel-Ahad, P | 1 |
| Vinckier, F | 1 |
| Jouvion, G | 1 |
| de Maricourt, P | 1 |
| De Medeiros, GF | 1 |
| Danckaert, A | 1 |
| Van Steenwinckel, J | 1 |
| Blatzer, M | 1 |
| Maignan, A | 1 |
| Langeron, O | 1 |
| Sharshar, T | 1 |
| Callebert, J | 1 |
| Launay, JM | 1 |
| Chrétien, F | 1 |
| Gaillard, R | 1 |
| Aleksandrova, LR | 1 |
| Wang, YT | 1 |
| Phillips, AG | 1 |
| Lasič, E | 1 |
| Lisjak, M | 1 |
| Horvat, A | 1 |
| Šakanović, A | 1 |
| Anderluh, G | 1 |
| Verkhratsky, A | 1 |
| Vardjan, N | 1 |
| Jorgačevski, J | 1 |
| Howland, RH | 1 |
| Zigman, D | 1 |
| Rasmussen, KG | 4 |
| Lineberry, TW | 1 |
| Galardy, CW | 1 |
| Lapid, MI | 2 |
| Palmer, BA | 3 |
| Ritter, MJ | 2 |
| Sola, CL | 1 |
| Hanson, AJ | 1 |
| Järventausta, K | 1 |
| Chrapek, W | 1 |
| Kampman, O | 1 |
| Tuohimaa, K | 1 |
| Björkqvist, M | 1 |
| Häkkinen, H | 1 |
| Yli-Hankala, A | 1 |
| Leinonen, E | 1 |
| Murck, H | 1 |
| Dilley, JD | 1 |
| Gentry, WB | 1 |
| Golden, KJ | 1 |
| Grott Zanicotti, C | 1 |
| Perez, D | 2 |
| Grunschel, BD | 1 |
| Corlett, PR | 1 |
| Briggs, MC | 1 |
| Pasculli, RM | 1 |
| Bryson, EO | 1 |
| Mathews, DC | 2 |
| Klirova, M | 1 |
| Kohutova, B | 1 |
| Palenicek, T | 1 |
| Zunszain, PA | 1 |
| Horowitz, MA | 1 |
| Cattaneo, A | 1 |
| Lupi, MM | 1 |
| Pariante, CM | 1 |
| Atigari, OV | 1 |
| Healy, D | 1 |
| Küçük, A | 1 |
| Karababa, F | 1 |
| Yüce, HH | 1 |
| Yalçin, S | 1 |
| Womble, AL | 1 |
| Al Jurdi, RK | 1 |
| Green, CE | 1 |
| Perez, AM | 7 |
| Pillemer, S | 1 |
| Foulkes, A | 3 |
| Shah, A | 1 |
| Rush, AJ | 1 |
| Yoosefi, A | 2 |
| Sepehri, AS | 1 |
| Kargar, M | 1 |
| Sadeghi, M | 1 |
| Rafei, A | 1 |
| Alimadadi, A | 1 |
| Ghaeli, P | 1 |
| Smith, MA | 2 |
| Pathak, S | 1 |
| Su, HL | 1 |
| Boeijinga, PH | 1 |
| McCarthy, DJ | 2 |
| Quirk, MC | 1 |
| Bortolozzi, A | 1 |
| Celada, P | 1 |
| Artigas, F | 1 |
| Ghasemi, M | 1 |
| Kazemi, MH | 1 |
| Ghasemi, A | 1 |
| Paragomi, P | 1 |
| Amini, H | 1 |
| Afzali, MH | 1 |
| Naughton, M | 1 |
| Clarke, G | 2 |
| O'Leary, OF | 1 |
| Cryan, JF | 2 |
| Dinan, TG | 2 |
| Oesterle, TS | 1 |
| Geske, JR | 1 |
| Nuttall, GA | 1 |
| Oliver, WC | 1 |
| Abenstein, JP | 1 |
| Dang, YH | 1 |
| Ma, XC | 1 |
| Wu, J | 1 |
| Gao, CG | 1 |
| Pozzi, L | 1 |
| Pollak Dorocic, I | 1 |
| Dorocic, IP | 1 |
| Carlén, M | 1 |
| Meletis, K | 1 |
| Gálvez, V | 3 |
| O'Keefe, E | 1 |
| Cotiga, L | 1 |
| Leyden, J | 1 |
| Harper, S | 1 |
| Mitchell, PB | 3 |
| DeLory, A | 1 |
| Loo, CK | 2 |
| Neotti, MV | 1 |
| Narang, P | 1 |
| Lippmann, S | 1 |
| Brittner, M | 2 |
| Micoulaud-Franchi, JA | 3 |
| Richieri, R | 2 |
| Boyer, L | 4 |
| Adida, M | 1 |
| Lancon, C | 3 |
| Fond, G | 4 |
| Nolan, NM | 2 |
| Guevara, S | 2 |
| Yen, T | 1 |
| Khafaja, M | 1 |
| Lam, N | 1 |
| Crumbacher, J | 1 |
| Schrader, R | 1 |
| Rask, J | 1 |
| Billstrand, M | 1 |
| Rothfork, J | 1 |
| Abbott, CC | 1 |
| Pałucha-Poniewiera, A | 2 |
| Lapidus, KA | 2 |
| Brallier, JW | 4 |
| Parides, MK | 1 |
| Greenberg, RM | 2 |
| Ahle, GM | 1 |
| Liebman, LS | 1 |
| Fleck, MP | 1 |
| Loundou, A | 2 |
| Rabu, C | 1 |
| Macgregor, A | 1 |
| Abbar, M | 1 |
| Roger, M | 1 |
| Leboyer, M | 1 |
| Erdil, F | 2 |
| Begeç, Z | 1 |
| Kayhan, GE | 1 |
| Yoloğlu, S | 1 |
| Ersoy, MÖ | 1 |
| Durmuş, M | 2 |
| Yang, JJ | 1 |
| Wang, N | 1 |
| Shi, JY | 1 |
| Yu, HY | 1 |
| Jackowski, A | 2 |
| Baldwin, P | 1 |
| Sato, JR | 2 |
| Ota, KT | 1 |
| Andres, W | 1 |
| Lewis, DA | 1 |
| Stockmeier, CA | 1 |
| Wink, LK | 1 |
| O'Melia, AM | 1 |
| Shaffer, RC | 1 |
| Pedapati, E | 1 |
| Friedmann, K | 1 |
| Schaefer, T | 1 |
| Erickson, CA | 1 |
| Demenescu, LR | 1 |
| Wan, LB | 1 |
| Slonena, EE | 1 |
| Sisti, D | 1 |
| Segal, AG | 1 |
| Bunney, BG | 1 |
| Li, JZ | 1 |
| Walsh, DM | 1 |
| Stein, R | 1 |
| Vawter, MP | 1 |
| Cartagena, P | 1 |
| Barchas, JD | 1 |
| Myers, RM | 1 |
| Watson, SJ | 1 |
| Akil, H | 1 |
| Bunney, WE | 1 |
| Burdick, KE | 1 |
| Xu, J | 1 |
| Lei, H | 1 |
| Dutta, A | 2 |
| McKie, S | 2 |
| Deakin, JFW | 1 |
| Lisanby, SH | 1 |
| Weiner, R | 1 |
| Prudic, J | 1 |
| Rudorfer, MV | 1 |
| Young, RC | 1 |
| Petrides, G | 1 |
| McCall, WV | 1 |
| Husain, M | 1 |
| Knapp, RG | 1 |
| Campion, P | 1 |
| Drewniany, E | 1 |
| Han, J | 1 |
| Hancock, C | 1 |
| Jones, RL | 1 |
| Lim, J | 1 |
| Nemat Gorgani, N | 1 |
| Sperry, JK | 1 |
| Yu, HJ | 1 |
| DeWilde, KE | 4 |
| Fields, J | 1 |
| Phillips, ML | 1 |
| Wong, E | 2 |
| Tang, CY | 2 |
| Ozgul, U | 1 |
| Çolak, C | 1 |
| Cumurcu, B | 1 |
| Coyle, CM | 1 |
| Laws, KR | 1 |
| Pekary, AE | 1 |
| Sattin, A | 1 |
| Lloyd, RL | 1 |
| Dwyer, JM | 1 |
| Maldonado-Avilés, JG | 1 |
| Lepack, AE | 1 |
| DiLeone, RJ | 1 |
| Dean, B | 1 |
| Gibbons, AS | 1 |
| Boer, S | 1 |
| Uezato, A | 1 |
| Meador-Woodruff, J | 1 |
| Scarr, E | 1 |
| McCullumsmith, RE | 1 |
| Melo, A | 1 |
| Kokras, N | 1 |
| Dalla, C | 1 |
| Ferreira, C | 1 |
| Ventura-Silva, AP | 1 |
| Sousa, N | 1 |
| Pêgo, JM | 1 |
| Gray, AL | 1 |
| Hyde, TM | 1 |
| Deep-Soboslay, A | 1 |
| Kleinman, JE | 1 |
| Sodhi, MS | 1 |
| Miller, OH | 1 |
| Moran, JT | 1 |
| Hall, BJ | 1 |
| Walls, TL | 1 |
| Piantadosi, SC | 1 |
| Wu, HQ | 1 |
| Pribut, HJ | 1 |
| Dell, MJ | 1 |
| Can, A | 1 |
| Snodgrass, HR | 1 |
| Schwarcz, R | 1 |
| Iacoviello, BM | 1 |
| Kautz, M | 1 |
| Kim, J | 1 |
| Stern, JB | 1 |
| Price, RB | 1 |
| Rodriguez, GJ | 1 |
| Goodman, WK | 1 |
| Proper, CJ | 1 |
| Parter, AL | 1 |
| Rodriguez, CI | 1 |
| Newport, DJ | 2 |
| Carpenter, LL | 1 |
| Potash, JB | 1 |
| Tohen, M | 1 |
| Fang, JX | 1 |
| Zu, S | 1 |
| Sha, S | 1 |
| Shi, H | 1 |
| Correll, CU | 2 |
| Chiu, HF | 1 |
| Xue, Y | 1 |
| Tian, TF | 1 |
| Wu, AS | 1 |
| Trevithick, L | 1 |
| Blamire, A | 1 |
| Branton, T | 1 |
| Clark, R | 1 |
| Dunn, G | 1 |
| Easton, A | 1 |
| Ellwell, C | 1 |
| Hayden, K | 1 |
| Holland, F | 1 |
| Karim, S | 1 |
| Lowe, J | 1 |
| Nair, R | 1 |
| Oakley, T | 1 |
| Prakash, A | 1 |
| Sharma, PK | 1 |
| Williams, SR | 1 |
| Hackett, M | 1 |
| Carter, G | 1 |
| Lapidus, K | 1 |
| Njau, SN | 1 |
| Cooper, MD | 1 |
| Kakar, R | 1 |
| Romeo, B | 2 |
| Choucha, W | 2 |
| Rotge, JY | 2 |
| Bennabi, D | 1 |
| Haffen, E | 1 |
| Brunel, L | 1 |
| Llorca, PM | 1 |
| Auquier, P | 1 |
| Yang, BH | 1 |
| Liu, RS | 1 |
| Gerhard, DM | 1 |
| Wohleb, ES | 2 |
| Kishimoto, T | 1 |
| Chawla, JM | 1 |
| Hagi, K | 1 |
| Kane, JM | 1 |
| Johnson, EK | 1 |
| Leung, JG | 2 |
| Gerhard, D | 1 |
| Thomas, A | 1 |
| Zhang, MW | 1 |
| Adams, TG | 2 |
| Kelmendi, B | 2 |
| Bobo, WV | 2 |
| Croarkin, PE | 1 |
| Ren, Z | 1 |
| Pribiag, H | 1 |
| Jefferson, SJ | 1 |
| Shorey, M | 1 |
| Fuchs, T | 1 |
| Stellwagen, D | 1 |
| Luscher, B | 1 |
| Dawson, GR | 1 |
| Dourish, CT | 1 |
| Craig, K | 1 |
| Goodwin, GM | 1 |
| Deakin, JF | 1 |
| Nyer, M | 1 |
| Cassano, P | 1 |
| Robinson, SE | 1 |
| Coppola, R | 2 |
| Rosa, PB | 1 |
| Ribeiro, CM | 1 |
| Rodrigues, AL | 1 |
| Gururajan, A | 1 |
| Naughton, ME | 1 |
| Scott, KA | 1 |
| O'Connor, RM | 1 |
| Moloney, G | 1 |
| Dowling, J | 1 |
| Walsh, A | 1 |
| Ismail, F | 1 |
| Shorten, G | 1 |
| Scott, L | 1 |
| Du Jardin, KG | 1 |
| Sanchez, C | 1 |
| Elfving, B | 1 |
| Geha, P | 1 |
| Averill, C | 1 |
| Anticevic, A | 1 |
| Rotroff, DM | 1 |
| Corum, DG | 1 |
| Motsinger-Reif, A | 1 |
| Fiehn, O | 1 |
| Bottrel, N | 1 |
| Salvadore, G | 6 |
| Kaddurah-Daouk, R | 1 |
| Morgan, RJ | 1 |
| Rico, J | 1 |
| Newman, LE | 1 |
| Chang, H | 1 |
| Bonnet, U | 1 |
| Ray, SM | 1 |
| Kious, BM | 1 |
| Aksay, SS | 1 |
| Hambsch, M | 1 |
| Janke, C | 3 |
| Bumb, JM | 1 |
| Kranaster, L | 4 |
| Sartorius, A | 4 |
| Hao, X | 1 |
| Peng, L | 1 |
| Meng, H | 1 |
| Luo, Q | 1 |
| Zhu, W | 1 |
| Ding, Z | 1 |
| Shi, J | 1 |
| Dhir, A | 1 |
| Apeldoorn, SY | 1 |
| de Boer, MK | 1 |
| Litvan, Z | 1 |
| Frey, R | 1 |
| Idell, RD | 1 |
| Florova, G | 1 |
| Komissarov, AA | 1 |
| Shetty, S | 1 |
| Girard, RB | 1 |
| Idell, S | 1 |
| Gupta, S | 1 |
| Coplan, JD | 1 |
| Cornwell, BR | 3 |
| Colon-Rosario, V | 2 |
| Grillon, C | 3 |
| Phelps, LE | 1 |
| Moral, JR | 1 |
| Stefanczyk-Sapieha, L | 1 |
| Oneschuk, D | 1 |
| Demas, M | 1 |
| Paul, R | 1 |
| Schaaff, N | 1 |
| Padberg, F | 1 |
| Möller, HJ | 1 |
| Frodl, T | 1 |
| Diazgranados, N | 5 |
| Luckenbaugh, D | 1 |
| Reich, DL | 1 |
| Bjerre, J | 1 |
| Fontenay, C | 1 |
| Sambataro, F | 1 |
| Latov, D | 1 |
| Carver, F | 1 |
| Holroyd, T | 1 |
| Ibrahim, LA | 2 |
| Valentine, GW | 1 |
| Mason, GF | 1 |
| Gomez, R | 1 |
| Fasula, M | 2 |
| Watzl, J | 1 |
| Pittman, B | 1 |
| Kammerer-Ciernioch, J | 1 |
| Hoyer, C | 3 |
| Gelenberg, AJ | 1 |
| Ibrahim, L | 1 |
| Baumann, J | 2 |
| Mallinger, AG | 1 |
| Gulati, A | 1 |
| Duffull, S | 1 |
| Larkin, GL | 1 |
| Beautrais, AL | 1 |
| Taylor, MJ | 1 |
| Tiangga, ER | 1 |
| Mhuircheartaigh, RN | 1 |
| Denk, MC | 1 |
| Rewerts, C | 1 |
| Holsboer, F | 1 |
| Erhardt-Lehmann, A | 1 |
| Turck, CW | 1 |
| Liu, RJ | 1 |
| Lee, FS | 1 |
| Li, XY | 1 |
| Bambico, F | 1 |
| van der Veen, JW | 1 |
| Marenco, S | 1 |
| Covvey, JR | 1 |
| Crawford, AN | 1 |
| Lowe, DK | 1 |
| Zanicotti, CG | 1 |
| Laje, G | 1 |
| Venkata, SL | 1 |
| Ramamoorthy, A | 1 |
| Wainer, IW | 1 |
| Marquardt, CA | 1 |
| Lewien, A | 1 |
| Lederbogen, F | 1 |
| Chen, Y | 1 |
| Zhou, X | 1 |
| Liu, F | 1 |
| Zhang, T | 1 |
| Ago, Y | 1 |
| Palucha-Paniewiera, A | 1 |
| Matrisciano, F | 1 |
| Sarasso, S | 2 |
| Ferrarelli, F | 1 |
| Selter, J | 2 |
| Riedner, BA | 1 |
| Tononi, G | 1 |
| Owen, RT | 1 |
| Ostroff, R | 1 |
| Katalinic, N | 1 |
| Garfield, JB | 1 |
| Sainsbury, K | 1 |
| Hadzi-Pavlovic, D | 1 |
| Mac-Pherson, R | 1 |
| Strakowski, SM | 1 |
| Lehmann, M | 1 |
| Metzger, C | 1 |
| Boeker, H | 1 |
| Boesiger, P | 1 |
| Kerman, IA | 1 |
| Szymkowicz, SM | 1 |
| Finnegan, N | 1 |
| Dale, RM | 1 |
| Dowben, JS | 1 |
| Grant, JS | 1 |
| Keltner, NL | 1 |
| Dolgin, E | 1 |
| Krystal, AD | 1 |
| Weiner, RD | 1 |
| Dean, MD | 1 |
| Lindahl, VH | 1 |
| Tramontozzi, LA | 1 |
| Falcone, G | 1 |
| Coffey, CE | 1 |
| Carlson, PJ | 1 |
| Goforth, HW | 1 |
| Liebrenz, M | 2 |
| Borgeat, A | 2 |
| Leisinger, R | 1 |
| Stohler, R | 2 |
| Maeng, S | 2 |
| Du, J | 1 |
| Schloesser, RJ | 1 |
| McCammon, J | 1 |
| Chen, G | 1 |
| Hillemacher, T | 1 |
| Bleich, S | 1 |
| Demling, J | 1 |
| Kornhuber, J | 2 |
| Kollmar, R | 1 |
| Markovic, K | 1 |
| Thürauf, N | 1 |
| Schmitt, H | 1 |
| Berman, RM | 1 |
| Cappiello, A | 1 |
| Oren, DA | 1 |
| Heninger, GR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| N-methyl-D-aspartate Receptor (NMDAR)-Based Pharmacotherapy With D-cycloserine for Treatment-resistant Major Depressive Disorder[NCT00408031] | Phase 2 | 26 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| A Phase IIa, Multi-Center, Randomized, Double-blind, Placebo-controlled, Parallel-Group Study to Assess the Antidepressant Effect and Onset of Effect of AZD6765 in Treatment-Resistant Major Depressive Disorder Patients[NCT00491686] | Phase 2 | 34 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| A Multi Center, Randomized, Double-blind, Placebo Controlled, Parallel-group Study to Investigate the Efficacy and Safety of RO4995819 Versus Placebo, as Adjunctive Therapy in Patients With Major Depressive Disorder Having Inadequate Response to Ongoing A[NCT01457677] | Phase 2 | 357 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| A Double-blind Randomised, Placebo-controlled Study of Adjunctive Ketamine Anaesthesia in ECT (Electroconvulsive Therapy)[NCT00680433] | Phase 4 | 83 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| AXS-05-MDD-301: A Randomized, Double-Blind, Placebo-Controlled Trial of AXS-05 in Subjects With Major Depressive Disorder[NCT04019704] | Phase 3 | 327 participants (Actual) | Interventional | 2019-06-20 | Completed | ||
| N-methylglycine (Sarcosine) for Treatment of Major Depressive Disorder[NCT00977353] | Phase 2 | 40 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression[NCT02417064] | Phase 3 | 346 participants (Actual) | Interventional | 2015-08-10 | Completed | ||
| An Investigation of the Antidepressant Effects of an NMDA Antagonist in Treatment-Resistant Major Depression[NCT00986479] | Phase 2 | 22 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Intranasal (IN) Ketamine in Treatment-Resistant Depression (TRD)[NCT01304147] | 20 participants (Actual) | Interventional | 2011-10-31 | Completed | |||
| Single Center, Randomized, Placebo-Controlled Trial to Establish Maximum Tolerated Dose, Optimal Titration Schedule, Safety, Tolerability, and Pharmacokinetics of Org 26576 in Patients Diagnosed With Major Depressive Disorder (Protocol No. P174001)[NCT00610649] | Phase 2 | 54 participants (Actual) | Interventional | 2007-09-20 | Completed | ||
| A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideati[NCT03039192] | Phase 3 | 226 participants (Actual) | Interventional | 2017-06-09 | Completed | ||
| A Multicentre, Double-blind, Randomised, Placebo - Controlled Phase II Study to Assess Efficacy, Safety and Pharmacokinetics of Inhaled Esketamine in Subject With Treatment-resistant Bipolar Depression[NCT03965871] | Phase 2 | 88 participants (Actual) | Interventional | 2019-03-28 | Completed | ||
| A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideati[NCT03097133] | Phase 3 | 230 participants (Actual) | Interventional | 2017-06-15 | Completed | ||
| A Randomized Double-Blind Pilot Study of Memantine Augmentation in Antidepressant Nonresponders or Incomplete Responders[NCT00344682] | Phase 4 | 31 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A Prophylactic Trial of Omega-3 Polyunsaturated Fatty Acids in Bipolar Disorder[NCT04210804] | Phase 2 | 80 participants (Actual) | Interventional | 2014-04-01 | Completed | ||
| A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants[NCT00781742] | Phase 2 | 152 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression[NCT02418585] | Phase 3 | 236 participants (Actual) | Interventional | 2015-08-07 | Completed | ||
| A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Subjects With Treatment Resistant Depression[NCT02918318] | Phase 2 | 202 participants (Actual) | Interventional | 2016-12-12 | Completed | ||
| Ketamine vs. Midazolam: Testing Rapid Relief of Suicide Risk in Depression[NCT01700829] | Phase 4 | 82 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| A Placebo- and Active-Controlled Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Subjects With Major Depressive Disorder (DriveSaFe2)[NCT02919579] | Phase 1 | 27 participants (Actual) | Interventional | 2016-10-07 | Completed | ||
| Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder[NCT03065335] | Phase 1 | 150 participants (Anticipated) | Interventional | 2017-05-25 | Recruiting | ||
| Naturalistic Study of Ketamine in the Treatment of Depression: Suicide Risk Assessment and Serum Measurements of SIRT3, suPAR, hsCRP, Interleukin 6, Complete Blood Count, Leptin, Lipid Profile and Blood Glucose[NCT05249309] | 90 participants (Anticipated) | Observational [Patient Registry] | 2021-05-01 | Active, not recruiting | |||
| An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression[NCT02497287] | Phase 3 | 802 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| A Randomized, Double-blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression[NCT02493868] | Phase 3 | 719 participants (Actual) | Interventional | 2015-10-01 | Completed | ||
| Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)[NCT01920555] | Phase 2 | 99 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| Investigation of the Rapid (Next Day) Antidepressant Effects of an NMDA Antagonist[NCT00088699] | Phase 1/Phase 2 | 67 participants (Actual) | Interventional | 2004-07-26 | Completed | ||
| Long-term Observation of Participants With Mood Disorders[NCT04877977] | 1,000 participants (Anticipated) | Observational | 2021-08-17 | Recruiting | |||
| Translational Biomarkers of Fast Acting Therapies in Major Depression[NCT02165449] | Phase 1 | 60 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| Effect of Intravenous Low-dose Esketamine on Maternal Depression at 2 Years After Childbirth in Women With Prenatal Depression: 2-year Follow-up of a Randomized Controlled Trial[NCT05698394] | Phase 4 | 364 participants (Actual) | Interventional | 2020-06-19 | Active, not recruiting | ||
| A Phase II, Randomised, Double-blind, Placebo- Controlled, Multi-site, Parallel Group Clinical Trial to Examine Ketamine as a Pharmacological Treatment for Alcohol Dependence in an Alcohol Dependent Population[NCT02649231] | Phase 2 | 96 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| Investigations on the Efficacy of Ketamine in Depression in Comparison to Electroconvulsive Therapy[NCT03674671] | Phase 3 | 240 participants (Anticipated) | Interventional | 2018-10-29 | Suspended (stopped due to insufficient funding) | ||
| Validation of the Glx Biomarker for Treatment of Moderate Bipolar Depression With NRX-101[NCT03402152] | Phase 2/Phase 3 | 8 participants (Actual) | Interventional | 2018-11-01 | Completed | ||
| The Antidepressant Action of Ketamine: Brain Chemistry[NCT01558063] | Phase 2 | 38 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Phenomenological Explorations of the Esketamine-Induced Transient Dissociative State[NCT06133309] | 15 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | |||
| Effect of Mini-dose Dexmedetomidine-Esketamine Infusion on Sleep Quality in Older Patients Undergoing Knee or Hip Replacement Surgery: A Multicenter Randomized Controlled Trial[NCT05950646] | Phase 4 | 154 participants (Anticipated) | Interventional | 2023-11-01 | Recruiting | ||
| Anhedonia, Development, and Emotions: Phenotyping and Therapeutics (ADEPT) Study[NCT05487885] | Phase 4 | 275 participants (Anticipated) | Interventional | 2022-07-22 | Recruiting | ||
| A Retrospective Chart Review of Patients Undergoing Ketamine Infusions at the Canadian Rapid Treatment Center of Excellence[NCT04209296] | 580 participants (Anticipated) | Observational | 2019-12-03 | Enrolling by invitation | |||
| Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) a Multicentre Open-label Randomized Controlled Trial Protocol[NCT05814640] | Phase 1/Phase 2 | 520 participants (Anticipated) | Interventional | 2023-02-20 | Recruiting | ||
| A Naturalistic Study of Ketamine for Treatment Resistant Mood Disorders: Gdansk Depression Ketamine Project[NCT04226963] | 80 participants (Actual) | Observational [Patient Registry] | 2019-12-04 | Completed | |||
| Ketamine Infusion for Social Anxiety Disorder[NCT02083926] | Early Phase 1 | 18 participants (Actual) | Interventional | 2015-01-02 | Completed | ||
| Effects of Low-dose Dexmedetomidine-esketamine Combined Nasal Administration at Night on Perioperative Sleep Quality in Breast Cancer Patients: a Randomized, Double-blind, Placebo-controlled Trial[NCT05732064] | Phase 4 | 180 participants (Anticipated) | Interventional | 2023-05-22 | Recruiting | ||
| Effect of S-ketamine on Depressed Patients Undergoing Electroconvulsive Therapy-a Randomized, Double-blind, Controlled Clinical Study[NCT04399070] | 150 participants (Anticipated) | Interventional | 2020-08-01 | Not yet recruiting | |||
| A Single Ketamine Infusion Combined With Music for Suicidal Ideation During a Depressive Episode: A Randomized Open Label Clinical Trial[NCT04658420] | Phase 2 | 200 participants (Anticipated) | Interventional | 2021-07-01 | Not yet recruiting | ||
| Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department[NCT04260607] | Phase 3 | 2 participants (Actual) | Interventional | 2020-01-14 | Terminated (stopped due to As a busy MTF we were unable to retain a health care provider with the appropriate expertise to buy-in to this study once the initiating PI left military service.) | ||
| Music as a Potential Intervention to Improve Hemodynamic Tolerability of Repetitive Sub-Anesthetic IV Ketamine Infusions in Bipolar and Unipolar Depression: A Pilot Study[NCT04701866] | 32 participants (Actual) | Interventional | 2021-01-11 | Completed | |||
| Intramuscular Ketamine Versus Escitalopram and Aripiprazole in Acute and Maintenance Treatment of Patients With Treatment-resistant Depression[NCT04234776] | Phase 4 | 88 participants (Anticipated) | Interventional | 2018-04-03 | Enrolling by invitation | ||
| Evaluation of Schemes of Administration of Intravenous Ketamine in Treatment-resistant Depression: Clinical-neuroimaging Correlation[NCT03742557] | Phase 3 | 30 participants (Anticipated) | Interventional | 2018-10-01 | Recruiting | ||
| A Double-Blind, Doubly-Randomized, Placebo-Controlled Study of Intranasal Esketamine in an Adaptive Treatment Protocol to Assess Safety and Efficacy in Treatment-Resistant Depression (SYNAPSE)[NCT01998958] | Phase 2 | 108 participants (Actual) | Interventional | 2014-01-27 | Completed | ||
| Dexmedetomidine-esketamine Combined With Oxycodone for Ultrasound-guided Percutaneous Radiofrequency Ablation in Patients With Liver Cancer: a Randomized Controlled Study[NCT06003218] | 88 participants (Anticipated) | Interventional | 2023-10-16 | Recruiting | |||
| Efficacy of Different Dose Esketamine and Dexmedetomidine Combination for Supplemental Analgesia After Scoliosis Correction Surgery: A Randomized, Double-blind Trial[NCT06062550] | Phase 4 | 312 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | ||
| Impact of Different Dose Esketamine and Dexmedetomidine Combination for Supplemental Analgesia on Long-term Outcomes After Scoliosis Correction Surgery: Follow-up of a Randomized Trial[NCT06087510] | Phase 4 | 312 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| Effects of Low-dose S-ketamine on the Incidence of Postpartum Depression in Women With Prenatal Depression: a Randomized, Double-blind, Placebo-controlled Trial[NCT04414943] | 364 participants (Actual) | Interventional | 2020-06-19 | Completed | |||
| A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Subjects Who Are Assessed to be at Immi[NCT02133001] | Phase 2 | 68 participants (Actual) | Interventional | 2014-05-23 | Completed | ||
| Effect of Mini-dose Esketamine-dexmedetomidine Supplemented Analgesia on Long-term Outcomes Following Scoliosis Correction Surgery: 2-year Follow-up of a Randomized Controlled Trial[NCT05718544] | Phase 4 | 199 participants (Actual) | Interventional | 2023-01-30 | Active, not recruiting | ||
| A Prospective Randomized Double Blinded Control Trial Using Ketamine or Propofol Anesthesia for Electroconvulsive Therapy: Improving Treatment-Resistant Depression[NCT01935115] | Phase 4 | 27 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| The Antidepressant Efficacy of the Anticholinergic Scopolamine[NCT00369915] | Phase 2 | 17 participants (Actual) | Interventional | 2006-08-31 | Terminated | ||
| A PILOT STUDY OF INTRAVENOUS, SUBANESTHETIC DOSE OF KETAMINE VS PLACEBO, A CROSSOVER DESIGN, FOR MULTIPLE SCLEROSIS RELATED FATIGUE[NCT06064162] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | ||
| Phase 2 Optimization of the Antidepressant Action of Ketamine in Treatment-Resistant Depression and Investigations on Its Mechanism of Action[NCT01945047] | Phase 2/Phase 3 | 46 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| Effects Of Different Anesthesia Applications On Mood, Depression, And Anxiety Levels In Burn Patients[NCT06165848] | 67 participants (Actual) | Observational [Patient Registry] | 2020-07-09 | Completed | |||
| Radical aiTBS Protocol for Intractable Depression[NCT04441008] | 50 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | |||
| A Pilot Study of the Use of Oral Ketamine for Treatment of Vaso-Occlusive Pain in Adolescents and Young Adults[NCT05378555] | Phase 3 | 10 participants (Anticipated) | Interventional | 2023-05-01 | Recruiting | ||
| A Double Blind, Placebo Controlled, Fixed-Flexible Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome[NCT05657860] | Phase 4 | 33 participants (Anticipated) | Interventional | 2020-12-17 | Recruiting | ||
| An Open-Label Clinical Trial of Simultaneous Administration of Oral Aspirin and Ketamine as Adjunct to Oral Antidepressant Therapy in Treatment-Resistant Depression[NCT05615948] | Phase 4 | 20 participants (Anticipated) | Interventional | 2022-12-06 | Recruiting | ||
| Prediction of the Therapeutic Response in Depression Based on an Early Neuro-computational Modeling Assessment of Motivation[NCT05866575] | 136 participants (Anticipated) | Interventional | 2023-06-01 | Not yet recruiting | |||
| Evaluation of Efficacy and Safety of add-on Sarcosine in Patients With Major Depressive Disorder: A Randomized Controlled Trial[NCT04975100] | Phase 4 | 60 participants (Actual) | Interventional | 2021-08-26 | Completed | ||
| Evaluation of the Initial Prescription of Ketamine and Milnacipran Forin Depression in Patients With a Progressive Disease[NCT02783430] | Phase 2/Phase 3 | 80 participants (Anticipated) | Interventional | 2016-09-08 | Recruiting | ||
| A Safe Ketamine-Based Therapy for Treatment Resistant Depression[NCT01179009] | 20 participants (Actual) | Interventional | 2012-04-30 | Completed | |||
| Magnesium Oral Supplementation to Reduce Pain in Patients With Severe Peripheral Arterial Occlusive Disease: The MAG-PAPER Randomized Clinical Trial[NCT02455726] | 150 participants (Anticipated) | Interventional | 2015-09-30 | Not yet recruiting | |||
| Ketamine Infusion for Obsessive-Compulsive Disorder[NCT01349231] | Phase 2 | 10 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Effect of Subanesthetic Dose of Ketamine Combined With Propofol on Cognitive Function in Depressive Patients Undergoing Electroconvulsive Therapy ---a Randomized Control Double-Blind Clinical Trial[NCT02305394] | Phase 4 | 132 participants (Anticipated) | Interventional | 2015-01-31 | Not yet recruiting | ||
| Clinical Trial of the Use of Ketamine in Treatment Resistant Depression[NCT02610712] | Phase 4 | 20 participants (Anticipated) | Interventional | 2014-05-31 | Recruiting | ||
| Optimization of Intravenous Ketamine for Treatment-Resistant Depression: A Randomized, Placebo-Controlled, Triple-masked, Clinical Trial[NCT00768430] | Phase 2 | 73 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Effects of Low-dose Ketamine as an Adjunct to Propofol-based Anesthesia for Electroconvulsive Therapy[NCT02579642] | Phase 4 | 48 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| A Pilot Study to Assess the Efficacy of Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy[NCT05019885] | Phase 2 | 6 participants (Anticipated) | Interventional | 2022-08-26 | Recruiting | ||
| Spreading Depolarization and Ketamine Suppression[NCT02501941] | Phase 1 | 10 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy[NCT03889756] | Phase 2/Phase 3 | 3 participants (Actual) | Interventional | 2019-07-17 | Terminated (stopped due to No more funding available to continue since we could not recruit throughout the pandemic.) | ||
| A Phase I, Randomized, Double-Blind, Four-way Cross-over Study in Healthy Subjects to Assess Quantitative Electroencephalography (qEEG) Parameters After the Administration of Ketamine, Two Doses of AZD6765 and Placebo[NCT01130909] | Phase 1 | 36 participants (Actual) | Interventional | 2010-05-31 | Terminated (stopped due to The benefit of halting the study to analyze the available data outweighs the benefit of delaying the analysis to include data from remaining treatment periods) | ||
| Efficacy of Rapid-Acting NMDA Antagonist for Treatment of Adolescent Depression and Anxiety Disorders[NCT02579928] | Phase 4 | 17 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| A Prospective Randomized Controlled Trial of Electroconvulsive Therapy With Ketamine Anesthesia (Standard Therapy) and High Intensity Ketamine With Electroconvulsive Therapy Rescue for Treatment-Resistant Depression - EAST HIKER Trial[NCT03272698] | Phase 4 | 62 participants (Anticipated) | Interventional | 2017-09-01 | Recruiting | ||
| Hyperventilation and ECT Seizure Duration: Effects on Cerebral Oxygen Saturation, and Therapeutic Outcome With Comparisons Between Etomidate and Ketamine in Patients With Major Depressive Disorder[NCT02924090] | Phase 4 | 48 participants (Anticipated) | Interventional | 2016-09-30 | Recruiting | ||
| Effects of Low Dose Ketamine Given at Induction of Anesthesia on Postoperative Mood in Patients With Depressive Symptoms[NCT02422303] | 12 participants (Actual) | Interventional | 2015-12-31 | Terminated | |||
| Conscious Dying/Conscious Living: Ketamine-Assisted Psychotherapy (KAP) for Patients at End of Life-A Pilot Study for Palliative and Hospice Care[NCT05214417] | Phase 2 | 120 participants (Anticipated) | Interventional | 2022-05-01 | Not yet recruiting | ||
| Ketamine Co-induction for Patients With Major Depressive Disorder; a Randomized Clinical Trial[NCT03666494] | Phase 4 | 50 participants (Anticipated) | Interventional | 2018-12-31 | Not yet recruiting | ||
| ED Treatment of Suicidal Patients With Ketamine Infusion[NCT03502551] | Phase 2 | 0 participants (Actual) | Interventional | 2019-04-01 | Withdrawn (stopped due to Trial never received funding.) | ||
| A Pilot Study of a Single Infusion of Ketamine in Relief of Depressive Symptoms of Elderly Patients With Visual Impairment.[NCT03473431] | 90 participants (Actual) | Interventional | 2018-04-15 | Completed | |||
| Effects of Low-dose S-Ketamine on Incidence of Postpartum Depression in Parturients With Prenatal Depression: A Randomized, Double-blind, Placebo-controlled Trial[NCT03927378] | 364 participants (Actual) | Interventional | 2020-06-19 | Completed | |||
| Continuation Intravenous Ketamine in Major Depressive Disorder - Modification: Lithium for Relapse Prevention[NCT00548964] | Phase 1 | 36 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women: Quantification of Ketamine and Metabolites[NCT04285684] | Early Phase 1 | 4 participants (Actual) | Interventional | 2019-12-20 | Completed | ||
| Continuation Riluzole in the Prevention of Relapse Following Ketamine in Major Depression[NCT00419003] | Phase 4 | 26 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Impact of Night-time Dexmedetomidine-esketamine Infusion on Sleep Quality of Patients With Mechanical Ventilation in ICU: a Randomized Controlled Trial[NCT05718024] | Phase 4 | 174 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| The Effect of Therapeutic Ketamine Infusions on the Symptoms of Post-Traumatic Stress Disorder in Combat Veterans[NCT03088384] | 30 participants (Actual) | Observational | 2016-11-28 | Completed | |||
| Evaluation of the Antidepressant Effects of Nitrous Oxide in People With Major Depressive Disorder[NCT05357040] | Phase 2 | 172 participants (Anticipated) | Interventional | 2021-06-30 | Recruiting | ||
| Investigating Rapid Anti-Suicidal Ideation Effects of Intravenous (IV) Ketamine in Hospitalized Patients[NCT01507181] | Phase 4 | 24 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)[NCT03113968] | Phase 2/Phase 3 | 403 participants (Actual) | Interventional | 2017-04-07 | Completed | ||
| Adjunctive Triple Chronotherapy in the Acute Treatment of Depression and Suicidality in the Adolescent Population: A Randomized Controlled Trial[NCT03679962] | 64 participants (Actual) | Interventional | 2019-01-25 | Completed | |||
| A Phase I, Multi-centre, Double-blind, Placebo-controlled Parallel Group Study to Assess the pharmacoMRI Effects of AZD6765 in Male and Female Subjects Fulfilling the Criteria for Major Depressive Disorder[NCT01046630] | Phase 1 | 128 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| N-methyl-D-aspartate Antagonist (Ketamine) Infusion for Treatment-resistant Major Depressive Disorder With Suicidal Ideation[NCT01582945] | 14 participants (Actual) | Interventional | 2012-04-30 | Completed | |||
| The Evaluation of Patients With Mood and Anxiety Disorders and Healthy Volunteers[NCT00024635] | 16,000 participants (Anticipated) | Observational | 2001-02-02 | Recruiting | |||
| Modulating Probabilities: Prediction, Assessment, and Treatment of Acute Mood Depressive Episode in Borderline Personality Disorder With rTMS[NCT04870255] | 45 participants (Anticipated) | Interventional | 2021-07-20 | Recruiting | |||
| The Effects of Stanford Accelerated Intelligent Neuromodulation Therapy on Explicit and Implicit Suicidal Cognition[NCT03693105] | 100 participants (Anticipated) | Interventional | 2021-11-07 | Enrolling by invitation | |||
| Rapid Acting Transcranial Magnetic Stimulation for Suicide Ideation in Depression[NCT05100004] | 100 participants (Anticipated) | Interventional | 2021-11-07 | Recruiting | |||
| Acute and Maintenance Intravenous Ketamine for Treatment Resistant Major Depression With Suicidal Ideation/Attempt[NCT02094898] | Phase 2 | 12 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| The Effects of a Single Dose on Reward and Emotional Processing in Healthy Volunteers[NCT04130087] | 54 participants (Anticipated) | Interventional | 2019-09-18 | Recruiting | |||
| A Prospective, Randomized, Single Blinded Comparison of Intraoperative Ketamine Infusion Versus Placebo in Patients Having Spinal Fusion[NCT02424591] | Phase 4 | 46 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| A Study of Ketamine as an Antidepressant[NCT01441505] | Phase 2 | 42 participants (Anticipated) | Interventional | 2011-09-30 | Recruiting | ||
| Effects of Intraoperative Low-dose Ketamine on Incidence of Postpartum Depression in Parturients With Prenatal Depression Undergoing Cesarean Delivery: Blind Test, Randomized, Placebo-controlled Trial[NCT03336541] | Phase 4 | 64 participants (Actual) | Interventional | 2017-11-23 | Completed | ||
| The Neurophysiological Effects of Intravenous Alcohol as Potential Biomarkers of Ketamine's Rapid Antidepressant Effects in Major Depressive Disorder[NCT02122562] | Phase 2 | 60 participants (Anticipated) | Interventional | 2014-04-23 | Recruiting | ||
| Low Dose Ketamine for Low Mood States: An Emergency Department Feasibility Study for Depressed Patients[NCT01209845] | Phase 1 | 14 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Precision Targeting of Propofol-induced Electroencephalographic Slow Waves: a Novel Phase I/2 Paradigm for Treatment-resistant Major Depressive Disorder[NCT04680910] | Phase 1/Phase 2 | 85 participants (Anticipated) | Interventional | 2021-01-14 | Recruiting | ||
| Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder[NCT00749203] | Phase 2 | 41 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Ketamine's Actions on Rumination Mechanisms as an Antidepressant[NCT04656886] | 37 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| Ketamine Frequency Treatment for Major Depressive Disorder[NCT00646087] | Phase 4 | 0 participants (Actual) | Interventional | 2008-03-31 | Withdrawn (stopped due to Pilot study determined that this study would not be feasible.) | ||
| Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)[NCT02422290] | Phase 1/Phase 2 | 5 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| Open Study of the Neurobiological Effects of Intranasal Ketamine in Children and Adults With Bipolar Disorder - Fear of Harm Phenotype[NCT05209217] | 20 participants (Anticipated) | Observational | 2019-06-04 | Recruiting | |||
| Comparing Therapeutic Efficacy and Cognitive Side Effects of Electroconvulsive Therapy (ECT) Using Ketamine Versus Methohexital Anesthesia[NCT01881763] | Phase 4 | 31 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Anesthesia and Brain Functional Connectivity: An Analysis of fMRI Changes in Chronic Pain and Refractory Depression[NCT02196259] | 16 participants (Actual) | Interventional | 2008-02-29 | Terminated (stopped due to Funding cessation.) | |||
| A Randomized Controlled Trial to Decrease Suicidal Thinking Using Ketamine[NCT02418702] | Phase 3 | 0 participants (Actual) | Interventional | 2016-08-31 | Withdrawn (stopped due to PI no longer at facility.) | ||
| Intravenous Ketamine Effects on Functional Neuroanatomy[NCT04205890] | Phase 1 | 0 participants (Actual) | Interventional | 2020-05-02 | Withdrawn (stopped due to Sponsor is no longer interested in funding the study) | ||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| A Randomized, Parallel-group，Placebo-controlled, Double-blind Clinical Trial to Evaluate the Efficacy and Safety of Ethosuximide in Chinese Patients With Treatment-Resistant Depression.[NCT03887624] | Early Phase 1 | 16 participants (Actual) | Interventional | 2019-05-21 | Terminated (stopped due to Participates could not stand the side effects) | ||
| Changes of the Short Portable Mental Status Questionnaire (SPMSQ-E) After Ketamine Administration on Ophthalmic Surgery in Geriatric Population.[NCT02049411] | Phase 2 | 80 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary objective of the study was to evaluate the efficacy of AXS-05 as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) for change in severity of depressive symptoms from baseline to Week 6. The MADRS is a 10-item scale and items are scored between 0-6 points. For each item, a score of 0 indicates the absence of symptoms, and a score of 6 indicates symptoms of maximum severity. A maximum total score is 60 points. (NCT04019704)
Timeframe: 6 weeks
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| AXS-05 | 15.91 |
| Placebo | 12.04 |
"CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients (a decrease in score indicates improvement). Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as End Point for that phase." (NCT02417064)
Timeframe: Baseline up to Double-blind Endpoint (Day 28)
| Intervention | Units on a scale (Median) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | -2.0 |
| Intranasal Esketamine 84 mg Plus Oral AD | -2.0 |
| Oral AD Plus Intranasal Placebo | -1.0 |
EQ-5D-5L measures health outcome self-completed by respondents. It consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). EQ-VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). (NCT02417064)
Timeframe: Baseline up to end of Double-blind induction phase (Day 28)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | 20.9 |
| Intranasal Esketamine 84 mg Plus Oral AD | 19.1 |
| Oral AD Plus Intranasal Placebo | 14.9 |
EQ-5D-5L measures health outcome self-completed by respondents. It consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). The descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each has 5 levels (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). The responses are used to generate Health Status Index (HSI). HSI range is -0.148 to 0.949, is anchored at 0 (dead) and 1 (full health). (NCT02417064)
Timeframe: Baseline up to End of Double-blind Induction Phase (Day 28)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | 0.224 |
| Intranasal Esketamine 84 mg Plus Oral AD | 0.243 |
| Oral AD Plus Intranasal Placebo | 0.181 |
EQ-5D-5L measures health outcome self-completed by respondents. It consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). The descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each has 5 levels (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). The responses are used to generate Health Status Index (HSI). HSI range is -0.148 to 0.949, is anchored at 0 (dead) and 1 (full health). EQ-VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) *5. Higher score indicates worst health state. (NCT02417064)
Timeframe: Baseline up to end of Double-blind Induction phase (Day 28)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | -19.0 |
| Intranasal Esketamine 84 mg Plus Oral AD | -19.4 |
| Oral AD Plus Intranasal Placebo | -14.6 |
"GAD-7 is a brief and validated 7-item self-reported assessment of overall anxiety. Participants responded to each item using a 4 point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15-21). Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as End Point for that phase." (NCT02417064)
Timeframe: Baseline up to Double-blind Endpoint (Day 28)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | -7.4 |
| Intranasal Esketamine 84 mg Plus Oral AD | -7.7 |
| Oral AD Plus Intranasal Placebo | -6.0 |
MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT02417064)
Timeframe: Baseline up to Day 28 of Double-blind Induction Phase
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | -19.0 |
| Intranasal Esketamine 84 mg Plus Oral AD | -18.8 |
| Oral AD Plus Intranasal Placebo | -14.8 |
"MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Missing data was imputed using Last Observation Carried Forward (LOCF) method and last post baseline observation during double-blind induction phase was carried forward as End Point for that phase." (NCT02417064)
Timeframe: Baseline up to Double-blind Endpoint (Day 28)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | -18.3 |
| Intranasal Esketamine 84 mg Plus Oral AD | -17.4 |
| Oral AD Plus Intranasal Placebo | -14.3 |
PHQ-9 is 9-item, self-reported scale assessing 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders, Major Depressive Disorder criteria. Each item is rated on 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half days, 3 = Nearly every day). The scores are summed for a total score ranging from 0-27. Higher score indicates greater severity of depression. Severity of PHQ-9 categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19), Severe (20-27). The recall period is 2 weeks. (NCT02417064)
Timeframe: Baseline up to Day 28 of Double-blind Induction phase
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | -11.0 |
| Intranasal Esketamine 84 mg Plus Oral AD | -11.7 |
| Oral AD Plus Intranasal Placebo | -9.1 |
"PHQ-9 is 9-item, self-reported scale assessing 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders, Major Depressive Disorder criteria. Each item is rated on 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half days, 3 = Nearly every day). The scores are summed for a total score ranging from 0-27. Higher score indicates greater severity of depression. Severity of PHQ-9 categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19), Severe (20-27). The recall period is 2 weeks. Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as End Point for that phase." (NCT02417064)
Timeframe: Baseline up to Double-blind Endpoint (Day 28)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | -10.9 |
| Intranasal Esketamine 84 mg Plus Oral AD | -10.9 |
| Oral AD Plus Intranasal Placebo | -8.9 |
The SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. The first 3 items assess disruption of 1) work/school, 2) social life, and 3) family life/home responsibilities using 0 (not at all) to 10 (extremely) rating scale. Score for first 3 items are summed to create total score of 0 (unimpaired) to 30 (highly impaired), where higher score indicates greater impairment. (NCT02417064)
Timeframe: Baseline up to Day 28 of Double-blind Induction phase
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | -11.0 |
| Intranasal Esketamine 84 mg Plus Oral AD | -11.1 |
| Oral AD Plus Intranasal Placebo | -8.4 |
"The SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. The first 3 items assess disruption of 1) work/school, 2) social life, and 3) family life/home responsibilities using 0 (not at all) to 10 (extremely) rating scale. Score for first 3 items are summed to create total score of 0 (unimpaired) to 30 (highly impaired) where higher score indicates greater impairment. Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as End Point for that phase." (NCT02417064)
Timeframe: Baseline up to Double-blind Endpoint (Day 28)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | -10.7 |
| Intranasal Esketamine 84 mg Plus Oral AD | -10.2 |
| Oral AD Plus Intranasal Placebo | -8.1 |
Participants who had a MADRS total score of less than or equal to (<=) 12 were considered as remitters. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT02417064)
Timeframe: At Day 28 of Double-blind Induction Phase
| Intervention | Percentage of participants (Number) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | 36 |
| Intranasal Esketamine 84 mg Plus Oral AD | 38.8 |
| Oral AD Plus Intranasal Placebo | 30.6 |
"Participants who had a MADRS total score of less than or equal to (<=) 12 were considered as remitters. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as End Point for that phase." (NCT02417064)
Timeframe: At Day 28 (Double-blind Endpoint)
| Intervention | Percentage of participants (Number) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | 34.8 |
| Intranasal Esketamine 84 mg Plus Oral AD | 35.4 |
| Oral AD Plus Intranasal Placebo | 29.2 |
A participant was defined as a responder (yes=1 and no=0) at a given time point if the percent reduction from baseline in MADRS total score is at least 50 percent (%). The percentage of participants who achieved at least 50% reduction from baseline were reported. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT02417064)
Timeframe: At Day 28 of Double-blind Induction phase
| Intervention | Percentage of Participants (Number) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | 54.1 |
| Intranasal Esketamine 84 mg Plus Oral AD | 53.1 |
| Oral AD Plus Intranasal Placebo | 38.9 |
"A participant was defined as a responder (yes=1 and no=0) at a given time point if the percent reduction from baseline in MADRS total score is at least 50 percent (%). The percentage of participants who achieved at least 50% reduction from baseline were reported. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as End Point for that phase." (NCT02417064)
Timeframe: At Day 28 (Double-blind Endpoint)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | 53.0 |
| Intranasal Esketamine 84 mg Plus Oral AD | 47.8 |
| Oral AD Plus Intranasal Placebo | 37.2 |
A participant was defined as having a clinical response if there was at least 50% improvement (decrease) from baseline in the MADRS total score with onset by Day 2 and Day 8 that was maintained to Day 28. Participants were allowed one excursion (non-response) on Days 8, 15 or 22, however score must show at least 25% improvement. Participants who did not meet these criteria or discontinued during the study before Day 28 were considered as non-responders and were assigned the value of 0 (that is no). MADRS is clinician-rated scale that consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), for total possible score of 0 to 60. Higher scores represent more severe condition. (NCT02417064)
Timeframe: Day 2 up to Day 28 and Day 8 up to Day 28
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Day 2 up to Day 28 | Day 8 up to Day 28 | |
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | 10.4 | 13.0 |
| Intranasal Esketamine 84 mg Plus Oral AD | 8.8 | 11.4 |
| Oral AD Plus Intranasal Placebo | 1.8 | 3.5 |
Beck Depression Inventory (BDI) is a 21-question instrument for measuring the severity of depression. Each question has a set of at least four possible answer choices, ranging in intensity. A value of 0 to 3 is assigned for each answer and the total score is computed. Higher total scores indicate more severe depressive symptoms. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.
| Intervention | Units on a scale (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| 60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
| AZD6765 (150 mg) | 21.081 | 22.217 | 21.535 | 21.126 | 22.444 | 22.923 | 23.494 | 24.447 |
| Placebo | 22.886 | 23.122 | 23.586 | 23.686 | 22.936 | 24.586 | 23.786 | 24.070 |
Brief Psychiatric Rating Scale (BPRS) Positive is a 4-item scale which measures positive symptoms of schizophrenia (conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content). Each item is rated from 1 to 7 with higher score indicating greater severity. The total score is the sum of the 4 items, resulting in a range of scores from 4-28. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.
| Intervention | Units on a scale (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| 60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
| AZD6765 (150 mg) | 9.433 | 8.751 | 8.660 | 8.751 | 9.114 | 9.118 | 9.118 | 9.356 |
| Placebo | 8.946 | 8.996 | 8.996 | 8.666 | 9.296 | 9.296 | 9.446 | 9.338 |
"The Brief Psychiatric Rating Scale (BPRS) is a 18-item scale which measures symptoms and behaviors that are characteristic of schizophrenia. Each item is rated from 1 to 7 with higher score indicating greater severity. The total score is the sum of the 18 items, resulting in a range of scores from 18-126.~18 is considered to be the best outcome, 126 the worst." (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.
| Intervention | Units on a scale (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| 60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
| AZD6765 (150 mg) | 32.191 | 30.237 | 30.555 | 30.737 | 33.418 | 32.882 | 34.168 | 35.739 |
| Placebo | 32.896 | 33.496 | 33.696 | 31.772 | 33.596 | 34.496 | 33.046 | 34.428 |
Clinician- Administered Dissociative States Scale (CADSS) is a clinician-administered measure of perceptual, behavioral, and attentional alterations occurring during dissociative experiences. This scale involves a 23 questions and each is rated from 0 (not at all) to 4 (extremely). The total score is sum of the 23 items and range from 0 to 92 - best is 0 and worst is 92. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing
| Intervention | Units on a scale (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| 60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
| AZD6765 (150 mg) | 4.104 | 3.324 | 2.831 | 1.240 | 1.013 | 1.360 | 1.456 | 1.313 |
| Placebo | 1.997 | 2.297 | 2.047 | 1.497 | 1.147 | 1.397 | 1.447 | 1.212 |
Hamilton Anxiety Rating Scale (HAM-A) is used as a rating measure of anxiety severity. The scale consists of 14 items. Each item is rated on a scale of 0 to 4. The HAM-A total score is the sum of the 14 items and the score ranges from 0 to 56. 0 is considered the best outcome, 56 the worst. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 230 min, 1 day, 2 days, 3 days and 7 days following dosing.
| Intervention | Units on a scale (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
| AZD6765 (150 mg) | 16.211 | 16.666 | 16.817 | 17.055 | 18.817 |
| Placebo | 17.160 | 17.675 | 18.125 | 18.525 | 19.631 |
Hamilton Depression Rating Scale-17 item (HDRS) is a scale that assesses depressive symptoms. HDRS consists of 17 symptoms, each of which is rated from 0 to 2 or 0 to 4, where 0 is none/absent. The total score is calculated as the sum of the 17 individual symptom scores; the total score can range from 0 to 52. Higher scores indicate more severe depression. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing
| Intervention | Units on a scale (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| 60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
| AZD6765 (150 mg) | 15.930 | 14.975 | 15.475 | 16.112 | 16.748 | 16.732 | 17.732 | 18.160 |
| Placebo | 17.389 | 17.739 | 18.039 | 17.339 | 17.639 | 19.289 | 19.039 | 19.438 |
Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item instrument used for the evaluation of depressive symptoms. Each item is rated on a scale of 0 to 6 (with higher scores indicating more severe depression). The individual item scores are added together to form a total score, ranging between 0 and 60. 0 is considered the best score, 60 the worst. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.
| Intervention | Units on a scale (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| 60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
| AZD6765 (150 mg) | 26.881 | 25.381 | 25.835 | 26.517 | 27.654 | 29.161 | 30.732 | 31.447 |
| Placebo | 28.618 | 29.718 | 29.818 | 29.418 | 29.118 | 31.368 | 30.368 | 31.222 |
Scale for Suicide Ideation (SSI) is a 19-item scale designed to quantify the intensity of current conscious suicide ideation. Each item is rated on a scale of 0 to 2 (with higher scores indicating greater suicidal ideation). The individual item scores are added together to form a total score, ranging between 0 and 38. 0 is considered the best outcome, 38 the worst. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.
| Intervention | Units on a scale (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| 60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
| AZD6765 (150 mg) | 0.955 | 1.137 | 1.137 | 0.864 | 1.364 | 1.236 | 1.379 | 1.379 |
| Placebo | 0.939 | 1.039 | 0.989 | 0.939 | 1.539 | 1.189 | 1.226 | 1.507 |
Response defined as a >= 50% reduction from baseline in MADRS total score. MADRS is a 10-item instrument used for the evaluation of depressive symptoms. Each item is rated on a scale of 0 to 6 (with higher scores indicating more severe depression). The individual item scores are added together to form a total score, ranging between 0 and 60. 0 is considered the best score, 60 the worst. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| 60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
| AZD6765 (150 mg) | 5 | 6 | 4 | 4 | 3 | 1 | 1 | 1 |
| Placebo | 3 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
Remission defined as a Montgomery-Asberg Depression Rating Scale (MADRS) total score <10. MADRS is a 10-item instrument used for the evaluation of depressive symptoms. Each item is rated on a scale of 0 to 6 (with higher scores indicating more severe depression). The individual item scores are added together to form a total score, ranging between 0 and 60. 0 is considered the best score, 60 the worst. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| 60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
| AZD6765 (150 mg) | 2 | 4 | 4 | 2 | 2 | 1 | 1 | 1 |
| Placebo | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
"The Visual Analog Scale (VAS) Anxious is a 0 to 100-mm self-administered scale where patients rate their mood between extreme sad (0-mm) and extreme happy (100-mm), with a median normal point." (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.
| Intervention | Units on a scale (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| 60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
| AZD6765 (150 mg) | 43.898 | 44.216 | 42.853 | 44.580 | 44.989 | 44.718 | 42.623 | 50.147 |
| Placebo | 41.929 | 44.079 | 44.729 | 46.029 | 47.229 | 50.479 | 48.279 | 56.595 |
"The Visual Analog Scale (VAS) Depressed is a 0 to 100-mm self-administered scale where patients rate their mood between extreme sad (0-mm) and extreme happy (100-mm), with a median normal point." (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing
| Intervention | Scores on a scale (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| 60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
| AZD6765 (150 mg) | 55.614 | 58.614 | 60.750 | 55.614 | 62.160 | 65.753 | 66.896 | 68.467 |
| Placebo | 60.562 | 57.662 | 59.062 | 61.212 | 64.762 | 63.262 | 63.312 | 65.576 |
Young Mania Rating Scale (YMRS) consists of 11 items, rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe) or from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60. 0 is considered to be the best outcome, 60 the worst. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.
| Intervention | Units on a scale (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| 60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
| AZD6765 (150 mg) | 4.294 | 3.748 | 3.475 | 3.748 | 3.748 | 3.699 | 4.270 | 4.366 |
| Placebo | 3.626 | 3.526 | 3.526 | 3.526 | 3.326 | 3.676 | 3.476 | 4.339 |
"Number of patients meeting response criteria of >=50% decrease in MADRS score from baseline , ie, difference in depressive symptoms using MADRS instrument, 24 hours following drug administration~10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Each of the 10 items is rated on a scale of 0 to 6, with differing descriptors for each item. These individual item scores are added together to form a total score, which can range between 0 and 60 points." (NCT01304147)
Timeframe: 24 hours
| Intervention | participants (Number) |
|---|---|
| Ketamine | 8 |
| Placebo | 1 |
This is a self-report measure for systematically assessing 48 possible adverse events. It documents their severity, relationship to study drug, and the action taken. (NCT01304147)
Timeframe: 2 weeks
| Intervention | events (Number) |
|---|---|
| Ketamine | 79 |
| Placebo | 57 |
The MADRS is a 10-item scale designed to assess the severity of depression. The questionnaire includes questions on the following symptoms: Apparent sadness, Reported sadness, Inner tension, Reduced sleep, Reduced appetite, Concentration difficulties, Lassitude, Inability to feel, Pessimistic thoughts, and Suicidal thoughts. Each of the 10 symptoms are rated on a scale of 1 to 6, with 1=absent to 6=severe. The MADRS score can range from 0 (symptoms absent) to 60 (severe depression), with a higher score indicating more severe depression. (NCT00610649)
Timeframe: Baseline and end of treatment (Up to Day 16)
| Intervention | score on a scale (Mean) |
|---|---|
| Part 1: Block A MK-8777 | -10.00 |
| Part 1: Block A Placebo | -24.50 |
| Part 1: Block B MK-8777 | -13.50 |
| Part 1: Block B Placebo | -7.00 |
| Part 1: Block C MK-8777 | -10.25 |
| Part 1: Block C Placebo | -9.50 |
| Part 1: Block D MK-8777 | -19.00 |
| Part 1: Block D Placebo | -2.00 |
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Discontinuation refers to discontinuation of study drug (MK-8777 or Placebo). (NCT00610649)
Timeframe: Up to the last dose of study drug (Up to 16 days)
| Intervention | participants (Number) |
|---|---|
| Part 1: Block A MK-8777 | 1 |
| Part 1: Block A Placebo | 0 |
| Part 1: Block B MK-8777 | 0 |
| Part 1: Block B Placebo | 0 |
| Part 1: Block C MK-8777 | 0 |
| Part 1: Block C Placebo | 0 |
| Part 1: Block D MK-8777 | 0 |
| Part 1: Block D Placebo | 0 |
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. A moderate intensity AE is defined as an AE that causes no significant interference with functioning. (NCT00610649)
Timeframe: Up to 7 days following the last dose of study drug (Up to 23 days)
| Intervention | participants (Number) |
|---|---|
| Part 1: Block A MK-8777 | 2 |
| Part 1: Block A Placebo | 0 |
| Part 1: Block B MK-8777 | 1 |
| Part 1: Block B Placebo | 2 |
| Part 1: Block C MK-8777 | 4 |
| Part 1: Block C Placebo | 0 |
| Part 1: Block D MK-8777 | 3 |
| Part 1: Block D Placebo | 2 |
An SAE is defined as any untoward medical occurrence that at any dose: results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect. (NCT00610649)
Timeframe: Up to 30 days following the last dose of study drug (Up to 46 days)
| Intervention | participants (Number) |
|---|---|
| Part 1: Block A MK-8777 | 0 |
| Part 1: Block A Placebo | 0 |
| Part 1: Block B MK-8777 | 0 |
| Part 1: Block B Placebo | 0 |
| Part 1: Block C MK-8777 | 0 |
| Part 1: Block C Placebo | 0 |
| Part 1: Block D MK-8777 | 0 |
| Part 1: Block D Placebo | 0 |
The MADRS is a 10-item scale designed to assess the severity of depression. The questionnaire includes questions on the following symptoms: Apparent sadness, Reported sadness, Inner tension, Reduced sleep, Reduced appetite, Concentration difficulties, Lassitude, Inability to feel, Pessimistic thoughts, and Suicidal thoughts. Each of the 10 symptoms are rated on a scale of 1 to 6, with 1=absent to 6=severe. The MADRS score can range from 0 (symptoms absent) to 60 (severe depression), with a higher score indicating more severe depression. (NCT00610649)
Timeframe: Baseline and end of treatment (Up to Day 28)
| Intervention | score on a scale (Mean) |
|---|---|
| Part 2: MK-8777 200 mg | -15.40 |
| Part 2: MK-8777 800 mg | -13.70 |
| Part 2: Placebo | -13.30 |
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. (NCT00610649)
Timeframe: Up to 7 days following the last dose of study drug (Up to 35 days)
| Intervention | participants (Number) |
|---|---|
| Part 2: MK-8777 200 mg | 10 |
| Part 2: MK-8777 800 mg | 9 |
| Part 2: Placebo | 9 |
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Discontinuation refers to discontinuation of study drug (MK-8777 or Placebo). (NCT00610649)
Timeframe: Up to the last dose of study drug (Up to 28 days)
| Intervention | participants (Number) |
|---|---|
| Part 2: MK-8777 200 mg | 0 |
| Part 2: MK-8777 800 mg | 0 |
| Part 2: Placebo | 1 |
CGI-SS-R was derived from the Clinical Global Impression Severity Scale (CGI-S), a global rating scale that gives an overall measure of the severity of a participants illness. The CGI-SS-R rating is scored on a 7-point scale from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal participants). A higher score indicates a more severe condition and a reduction in score indicates improvement (that is, lower severity of suicidality). (NCT03039192)
Timeframe: Baseline (Day 1, predose) and 24 hours first post dose (Day 2)
| Intervention | units on a scale (Median) |
|---|---|
| Placebo Plus SOC Antidepressant Treatment | -1.0 |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | -1.0 |
MADRS is clinician-rated scale designed to be used in participants with Major Depressive Disorder (MDD) to measure depression severity and detect changes due to antidepressant treatment. It evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic and suicidal thoughts. Scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), summed for total possible score of 0 to 60. Higher scores represent more severe condition. Negative change in score indicates improvement. (NCT03039192)
Timeframe: Baseline (Day 1, predose) and 24 hours first post dose (Day 2)
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo Plus SOC Antidepressant Treatment | -12.8 |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | -16.4 |
Pulse oximetry was used to measure arterial SpO2 levels. On each dosing day, the device was attached to the finger, toe, or ear, and SpO2 was monitored and documented. If oxygen saturation levels were less than (<) 93% at any time during the 1.5 hours postdose interval, pulse oximetry was recorded every 5 minutes until levels return to >= 93% or until the participant is referred for appropriate medical care, if clinically indicated. Participants with at least 2 consecutive postdose oxygen saturation below 93% during the DB treatment phase were reported. (NCT03039192)
Timeframe: Up to Day 25
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo Plus SOC Antidepressant Treatment | 2 |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | 1 |
An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. A TEAE is categorized as related if assessed by the investigator as possibly, probably, or very likely related to study agent. (NCT03039192)
Timeframe: Up to Day 25
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo Plus SOC Antidepressant Treatment | 83 |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | 100 |
BHS is a self-reported measure to assess one's level of negative expectations or pessimism regarding future. It consists of 20 true-false items that examine respondent's attitude over past week by either endorsing a pessimistic statement or denying an optimistic statement; 9 are keyed false and 11 are keyed true. For every statement, each response was assigned score of 0 or 1. Total BHS score is sum of item responses, ranged from 0-20, where higher score represented higher level of hopelessness. (NCT03039192)
Timeframe: Baseline, Days 8 and 25
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change at Day 8 | Change at Day 25 | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | -5.3 | -6.9 |
| Placebo Plus SOC Antidepressant Treatment | -4.4 | -6.6 |
The CGI-SR-I is a scale summarizing the clinician's best assessment of the likelihood that the participant will attempt suicide in the next 7 days. The CGI-SR-I rating is scored on a 7-point scale: where' 0 (no imminent suicide risk); 1 (minimal imminent suicide risk), 2 (mild imminent suicide risk), 3 (moderate imminent suicide risk), 4 (marked imminent suicide risk), 5 (severely imminent suicide risk), 6 (extreme imminent suicide risk). Higher score indicates a more severe condition. Negative change in score indicates improvement. (NCT03039192)
Timeframe: Baseline and Days 1, 2, 4, 8, 11, 15, 18, 22 and 25
| Intervention | units on a scale (Median) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Change at Day 1 | Change at Day 2 | Change at Day 4 | Change at Day 8 | Change at Day 11 | Change at Day 15 | Change at Day 18 | Change at Day 22 | Change at Day 25 | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | -1.0 | -1.0 | -2.0 | -2.0 | -2.0 | -3.0 | -3.0 | -3.0 | -3.0 |
| Placebo Plus SOC Antidepressant Treatment | 0.0 | -1.0 | -1.0 | -2.0 | -2.0 | -2.0 | -3.0 | -3.0 | -3.0 |
CGI-SS-R was derived from the Clinical Global Impression Severity Scale (CGI-S), a global rating scale that gives an overall measure of the severity of a participants illness. The CGI-SS-R rating is scored on a 7-point scale from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal participants). A higher score indicates a more severe condition. Negative change in score indicates improvement. (NCT03039192)
Timeframe: Baseline and Days 1, 2, 4, 8, 11, 15, 18, 22 and 25
| Intervention | units on a scale (Median) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Change at Day 1 | Change at Day 2 | Change at Day 4 | Change at Day 8 | Change at Day 11 | Change at Day 15 | Change at Day 18 | Change at Day 22 | Change at Day 25 | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | -1.0 | -1.0 | -2.0 | -2.0 | -3.0 | -3.0 | -3.0 | -3.0 | -3.0 |
| Placebo Plus SOC Antidepressant Treatment | 0.0 | -1.0 | -1.0 | -2.0 | -2.0 | -2.0 | -2.5 | -3.0 | -3.0 |
EQ-5D-5L measures health outcome. It consists of EQ-5D-5L descriptive system and the EQ visual analogue scale (EQ-VAS). EQ-VAS score from 0 (worst health) to 100 (best health), positive change in score indicates improvement. (NCT03039192)
Timeframe: Baseline, Days 2, 11 and 25
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Change at Day 2 | Change at Day 11 | Change at Day 25 | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | 13.5 | 17.9 | 21.4 |
| Placebo Plus SOC Antidepressant Treatment | 7.8 | 16.3 | 20.0 |
"EQ-5D-5L measures health outcome. It consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). EQ-5D-5L system comprises following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of 5 dimensions is divided into 5 levels of perceived problems (Level 1-no problem, Level 2-slight problems, Level 3-moderate problems, Level 4-severe problems, Level 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a health status index (HSI). Health Status Index ranges from 0.148 - 0.949, anchored at 0 (dead) and 1 (full health). Positive change in score indicates improvement." (NCT03039192)
Timeframe: Baseline and Days 2, 11 and 25
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Change at Day 2 | Change at Day 11 | Change at Day 25 | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | 0.156 | 0.206 | 0.227 |
| Placebo Plus SOC Antidepressant Treatment | 0.096 | 0.169 | 0.189 |
"EQ-5D-5L measures health outcome. It consists of EQ-5D-5L system and EQ-VAS. EQ-5D-5L system comprises following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of 5 dimensions is divided into 5 levels of perceived problems (Level 1-no problem, Level 2-slight problems, Level 3-moderate problems, Level 4-severe problems, and Level 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a health status index (HSI). Health Status Index ranges from 0.148 - 0.949, anchored at 0 (dead) and 1 (full health), a lower score indicates worse health. Sum score=(sum of the scores from the 5 dimensions minus 5)*5. Sum score ranges from 0-100. Higher score indicates a more severe problem. Negative change in score indicates improvement." (NCT03039192)
Timeframe: Baseline, Days 2, 11 and 25
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Change at Day 2 | Change at Day 11 | Change at Day 25 | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | -11.2 | -15.2 | -16.8 |
| Placebo Plus SOC Antidepressant Treatment | -6.1 | -12.3 | -13.4 |
MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition and a negative change in score indicates improvement. (NCT03039192)
Timeframe: Baseline and Days 1, 2, 4, 8, 11, 15, 18, 22 and 25 (predose and 4 hours postdose)
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Change at Day 1 | Change at Day 2 | Change at Day 4 | Change at Day 8 | Change at Day 11 | Change at Day 15 | Change at Day 18 | Change at Day 22 | Change at Day 25: predose | Change at Day 25 (4 hours postdose) | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | -13.5 | -16.4 | -19.1 | -19.7 | -21.8 | -22.3 | -23.9 | -24.0 | -24.8 | -29.5 |
| Placebo Plus SOC Antidepressant Treatment | -10.9 | -12.9 | -14.5 | -17.4 | -19.0 | -20.4 | -21.4 | -21.6 | -23.0 | -25.8 |
"The QLDS is a disease specific patient-reported outcome designed to assess health related quality of life in participants with major depressive disorder (MDD). The instrument has a recall period of at the moment, contains 34-items with true/not true response options and takes approximately 5-10 minutes to complete. The total score range is from 0 (good quality of life) to 34 (very poor quality of life). A higher score indicates a more severe condition. Negative change indicates improvement." (NCT03039192)
Timeframe: Baseline and Days 2, 11 and 25
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Change at Day 2 | Change at Day 11 | Change at Day 25 | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | -3.1 | -5.6 | -6.8 |
| Placebo Plus SOC Antidepressant Treatment | -2.5 | -4.4 | -5.6 |
SIBAT is an assessment tool that captures suicidal ideation, behavior, and risk. It permits assessment of change in suicidal ideation and behavior and documents clinician assessment of severity of suicidality and suicide risk. SIBAT is organized into 8 modules divided into 2 major divisions: patient-reported section (Modules 1-5) and clinician-rated section (Modules 6-8). Patient-reported section has modules of demographics and suicide history, risk/protective factors, suicidal thinking, suicide behavior, and suicide risk. Question 3 from Module 5 asks participants to describe their thinking about suicide right now from 5 response options ranging from 0 (I have no suicidal thoughts) to 4 (I have suicidal thoughts all of time). SIBAT Module 5 (My Risk) Question 3 (Patient-reported FoST) total score ranges from 0 to 4; a higher score indicates a more severe condition. Negative change in score indicates improvement. (NCT03039192)
Timeframe: Baseline, Days 1, 2, 4, 8, 11, 15, 18, 22 and 25
| Intervention | units on a scale (Median) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Change at Day 1 | Change at Day 2 | Change at Day 4 | Change at Day 8 | Change at Day 11 | Change at Day 15 | Change at Day 18 | Change at Day 22 | Change at Day 25 | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | 0.0 | -1.0 | -1.0 | -1.0 | -1.5 | -2.0 | -2.0 | -2.0 | -2.0 |
| Placebo Plus SOC Antidepressant Treatment | 0.0 | -1.0 | -1.0 | -1.0 | -1.0 | -1.0 | -2.0 | -2.0 | -2.0 |
SIBAT is assessment tool that captures suicidal ideation, behavior, and risk. It permits assessment of change in suicidal ideation and behavior and documents clinician assessment of severity of suicidality and suicide risk. SIBAT has 8 modules divided into 2 major divisions: patient-reported section (Modules 1-5) and clinician-rated section (Modules 6-8). Clinician-rated section has modules for semi-structured interview, clinical global impressions of current severity of suicidality and imminent suicide risk, clinical global impression of long-term suicide risk, and clinical judgment of optimal suicide management. The score anchor point as in participant report frequency of suicidal thinking (FoST) that is, response options from never to all the time. Module 7-FoST score ranges from 0-5; higher score indicates more severe condition. Negative change in score indicates improvement. (NCT03039192)
Timeframe: Baseline and Days 1, 2, 4, 8, 11, 15, 18, 22 and 25
| Intervention | units on a scale (Median) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Change at Day 1 | Change at Day 2 | Change at Day 4 | Change at Day 8 | Change at Day 11 | Change at Day 15 | Change at Day 18 | Change at Day 22 | Change at Day 25 | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | -1.0 | -1.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -3.0 |
| Placebo Plus SOC Antidepressant Treatment | -1.0 | -1.0 | -1.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 |
Participants who had a MADRS total score of <=12 were considered remitters. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition and a negative change in score indicates improvement. (NCT03039192)
Timeframe: Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and Day 25 (predose and 4 hours postdose)
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 (4 Hours postdose) | Day 2 | Day 4 | Day 8 | Day 11 | Day 15 | Day 18 | Day 22 | Day 25 (Predose) | Day 25 (4 hours postdose) | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | 12 | 21 | 28 | 30 | 33 | 38 | 42 | 41 | 46 | 60 |
| Placebo Plus SOC Antidepressant Treatment | 9 | 10 | 13 | 23 | 26 | 29 | 30 | 25 | 38 | 42 |
CGI-SS-R was derived from the Clinical Global Impression Severity Scale (CGI-S), a global rating scale that gives an overall measure of the severity of a participants illness. The CGI-SS-R rating is scored on a 7-point scale from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal participants). A higher score indicates a more severe condition. Negative change in score indicates improvement. A participant was considered to achieve resolution of suicidality at a given time point if the CGI-SS-R score was 0 (normal, not at all suicidal) or 1 (questionably suicidal). (NCT03039192)
Timeframe: Days 1, 2, 4, 8, 11, 15, 18, 22 and 25
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Day 1 | Day 2 | Day 4 | Day 8 | Day 11 | Day 15 | Day 18 | Day 22 | Day 25 | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | 37 | 42 | 49 | 53 | 60 | 68 | 68 | 70 | 71 |
| Placebo Plus SOC Antidepressant Treatment | 25 | 39 | 45 | 48 | 46 | 52 | 55 | 62 | 57 |
Number of participants with abnormal nasal examination were reported. Nasal examination of visual inspection of the epistaxis, nasal crusts, nasal discharge, and nasal erythema was performed. (NCT03039192)
Timeframe: At Day 25
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Epistaxis: Mild | Epistaxis: Moderate | Epistaxis: Severe | Nasal Crusts: Mild | Nasal Crusts: Moderate | Nasal Crusts: Severe | Nasal Discharge: Mild | Nasal Discharge: Moderate | Nasal Discharge: Severe | Nasal Erythema: Mild | Nasal Erythema: Moderate | Nasal Erythema: Severe | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | 1 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 3 | 0 | 0 |
| Placebo Plus SOC Antidepressant Treatment | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 |
"The CADSS used to measure present-state dissociative symptoms, and to assess treatment-emergent dissociative symptoms. It comprises 23 subjective items divided into 3 components: depersonalization (with score range from 0 to 28), derealization (with score range from 0 to 52), and amnesia (with score range from 0 to 8). Participants responses are coded on a 5-point scale (0 = Not at all, 1 = Mild, 2 = Moderate, 3 = 'Severe and 4 = Extreme). The total score is sum of the 23 items and range from 0 to 92, where 0 (best) and 92 (worst). A higher score indicates a more severe condition. Number of participants with an increase in CADSS total score (increase based on maximum CADSS total score change from predose of > 0) was reported." (NCT03039192)
Timeframe: Days 1, 4, 8, 11, 15, 18, 22 and 25
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 1 | Day 4 | Day 8 | Day 11 | Day 15 | Day 18 | Day 22 | Day 25 | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | 95 | 84 | 81 | 77 | 69 | 70 | 70 | 72 |
| Placebo Plus SOC Antidepressant Treatment | 34 | 23 | 29 | 19 | 17 | 19 | 16 | 14 |
Number of participants with treatment emergent abnormal ECG values for variables including heart rate (abnormally low refers to less than or equal to [<=] 50 beats per minute [bpm] , abnormally high refers greater than or equal to [>=] 100 bpm), pulse rate (PR) interval (abnormally high refers to >= 210 milliseconds [msec]), QRS interval (abnormally Low refers to <= 50, abnormally high refers to >= 120 msec) and QT interval (abnormally low refers to <= 200, abnormally high >= 500 msec) were reported. (NCT03039192)
Timeframe: Up to Day 25
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Heart Rate <= 50 bpm | Heart Rate >= 100 bpm | PR Duration >= 210 msec | QRS Duration <= 50 msec | QRS Duration >= 120 msec | QT Duration <= 200 msec | QT Duration >= 500 msec | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | 2 | 5 | 5 | 0 | 0 | 0 | 0 |
| Placebo Plus SOC Antidepressant Treatment | 8 | 4 | 3 | 0 | 0 | 0 | 0 |
Low/high abnormal values are: Alanine aminotransferase (ALT)-high=200 Units per liter(U/L); ALP-high=250U/L; aspartate aminotransferase(AST)-high=250U/L; gamma glutamyl transferase(GGT)=300U/L; Albumin(low=24g/L,high=60 g/L); Bicarbonate(low=15.1, high=34.9mmol/L); Bilirubin(high=51.3micromol/L); calcium(low=1.5,high=3mmol/L);Chloride(low=94,high=112mmol/L); CK(High=990U/L); Creatinine(High=265.2micromol/L); Eosinophils(High=10%); Erythrocytes(low=3.0*1012/L,high=6.4*1012/L); Glucose(low=2.2,high=16.7mmol/L); Hemoglobin(low=80g/L,high=190g/L);Hematocrit(low=0.28, high=0.55 fraction); LD(high=500U/L); Leukocytes(low=2.5*109/L,high=15.5*109/L); Lymphocytes(low=10%,high=60%); Monocytes(high=20%); Neutrophils(low=30%,high=90%); Phosphate(low=0.7 mmol/L,high=2.6mmol/L); Platelet count(low=100*109/L,high=600*109/L]; Potassium(low=3.0mmol/L,high=5.8 mmol/L]; Protein(low=50 g/L); Sodium(low=125 mmol/L,high=155 mmol/L); Urate(low=89.2 micromol/L,high=594.8micromol/L); Urine(high=8.0 pH). (NCT03039192)
Timeframe: Up to Day 25
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT>3*ULN | ALT: Abnormal High | Albumin: Abnormal High | Albumin: Abnormal Low | Alkaline phosphatase (ALP): Abnormal High | AST: AST>3*ULN | AST: Abnormal High | Bicarbonate: Abnormal High | Bicarbonate: Abnormal Low | Bilirubin: Abnormal High | Calcium: Abnormal High | Calcium: Abnormal Low | Chloride: Abnormal High | Chloride: Abnormal Low | Creatine Kinase (CK): Abnormal High | Creatinine: Abnormal High | GGT: Abnormal High | Glucose: Abnormal High | Glucose: Abnormal Low | ALT>3*ULN or AST>3*ULN and BILI>2*ULN | Lactate Dehydrogenase(LD): Abnormal High | Phosphate: Abnormal High | Phosphate: Abnormal Low | Potassium: Abnormal High | Potassium: Abnormal Low | Protein: Abnormal Low | Sodium: Abnormal High | Sodium: Abnormal Low | Urate: Abnormal High | Urate: Abnormal Low | Basophils: Abnormal High | Eosinophils: Abnormal High | Erythrocytes: Abnormal High | Erythrocytes: Abnormal Low | Hematocrit: Abnormal High | Hematocrit: Abnormal Low | Hemoglobin(Hb): Abnormal High | Hemoglobin: Abnormal Low | Leukocytes: Abnormal High | Leukocytes: Abnormal Low | Lymphocytes: Abnormal High | Lymphocytes: Abnormal Low | Monocytes: Abnormal High | Neutrophils: Abnormal High | Neutrophils: Abnormal Low | Platelets: Abnormal High | Platelets: Abnormal Low | Urine pH: Abnormal High | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Placebo Plus SOC Antidepressant Treatment | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants with treatment emergent vital signs abnormalities (pulse rate in bpm [abnormally low = a decrease from baseline of >= 15 to a value <= 50; abnormally high = an increase from baseline of >=15 to a value >=100] , systolic blood pressure [SBP] in mmHg [abnormally low = a decrease from baseline of >= 20 to a value <= 90; abnormally high = an increase from baseline of >= 20 to a value >= 180], and diastolic blood pressure [DBP] in mmHg [abnormally low= a decrease from baseline of >=15 to a value <= 50; abnormally high = an increase from baseline of >= 15 to a value >= 105) were reported. (NCT03039192)
Timeframe: Up to Day 25
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Pulse rate (bpm): Decrease of >=15 to <=50 | Pulse rate (bpm): Increase of >=15 to >=100 | SBP (mmHg): Decrease of >=20 to <=90 | SBP (mmHg): Increase of >=20 to >=180 | DBP (mmHg): Decrease of >=15 to <=50 | DBP (mmHg): Increase of >=15 to >=105 | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | 3 | 13 | 0 | 2 | 0 | 11 |
| Placebo Plus SOC Antidepressant Treatment | 2 | 6 | 4 | 0 | 4 | 1 |
MOAA/S was used to measure treatment-emergent sedation with correlation to levels of sedation defined by the American society of anesthesiologists (ASA) continuum. The MOAA/S scores range from 0 to 5 where,0 = no response to painful stimulus; ASA continuum = general anesthesia, 1 = responds to trapezius squeeze; ASA continuum = deep sedation, 2 = purposeful response to mild prodding or mild shaking; ASA continuum = moderate sedation, 3 = responds after name called loudly or repeatedly; ASA continuum = moderate sedation, 4 = lethargic response to name spoken in normal tone; ASA continuum = moderate sedation and 5 = readily responds to name spoken in normal tone (awake); ASA continuum = minimal sedation. (NCT03039192)
Timeframe: Up to Day 25
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Score <=2: Yes | Score <=3: Yes | Score <=4: Yes | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | 3 | 13 | 43 |
| Placebo Plus SOC Antidepressant Treatment | 0 | 1 | 20 |
The TSQM-9 is a 9-item generic patient-reported outcome instrument to assess participants' satisfaction with medication. It covers domains of effectiveness, convenience, and global satisfaction. The TSQM-9 domain scores were calculated as recommended by the instrument authors. (i) Effectiveness = [(item 1 + item 2 + item 3) - 3]/18*100, (ii) Convenience = [(item 4 + item 5 + item 6) - 3]/18*100 and (iii) Global satisfaction = [(item 7 + item 8 + item 9) - 3]/14*100. Each domain score can be calculated only if all the three items considered in the calculation of that score are not missing. The TSQM-9 domain score ranges from 0 to 100, with higher scores representing higher satisfaction. (NCT03039192)
Timeframe: Days 15 and 25
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Effectiveness: Day 15 | Effectiveness: Day 25 | Convenience: Day 15 | Convenience: Day 25 | Global Satisfaction: Day 15 | Global Satisfaction: Day 25 | |
| Esketamine 84 mg Plus SOC Antidepressant Treatment | 63.5 | 65.8 | 70.5 | 71.3 | 64.5 | 68.5 |
| Placebo Plus SOC Antidepressant Treatment | 51.7 | 57.6 | 70.9 | 74.0 | 52.2 | 55.7 |
Clinical global impression-severity of suicidality-revised (CGI-SS-R) scale is revised version of the clinical global impression severity scale (CGI-S),a global rating scale that gives an overall measure of the severity of a participants illness. The CGI-SS-R summarizes the clinician's overall impression of severity of suicidality on a 7-point scale from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal participants), based on the totality of information available to the clinician. Higher score indicates a more severe condition. Negative change in score indicates improvement. (NCT03097133)
Timeframe: Baseline (Day 1, predose) and 24 hours first post dose (Day 2)
| Intervention | units on a scale (Median) |
|---|---|
| Placebo + Standard of Care (SOC) | -1.0 |
| Esketamine 84 mg + SOC | -1.0 |
MADRS is clinician-rated scale designed to be used in participants with Major Depressive Disorder (MDD) to measure depression severity and detect changes due to antidepressant treatment. It evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic and suicidal thoughts. Scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), summed for total possible score of 0 to 60. Higher scores represent more severe condition. Negative change in score indicates improvement. (NCT03097133)
Timeframe: Baseline (Day 1, predose) and 24 hours first post dose (Day 2)
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo + Standard of Care (SOC) | -12.4 |
| Esketamine 84 mg + SOC | -15.7 |
Pulse oximetry was used to measure arterial SpO2 levels. On each dosing day, the device was attached to the finger, toe, or ear, and SpO2 was monitored and documented. If oxygen saturation levels were less than (<) 93% at any time during the 1.5 hours postdose interval, pulse oximetry was recorded every 5 minutes until levels return to >= 93% or until the participant is referred for appropriate medical care, if clinically indicated. Participants with at least 2 consecutive postdose oxygen saturation below 93% during the DB treatment phase were reported. (NCT03097133)
Timeframe: Up to Day 25
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Standard of Care (SOC) | 2 |
| Esketamine 84 mg + SOC | 3 |
An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. A TEAE is categorized as related if assessed by the investigator as possibly, probably, or very likely related to study agent. (NCT03097133)
Timeframe: Up to Day 25
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Standard of Care (SOC) | 87 |
| Esketamine 84 mg + SOC | 104 |
BHS is a self-reported measure to assess one's level of negative expectations or pessimism regarding future. It consists of 20 true-false items that examine respondent's attitude over past week by either endorsing a pessimistic statement or denying an optimistic statement; 9 are keyed false and 11 are keyed true. For every statement, each response was assigned score of 0 or 1. Total BHS score is sum of item responses, ranged from 0-20, where higher score represented higher level of hopelessness. (NCT03097133)
Timeframe: Baseline, Days 8 and 25
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change at Day 8 | Change at Day 25 | |
| Esketamine 84 mg + SOC | -6.1 | -8.0 |
| Placebo + Standard of Care (SOC) | -6.3 | -7.0 |
CGI-SS-R is revised version of the CGI-S. The CGI-SS-R summarizes the clinician's overall impression of severity of suicidality on a 7-point scale from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal participants), based on the totality of information available to the clinician. A higher score indicates a more severe condition. Negative change in score indicates improvement. (NCT03097133)
Timeframe: Baseline (Day 1, predose), Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and 25
| Intervention | units on a scale (Median) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Change at Day 1: 4 hours postdose | Change at Day 2 | Change at Day 4 | Change at Day 8 | Change at Day 11 | Change at Day 15 | Change at Day 18 | Change at Day 22 | Change at Day 25 | |
| Esketamine 84 mg + SOC | -1.0 | -1.0 | -2.0 | -2.0 | -3.0 | -3.0 | -3.0 | -3.0 | -3.0 |
| Placebo + Standard of Care (SOC) | -1.0 | -1.0 | -2.0 | -2.0 | -2.0 | -3.0 | -3.0 | -3.0 | -3.0 |
The CGI-SR-I is a scale summarizing the clinician's best assessment of the likelihood that the participant will attempt suicide in the next 7 days. The CGI-SR-I rating is scored on a 7-point scale: where' 0 (no imminent suicide risk); 1 (minimal imminent suicide risk), 2 (mild imminent suicide risk), 3 (moderate imminent suicide risk), 4 (marked imminent suicide risk), 5 (severely imminent suicide risk), 6 (extreme imminent suicide risk). Higher score indicates a more severe condition. Negative change in score indicates improvement. (NCT03097133)
Timeframe: Baseline (Day 1, predose), Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and 25
| Intervention | units on a scale (Median) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Change at Day 1: 4 hours postdose | Change at Day 2 | Change at Day 4 | Change at Day 8 | Change at Day 11 | Change at Day 15 | Change at Day 18 | Change at Day 22 | Change at Day 25 | |
| Esketamine 84 mg + SOC | -1.0 | -1.0 | -2.0 | -2.0 | -2.0 | -2.0 | -3.0 | -3.0 | -3.0 |
| Placebo + Standard of Care (SOC) | 0.0 | -1.0 | -2.0 | -2.0 | -2.0 | -3.0 | -3.0 | -3.0 | -3.0 |
"EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a HSI. HSI ranges from 0 (dead) to 1.00 (full health). Positive change in score indicates improvement." (NCT03097133)
Timeframe: Baseline, Days 2, 11 and 25
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Change at Day 2 | Change at Day 11 | Change at Day 25 | |
| Esketamine 84 mg + SOC | 0.160 | 0.202 | 0.235 |
| Placebo + Standard of Care (SOC) | 0.129 | 0.194 | 0.194 |
"EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). EQ-5D-5L descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (no problem, slight, moderate, severe and extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate Health Status Index (HSI). HSI ranges from 0 (dead) to 1.00 (full health). EQ-VAS self-rating records respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst imaginable health)-100 (best imaginable health). Sum score ranges from 0 -100. Sum score=(sum of the scores from the 5 dimensions minus 5)*5. Higher score indicates worse health state. Negative change in score indicates improvement." (NCT03097133)
Timeframe: Baseline, Days 2, 11 and 25
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Change at Day 2 | Change at Day 11 | Change at Day 25 | |
| Esketamine 84 mg + SOC | -11.8 | -15.0 | -18.8 |
| Placebo + Standard of Care (SOC) | -9.0 | -15.1 | -15.3 |
EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). Positive change in score indicates improvement. (NCT03097133)
Timeframe: Baseline, Days 2, 11 and 25
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Change at Day 2 | Change at Day 11 | Change at Day 25 | |
| Esketamine 84 mg + SOC | 13.4 | 21.4 | 27.0 |
| Placebo + Standard of Care (SOC) | 9.7 | 17.6 | 18.6 |
MADRS is a clinician-rated scale designed to be used in participants with MDD to measure depression severity and detect changes due to antidepressant treatment. MADRS evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts. The instrument consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement. (NCT03097133)
Timeframe: Baseline (Day 1, predose), Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and 25 (predose and 4 hours postdose)
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Change at Day 1: 4 hours postdose | Change at Day 2 | Change at Day 4 | Change at Day 8 | Change at Day 11 | Change at Day 15 | Change at Day 18 | Change at Day 22 | Change at Day 25: Predose | Change at Day 25: 4 hours postdose | |
| Esketamine 84 mg + SOC | -12.2 | -16.0 | -17.7 | -20.1 | -21.3 | -23.4 | -23.1 | -24.5 | -26.2 | -28.7 |
| Placebo + Standard of Care (SOC) | -8.2 | -12.4 | -15.7 | -17.4 | -19.5 | -20.0 | -21.4 | -22.0 | -22.5 | -26.4 |
"The QLDS is a disease-specific patient-reported outcome designed to assess health-related quality of life in patients with MDD, it captures the impact of depression and its treatment from the participant's perspective. The instrument has a recall period of at the moment and contains 34 items with true/not true response options. The total score range is from 0 (good quality of life) to 34 (very poor quality of life). A higher score indicates a more severe condition. Negative change indicates improvement." (NCT03097133)
Timeframe: Baseline, Days 2, 11 and 25
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Change at Day 2 | Change at Day 11 | Change at Day 25 | |
| Esketamine 84 mg + SOC | -3.5 | -5.1 | -6.3 |
| Placebo + Standard of Care (SOC) | -2.5 | -5.2 | -5.5 |
SIBAT is an assessment tool that captures suicidal ideation, behavior, and risk. It permits assessment of change in suicidal ideation and behavior and documents clinician assessment of severity of suicidality and suicide risk. SIBAT is organized into 8 modules divided into 2 major divisions: patient-reported section (Modules 1-5) and clinician-rated section (Modules 6-8). Patient-reported section has modules of demographics and suicide history, risk/protective factors, suicidal thinking, suicide behavior, and suicide risk. Question 3 from Module 5 asks participants to describe their thinking about suicide right now from 5 response options ranging from 0 (I have no suicidal thoughts) to 4 (I have suicidal thoughts all of time). (NCT03097133)
Timeframe: Baseline, Days 1 (4h postdose), 2, 4, 8, 11, 15, 18, 22 and 25
| Intervention | units on a scale (Median) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Change at Day 1: 4 hours postdose | Change at Day 2 | Change at Day 4 | Change at Day 8 | Change at Day 11 | Change at Day 15 | Change at Day 18 | Change at Day 22 | Change at Day 25 | |
| Esketamine 84 mg + SOC | -1.0 | -1.0 | -1.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 |
| Placebo + Standard of Care (SOC) | -1.0 | -1.0 | -1.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 |
SIBAT is assessment tool that captures suicidal ideation, behavior, and risk. It permits assessment of change in suicidal ideation and behavior and documents clinician assessment of severity of suicidality and suicide risk. SIBAT has 8 modules divided into 2 major divisions: patient-reported section (Modules 1-5) and clinician-rated section (Modules 6-8). Clinician-rated section has modules for semi-structured interview, clinical global impressions of current severity of suicidality and imminent suicide risk, clinical global impression of long-term suicide risk, and clinical judgment of optimal suicide management. The score anchor point as in participant report frequency of suicidal thinking that is, response options from never to all the time. Module 7-FoST score ranges from 0-5; higher score indicates more severe condition. Negative change in score indicates improvement. (NCT03097133)
Timeframe: Baseline, Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and 25
| Intervention | units on a scale (Median) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Change at Day 1: 4 hours postdose | Change at Day 2 | Change at Day 4 | Change at Day 8 | Change at Day 11 | Change at Day 15 | Change at Day 18 | Change at Day 22 | Change at Day 25 | |
| Esketamine 84 mg + SOC | -1.0 | -1.0 | -2.0 | -2.0 | -2.0 | -3.0 | -3.0 | -3.0 | -3.0 |
| Placebo + Standard of Care (SOC) | -1.0 | -1.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 |
CGI-SS-R is revised version of the CGI-S. The CGI-SS-R summarizes the clinician's overall impression of severity of suicidality on a 7-point scale from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal participants), based on the totality of information available to the clinician. Higher score indicates a more severe condition. A participant was considered to have achieved resolution of suicidality at a given time point if the CGI-SS-R score was 0 (normal, not at all suicidal) or 1 (questionably suicidal). Participants who did not met such criterion or discontinued prior to the time point for any reason were not considered to have resolution of suicidality. (NCT03097133)
Timeframe: Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and 25
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Day 1: 4 hours postdose | Day 2 | Day 4 | Day 8 | Day 11 | Day 15 | Day 18 | Day 22 | Day 25 | |
| Esketamine 84 mg + SOC | 38 | 36 | 52 | 53 | 62 | 65 | 62 | 68 | 69 |
| Placebo + Standard of Care (SOC) | 20 | 35 | 51 | 54 | 58 | 58 | 59 | 65 | 66 |
Number of participants with abnormal nasal examination were reported. Nasal examination of visual inspection of the epistaxis, nasal crusts, nasal discharge, and nasal erythema was performed. (NCT03097133)
Timeframe: At Day 25
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Epistaxis: Mild | Epistaxis: Moderate | Epistaxis: Severe | Nasal Crusts: Mild | Nasal Crusts: Moderate | Nasal Crusts: Severe | Nasal Discharge: Mild | Nasal Discharge: Moderate | Nasal Discharge: Severe | Nasal Erythema: Mild | Nasal Erythema: Moderate | Nasal Erythema: Severe | |
| Esketamine 84 mg + SOC | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 4 | 0 | 0 |
| Placebo + Standard of Care (SOC) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
"The CADSS used to measure present-state dissociative symptoms, and to assess treatment-emergent dissociative symptoms. It comprises 23 subjective items divided into 3 components: depersonalization (with score range from 0 to 28), derealization (with score range from 0 to 52), and amnesia (with score range from 0 to 8). Participants responses are coded on a 5-point scale (0 = Not at all, 1 = Mild, 2 = Moderate, 3 = 'Severe and 4 = Extreme). The total score is sum of the 23 items and range from 0 to 92, where 0 (best) and 92 (worst). A higher score indicates a more severe condition. Number of participants with an increase in CADSS total score (increase based on maximum CADSS total score change from predose of > 0) was reported." (NCT03097133)
Timeframe: Days 1, 4, 8, 11, 15, 18, 22 and 25
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 1 | Day 4 | Day 8 | Day 11 | Day 15 | Day 18 | Day 22 | Day 25 | |
| Esketamine 84 mg + SOC | 106 | 86 | 75 | 68 | 68 | 53 | 58 | 56 |
| Placebo + Standard of Care (SOC) | 28 | 21 | 16 | 8 | 11 | 8 | 7 | 4 |
MADRS is clinician-rated scale designed to be used in participants with Major Depressive Disorder (MDD) to measure depression severity and detect changes due to antidepressant treatment. It evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic and suicidal thoughts. Scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), summed for total possible score of 0 to 60. Higher scores represent more severe condition. Negative change in score indicates improvement. (NCT03097133)
Timeframe: Days 1 (4 hours [h] postdose), 2, 4, 8, 11, 15, 18, 22 and 25 (predose and 4 hours postdose)
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1: 4 hours post dose | Day 2 | Day 4 | Day 8 | Day 11 | Day 15 | Day 18 | Day 22 | Day 25: Predose | Day 25: 4 hours postdose | |
| Esketamine 84 mg + SOC | 12 | 25 | 26 | 28 | 32 | 36 | 29 | 42 | 49 | 54 |
| Placebo + Standard of Care (SOC) | 4 | 12 | 20 | 23 | 26 | 29 | 32 | 37 | 31 | 42 |
Number of participants with treatment emergent abnormal ECG values for variables including heart rate (abnormally low refers to less than or equal to [<=] 50 beats per minute [bpm] , abnormally high refers greater than or equal to [>=] 100 bpm), pulse rate (PR) interval (abnormally high refers to >= 210 milliseconds [msec]), QRS interval (abnormally Low refers to <= 50, abnormally high refers to >= 120 msec) and QT interval (abnormally low refers to <= 200, abnormally high >= 500 msec) were reported. (NCT03097133)
Timeframe: Up to Day 25
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Heart Rate <= 50 bpm | Heart Rate >= 100 bpm | PR Duration >= 210 msec | QRS Duration <= 50 msec | QRS Duration >= 120 msec | QT Duration <= 200 msec | QT Duration >= 500 msec | |
| Esketamine 84 mg + SOC | 2 | 2 | 2 | 0 | 0 | 0 | 0 |
| Placebo + Standard of Care (SOC) | 9 | 3 | 2 | 0 | 1 | 0 | 0 |
Low/high abnormal values are: Alanine aminotransferase (ALT)-high=200 Units per liter(U/L); ALP-high=250U/L; aspartate aminotransferase(AST)-high=250U/L; gamma glutamyl transferase(GGT)=300U/L; Albumin (low=24g/L,high=60 g/L); Bicarbonate(low=15.1, high=34.9mmol/L); Bilirubin(high=51.3micromol/L); calcium(low=1.5,high=3mmol/L);Chloride(low=94,high=112mmol/L); CK(High=990U/L); Creatinine (High=265.2micromol/L); Eosinophils(High=10%); Erythrocytes(low=3.0*1012/L,high=6.4*1012/L); Glucose(low=2.2,high=16.7mmol/L); Hemoglobin(low=80g/L,high=190g/L);Hematocrit(low=0.28, high=0.55 fraction); LD(high=500U/L); Leukocytes(low=2.5*109/L,high=15.5*109/L); Lymphocytes(low=10%,high=60%); Monocytes(high=20%); Neutrophils(low=30%,high=90%); Phosphate(low=0.7 mmol/L,high=2.6mmol/L); Platelet count(low=100*109/L,high=600*109/L]; Potassium(low=3.0mmol/L,high=5.8 mmol/L]; Protein(low=50 g/L); Sodium(low=125 mmol/L,high=155 mmol/L); Urate(low=89.2 micromol/L,high=594.8micromol/L); Urine(high=8.0 pH). (NCT03097133)
Timeframe: Up to Day 25
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT: ALT>3*ULN | ALT: Abnormal High | Albumin: Abnormal High | Albumin: Abnormal Low | Alkaline phosphatase (ALP): Abnormal High | AST: AST>3*ULN | AST: Abnormal High | Bicarbonate: Abnormal High | Bicarbonate: Abnormal Low | Bilirubin: Abnormal High | Calcium: Abnormal High | Calcium: Abnormal Low | Chloride: Abnormal High | Chloride: Abnormal Low | Creatine Kinase (CK): Abnormal High | Creatinine: Abnormal High | GGT: Abnormal High | Glucose: Abnormal High | Glucose: Abnormal Low | ALT>3*ULN or AST>3*ULN and BILI>2*ULN | Lactate Dehydrogenase (LD): Abnormal High | Phosphate: Abnormal High | Phosphate: Abnormal Low | Potassium: Abnormal High | Potassium: Abnormal Low | Protein: Abnormal Low | Sodium: Abnormal High | Sodium: Abnormal Low | Urate: Abnormal High | Urate: Abnormal Low | Basophils: Abnormal High | Eosinophils: Abnormal High | Erythrocytes: Abnormal High | Erythrocytes: Abnormal Low | Hematocrit: Abnormal High | Hematocrit: Abnormal Low | Hemoglobin (Hb): Abnormal High | Hemoglobin: Abnormal Low | Leukocytes: Abnormal High | Leukocytes: Abnormal Low | Lymphocytes: Abnormal High | Lymphocytes: Abnormal Low | Monocytes: Abnormal High | Neutrophils: Abnormal High | Neutrophils: Abnormal Low | Platelets: Abnormal High | Platelets: Abnormal Low | Urine pH: Abnormal High | |
| Esketamine 84 mg + SOC | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 |
| Placebo + Standard of Care (SOC) | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants with treatment emergent vital signs abnormalities (pulse rate in bpm [abnormally low = a decrease from baseline of >= 15 to a value <= 50; abnormally high = an increase from baseline of >=15 to a value >=100] , systolic blood pressure [SBP] in mmHg [abnormally low = a decrease from baseline of >= 20 to a value <= 90; abnormally high = an increase from baseline of >= 20 to a value >= 180], and diastolic blood pressure [DBP] in mmHg [abnormally low= a decrease from baseline of >=15 to a value <= 50; abnormally high = an increase from baseline of >= 15 to a value >= 105) were reported. (NCT03097133)
Timeframe: Up to Day 25
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Pulse rate (bpm): Decrease of >=15 to <=50 | Pulse rate (bpm): Increase of >=15 to >=100 | SBP: Decrease of >=20 to <=90 | SBP (mmHg): Increase of >=20 to >=180 | DBP (mmHg): Decrease of >=15 to <=50 | DBP (mmHg): Increase of >=15 to >=105 | |
| Esketamine 84 mg + SOC | 1 | 12 | 2 | 3 | 4 | 6 |
| Placebo + Standard of Care (SOC) | 2 | 11 | 5 | 2 | 4 | 3 |
MOAA/S was used to measure treatment-emergent sedation with correlation to levels of sedation defined by the American society of anesthesiologists (ASA) continuum. The MOAA/S scores range from 0 to 5 where,0 = no response to painful stimulus; ASA continuum = general anesthesia, 1 = responds to trapezius squeeze; ASA continuum = deep sedation, 2 = purposeful response to mild prodding or mild shaking; ASA continuum = moderate sedation, 3 = responds after name called loudly or repeatedly; ASA continuum = moderate sedation, 4 = lethargic response to name spoken in normal tone; ASA continuum = moderate sedation and 5 = readily responds to name spoken in normal tone (awake); ASA continuum = minimal sedation. (NCT03097133)
Timeframe: Up to Day 25
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Score <=2: Yes | Score <=3: Yes | Score <=4: Yes | |
| Esketamine 84 mg + SOC | 4 | 21 | 65 |
| Placebo + Standard of Care (SOC) | 0 | 3 | 20 |
The TSQM-9 is a 9-item generic patient-reported outcome instrument to assess participants' satisfaction with medication. It covers domains of effectiveness, convenience, and global satisfaction. The TSQM-9 domain scores were calculated as recommended by the instrument authors. (i) Effectiveness = [(item 1 + item 2 + item 3) - 3]/18*100, (ii) Convenience = [(item 4 + item 5 + item 6) - 3]/18*100 and (iii) Global satisfaction = [(item 7 + item 8 + item 9) - 3]/14*100. Each domain score can be calculated only if all the three items considered in the calculation of that score are not missing. The TSQM-9 domain score ranges from 0 to 100, with higher scores representing higher satisfaction. (NCT03097133)
Timeframe: Days 15 and 25
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Effectiveness: Day 15 | Effectiveness: Day 25 | Convenience: Day 15 | Convenience: Day 25 | Global Satisfaction: Day 15 | Global Satisfaction: Day 25 | |
| Esketamine 84 mg + SOC | 63.5 | 68.8 | 71.3 | 77.0 | 63.6 | 71.5 |
| Placebo + Standard of Care (SOC) | 55.3 | 54.8 | 77.2 | 76.9 | 59.7 | 56.8 |
Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Scores > 30 indicate severe anxiety. (NCT00344682)
Timeframe: baseline & week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -4.13 |
| Memantine | -5.53 |
The 16 item Quick Inventory of Depressive Symptomatology (QIDS-SR16) (Rush et al. 2003) is designed to assess the severity of depressive symptoms, with higher scores representing more severe forms of depression. When complete, the QIDS are scored by summing responses to obtain a total score ranging from 0 to 27. Either appetite increase or decrease, but not both, are used to calculate the total score. Weight increase or decrease, but not both, are used to calculate the total score. Scores 0-5 indicate no severity of depression; 6-10 is mild; 11-15 is moderate; 16-20 is severe; 21-27 is very severe levels of depression. Participants were evaluated at baseline and at weeks 1, 2, 3, 4, 6 & 8. (NCT00344682)
Timeframe: baseline & week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -3.69 |
| Memantine | -6.47 |
Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6 on 10 items. The overall score ranges from 0 to 60. Scores 0 to 6 indicate symptoms absent; 7 to 19 indicates mild depression; 30 to 34 defines moderate; 35 to 60 indicates severe depression. Changes in response rate and remission rate were assessed for secondary measures. (NCT00344682)
Timeframe: baseline and week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -10.75 |
| Memantine | -7.13 |
Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. Scores 0 to 6 indicate symptoms absent; 7 to 19 indicates mild depression; 30 to 34 defines moderate; 35 to 60 indicates severe depression. Changes in MADRS score was a primary measure. (NCT00344682)
Timeframe: Baseline & week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -7.25 |
| Memantine | -7.13 |
"CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. CGI-S permits global evaluation of participant's condition at given time. The last post baseline observation during the phase was carried forward as End Point for that phase." (NCT02418585)
Timeframe: Baseline up to Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Units on a scale (Median) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -2.0 |
| Intranasal Placebo Plus Oral AD | -2.0 |
EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). (NCT02418585)
Timeframe: Baseline up to End of Double-blind Induction Phase (Day 28)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | 29.1 |
| Intranasal Placebo Plus Oral AD | 20.9 |
"EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ VAS). EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a Health Status Index (HSI). Health Status Index range is -0.148 - 0.949, is anchored at 0 (dead) and 1 (full health). EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) *5. Higher score indicates worst health state." (NCT02418585)
Timeframe: Baseline up to End of Double-blind Induction Phase (Day 28)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -23.2 |
| Intranasal Placebo Plus Oral AD | -17.1 |
"European Quality of Life Group-5 Dimension-5-Level (EQ-5D-5L) is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a Health Status Index (HSI). Health Status Index range is -0.148 - 0.949, is anchored at 0 (dead) and 1 (full health)." (NCT02418585)
Timeframe: Baseline up to End of Double-blind Induction Phase (Day 28)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | 0.288 |
| Intranasal Placebo Plus Oral AD | 0.231 |
"GAD-7 is a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21). The last post baseline observation during the phase was carried forward as End Point for that phase." (NCT02418585)
Timeframe: Baseline up to Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -7.9 |
| Intranasal Placebo Plus Oral AD | -6.8 |
MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT02418585)
Timeframe: Baseline up to Day 28 of Double-blind Induction Phase
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -21.4 |
| Intranasal Placebo Plus Oral AD | -17.0 |
"MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. The last post baseline observation during the phase was carried forward as End Point for that phase." (NCT02418585)
Timeframe: Baseline up to Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -19.6 |
| Intranasal Placebo Plus Oral AD | -16.3 |
PHQ-9 is 9-item, self-report scale assessing depressive symptoms. Each item is rated on 4-point scale (0=Not at all, 1=Several Days, 2=More than half days, 3=Nearly every day. Scale scores each of 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders, Major Depressive Disorder criteria and it has been used both as screening tool and measure of response to treatment for depression. The participant's item responses are summed to provide a total score (range of 0 to 27) with higher scores indicating greater severity of depressive symptoms. Severity of PHQ-9 categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19), Severe (20-27). (NCT02418585)
Timeframe: Baseline up to Day 28 of Double-blind Induction phase
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -13.0 |
| Intranasal Placebo Plus Oral AD | -10.2 |
"PHQ-9 is 9-item, self-report scale assessing depressive symptoms. Each item is rated on 4-point scale (0=Not at all, 1=Several Days, 2=More than half days, 3=Nearly every day). Scale scores each of 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders, Major Depressive Disorder criteria and it has been used both as screening tool and measure of response to treatment for depression. The participant's item responses are summed to provide a total score (range of 0 to 27) with higher scores indicating greater severity of depressive symptoms. Severity of PHQ-9 categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19), Severe (20-27). The last post baseline observation during the phase was carried forward as End Point for that phase." (NCT02418585)
Timeframe: Baseline up to Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -12.2 |
| Intranasal Placebo Plus Oral AD | -10.1 |
The SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. First three items assess disruption of 1 work/school, 2 social life, 3 family life/home responsibilities using a 0(no impairment)-10 (most severe impairment). Score for first 3 items are summed to create total score of 0-30 where higher score indicates greater impairment and a negative change in score indicates improvement. It also has one item on days lost from school or work and one item on days when under productive. (NCT02418585)
Timeframe: Baseline up to Day 28 of Double-blind Induction phase
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -13.6 |
| Intranasal Placebo Plus Oral AD | -9.4 |
"The SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. First three items assess disruption of 1 work/school, 2 social life, 3 family life/home responsibilities using a 0(no impairment)-10 (most severe impairment). Score for first 3 items are summed to create total score of 0-30 where higher score indicates greater impairment and a negative change in score indicates improvement. It also has one item on days lost from school or work and one item on days when under productive. The last post baseline observation during the phase was carried forward as End Point for that phase." (NCT02418585)
Timeframe: Baseline up to Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -12.5 |
| Intranasal Placebo Plus Oral AD | -9.3 |
"Remission was defined as participants who had a MADRS total score of less than or equal to (=<) 12. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. The last post baseline observation during the phase was carried forward as End Point for that phase." (NCT02418585)
Timeframe: At Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Percentage of participants (Number) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | 48.2 |
| Intranasal Placebo Plus Oral AD | 30.3 |
Remission defined as SDS total score <= 6 and individual item scores each <= 2. SDS is a participant reported outcome measure and is a 5-item questionnaire which has been widely used and accepted for assessment of functional impairment and associated disability. The first three items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a 0-10 rating scale. The score for the first three items were summed to create a total score of 0-30 where a higher score indicates greater impairment. It also has one item on days lost from school or work and one item on days when under productive. (NCT02418585)
Timeframe: At Day 28 (End of Double-blind Induction Phase)
| Intervention | Percentage of participants (Number) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | 39.5 |
| Intranasal Placebo Plus Oral AD | 20.9 |
Response defined as SDS total score <= 12 and individual item scores each <= 4. SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. First three items assess disruption of 1 work/school, 2 social life, 3 family life/home responsibilities using a 0(no impairment)-10 (most severe impairment). Score for first 3 items are summed to create total score of 0-30 where higher score indicates greater impairment and a negative change in score indicates improvement. It also has one item on days lost from school or work and one item on days when under productive. (NCT02418585)
Timeframe: At Day 28 [end of Double-blind Induction Phase]
| Intervention | Percentage of participants (Number) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | 57.0 |
| Intranasal Placebo Plus Oral AD | 39.5 |
"MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. The percentage of participants with greater than or equal to (>=) 50 % reduction from baseline in MADRS total score was reported. The last post baseline observation during the phase was carried forward as End Point for that phase." (NCT02418585)
Timeframe: At Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Percentage of participants (Number) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | 63.4 |
| Intranasal Placebo Plus Oral AD | 49.5 |
A participant was defined as having a clinical response if there is at least 50 percent (%) improvement from baseline in the MADRS total score with onset by Day 2 and Day 8 that was maintained to Day 28. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Participants who did not meet such criterion or discontinue during the study before Day 28 for any reason were considered as non-responders. (NCT02418585)
Timeframe: Day 2 up to Day 28 and Day 8 up to Day 28
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Onset of Clinical response on Day 2 | Onset of Clinical response on Day 8 | |
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | 7.9 | 10.5 |
| Intranasal Placebo Plus Oral AD | 4.6 | 6.4 |
CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. Values of 0 (not assessed) were excluded from analysis. CGI-S permits global evaluation of participant's condition at given time. (NCT02918318)
Timeframe: Baseline (Day 1) up to Day 28 (DB induction pahse)
| Intervention | Units on a scale (Median) |
|---|---|
| Esketamine 28 Milligrams (mg) | -1.0 |
| Esketamine 56 mg | -1.0 |
| Esketamine 84 mg | -1.0 |
| Placebo | -1.0 |
GAD-7 was a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21). (NCT02918318)
Timeframe: Baseline (Day 1) up to Day 28 (DB induction phase)
| Intervention | Units on a scale (Mean) |
|---|---|
| Esketamine 28 Milligrams (mg) | -8.2 |
| Esketamine 56 mg | -7.8 |
| Esketamine 84 mg | -8.1 |
| Placebo | -7.7 |
SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. First three items assess disruption of 1 work/school, 2 social life, 3 family life/home responsibilities using a 0(no impairment)-10 (most severe impairment). Score for first 3 items are summed to create total score of 0-30 where higher score indicates greater impairment and a negative change in score indicates improvement. It also has one item on days lost from school or work and one item on days when under productive. (NCT02918318)
Timeframe: Baseline (Day 1) to Day 28 (DB induction phase)
| Intervention | Units on a scale (Mean) |
|---|---|
| Esketamine 28 Milligrams (mg) | -8.6 |
| Esketamine 56 mg | -7.9 |
| Esketamine 84 mg | -9.5 |
| Placebo | -7.0 |
MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Negative change in score indicates improvement. (NCT02918318)
Timeframe: Baseline (Day 1) up to Day 28 (DB phase) induction
| Intervention | Units on a scale (Mean) |
|---|---|
| Esketamine 28 Milligrams (mg) | -15.2 |
| Esketamine 56 mg | -14.5 |
| Esketamine 84 mg | -15.1 |
| Placebo | -15.3 |
Time to relapse in participants with remission at the end of the double-blind phase was defined as the time between induction phase and the first documentation of a relapse event during the posttreatment phase. Relapse was defined as any of the following: 1) MADRS total score >= 22 for 2 consecutive assessments. The date of the second MADRS assessment was used for the date of relapse; 2) Hospitalization for worsening depression or any other clinically relevant event determined per clinical judgment to be suggestive of relapse of depressive illness like suicide attempt, completed suicide, or hospitalization for suicide prevention. If hospitalized for any of these events, start date of hospitalization was used as relapse date. If participant was not hospitalized, event date was used. 3) If both relapse criteria were met, earlier date was defined as date of relapse. Remission was defined as MADRS total score <=12. (NCT02918318)
Timeframe: From EndPoint (last post baseline assessment value during the DB induction phase [up to Day 28]) up to 24 weeks (posttreatment phase)
| Intervention | Days (Median) |
|---|---|
| Esketamine 28 Milligrams (mg) | 34.0 |
| Esketamine 56 mg | 52.0 |
| Esketamine 84 mg | 37.0 |
| Placebo | 30.0 |
Time to relapse in participants with response (>=50% reduction from baseline in MADRS total score) but who are not in remission was reported. Relapse is defined as any of the following: 1) MADRS total score >= 22 for 2 consecutive assessments. The date of the second MADRS assessment was used for the date of relapse. 2)Hospitalization for worsening depression or any other clinically relevant event determined per clinical judgment to be suggestive of relapse of depressive illness like suicide attempt, completed suicide, or hospitalization for suicide prevention. If hospitalized for any of these events, start date of hospitalization was used as relapse date. If participant was not hospitalized, event date was used. 3) If both relapse criteria were met, earlier date was defined as date of relapse. Remission was defined as MADRS total score <=12. (NCT02918318)
Timeframe: From EndPoint (last post baseline assessment value during the DB induction phase [up to Day 28]) up to 24 weeks (posttreatment phase)
| Intervention | Days (Median) |
|---|---|
| Esketamine 28 Milligrams (mg) | 32.0 |
| Esketamine 56 mg | 26.0 |
| Esketamine 84 mg | 79.5 |
| Placebo | 91.0 |
A participant was defined as having a clinical response if there was at least 50% improvement from baseline in the MADRS total score with onset by Day 2 that was maintained to Day 28 in DB induction phase. Participants were allowed one excursion (non-response) on Days 8, 15 or 22, provided the score is at least 25% improvement. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT02918318)
Timeframe: Day 2 up to Day 28 (DB induction phase)
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Onset of clinical response: Yes | Onset of clinical response: No | |
| Esketamine 28 Milligrams (mg) | 2.4 | 97.6 |
| Esketamine 56 mg | 2.6 | 97.4 |
| Esketamine 84 mg | 7.3 | 92.7 |
| Placebo | 6.3 | 93.7 |
A participant was considered in remission at a given time point if the MADRS total score <=12. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT02918318)
Timeframe: Days 2, 8, 15, 22 and 28 (DB induction phase)
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Day 2 | Day 8 | Day 15 | Day 22 | Day 28 | |
| Esketamine 28 Milligrams (mg) | 9.8 | 2.4 | 7.5 | 10.3 | 23.1 |
| Esketamine 56 mg | 0 | 0 | 2.8 | 5.6 | 11.8 |
| Esketamine 84 mg | 7.5 | 4.9 | 10.0 | 7.7 | 23.1 |
| Placebo | 3.8 | 1.3 | 3.9 | 14.9 | 20.8 |
A participant is defined as responder (yes=1 and no=0) at a given time point if the percent improvement from baseline in MADRS is greater than or equal to (>=) 50 percent (%). MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT02918318)
Timeframe: Days 2, 8, 15, 22 and 28 (DB induction phase)
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Day 2 | Day 8 | Day 15 | Day 22 | Day 28 | |
| Esketamine 28 Milligrams (mg) | 22.0 | 2.4 | 17.5 | 23.1 | 33.3 |
| Esketamine 56 mg | 13.2 | 2.6 | 8.3 | 13.9 | 35.3 |
| Esketamine 84 mg | 10.0 | 9.8 | 15.0 | 20.5 | 43.6 |
| Placebo | 9.0 | 3.8 | 18.2 | 29.7 | 37.5 |
MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT02918318)
Timeframe: Baseline (Prior to first Dose of OL induction phase on Day 1) up to endpoint of OL induction phase (last post baseline assessment value during OL induction phase [OL: up to Day 28])
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from baseline | |
| Esketamine: Flexible Dose | 16.1 | -14.5 |
A participant was considered in remission at a given time point if the MADRS total score <=12. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT02918318)
Timeframe: Days 8, 15, 22 and 28 (OL induction phase)
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Day 8 | Day 15 | Day 22 | Day 28 | |
| Esketamine: Flexible Dose | 14.6 | 23.4 | 31.9 | 42.6 |
CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. CGI-S permits global evaluation of participant's condition at given time. (NCT02918318)
Timeframe: Baseline (Prior to first dose of OL induction phase on Day 1), endpoint of OL induction phase (last post baseline assessment value during the OL induction phase [OL: up to Day 28])
| Intervention | Percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Normal, not at all ill:Baseline | Normal, not at all ill:Endpoint | Borderline mentally ill:Baseline | Borderline mentally ill:Endpoint | Mildly ill:Baseline | Mildly ill:Endpoint | Moderately ill:Baseline | Moderately ill:Endpoint | Markedly ill:Baseline | Markedly ill:Endpoint | Severely ill:Baseline | Severely ill:Endpoint | Among the most extremely ill patients:Baseline | Among the most extremely ill patients:Endpoint | |
| Esketamine: Flexible Dose | 0 | 14.6 | 0 | 16.7 | 4.2 | 43.8 | 75.0 | 20.8 | 14.6 | 4.2 | 4.2 | 0 | 2.1 | 0 |
SDS is a participant-reported outcome measure and is a 5-item questionnaire which has been widely used and accepted for assessment of functional impairment and associated disability. The first three items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a 0-10 rating scale. The score for the first three items are summed to create a total score of 0-30, where a higher score indicates greater impairment. It also has one item on days lost from school or work and one item on days when under productive. FAS (responders): All randomized participants who received at least 1 dose of intranasal study medication during DB induction phase and who were responders at the end of DB induction phase and entered posttreatment phase (NCT02918318)
Timeframe: Baseline (DB induction phase), Weeks 2, 4, 6, 8, 12, 16, 20 and 24 (posttreatment phase)
| Intervention | Units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 2 | Week 4 | Week 6 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | |
| Esketamine 28 Milligrams (mg) | -14.6 | -12.9 | -17.7 | -12.0 | -20.5 | -21.5 | -22.0 | -21.5 |
| Esketamine 56 mg | -8.1 | -8.3 | -11.0 | -13.3 | -13.0 | -17.5 | -18.0 | -16.0 |
| Esketamine 84 mg | -13.1 | -13.6 | -14.6 | -15.3 | -18.3 | -12.5 | -28.0 | -28.0 |
| Placebo | -11.2 | -9.8 | -12.0 | -11.4 | -14.8 | -15.8 | -14.0 | -14.8 |
Change in suicidal ideation in depressed patients with moderate to severe suicidal thoughts from the pre-infusion baseline to 24 hours after the infusion with ketamine or midazolam, a sedative not known to reduce suicidal ideation, measured with Beck Scale for Suicidal Ideation - clinician rated version. This scale has 19 items scaled 0 (least severe) to 2 (most severe) and a potential score ranging from 0 to 38, with higher score indicating greater severity. (NCT01700829)
Timeframe: Day 1 (24 hours) post-treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Midazolam | -3.66 |
| Ketamine | -8.62 |
The average Z-scores reported below are the average of the Z-scores for all tests administered. The Z-scores for each test were based on published normative data and normative data available in our laboratory. The population mean for a Z-score is zero, with a SD of 1, thus scores below zero would indicate performance below the population norm; a score close to zero indicates performance close to the population norm (or a normalizing of performance). (NCT01700829)
Timeframe: Baseline and Day 1
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Pre-infusion overall neuropsych performance | Day1 post-infusion overall neuropsych performance | |
| Ketamine | -0.306 | -0.01 |
| Midazolam | -0.252 | -0.146 |
"On the mornings of an infusion day and on post-treatment day1, participants used salivettes (Sarstedt AG & Co.) to provide saliva samples upon awakening (Cort1) and 30 minutes later (Cort2) to measure cortisol awakening response (CAR) = (Cort2 - Cort1).~Differences between the midazolam and ketamine groups were tested using an analysis of covariance (ANCOVA) model of the change in CAR from baseline to day1, with treatment group and baseline measurement of the outcome variable as predictors.~Range from 0.1 to 12.5 ng/ml and lower means less stress response, higher means greater stress response." (NCT01700829)
Timeframe: Cort2 - Cort1 = (Day 1 30-mins post-awakening cortisol) - (Day 1 awakening cortisol)
| Intervention | log(ng/mL) (Mean) | |||
|---|---|---|---|---|
| Baseline awakening | Baseline 30 mins post-awakening | Day1 awakening | Day1 30 minutes post-awakening | |
| Ketamine | 0.47 | 0.88 | 0.74 | 1.06 |
| Midazolam | 0.94 | 1.29 | 0.77 | 1.19 |
This battery is a series of computerized cognition tests (detection, identification, one card learning, one back and groton maze learning) designed to measure reaction time, visual learning and memory, and executive function/sequencing. The DET is a measure of psychomotor function and uses a well-validated simple reaction time. In this outcome measure, speed of performance of participants (calculated as mean of the logarithmic base 10 transformed reaction times) for correct responses was reported. Total score ranges from 2 to 3.3 log 10 milliseconds (msec). Lower score indicates better performance. Higher change from baseline indicates better performance. (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of Optimization/Maintenance [OP/MA] Phase)
| Intervention | log10 msec (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -0.0028 |
This battery is a series of computerized cognition tests (detection, identification, one card learning, one back and groton maze learning) designed to measure reaction time, visual learning and memory, and executive function/sequencing. GMLT measures executive function; maze/sequencing test, scored for total number of errors. Total score ranges from 0 to 999 number of errors. Lower score indicates better performance. Higher change from baseline indicates better performance. (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)
| Intervention | Number of Errors (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 6.9 |
This battery is a series of computerized cognition tests (detection, identification, one card learning, one back and groton maze learning) designed to measure reaction time, visual learning and memory, and executive function/sequencing. IDN test is a measure of visual attention (choice reaction time) and scored for speed of response (mean of the log10 transformed reaction times for correct responses). Total score ranges from 2 to 3.3 log 10 msec. Lower score indicates better performance. Higher change from baseline indicates better performance. (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)
| Intervention | log10 msec (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -0.0083 |
The ONB is a measure of working memory and scored for speed of correct response (mean of the log10-transformed reaction times for correct responses). Total score ranges from 2 to 3.54 log10 msec. Lower score indicates better performance. Higher change from baseline indicates better performance. (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)
| Intervention | log10 msec (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 0.0177 |
This battery is a series of computerized cognition tests (detection, identification, one card learning, one back and groton maze learning) designed to measure reaction time, visual learning and memory, and executive function/sequencing. OCL test is a measure of visual episodic memory and visual recall test scored using arcsine transformation of the percentage of correct responses (CR). The range for OCL is 0 to 100 percent (%) accuracy; presented as an arcsin transformation, the range is 0 to 1.57. Higher score indicates better performance. Higher change from baseline indicates better performance. (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)
| Intervention | Arcsine ([sqrt] of proportion of [CR]) (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 0.0502 |
HVLT measures performance in verbal memory, learning, and long-term recall in which a list of words is read up to three times. Approximately 20-25 minutes later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score (0 -12); the retention (%) score (0-100%) is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher score = higher cognition. (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)
| Intervention | Number correct (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 0.8 |
HVLT measures performance in verbal memory, learning, and long-term recall in which a list of words is read up to three times. Approximately 20-25 minutes later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score (0 -12); the retention (%) score (0-100%) is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher score = higher cognition. (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)
| Intervention | Number of words recalled (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 0.3 |
HVLT measures performance in verbal memory, learning, and long-term recall in which a list of words is read up to three times. Approximately 20-25 minutes later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score (0 -12); the retention (%) score (0-100%) is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher score = higher cognition. (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)
| Intervention | Number of words (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 0.5 |
Hopkins Verbal Learning Test (HVLT) measures performance in verbal memory, learning, and long-term recall in which a list of words is read up to three times. Approximately 20-25 minutes later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score (0 -12); the retention (%) score (0-100%) is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher score = higher cognition. (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)
| Intervention | Number correct (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 2.8 |
"SDS was a 5 item questionnaire used for assessment of functional impairment and associated disability. The first three items assess disruption of (1) work/school, (2) social life, (3) family life/home responsibilities using a 0 to 10 rating scale. Score for the first three items are summed to create a total score of 0 to 30, higher score indicates greater impairment and a negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND Phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -9.3 |
"SDS was a participant-reported outcome measure and was a 5 item questionnaire used for assessment of functional impairment and associated disability. The first three items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a 0 to 10 rating scale. The score for the first three items are summed to create a total score of 0 to 30 where a higher score indicates greater impairment and a negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -1.6 |
"The CGI-S measures the severity of the participant's illness that include knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S evaluates the severity of psychopathology on a scale of 0 to 7, where 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)
| Intervention | Units on a Scale (Median) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 0.0 |
"CGI-S measures severity of participant's illness that include knowledge of participant's history, psychosocial circumstances, symptoms, behavior, impact of symptoms on participant's ability to function. CGI-S evaluates severity of psychopathology on a scale range from 0 - 7, where 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as Endpoint." (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)
| Intervention | Units on a Scale (Median) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -2.0 |
"EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a HSI. HSI ranges from -0.148 to 0.949 and is anchored at 0 (health state value equal to dead) and 1 (full health)." (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 0.190 |
"EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a HSI. HSI ranges from -0.148 to 0.949 and is anchored at 0 (health state value equal to dead) and 1 (full health)." (NCT02497287)
Timeframe: Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -0.009 |
EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ VAS. EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 17.0 |
EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ VAS. EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). (NCT02497287)
Timeframe: Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 1.6 |
"EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ VAS). EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a Health Status Index (HSI). HSI ranges from -0.148 to 0.949 and is anchored at 0 (health state value equal to dead) and 1 (full health). EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) *5. Higher score indicates worst health state." (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -15.3 |
"EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a Health Status Index (HSI). HSI ranges from -0.148 to 0.949 and is anchored at 0 (health state value equal to dead) and 1 (full health). EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) *5. Higher score indicates worst health state." (NCT02497287)
Timeframe: Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -0.7 |
"GAD-7 is brief and validated 7-item self-reported assessment of overall anxiety. Participants respond to each item using a 4 point scale with response categories: 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score ranges from 0 to 21, higher scores indicate more anxiety. Negative change in score indicates improvement. Severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14), Severe (15 -21). Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 0.2 |
"GAD-7 is brief, validated 7-item self-reported assessment of overall anxiety. Participant's responded to each item using a 4 point scale with response categories: 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield total score ranges from 0 to 21, higher scores indicate more anxiety. Negative change in score indicates improvement. Severity of GAD-7 is categorized as: None (0-4), Mild (5-9), Moderate (10-14), Severe (15 -21). Missing data was imputed using LOCF method, last post baseline observation during the phase was carried forward as Endpoint." (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -5.9 |
"MADRS measure depression severity, detects changes due to AD treatment. It evaluates 10 items: apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, suicidal thoughts, each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 0.3 |
"MADRS measures depression severity, detects changes due to AD treatment. It consists 10 items (evaluate apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, suicidal thoughts), scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score of 0 to 60. Higher scores indicate more severe condition. Negative change in score indicates improvement. Missing data was imputed using last observation carried forward (LOCF) method, last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -16.4 |
"PHQ-9 is a 9-item, self-reporting scale assessing depressive symptoms. Each item was rated on a 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half the days, and 3 = Nearly every day), with a total score range of 0-27. A higher score indicates greater severity of depression. Severity of PHQ-9 categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), severe (20-27). The recall period is 2 weeks. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)
| Intervention | Unit on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -8.9 |
"PHQ-9 is a 9-item, self-reporting scale assessing depressive symptoms. Each item was rated on a 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half the days, and 3 = Nearly every day), with a total score range of 0-27. A higher score indicates greater severity of depression. severity of PHQ-9 categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), severe (20-27). The recall period is 2 weeks. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -0.2 |
"The CADSS used to measure present-state dissociative symptoms, and to assess treatment-emergent dissociative symptoms. It comprises 23 subjective items divided into 3 components: depersonalization (with score range from 0 to 28), derealization (with score range from 0 to 52), and amnesia (with score range from 0 to 8). Participants responses are coded on a 5-point scale (0 = Not at all, 1 = Mild, 2 = Moderate, 3 = 'Severe and 4 = Extreme). The total score is sum of the 23 items and range from 0 to 92, where 0 (best) and 92 (worst). A higher score indicates a more severe condition." (NCT02497287)
Timeframe: Predose, up to 1.5 hours postdose (up to end of OP/MA phase [Week 52])
| Intervention | Percentage of participants (Number) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 86.1 |
"The CADSS used to measure present-state dissociative symptoms, and to assess treatment-emergent dissociative symptoms. It comprises 23 subjective items divided into 3 components: depersonalization (with score range from 0 to 28), derealization (with score range from 0 to 52), and amnesia (with score range from 0 to 8). Participants responses are coded on a 5-point scale (0 = Not at all, 1 = Mild, 2 = Moderate, 3 = 'Severe and 4 = Extreme). The total score is sum of the 23 items and range from 0 to 92, where 0 (best) and 92 (worst). A higher score indicates a more severe condition." (NCT02497287)
Timeframe: Predose, up to 1.5 hours postdose (up to end of IND phase [Week 4])
| Intervention | Percentage of participants (Number) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 92.0 |
An adverse event is any untoward medical occurrence in a clinical study participants who administered a medicinal (investigational or non-investigational) product and does not necessarily have a causal relationship with the treatment. A TEAE defined as an event that was new in onset or increased in severity following treatment initiation. (NCT02497287)
Timeframe: Up to End of Follow up Phase (Week 56)
| Intervention | Percentage of participants (Number) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 90.1 |
"Percentage of participants with cystitis, urinary tract infections, renal and urinary tract symptoms, renal and urinary disorders were evaluated. Cystitis and urinary tract infections are selected MedDRA preferred terms, renal and urinary tract symptoms refers to any preferred term (PT) in the group of selected PTs; and renal and urinary disorders refers to a MedDRA System Organ Class (SOC)." (NCT02497287)
Timeframe: Up to End of Follow up Phase (Week 56)
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Cystitis | Urinary tract infections | Renal and urinary disorders | Renal and urinary tract symptoms | |
| Intranasal Esketamine + Oral Antidepressant | 0.6 | 8.1 | 10.5 | 17.0 |
"Remission is defined as MADRS total score less than or equal to (<=) 12. MADRS measures depression severity, detects changes due to AD treatment. It consists 10 items (evaluate apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, suicidal thoughts), scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score of 0 to 60. Higher scores indicate more severe condition. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Days 8, 15, 22 and Endpoint (last post-baseline assessment value during 4 weeks of IND Phase)
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Day 8 | Day 15 | Day 22 | End point | |
| Intranasal Esketamine + Oral Antidepressant | 7.3 | 15.6 | 27.2 | 47.2 |
"Remission is defined as PHQ-9 total score <= 4. PHQ-9 is a 9-item, self-reporting scale assessing depressive symptoms. Each item was rated on a 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half the days, and 3 = Nearly every day), with a total score range of 0-27. The scores are summed for a total score ranging from 0-27. A higher score indicates greater severity of depression. severity of PHQ-9 categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), severe (20-27). The recall period is 2 weeks. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Day 15 and Endpoint (last post-baseline assessment value during 4 weeks of IND phase)
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Day 15 | Endpoint | |
| Intranasal Esketamine + Oral Antidepressant | 12.7 | 26.9 |
"Response is defined as greater than or equal to (>=) 50 % reduction from baseline in the MADRS total score. MADRS measures depression severity, detects changes due to AD treatment. It consists 10 items (evaluate apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, suicidal thoughts), scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score of 0 to 60. Higher scores indicate more severe condition. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Days 8, 15, 22 and Endpoint (last post-baseline assessment during 4 weeks of IND phase)
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Day 8 | Day 15 | Day 22 | End point | |
| Intranasal Esketamine + Oral Antidepressant | 11.6 | 25.0 | 42.8 | 78.4 |
"Response is defined as >= 50 % reduction from baseline (IND phase) in PHQ-9 total score. PHQ-9 is a 9-item, self-reporting scale assessing depressive symptoms. Each item was rated on a 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half the days, and 3 = Nearly every day), with a total score range of 0-27. The scores are summed for a total score ranging from 0-27. A higher score indicates greater severity of depression. Severity of PHQ-9 categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), severe (20-27). The recall period is 2 weeks. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Day 15 and Endpoint (last post-baseline assessment value during 4 Week IND phase)
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Day 15 | End point | |
| Intranasal Esketamine + Oral Antidepressant | 37.2 | 62.0 |
Percentage of participants with treatment-emergent acute hypertension (Systolic Blood Pressure >=180 millimeters of mercury [mm Hg] or Diastolic Blood Pressure >= 110 mm Hg) during IND and OP/MA Phases were evaluated. (NCT02497287)
Timeframe: Up to End of OP/MA phase (Week 52)
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| Systolic BP >=180 | Diastolic BP >=110 | Acute hypertension | |
| Intranasal Esketamine + Oral Antidepressant | 2.2 | 2.4 | 4.1 |
CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S evaluates the severity of psychopathology on a scale of 0 to 7. Considering total clinical experience, a participant is assessed on severity of mental illness at the time of rating according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. The change from baseline in CGI-S score, (LOCF data) at endpoint was reported. The last post baseline observation was carried forward as the endpoint. (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Median) |
|---|---|
| Intranasal Esketamine + Oral AD | 0.0 |
| Oral AD+ Intranasal Placebo | 1.0 |
CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S evaluates the severity of psychopathology on a scale of 0 to 7. Considering total clinical experience, a participant is assessed on severity of mental illness at the time of rating according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. The change from baseline in CGI-S score, (LOCF data) at endpoint was reported. The last post baseline observation was carried forward as the endpoint. (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Median) |
|---|---|
| Intranasal Esketamine + Oral AD | 0.0 |
| Oral AD+ Intranasal Placebo | 1.0 |
EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | -10.4 |
| Oral AD+ Intranasal Placebo | -16.1 |
EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | -1.3 |
| Oral AD+ Intranasal Placebo | -13.8 |
"EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a HSI. HSI ranges from 0 (dead) to 1.00 (full health)." (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | -0.067 |
| Oral AD+ Intranasal Placebo | -0.096 |
"EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a HSI. HSI ranges from 0 (dead) to 1.00 (full health)." (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | -0.023 |
| Oral AD+ Intranasal Placebo | -0.073 |
"EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ VAS). EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a Health Status Index (HSI). HSI ranges from 0 (dead) to 1.00 (full health). EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) *5. Higher score indicates worst health state." (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | 7.5 |
| Oral AD+ Intranasal Placebo | 10.9 |
"EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a HSI. HSI ranges from 0 (dead) to 1.00 (full health). EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) *5. Higher score indicates worst health state." (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | 3.0 |
| Oral AD+ Intranasal Placebo | 8.4 |
GAD-7 is a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21). Item responses are summed to yield a total score (range of 0 to 21), with higher scores indicating more anxiety. The change from baseline in GAD-7 total score, (LOCF data), at endpoint was reported. The last post baseline observation was carried forward as the endpoint. (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | 2.2 |
| Oral AD+ Intranasal Placebo | 4.0 |
GAD-7 is a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21). Item responses are summed to yield a total score (range of 0 to 21), with higher scores indicating more anxiety. The change from baseline in GAD-7 total score, (LOCF data), at endpoint was reported. The last post baseline observation was carried forward as the endpoint. (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | 1.4 |
| Oral AD+ Intranasal Placebo | 2.6 |
MADRS: clinician-rated scale to measure depression severity and to detect changes due to antidepressant treatment. It has 10 items, scored from 0-6 (not present/normal - severe/continuous symptoms), with total score of 60. Higher scores mean more severe condition. The change from baseline in MADRS total score (last observation carried forward [LOCF] data), at endpoint was reported. The last post baseline observation was carried forward as the endpoint. (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | 7.5 |
| Oral AD+ Intranasal Placebo | 12.5 |
MADRS: clinician-rated scale to measure depression severity and to detect changes due to antidepressant treatment. It has 10 items, scored from 0-6 (not present/normal - severe/continuous symptoms), with total score of 60. Higher scores mean more severe condition. The change from baseline in MADRS total score (LOCF data), at endpoint was reported. The last post baseline observation was carried forward as the endpoint. (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | 4.4 |
| Oral AD+ Intranasal Placebo | 11.4 |
PHQ-9 is a 9-item, self-report scale assessing depressive symptoms. Each item is rated on a 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half the days, and 3 = Nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27) with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 is categorized as follows: None-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19) and severe (20-27). The change from baseline in PHQ-9 total score, (LOCF data) at endpoint was reported. The last post baseline observation was carried forward as the endpoint. (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | 3.3 |
| Oral AD+ Intranasal Placebo | 5.9 |
PHQ-9 is a 9-item, self-report scale assessing depressive symptoms. Each item is rated on a 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half the days, and 3 = Nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27) with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 is categorized as follows: None-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19) and severe (20-27). The change from baseline in PHQ-9 total score, (LOCF data) at endpoint was reported. The last post baseline observation was carried forward as the endpoint. (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | 1.7 |
| Oral AD+ Intranasal Placebo | 4.7 |
The SDS is a participant-reported outcome measure and is a 5-item questionnaire used and accepted for assessment of functional impairment and associated disability. The first 3 items assess disruption of 1: work/school 2: social life 3: family life/home responsibilities using a 0-10 rating scale. It also has one item on days lost from school or work and one item on days when underproductive. The score for the first 3 items are summed to create a total score of 0-30 where a higher score indicates greater impairment. The recall period is 7 days. Scores <= 4 for each item and <= 12 for the total score are considered response. Scores <= 2 for each item and <= 6 for the total score are considered remission. The change from baseline in SDS total Score, (LOCF data), at endpoint was reported. The last post baseline observation was carried forward as the endpoint. (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | 4.7 |
| Oral AD+ Intranasal Placebo | 7.2 |
The SDS is a participant-reported outcome measure and is a 5-item questionnaire used and accepted for assessment of functional impairment and associated disability. The first 3 items assess disruption of 1: work/school 2: social life 3: family life/home responsibilities using a 0-10 rating scale. It also has one item on days lost from school or work and one item on days when underproductive. The score for the first 3 items are summed to create a total score of 0-30 where a higher score indicates greater impairment. The recall period is 7 days. Scores <= 4 for each item and <= 12 for the total score are considered response. Scores <= 2 for each item and <= 6 for the total score are considered remission. The change from baseline in SDS total Score, (LOCF data), at endpoint was reported. The last post baseline observation was carried forward as the endpoint. (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | 2.2 |
| Oral AD+ Intranasal Placebo | 6.8 |
Relapse is defined as any of following: Montgomery-asberg depression rating scale (MADRS) total score greater than or equal to (>=) 22 for 2 consecutive assessments separated by 5-15 days and/or hospitalization for worsening depression or any other clinically relevant event to be suggestive of a relapse of depressive illness such as suicide attempt/completed suicide/hospitalization for suicide prevention; If hospitalized, start date of hospitalization will be date of relapse, if not hospitalized date of event will be used. MADRS: clinician-rated scale to measure depression severity and to detect changes due to antidepressant treatment. It has 10 items, scored from 0-6 (not present/normal-severe/continuous symptoms), with total score of 60. Higher scores mean more severe condition. Stable remission: MADRS total score less than or equal to (<=) 12 for at least 3 of last 4 weeks of OP phase, with 1 excursion total score greater than (>) 12 or one missing assessment at OP week 13 or 14. (NCT02493868)
Timeframe: Time from randomization to the first relapse during the maintenance phase (up to 92 Weeks)
| Intervention | Days (Median) |
|---|---|
| Intranasal Esketamine + Oral AD | NA |
| Oral AD+ Intranasal Placebo | 273.0 |
Relapse is defined as any of following: MADRS total score >= 22 for 2 consecutive assessments separated by 5-15 days and/or hospitalization for worsening depression or any other clinically relevant event to be suggestive of a relapse of depressive illness such as suicide attempt/completed suicide/hospitalization for suicide prevention; If hospitalized, start date of hospitalization will be date of relapse, if not hospitalized date of event will be used. MADRS: clinician-rated scale to measure depression severity and to detect changes due to antidepressant treatment. It has 10 items, scored from 0-6 (not present/normal-severe/continuous symptoms), with total score of 60. Higher scores mean more severe condition. Stable response is defined as >= 50 percent (%) reduction in MADRS total score from baseline (Day 1 of induction phase, prior to first intranasal dose) in each of the last 2 weeks of the OP phase, but without meeting criteria for stable remission. (NCT02493868)
Timeframe: Time from randomization to the first relapse during the maintenance phase (up to 92 Weeks)
| Intervention | Days (Median) |
|---|---|
| Intranasal Esketamine + Oral AD | 635.0 |
| Oral AD+ Intranasal Placebo | 88.0 |
"The CGI-I is a clinician rated single-item scale: Compared to the patient's condition at admission, how much has the patient changed?, rated on a 7-point response scale: 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, and 7 = Very much worse. In this case, admission referred to the CGI-S screening assessments performed between Day -28 an -7, one conducted during the screening visit, and a second rating conducted by a remote, independent rater." (NCT01920555)
Timeframe: A baseline assessment was made on Day 0, preceding infusion (i.e., treatment). Outcome assessments were made on days 1, 3, 5, 7, 14, and 30. The primary endpoint for this study was Day 3. Thus, the outcome measure table provides data on Days 0, 1 and 3
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Day 0 | Day 1 | Day 3 | |
| Ketamine 0.1mg | 3.8888889 | 3.0625000 | 2.9333333 |
| Ketamine 0.2mg | 4.0500000 | 3.3684211 | 2.8421053 |
| Ketamine 0.5mg | 4.1363636 | 2.6363636 | 2.5714286 |
| Ketamine 1.0mg | 4.0000000 | 3.0500000 | 2.5500000 |
| Midazolam 0.045mg | 4.1578947 | 3.6111111 | 3.1666667 |
"The CGI-S is a clinician rated single-item scale: How depressed is the patient at this time?, rated on a 7-point response scale: 1 = Normal, not at all depressed, 2 = Borderline depressed, 3 = Mildly depressed, 4 = Moderately depressed. 5 = Markedly depressed, 6 = severely depressed, 7 = Among the most severely depressed patients. When rating patients, clinicians were asked to consider the past 24 hours." (NCT01920555)
Timeframe: A baseline assessment was made on Day 0, preceding infusion (i.e., treatment). Outcome assessments were made on days 1, 3, 5, 7, 14, and 30. The primary endpoint for this study was Day 3. Thus, the outcome measure table provides data on Days 0, 1 and 3
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Day 0 | Day 1 | Day 3 | |
| Ketamine 0.1mg | 5.0000000 | 3.5625000 | 3.4000000 |
| Ketamine 0.2mg | 5.2000000 | 4.2631579 | 3.7368421 |
| Ketamine 0.5mg | 4.8636364 | 3.2727273 | 3.1428571 |
| Ketamine 1.0mg | 5.2000000 | 3.5000000 | 3.3000000 |
| Midazolam 0.045mg | 5.000000 | 4.555556 | 4.1666667 |
"The CPAS is a 16-item self-report scale to assess the level to which participants experience persistent distress due to feeling that they have not returned to their normal or premorbid state. Items (e.g., I look forward to things) are rated on a 5-point scale (0=not at all, 1=very much less than normal, 2=much less than normal, 3=slightly less than normal, 4=same as best or normal self). The possible scale range is 0 to 64, with higher scores indicating greater recovery from depression. Patients were asked to rate their experience of the past 24 hours." (NCT01920555)
Timeframe: A baseline assessment was made on Day 0, preceding infusion (i.e., treatment). Outcome assessments were made on days 1, 3, 5, 7, 14, and 30. The primary endpoint for this study was Day 3. Thus, the outcome measure table provides data on Days 0, 1 and 3
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Day 0 | Day 1 | Day 3 | |
| Ketamine 0.1mg | 19.3333333 | 35.2500000 | 38.8666667 |
| Ketamine 0.2mg | 20.5000000 | 27.0526316 | 28.3888889 |
| Ketamine 0.5mg | 20.6363636 | 40.8696964 | 39.7619048 |
| Ketamine 1.0mg | 21.2500000 | 33.0000000 | 37.4500000 |
| Midazolam 0.045mg | 21.2631579 | 24.4444444 | 33.3750000 |
"The CADSS is a 23-item self-report scale for the assessment of dissociative states. It is a reliable, valid self-report instrument. The severity of each dissociative symptom ranges from 0 (not present) to 4 (extreme). The total score is calculated by summing across items, with a total possible range of 0-92. The CADSS was administered right before infusion, and 40, 80 minute and 120 minutes after the start of infusion. The timeframe is at this moment." (NCT01920555)
Timeframe: Day 0/baseline at 0, 40, 80, and 120 minutes
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Minute 0 | Minute 40 | Minute 80 | Minute 120 | |
| Ketamine 0.1mg | 0.1111111 | 3.0000000 | 0.4444444 | 0.0555556 |
| Ketamine 0.2mg | 0.1000000 | 4.0500000 | 0.1000000 | 0 |
| Ketamine 0.5mg | 0 | 14.2727273 | 0.7727273 | 0.1363636 |
| Ketamine 1.0mg | 0.1000000 | 24.6842105 | 1.8000000 | 0.6500000 |
| Midazolam 0.045mg | 0.4210526 | 2.6842105 | 1.1578947 | 0.5789474 |
The HAMD6 is a 6-item clinician-rated scale, where clinicians rate the presence of depression symptoms (i.e., depressed mood, guilt, work and interests, psychomotor retardation, psychic anxiety, somatic symptoms) on a 5-point scale, where 0 = not present, and 1-4 represent increasingly severe symptoms. One item (i.e., somatic symptoms) is rated on only a 3-point scale, ranging from 0-2. The possible scale range is 0-22, where higher values represent more severe depression. This instrument is completed with a structured interview guide by the clinician based on his/her assessment of the patient's symptoms. This structured interview has been validated for use with time frames shorter than one week. In this study, the HAMD6 was used to assess symptoms occurring in the past 24 hours. (NCT01920555)
Timeframe: A baseline assessment was made on Day 0, preceding infusion (i.e., treatment). Outcome assessments were made on days 1, 3, 5, 7, 14, and 30. The primary endpoint for this study was Day 3. Thus, the outcome measure table provides data on Days 0, 1, & 3
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Day 0 | Day 1 | Day 3 | |
| Ketamine 0.1mg | 12.5555556 | 7.5000000 | 6.8000000 |
| Ketamine 0.2mg | 12.7500000 | 9.2631579 | 8.4736842 |
| Ketamine 0.5mg | 12.5909091 | 5.8636364 | 5.9047619 |
| Ketamine 1.0mg | 12.6315789 | 6.9000000 | 7.2000000 |
| Midazolam 0.045mg | 13.0526316 | 10.6666667 | 9.0555556 |
"The MADRS is a 10-item clinician-rated scale measuring depression severity. Symptoms are rated on a 7-point scale, where 0 = not present, and 1-6 represent increasing severity. Values 2, 4, and 6 have specific anchoring text (e.g., 2=Difficulties in starting activities. 4=Difficulties in starting simple routine activities which are carried out with effort, 6=Complete lassitude. Unable to do anything without help.) Values 1, 3, and 5 do not have specific text. The possible scale range is 0-60, where higher values represent higher severity. In this study, the MADRS was used to rate symptoms occurring in the past 3 days." (NCT01920555)
Timeframe: A baseline assessment was made on Day 0, preceding infusion (i.e., treatment). Outcome assessments were made on days 3, 5, 7, 14, and 30. The primary endpoint for this study was Day 3. Thus, the outcome measure table provides data on Days 0 and 3.
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Day 0 | Day 3 | |
| Ketamine 0.1mg | 33.8333333 | 19.6666667 |
| Ketamine 0.2mg | 34.4500000 | 22.6315789 |
| Ketamine 0.5mg | 31.5909091 | 14.7619048 |
| Ketamine 1.0mg | 32.6500000 | 17.1000000 |
| Midazolam 0.045mg | 33.6315789 | 24.8333333 |
The Columbia Suicide Severity Rating Scale (C-SSRS): The C-SSRS is a low-burden measure of the spectrum of suicidal ideation and behavior that was developed in the National Institute of Mental Health Treatment of Adolescent Suicide Attempters Study to assess severity and track suicidal events through any treatment. It is a clinical interview providing a summary of both ideation and behavior that can be administered during any evaluation or risk assessment to identify the level and type of suicidality present. The C-SSRS can also be used during treatment to monitor for clinical worsening or improvement. It contains 5 rating scale questions (yes/no) for suicidal ideation increasing severity and 5 rating scale questions (yes/no) for suicidal behavior of increasing severity. The time frame is for both lifetime and the past six months for the Baseline/Screening scale and since the last visit for the Since Last Visit scale. (NCT01920555)
Timeframe: Screening Visit and Days 0, 1, 3, 5, 7, 14 and 30 combined
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Screening: # with suicidal ideation/behavior | Follow-Up: # with suicidal ideation/behavior | |
| Ketamine 0.1mg | 17 | 15 |
| Ketamine 0.2mg | 15 | 9 |
| Ketamine 0.5mg | 17 | 10 |
| Ketamine 1.0mg | 14 | 6 |
| Midazolam 0.045mg | 17 | 13 |
"CBC~Chemistry (Total bilirubin, AST, ALT, GGT, ALK Phosphatase, Creatinine, BUN/Urea, Glucose, Uric Acid)~Testing was performed by study site laboratories and used institutional normal lab value ranges." (NCT01920555)
Timeframe: Day 3 and Early Termination Visit (approximately 3 weeks following intervention)
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Chemistry ALT(SGPT) | Chemistry AST(SGOT) | Chemistry Total Bilirubin | Chemistry Remaining Tests | CBC | |
| Ketamine 0.1mg | 0 | 0 | 0 | 0 | 0 |
| Ketamine 0.2mg | 1 | 1 | 1 | 0 | 0 |
| Ketamine 0.5mg | 0 | 0 | 0 | 0 | 0 |
| Ketamine 1.0mg | 0 | 0 | 0 | 0 | 0 |
| Midazolam 0.045mg | 0 | 0 | 0 | 0 | 0 |
"The SHAPS is a 14-item self-report scale to measure hedonic tone. Items (e.g., I would enjoy reading a book, magazine, or newspaper.) are rated on a 4-point scale (1=strongly disagree, 2=disagree, 3=agree, 4=strongly agree). Either of the 'disagree' responses scores 1 point, and either of the 'agree' responses scores 0 points, for a total scale range of 0-14. Higher scores indicate greater inability to experience pleasure. Patients were asked to rate their experience of the past 24 hours." (NCT01920555)
Timeframe: A baseline assessment was made on Day 0, preceding infusion (i.e., treatment). Outcome assessments were made on days 1, 3, 5, 7, 14, and 30. The primary endpoint for this study was Day 3. Thus, the outcome measure table provides data on Days 0, 1 and 3
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Day 0 | Day 1 | Day 3 | |
| Ketamine 0.1mg | 7.2222222 | 3.9375000 | 3.5333333 |
| Ketamine 0.2mg | 7.5500000 | 5.7368421 | 6.3888889 |
| Ketamine 0.5mg | 6.5909091 | 2.22727273 | 3.0000000 |
| Ketamine 1.0mg | 7.3500000 | 4.3000000 | 3.6500000 |
| Midazolam 0.045mg | 6.4736842 | 5.0000000 | 4.2500000 |
"The SDQ is a 44-item self-report scale, which aims to measure depression more comprehensively by including the assessment of symptoms in the anxiety-depression spectrum, including symptoms of irritability, anger attacks, and anxiety. Items are rated on an 6-point Likert scale, where participants are asked to rate if a specific symptom (e.g. How has your mood been over the past 24 hours?) is normal for him or her (score = 2), what is better than normal (score = 1), and what is worse than normal (scores = 3-6). The total scale score is calculated by averaging across the items, resulting in a possible range from 1 to 6. Higher scores indicate greater depression severity. When rating, patients were asked to consider their symptoms during the past 24 hours." (NCT01920555)
Timeframe: A baseline assessment was made on Day 0, preceding infusion (i.e., treatment). Outcome assessments were made on days 1, 3, 5, 7, 14, and 30. The primary endpoint for this study was Day 3. Thus, the outcome measure table provides data on Days 0, 1 and 3
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Day 0 | Day 1 | Day 3 | |
| Ketamine 0.1mg | 3.5164141 | 2.5752843 | 2.5106061 |
| Ketamine 0.2mg | 3.4636364 | 2.9096195 | 2.7828283 |
| Ketamine 0.5mg | 3.5392562 | 2.3109504 | 2.5573593 |
| Ketamine 1.0mg | 3.4113636 | 2.6113636 | 2.5909091 |
| Midazolam 0.045mg | 3.4264507 | 2.9200573 | 2.8751353 |
Antidepressant effects were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT00088699)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine - Healthy Volunteers | 1.17 |
| Placebo - Healthy Volunteers | 1.48 |
| Ketamine - MDD Patients | 33.83 |
| Placebo - MDD Patients | 31.82 |
Antidepressant effects were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT00088699)
Timeframe: Day 1
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine - Healthy Volunteers | 2.45 |
| Placebo - Healthy Volunteers | 0.67 |
| Ketamine - MDD Patients | 23.73 |
| Placebo - MDD Patients | 30.68 |
Time line follow back (NCT02649231)
Timeframe: 6 months
| Intervention | percentage of days abstinent (Mean) |
|---|---|
| Ketamine+Psychological Therapy | 86.4 |
| Ketamine+Education | 82.5 |
| Placebo+Psychological Therapy | 78.3 |
| Placebo+Education | 70.7 |
Time line follow back (NCT02649231)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketamine+Psychological Therapy | 13 |
| Ketamine+Education | 15 |
| Placebo+Psychological Therapy | 14 |
| Placebo+Education | 18 |
"The quantitative depressive symptom ratings were collected at Baseline, Day 1 (post ketamine), Day 3 using HDRS-24 (a 24-item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery). The total score can range from 0 to a maximum score of 15 with a higher score indicating a worse outcome. A responder was defined as an individual exhibiting a reduction in the HDRS score from baseline to 24 hours (day 1) post-treatment, and all other individuals were classified as non-responders." (NCT01558063)
Timeframe: Day 1 (post ketamine)
| Intervention | participants (Number) |
|---|---|
| Ketamine Dose 1 | 3 |
| Ketamine Dose 2 | 1 |
| Ketamine Dose 3 | 3 |
| Ketamine Dose 4 | 2 |
| Ketamine Dose 5 | 2 |
| Saline Solution | 0 |
Clinician-administered scale for the assessment of fear and avoidance found in social phobia (SAD); it has 24 items divided into 2 subscales, 13 for performance anxiety, and 11 for social situations each rated from 0 to 3 (0=none,1=mild,2=moderate,3=definite). The sum scores for Fear and Avoidance results in an overall score (max 144 points). There are 4 clinician subscales: fear of social interaction, fear of performance, avoidance of social interaction and avoidance of performance 0 to 30= SAD is unlikely 30 to 60=SAD is probable 60 to 90=SADis very probable >90= SAD highly probable (NCT02083926)
Timeframe: Day 1 (1+28)
| Intervention | score on a scale (Mean) |
|---|---|
| Ketamine Infusion on Day 0 or Day 28 | 66.1 |
| Saline Infusion on Day 0 or Day 28 | 86.1 |
"Instrument that tries to measure anxiety, that is believed to range across a continuum of values and cannot easily be directly measured.We used a straight horizontal line of 100 mm in length. The ends were defined as the extreme limits of the parameter to be measured (anxiety); oriented from the left (no anxiety) to the right (worst anxiety ever felt). The patient marks on the line the point that they feel represents their perception of their current state.The VAS score is determined by measuring in millimeters from the left hand end of the line to the point that the patient marks.~We examined Visual Analog Scale (VAS) for anxiety symptoms at screening, 1 hour prior to infusion, 1, 2 and 3 hours after infusion, 1, 2, 3, 5, 7, 10, and 14 days following a single ketamine/saline infusion." (NCT02083926)
Timeframe: Day 1 (1+28)
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine Infusion on Day 0 or Day 28 | 12.1 |
| Saline Infusion on Day 0 or Day 28 | 19.6 |
CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. CGI-S permits global evaluation of participant's condition at given time. A negative change in score indicates improvement. (NCT01998958)
Timeframe: Baseline (Day 1) and Endpoint (Day 8) of Period 1
| Intervention | Units on a scale (Median) |
|---|---|
| Panel A: Period 1 Placebo | 5.0 |
| Panel A: Period 1 Esketamine 28 mg | 4.0 |
| Panel A: Period 1 Esketamine 56 mg | 4.0 |
| Panel A: Period 1 Esketamine 84 mg | 4.0 |
| Panel B: Period 1 Placebo | 4.0 |
| Panel B: Period 1 Esketamine 14 mg | 4.0 |
| Panel B: Period 1 Esketamine 56 mg | 3.0 |
GAD-7 is a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21). (NCT01998958)
Timeframe: Baseline (Day 1) and Endpoint (Day 8) of Period 1
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Panel A: Period 1 Placebo | -1.7 |
| Panel A: Period 1 Esketamine 28 mg | -1.5 |
| Panel A: Period 1 Esketamine 56 mg | -3.1 |
| Panel A: Period 1 Esketamine 84 mg | -5.1 |
| Panel B: Period 1 Placebo | -1.7 |
| Panel B: Period 1 Esketamine 14 mg | -1.9 |
| Panel B: Period 1 Esketamine 56 mg | -3.2 |
MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. A negative change in score indicates improvement. (NCT01998958)
Timeframe: Baseline (Day 1) and Endpoint (Day 8) of Period 1
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Panel A: Period 1 Placebo | -4.9 |
| Panel A: Period 1 Esketamine 28 mg | -9.8 |
| Panel A: Period 1 Esketamine 56 mg | -12.4 |
| Panel A: Period 1 Esketamine 84 mg | -15.3 |
| Panel B: Period 1 Placebo | -6.6 |
| Panel B: Period 1 Esketamine 14 mg | -4.8 |
| Panel B: Period 1 Esketamine 56 mg | -10.3 |
PGI-S is a patient-rated scale that assesses the severity of their illness at the time of assessment, relative to participants past experience. It is a 4-point (1 to 4) scale in response to the question 'Considering all aspects of your depression right now would you say your depression is?' with scores as follows: 1: none; 2: mild; 3: moderate; 4: severe. A higher score implies a more severe condition. (NCT01998958)
Timeframe: Baseline (Day 1) and Endpoint (Day 8) of Period 1
| Intervention | Unit on a scale (Median) |
|---|---|
| Panel A: Period 1 Placebo | 3.0 |
| Panel A: Period 1 Esketamine 28 mg | 3.0 |
| Panel A: Period 1 Esketamine 56 mg | 3.0 |
| Panel A: Period 1 Esketamine 84 mg | 3.0 |
| Panel B: Period 1 Placebo | 3.0 |
| Panel B: Period 1 Esketamine 14 mg | 3.0 |
| Panel B: Period 1 Esketamine 56 mg | 3.0 |
QIDS-SR16 is self-rated scale assesses severity of depressive symptoms. Total scores range from 0-27. Higher score indicates greater severity of depression. Negative change in score indicates improvement. Total score obtained by adding scores for each of 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders-4th edition major depressive disorder (DSM-IV MDD) criteria: depressed mood, loss of interest/pleasure, concentration/decision making, self-outlook, suicidal ideation, energy/fatigability, sleep, weight/appetite change, psychomotor changes. 16 items used to rate 9 criterion domains: 4 items used to rate sleep disturbance (early/middle/late insomnia/hypersomnia); 2 items used to rate psychomotor disturbance (agitation, retardation); 4 items used to rate appetite/weight disturbance. 1 item used to rate 6 domains (depressed mood, decreased interest, decreased energy, worthlessness/guilt, concentration/decision making, suicidal ideation). Each item was rated 0-3. (NCT01998958)
Timeframe: Baseline (Day 1) and Endpoint (Day 8) of Period 1
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Panel A: Period 1 Placebo | -1.8 |
| Panel A: Period 1 Esketamine 28 mg | -4.0 |
| Panel A: Period 1 Esketamine 56 mg | -4.4 |
| Panel A: Period 1 Esketamine 84 mg | -4.2 |
| Panel B: Period 1 Placebo | -1.1 |
| Panel B: Period 1 Esketamine 14 mg | -0.6 |
| Panel B: Period 1 Esketamine 56 mg | -3.0 |
CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. CGI-S permits global evaluation of participant's condition at given time. A negative change in score indicates improvement. (NCT01998958)
Timeframe: Baseline (Day 8) and Endpoint (Day 15) of Period 2
| Intervention | Units on a scale (Median) |
|---|---|
| Panel A: Period 2 Placebo | 5.0 |
| Panel A: Period 2 Esketamine 28 mg | 4.0 |
| Panel A: Period 2 Esketamine 56 mg | 5.0 |
| Panel A: Period 2 Esketamine 84 mg | 4.0 |
| Panel B: Period 2 Placebo | 4.0 |
| Panel B: Period 2 Esketamine 14 mg | 3.0 |
| Panel B: Period 2 Esketamine 56 mg | 4.0 |
GAD-7 is a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21). (NCT01998958)
Timeframe: Baseline (Day 8) and Endpoint (Day 15) of Period 2
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Panel A: Period 2 Placebo | 0.4 |
| Panel A: Period 2 Esketamine 28 mg | -1.6 |
| Panel A: Period 2 Esketamine 56 mg | 1.0 |
| Panel A: Period 2 Esketamine 84 mg | -0.9 |
| Panel B: Period 2 Placebo | -2.7 |
| Panel B: Period 2 Esketamine 14 mg | -6.6 |
| Panel B: Period 2 Esketamine 56 mg | -0.7 |
MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. A negative change in score indicates improvement. (NCT01998958)
Timeframe: Baseline (Day 8) and Endpoint (Day 15) of Period 2
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Panel A: Period 2 Placebo | -4.5 |
| Panel A:Period 2 Esketamine 28 mg | -7.6 |
| Panel A: Period 2 Esketamine 56 mg | -8.9 |
| Panel A: Period 2 Esketamine 84 mg | -11.4 |
| Panel B: Period 2 Placebo | -0.7 |
| Panel B: Period 2 Esketamine 14 mg | -6.6 |
| Panel B:Period 2 Esketamine 56 mg | -1.2 |
PGI-S is a patient-rated scale that assesses the severity of their illness at the time of assessment, relative to participants past experience. It is a 4-point (1 to 4) scale in response to the question 'Considering all aspects of your depression right now would you say your depression is?' with scores as follows: 1: none; 2: mild; 3: moderate; 4: severe. A higher score implies a more severe condition. A negative change in score indicates improvement. (NCT01998958)
Timeframe: Baseline (Day 8) and Endpoint (Day 15) of Period 2
| Intervention | Unit on a scale (Median) |
|---|---|
| Panel A: Period 2 Placebo | 3.0 |
| Panel A: Period 2 Esketamine 28 mg | 3.0 |
| Panel A: Period 2 Esketamine 56 mg | 4.0 |
| Panel A: Period 2 Esketamine 84 mg | 3.0 |
| Panel B: Period 2 Placebo | 3.0 |
| Panel B: Period 2 Esketamine 14 mg | 3.0 |
| Panel B: Period 2 Esketamine 56 mg | 3.0 |
QIDS-SR16 is self-rated scale assesses severity of depressive symptoms. Total scores range from 0-27. Higher score indicates greater severity of depression. Negative change in score indicates improvement. Total score obtained by adding scores for each of 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders-4th edition major depressive disorder (DSM-IV MDD) criteria: depressed mood, loss of interest/pleasure, concentration/decision making, self-outlook, suicidal ideation, energy/fatigability, sleep, weight/appetite change, psychomotor changes. 16 items used to rate 9 criterion domains: 4 items used to rate sleep disturbance (early/middle/late insomnia/hypersomnia); 2 items used to rate psychomotor disturbance (agitation, retardation); 4 items used to rate appetite/weight disturbance. 1 item used to rate 6 domains (depressed mood, decreased interest, decreased energy, worthlessness/guilt, concentration/decision making, suicidal ideation). Each item was rated 0-3. (NCT01998958)
Timeframe: Baseline (Day 8) and Endpoint (Day 15) of Period 2
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Panel A: Period 2 Placebo | -2.0 |
| Panel A: Period 2 Esketamine 28 mg | -3.1 |
| Panel A: Period 2 Esketamine 56 mg | -2.0 |
| Panel A: Period 2 Esketamine 84 mg | -3.3 |
| Panel B: Period 2 Placebo | -2.1 |
| Panel B: Period 2 Esketamine 14 mg | -5.7 |
| Panel B: Period 2 Esketamine 56 mg | -1.5 |
Sustained response was defined as at least 50% improvement from baseline in the MADRS total score with onset by Day 2 that is maintained to study Day 15. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT01998958)
Timeframe: Day 2 Up to Day 15
| Intervention | Percentage of participants (Number) |
|---|---|
| Panel A: Placebo (Period 1 and 2) | 0 |
| Panel A: Esketamine 28 mg (Period 1 and 2) | 12.5 |
| Panel A: Esketamine 56 mg (Period 1 and 2) | 9.1 |
| Panel A: Esketamine 84 mg (Period 1 and 2) | 30.0 |
| Panel B: Placebo (Period 1 and 2) | 15.4 |
| Panel B: Esketamine 14 mg (Period 1 and 2) | 18.2 |
| Panel B: Esketamine 56 mg (Period 1 and 2) | 22.2 |
Sustained response was defined as at least 50 percent (%) improvement from baseline in the MADRS total score with onset by Day 2 that is maintained to study Day 15. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT01998958)
Timeframe: Day 2 Up to Day 15
| Intervention | Percentage of participants (Number) |
|---|---|
| Panel A: Placebo (Period 1 and 2) | 0 |
| Panel A: Esketamine 28 mg (Period 1 and 2) | 12.5 |
| Panel A: Esketamine 56 mg (Period 1 and 2) | 9.1 |
| Panel A: Esketamine 84 mg (Period 1 and 2) | 25.0 |
| Panel B: Placebo (Period 1 and 2) | 15.4 |
| Panel B: Esketamine 14 mg (Period 1 and 2) | 18.2 |
| Panel B: Esketamine 56 mg (Period 1 and 2) | 22.2 |
Participants who had a MADRS total score of <=10 were considered remitters. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT01998958)
Timeframe: Days 1, 2 and 8 of Double-blind Phase of Period 1
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| Day 1 | Day 2 | Day 8 | |
| Panel A: Period 1 Esketamine 28 mg | 27.3 | 36.4 | 9.1 |
| Panel A: Period 1 Esketamine 84 mg | 25.0 | 25.0 | 25.0 |
| Panel A: Period 1: Esketamine 56 mg | 18.2 | 18.2 | 9.1 |
| Panel A: Period 1: Placebo | 3.0 | 0 | 3.0 |
| Panel B: Period 1 Esketamine 14 mg | 36.4 | 27.3 | 18.2 |
| Panel B: Period 1 Esketamine 56 mg | 33.3 | 33.3 | 22.2 |
| Panel B: Period 1 Placebo | 19.0 | 19.0 | 14.3 |
Participants who had a MADRS total score of less than or equal to (<=10) were considered remitters. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. A negative change in score indicates improvement. (NCT01998958)
Timeframe: Days 1, 2 and 8 of Double-blind Phase of Period 2
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| Day 1 | Day 2 | Day 8 | |
| Panel A: Period 2 Esketamine 28 mg | 12.5 | 0 | 12.5 |
| Panel A: Period 2 Esketamine 56 mg | 0 | 0 | 0 |
| Panel A: Period 2 Esketamine 84 mg | 40.0 | 20.0 | 20.0 |
| Panel A: Period 2 Placebo | 16.7 | 0 | 0 |
| Panel B: Period 2 Esketamine 14 mg | 60.0 | 80.0 | 0 |
| Panel B: Period 2 Esketamine 56 mg | 0 | 0 | 0 |
| Panel B: Period 2 Placebo | 0 | 0 | 0 |
A participant is defined a responder at a given time point if the percent improvement in MADRS is >=50%. Participant who do not meet such criterion, worsen or discontinue during the DB phase for any reason was considered as non-responders, that is, was assigned a value of 0. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT01998958)
Timeframe: Period 2: Days 1 (2 hour), 2 and 8 of Double-blind Phase
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| Day 1 (2 hour) | Day 2 | Day 8 | |
| Panel A: Period 2 Esketamine 28 mg | 12.5 | 0 | 12.5 |
| Panel B: Period 2 Placebo | 0 | 0 | 0 |
| Panel A: Period 2 Esketamine 56 mg | 22.2 | 11.1 | 0 |
| Panel A: Period 2 Esketamine 84 mg | 40.0 | 40.0 | 20.0 |
| Panel A: Period 2 Placebo | 16.7 | 0 | 0 |
| Panel B: Period 2 Esketamine 14 mg | 60.0 | 80.0 | 0 |
| Panel B: Period 2 Esketamine 56 mg | 0 | 0 | 33.3 |
A participant is defined a responder at a given time point if the percent improvement in MADRS is greater than or equal to (>=) 50%. Participant who do not meet such criterion, worsen or discontinue during the DB phase for any reason was considered as non-responders, that is, was assigned a value of 0. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT01998958)
Timeframe: Period 1: Days 1 (2 hour), 2 and 8 of Double-blind Phase
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| Day 1 (2 hour) | Day 2 | Day 8 | |
| Panel A: Period 1 Esketamine 28 mg | 54.5 | 36.4 | 9.1 |
| Panel A: Period 1 Esketamine 84 mg | 58.3 | 41.7 | 41.7 |
| Panel A: Period 1 Placebo | 18.2 | 3.0 | 6.1 |
| Panel B: Period 1 Esketamine 14 mg | 36.4 | 36.4 | 18.2 |
| Panel B: Period 1 Esketamine 56 mg | 44.4 | 44.4 | 22.2 |
| Panel B: Period 1 Placebo | 33.3 | 28.6 | 23.8 |
| Panel A: Period 1 Esketamine 56 mg | 36.4 | 27.3 | 18.2 |
SIBAT was specifically developed to measure rapid change in suicidality, based on concerns that existing scales such as Beck Scale for Suicidal Ideation (BSS) are not designed to discriminate differences associated with rapid change. Patient-rated section includes following modules: Module 1 (M-1)(demographic information,suicide history), M-2(current suicidal thinking),M-3 (protective factors), M-4 (suicide behavior),M-5(suicide risk),M-6(suicide-implicit association test).Patient-reported global assessment of suicide risk summarizes patient's judgment of suicide risk (Module 6). Scores: 0(None), 1(Very weak), 2(Weak), 3(Moderately weak), 4(Mild), 5(Moderate), 6 (Moderately strong), 7(Strong), 8(Extremely strong), 9(Extremely strong,constant). Negative change in score indicates improvement. LOCF approach used for missing visit data in the ITT LOCF efficacy analyses. (NCT02133001)
Timeframe: Baseline (Day 1-predose) to Day 1: 4-hours postdose
| Intervention | Units on scale (Median) |
|---|---|
| Placebo | -1.0 |
| Esketamine 84 mg | -1.0 |
The MADRS consists of 10 items that cover all of the core depressive symptoms (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts). Each item is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of the symptom). A total score (0 to 60) is calculated by adding the scores of all 10 items. For each item as well as the total score, a higher score represents a more severe condition. The last observation carried forward (LOCF) approach was used for missing visit data in the ITT LOCF efficacy analyses. (NCT02133001)
Timeframe: Baseline (Day 1-Predose) to Day 1: 4-hours post-dose
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | -9.1 |
| Esketamine 84 mg | -13.4 |
SIBAT CGJ-SR: Module 8 operates numerous clinical global impression (CGI) severity scales used in other psychiatric studies. Changes in CGJ-SR designed to categorize clinically meaningful changes in clinician rated suicide risk from 'not at all suicidal' to 'participant is at imminent risk of suicide and immediate need for strong intervention (hospitalization with 24 hour 1:1 observation).' Patient scores for clinician-rated suicide risk: 0 (not suicidal); 1(occasional suicidal ideas, no intervention required);2(some clear suicidal ideas present),3(suicidal risk requires scheduled outpatient follow-up,no immediate intervention),4(suicidal risk requires immediate intervention, no hospitalization). 5( suicidal risk requires immediate hospitalization, no suicide precautions),6 (suicide risk requires hospitalization with suicide precautions). LOCF approach used for missing visit data in ITT LOCF efficacy analyses. (NCT02133001)
Timeframe: Baseline (Day 1-predose) to Day 1: 4-hours Postdose
| Intervention | Units on a scale (Median) |
|---|---|
| Placebo | 0 |
| Esketamine 84 mg | 0 |
BHS is paper-based self-reported measure to assess one's level of negative expectations or pessimism regarding future. Consists of 20 true-false items that examine the respondent's attitude over past week by either endorsing a pessimistic statement or denying an optimistic statement; 9 are keyed false and 11 are keyed true. Items fall within 3 domains: feelings about future; loss of motivation; future expectations. each response is assigned a score of 0 or 1. Total BHS score is sum of item responses, with range from 0 to 20, with a higher score representing higher level of hopelessness. Total scores that range from 0 to 3 are (normal range), scores 4 to 8 (mild hopelessness, scores 9 to 14 (moderate hopelessness), scores <14 (severe hopelessness). Negative change in score indicates improvement. The LOCF approach was used for missing visit data in the ITT LOCF efficacy analyses. (NCT02133001)
Timeframe: Baseline (Day 1-predose) to Day 1: 4-hours Postdose
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | -3.1 |
| Esketamine 84 mg | -4.1 |
BSS is 21-item self-reported instrument to detect and measure severity of suicidal ideation. BSS measures broad spectrum of attitudes and behaviors associated with risk of suicide. Items in scale assess respondent's suicidal plans, deterrents to suicide, level of openness to revealing suicidal thoughts. First 19 items of scale measure gradations of severity of suicidal wishes,attitude, plans.Statements reflect increasing gradations of this severity,are scored from 0 to 2. Final two items ask about number of suicide attempts, seriousness of intention to die associated with last attempt,they are not used in calculating BSS total score. Total BSS score represents severity of suicide ideation, calculated by summing ratings of first 19 items;total score ranges from 0 to 38, with higher score representing greater suicide ideation. LOCF approach used for missing visit data in ITT LOCF efficacy analyses. (NCT02133001)
Timeframe: Baseline (Day 1-predose) to Day 1: 4-hours postdose
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | -8.3 |
| Esketamine 84 mg | -10.2 |
BSS is 21-item self-reported instrument to detect and measure severity of suicidal ideation. BSS measures broad spectrum of attitudes and behaviors associated with risk of suicide. Items in scale assess respondent's suicidal plans, deterrents to suicide,level of openness to revealing suicidal thoughts. First 19 items of scale measure gradations of severity of suicidal wishes, attitude, plans.Statements reflect increasing gradations of this severity,are scored from 0 to 2. Final two items ask about number of suicide attempts, seriousness of intention to die associated with last attempt,they are not used in calculating BSS total score. Total BSS score represents severity of suicide ideation, calculated by summing ratings of first 19 items;total score ranges from 0 to 38, with higher score representing greater suicide ideation. LOCF approach used for missing visit data in ITT LOCF efficacy analyses. (NCT02133001)
Timeframe: Baseline (Day 1-predose) to Day 2
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | -10.7 |
| Esketamine 84 mg | -12.9 |
The MADRS consists of 10 items that cover all of the core depressive symptoms (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts). Each item is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of the symptom). A total score (0 to 60) is calculated by adding the scores of all 10 items. For each item as well as the total score, a higher score represents a more severe condition. The LOCF approach was used for missing visit data in the ITT LOCF efficacy analyses. (NCT02133001)
Timeframe: Baseline (Day 1-predose) to Day 2
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | -12.8 |
| Esketamine 84 mg | -19.3 |
SIBAT CGJ-SR: Module 8 operates like numerous other CGI severity scales used in other psychiatric studies. Changes in CGJ-SR designed to categorize clinically meaningful changes in clinician rated suicide risk from 'not at all suicidal' to 'participant is at imminent risk of suicide and immediate need for strong intervention (hospitalization with 24 hour 1:1 observation).' Patient scores for clinician-rated suicide risk: 0 (not suicidal); 1(occasional suicidal ideas, no intervention required);2(some clear suicidal ideas present),3(suicidal risk requires scheduled outpatient follow-up,no immediate intervention),4(suicidal risk requires immediate intervention, no hospitalization). 5( suicidal risk requires immediate hospitalization, no suicide precautions),6 (suicide risk requires hospitalization with suicide precautions). LOCF approach used for missing visit data in ITT LOCF efficacy analyses. (NCT02133001)
Timeframe: Baseline (Day 1-predose) to Day 2
| Intervention | Units on a scale (Median) |
|---|---|
| Placebo | 0 |
| Esketamine 84 mg | -1.0 |
SIBAT was specifically developed to measure rapid change in suicidality, based on concerns that existing scales such as BSS are not designed to discriminate differences associated with rapid change. Patient-rated section includes following modules: Module 1 (M-1)(demographic information,suicide history), M-2(current suicidal thinking),M-3 (protective factors), M-4 (suicide behavior),M-5(suicide risk),M-6(suicide-implicit association test).Patient-reported global assessment of suicide risk summarizes patient's judgment of suicide risk (Module 6). Scores: 0(None), 1(Very weak), 2(Weak), 3(Moderately weak), 4(Mild), 5(Moderate), 6 (Moderately strong), 7(Strong), 8(Extremely strong), 9(Extremely strong,constant). Negative change in score indicates improvement. LOCF approach used for missing visit data in the ITT LOCF efficacy analyses. (NCT02133001)
Timeframe: Baseline (Day 1-predose) to Day 2
| Intervention | Units on a scale (Median) |
|---|---|
| Placebo | -1.5 |
| Esketamine 84 mg | -2 |
"SIBAT was specifically developed to measure rapid change in suicidality, based on concerns that existing scales such as BSS are not designed to discriminate differences associated with rapid change. Patient-rated section includes following modules: Module 1 (M-1)(demographic information,suicide history), M-2(current suicidal thinking),M-3 (protective factors), M-4 (suicide behavior),M-5(suicide risk),M-6(suicide-implicit association test).Patient-reported global assessment of suicide risk summarizes patient's judgment of suicide risk (Module 6). Scores: 0(None), 1(Very weak), 2(Weak), 3(Moderately weak), 4(Mild), 5(Moderate), 6 (Moderately strong), 7(Strong), 8(Extremely strong), 9(Extremely strong,constant). Negative change in score indicates improvement. LOCF approach used for missing visit data in the ITT LOCF efficacy analyses. Last post baseline observation was carried forward as End Point for double-blind phase." (NCT02133001)
Timeframe: Baseline (Day 1-predose) to Double-blind Phase-Endpoint (Day 25)
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | -3.0 |
| Esketamine 84 mg | -4.0 |
"The MADRS consists of 10 items that cover all of the core depressive symptoms (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts). Each item is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of the symptom). A total score (0 to 60) is calculated by adding the scores of all 10 items. For each item as well as the total score, a higher score represents a more severe condition. The LOCF approach was used for missing visit data in the ITT LOCF efficacy analyses. The last post baseline observation was carried forward as the End Point for the double-blind phase." (NCT02133001)
Timeframe: Baseline (Day 1-predose) to Double-blind Phase-End Point (Day 25)
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -23.0 |
| Esketamine 84 mg | -26.4 |
"BHS is paper-based self-reported measure to assess one's level of negative expectations or pessimism regarding future. Consists of 20 true-false items that examine the respondent's attitude over past week by either endorsing a pessimistic statement or denying an optimistic statement; 9 are keyed false and 11 are keyed true. Items fall within 3 domains: feelings about future; loss of motivation; future expectations. each response is assigned a score of 0 or 1. Total BHS score is sum of item responses, with range from 0 to 20, with a higher score representing higher level of hopelessness. Total scores that range from 0 to 3 are (normal range), scores 4 to 8 (mild hopelessness, scores 9 to 14 (moderate hopelessness), scores <14 (severe hopelessness). Negative change in score indicates improvement. The LOCF approach was used for missing visit data in the ITT LOCF efficacy analyses. The last post baseline observation was carried forward as the End Point for the double-blind phase." (NCT02133001)
Timeframe: Baseline (Day 1-predose) to Double-blind Phase-Endpoint (Day 25)
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | -7.7 |
| Esketamine 84 mg | -10.3 |
"BSS is 21-item self-reported instrument to detect and measure severity of suicidal ideation.BSS measures broad spectrum of attitudes and behaviors associated with risk of suicide. Items in scale assess respondent's suicidal plans, deterrents to suicide, level of openness to revealing suicidal thoughts. First 19 items of scale measure gradations of severity of suicidal wishes, attitude, plans.Statements reflect increasing gradations of this severity,are scored from 0 to 2. Final two items ask about number of suicide attempts, seriousness of intention to die associated with last attempt,they are not used in calculating BSS total score. Total BSS score represents severity of suicide ideation, calculated by summing ratings of first 19 items;total score ranges from 0 to 38, with higher score representing greater suicide ideation. LOCF approach used for missing visit data in ITT LOCF efficacy analyses. Last post baseline observation was carried forward as End Point for double-blind phase." (NCT02133001)
Timeframe: Baseline (Day 1-predose) to Double-blind Phase-endpoint (Day 25)
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | -16.0 |
| Esketamine 84 mg | -19.3 |
"SIBAT CGJ-SR: Module 8 operates like numerous other CGI severity scales used in other psychiatric studies. Changes in CGJ-SR designed to categorize clinically meaningful changes in clinician rated suicide risk from 'not at all suicidal' to 'participant is at imminent risk of suicide and immediate need for strong intervention (hospitalization with 24 hour 1:1 observation).' Patient scores for clinician-rated suicide risk: 0 (not suicidal); 1(occasional suicidal ideas, no intervention required);2(some clear suicidal ideas present),3(suicidal risk requires scheduled outpatient follow-up,no immediate intervention),4(suicidal risk requires immediate intervention, no hospitalization). 5( suicidal risk requires immediate hospitalization, no suicide precautions),6 (suicide risk requires hospitalization with suicide precautions). LOCF approach used for missing visit data in ITT LOCF efficacy analyses. Last post baseline observation was carried forward as End Point for the double-blind phase." (NCT02133001)
Timeframe: Baseline (Day 1-predose) to Double-blind Phase-Endpoint (Day 25)
| Intervention | Units on a scale (Median) |
|---|---|
| Placebo | -5.0 |
| Esketamine 84 mg | -5.0 |
"BSS is 21-item self-reported instrument to detect and measure severity of suicidal ideation. BSS measures broad spectrum of attitudes and behaviors associated with risk of suicide. Items in scale assess respondent's suicidal plans, deterrents to suicide, level of openness to revealing suicidal thoughts. First 19 items of scale measure gradations of severity of suicidal wishes, attitude, plans.Statements reflect increasing gradations of this severity,are scored from 0 to 2. Final two items ask about number of suicide attempts, seriousness of intention to die associated with last attempt,they are not used in calculating BSS total score. Total BSS score represents severity of suicide ideation, calculated by summing ratings of first 19 items;total score ranges from 0 to 38, with higher score representing greater suicide ideation. LOCF approach used for missing visit data in ITT LOCF efficacy analyses, last post baseline observation was carried forward as the End Point follow up phase." (NCT02133001)
Timeframe: Baseline (Day 1-predose) to Follow-up Phase-Endpoint (Day 81)
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | -18.0 |
| Esketamine 84 mg | -20.3 |
"SIBAT CGJ-SR: Module 8 operates like numerous other CGI severity scales used in other psychiatric studies. Changes in CGJ-SR designed to categorize clinically meaningful changes in clinician rated suicide risk from 'not at all suicidal' to 'participant is at imminent risk of suicide and immediate need for strong intervention (hospitalization with 24 hour 1:1 observation).' Patient scores for clinician-rated suicide risk: 0 (not suicidal); 1(occasional suicidal ideas, no intervention required);2(some clear suicidal ideas present),3(suicidal risk requires scheduled outpatient follow-up,no immediate intervention),4(suicidal risk requires immediate intervention, no hospitalization). 5( suicidal risk requires immediate hospitalization, no suicide precautions),6 (suicide risk requires hospitalization with suicide precautions). LOCF approach used for missing visit data in ITT LOCF efficacy analyses. Last post baseline observation was carried forward as End Point for follow up phase." (NCT02133001)
Timeframe: Baseline (Day 1-predose) to Follow-up Phase-Endpoint (Day 81)
| Intervention | Units on a scale (Median) |
|---|---|
| Placebo | -5.0 |
| Esketamine 84 mg | -5.0 |
"SIBAT was specifically developed to measure rapid change in suicidality, based on concerns that existing scales such as BSS are not designed to discriminate differences associated with rapid change. Patient-rated section includes following modules: Module 1 (M-1)(demographic information,suicide history), M-2(current suicidal thinking),M-3 (protective factors), M-4 (suicide behavior),M-5(suicide risk),M-6(suicide-implicit association test).Patient-reported global assessment of suicide risk summarizes patient's judgment of suicide risk (Module 6). Scores: 0(None), 1(Very weak), 2(Weak), 3(Moderately weak), 4(Mild), 5(Moderate), 6 (Moderately strong), 7(Strong), 8(Extremely strong), 9(Extremely strong,constant). Negative change in score indicates improvement. LOCF approach used for missing visit data in ITT LOCF efficacy analyses, last post baseline observation was carried forward as the End Point follow up phase." (NCT02133001)
Timeframe: Baseline (Day 1-predose) to Follow-up Phase Endpoint (Day 81)
| Intervention | Units on a scale (Median) |
|---|---|
| Placebo | -4.0 |
| Esketamine 84 mg | -3.0 |
Percentage of participants with response (greater than or equal to (>=) 50% improvement from baseline in MADRS total score) during the follow up was assessed. The MADRS consists of 10 items that cover all of the core depressive symptoms (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts). Each item is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of the symptom). A total score (0 to 60) is calculated by adding the scores of all 10 items. For each item as well as the total score, a higher score represents a more severe condition. (NCT02133001)
Timeframe: Follow up phase-endpoint (Day 81)
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo | 63.6 |
| Esketamine 84 mg | 66.7 |
Sustained response is defined as a reduction from baseline in MADRS total score of greater than or equal to 50 percent, with onset on Day 1 that is maintained through the end of the double-blind phase (Day 25). The MADRS consists of 10 items that cover all of the core depressive symptoms (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts). Each item is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of the symptom). A total score (0 to 60) is calculated by adding the scores of all 10 items. For each item as well as the total score, a higher score represents a more severe condition. The LOCF approach was used for missing visit data in the ITT LOCF efficacy analyses. (NCT02133001)
Timeframe: Day 1 to Day 25
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo | 6.7 |
| Esketamine 84 mg | 11.8 |
Percentage of participants with response (greater than or equal to (>=) 50% improvement from baseline in MADRS total score) during the double- blind phase was assessed. The MADRS consists of 10 items that cover all of the core depressive symptoms (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts). Each item is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of the symptom). A total score (0 to 60) is calculated by adding the scores of all 10 items. For each item as well as the total score, a higher score represents a more severe condition. (NCT02133001)
Timeframe: Day 1 (4 hours postdose), Day 2 (double blind phase), Double blind phase -Endpoint (Day 25)
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| Day 1 (4 hours postdose) | Day 2 (double blind phase) | Double blind phase -Endpoint (Day 25) | |
| Esketamine 84 mg | 25.7 | 54.3 | 74.3 |
| Placebo | 12.9 | 29.0 | 54.8 |
The Montgomery-Asberg Depression Rating Scale (MADRS) has a range of scores from 0 to 60 where the highest values indicate the most depression. (NCT00369915)
Timeframe: Outcome measures obtained at each of 12 sessions
| Intervention | units on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Block 1 - Session 1 | Block 1 - Session 2 | Block 1 - Session 3 | Block 1 - Session 4 | Block 1 - Session 5 | Block 1 - Session 6 | Block 2 - Session 1 | Block 2 - Session 2 | Block 2 - Session 3 | Block 2 - Session 4 | Block 2 - Session 5 | Block 2 - Session 6 | |
| Plac/Scop | 29.5 | 26.5 | 24.5 | 19.5 | 19.3 | 20.8 | 23.3 | 18.0 | 19.8 | 18 | 16.3 | 15.5 |
| Scop/Plac | 30.5 | 29.8 | 31.0 | 27.0 | 27.8 | 28.5 | 27.5 | 23.8 | 20.0 | 17.3 | 16.8 | 20.3 |
The Hamilton Anxiety Rating Scale (HARS) has a range of scores from 0 to 56 where the highest values indicate the most anxiety. (NCT00369915)
Timeframe: Each of 12 sessions.
| Intervention | units on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Block 1 - Session 1 | Block 1 - Session 2 | Block 1 - Session 3 | Block 1 - Session 4 | Block 1 - Session 5 | Block 1 - Session 6 | Block 2 - Session 1 | Block 2 - Session 2 | Block 2 - Session 3 | Block 2 - Session 4 | Block 2 - Session 5 | Block 2 - Session 6 | |
| Plac/Scop | 17.0 | 16.8 | 14.5 | 14.3 | 12.8 | 17.8 | 14.8 | 13.3 | 14.3 | 10.5 | 9.8 | 11.8 |
| Scop/Plac | 20.3 | 14.5 | 14.3 | 13.0 | 12.0 | 11.5 | 13.5 | 12.0 | 13.3 | 14.3 | 10.3 | 11.8 |
The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item scale that measures the severity of depression, with a higher score indicating a higher level of depression. The range of scores is 0 to 60. (NCT01179009)
Timeframe: 8 weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| Ketamine 100-hour Infusion | -9.0 |
| Ketamine 40-minute Infusion | -6.4 |
We will examine change from baseline in the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) ratings of OCD severity at 1 day following infusion. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) assesses obsessive and compulsive symptom severity. Obsessions are rated on a scale from 0-20 and compulsions are rated on a scale of 0-20, for a total scale of 0-40. Scores on the obsessions scale and scores on the compulsions scale are summed to obtain the total score. The higher the score, the more severe the OCD. (NCT01349231)
Timeframe: Baseline and 1 day after ketamine infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | -2.7 |
We will examine change from baseline in the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) ratings of OCD severity at 2 days following infusion. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) assesses obsessive and compulsive symptom severity. Obsessions are rated on a scale from 0-20 and compulsions are rated on a scale of 0-20, for a total scale of 0-40. Scores on the obsessions scale and scores on the compulsions scale are summed to obtain the total score. The higher the score, the more severe the OCD. (NCT01349231)
Timeframe: Baseline and 2 days following infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | -3.6 |
We will examine change from baseline in the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) ratings of OCD severity at 3 days following infusion. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) assesses obsessive and compulsive symptom severity. Obsessions are rated on a scale from 0-20 and compulsions are rated on a scale of 0-20, for a total scale of 0-40. Scores on the obsessions scale and scores on the compulsions scale are summed to obtain the total score. The higher the score, the more severe the OCD. (NCT01349231)
Timeframe: Baseline and 3 days following infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | -2.9 |
We will examine change from baseline in Hamilton Rating Scale for Depression (HRDS) ratings of depression severity at day 1-3 following a single ketamine infusion. The HRDS assesses severity of, and change in, depressive symptoms. The HRDS is a 21 item scale with scores ranging from 0-66. The higher the score, the more severe the depression. (NCT01349231)
Timeframe: Baseline, Day 1, Day 2, and Day 3
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| HRDS change from Baseline to Day 1 | HRDS change from Baseline to Day 2 | HRDS change from Baseline to Day 3 | |
| Ketamine | -6.57 | -7.29 | -5.14 |
Montgomery-Asberg Depression Rating Scale, each of the ten items can be scored from 0 (absence of symptoms to 6 most severe) and has a total score range of 0-60. A lower score on a MADRS indicates a less severe depression. (NCT00768430)
Timeframe: 24 hours post-infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 14.77 |
| Midazolam | 22.72 |
Establish if repeated ketamine will be efficacious medically and psychiatrically, as measured by a significant reduction in CDRS score in those treated with ketamine at the end of the dosing paradigm. The Children's Depression Rating Scale (CDRS) is a clinician-rated instrument with 17 items scored on a 1 to 5 or 1 to 7 scale. A rating of 1 indicates normal, thus the minimum score is 17. The maximum score is 113. Scores of 20-30 suggest borderline depression. Scores of 40-60 indicate moderate depression. (NCT03889756)
Timeframe: Day 18
| Intervention | score on a scale (Mean) |
|---|---|
| Ketamine | 42 |
| Midazolam | 62 |
Establish if repeated ketamine will be tolerated as measured by drop-out counts. (NCT03889756)
Timeframe: Day 18
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketamine | 0 |
| Midazolam | 0 |
"Depressive symptoms (measured by Montgomery-Asberg Depression Rating Scale, revised (MADRS) score) on 1 day after infusion, for the cohort of subjects enrolled in the MDD arm of this trial.~Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60.~Usual cutoff points are:~0 to 6 - normal /symptom absent. 7 to 19 - mild depression. 20 to 34 - moderate depression. >34 - severe depression." (NCT02579928)
Timeframe: 1 day after the infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 15.44 |
| Midazolam | 24.13 |
"Quantitative analysis of the concentration of ketamine and its metabolites in breast milk (collected by pumping breast milk into containers at 24 and 30 hours post ketamine IM administration) was performed at the Clinical Medicine and Toxicology Laboratory at UCSF School of Medicine. Sample aliquots were frozen in our conventional freezer at the clinic where the sessions took place, labelled with a HIPAA compliant code which blinded the lab to all patient data.~The limits of sensitivity for the quantification of each substance were:~Ketamine: 0.25 ng Norketamine: 0.25 ng Dehydronorketamine: 0.1 ng Hydroxynorketamine: 0.25 ng" (NCT04285684)
Timeframe: 24 and 30 hour collections
| Intervention | ng/mL (Mean) | |
|---|---|---|
| 24 Hours | 30 Hours | |
| Ketamine During Lactation | .3 | .3 |
"Quantitative analysis of the concentration of ketamine and its metabolites in breast milk (collected by pumping breast milk into containers at 3, 6, 9, and 12 hours post ketamine IM administration) was performed at the Clinical Medicine and Toxicology Laboratory at UCSF School of Medicine. Sample aliquots were frozen in our conventional freezer at the clinic where the sessions took place, labelled with a HIPAA compliant code which blinded the lab to all patient data.~The limits of sensitivity for the quantification of each substance were:~Ketamine: 0.25 ng Norketamine: 0.25 ng Dehydronorketamine: 0.1 ng Hydroxynorketamine: 0.25 ng" (NCT04285684)
Timeframe: 3, 6, 9, and 12 hour collections
| Intervention | ng/mL (Mean) | |||
|---|---|---|---|---|
| 3 Hours | 6 Hours | 9 Hours | 12 Hours | |
| Ketamine During Lactation | .56 | .55 | .45 | .21 |
"Quantitative analysis of the concentration of ketamine and its metabolites in breast milk (collected by pumping breast milk into containers at 3, 6, 9, and 12 hours post ketamine IM administration) was performed at the Clinical Medicine and Toxicology Laboratory at UCSF School of Medicine. Sample aliquots were frozen in our conventional freezer at the clinic where the sessions took place, labelled with a HIPAA compliant code which blinded the lab to all patient data.~The limits of sensitivity for the quantification of each substance were:~Ketamine: 0.25 ng Norketamine: 0.25 ng Dehydronorketamine: 0.1 ng Hydroxynorketamine: 0.25 ng" (NCT04285684)
Timeframe: 3, 6, 9, and 12 hour collections
| Intervention | ng/mL (Mean) | |||
|---|---|---|---|---|
| 3 Hours | 6 Hours | 9 Hours | 12 Hours | |
| Ketamine During Lactation | 2.0 | 1.9 | 1.4 | 1.1 |
"Quantitative analysis of the concentration of ketamine and its metabolites in breast milk (collected by pumping breast milk into containers at 24 and 30 hours post ketamine IM administration) was performed at the Clinical Medicine and Toxicology Laboratory at UCSF School of Medicine. Sample aliquots were frozen in our conventional freezer at the clinic where the sessions took place, labelled with a HIPAA compliant code which blinded the lab to all patient data.~The limits of sensitivity for the quantification of each substance were:~Ketamine: 0.25 ng Norketamine: 0.25 ng Dehydronorketamine: 0.1 ng Hydroxynorketamine: 0.25 ng" (NCT04285684)
Timeframe: 24 and 30 hour collections
| Intervention | ng/mL (Mean) | |
|---|---|---|
| 24 Hours | 30 Hours | |
| Ketamine During Lactation | 30.5 | 13.9 |
"Quantitative analysis of the concentration of ketamine and its metabolites in breast milk (collected by pumping breast milk into containers at 3, 6, 9, and 12 hours post ketamine IM administration) was performed at the Clinical Medicine and Toxicology Laboratory at UCSF School of Medicine. Sample aliquots were frozen in our conventional freezer at the clinic where the sessions took place, labelled with a HIPAA compliant code which blinded the lab to all patient data.~The limits of sensitivity for the quantification of each substance were:~Ketamine: 0.25 ng Norketamine: 0.25 ng Dehydronorketamine: 0.1 ng Hydroxynorketamine: 0.25 ng" (NCT04285684)
Timeframe: 3, 6, 9, and 12 hour collections
| Intervention | ng/mL (Mean) | |||
|---|---|---|---|---|
| 3 Hours | 6 Hours | 9 Hours | 12 Hours | |
| Ketamine During Lactation | 29.9 | 28.3 | 25.6 | 17.5 |
"Quantitative analysis of the concentration of ketamine and its metabolites in breast milk (collected by pumping breast milk into containers at 3, 6, 9, and 12 hours post ketamine IM administration) was performed at the Clinical Medicine and Toxicology Laboratory at UCSF School of Medicine. Sample aliquots were frozen in our conventional freezer at the clinic where the sessions took place, labelled with a HIPAA compliant code which blinded the lab to all patient data.~The limits of sensitivity for the quantification of each substance were:~Ketamine: 0.25 ng Norketamine: 0.25 ng Dehydronorketamine: 0.1 ng Hydroxynorketamine: 0.25 ng" (NCT04285684)
Timeframe: 3, 6, 9, and 12 hour collections
| Intervention | ng/mL (Mean) | |||
|---|---|---|---|---|
| 3 Hours | 6 Hours | 9 Hours | 12 Hours | |
| Ketamine During Lactation | 64.1 | 66.9 | 54.6 | 41.6 |
"Quantitative analysis of the concentration of ketamine and its metabolites in breast milk (collected by pumping breast milk into containers at 24 and 30 hours post ketamine IM administration) was performed at the Clinical Medicine and Toxicology Laboratory at UCSF School of Medicine. Sample aliquots were frozen in our conventional freezer at the clinic where the sessions took place, labelled with a HIPAA compliant code which blinded the lab to all patient data.~The limits of sensitivity for the quantification of each substance were:~Ketamine: 0.25 ng Norketamine: 0.25 ng Dehydronorketamine: 0.1 ng Hydroxynorketamine: 0.25 ng" (NCT04285684)
Timeframe: 24 and 30 hour collections
| Intervention | ng/mL (Mean) | |
|---|---|---|
| 24 Hours | 30 Hours | |
| Ketamine During Lactation | 4.9 | 6.4 |
"Quantitative analysis of the concentration of ketamine and its metabolites in breast milk (collected by pumping breast milk into containers at 3, 6, 9, and 12 hours post ketamine IM administration) was performed at the Clinical Medicine and Toxicology Laboratory at UCSF School of Medicine. Sample aliquots were frozen in our conventional freezer at the clinic where the sessions took place, labelled with a HIPAA compliant code which blinded the lab to all patient data.~The limits of sensitivity for the quantification of each substance were:~Ketamine: 0.25 ng Norketamine: 0.25 ng Dehydronorketamine: 0.1 ng Hydroxynorketamine: 0.25 ng" (NCT04285684)
Timeframe: 3, 6, 9, and 12 hour collections
| Intervention | ng/mL (Mean) | |||
|---|---|---|---|---|
| 3 Hours | 6 Hours | 9 Hours | 12 Hours | |
| Ketamine During Lactation | 51.2 | 22.6 | 10.6 | 4.5 |
"Quantitative analysis of the concentration of ketamine and its metabolites in breast milk (collected by pumping breast milk into containers at 3, 6, 9, and 12 hours post ketamine IM administration) was performed at the Clinical Medicine and Toxicology Laboratory at UCSF School of Medicine. Sample aliquots were frozen in our conventional freezer at the clinic where the sessions took place, labelled with a HIPAA compliant code which blinded the lab to all patient data.~The limits of sensitivity for the quantification of each substance were:~Ketamine: 0.25 ng Norketamine: 0.25 ng Dehydronorketamine: 0.1 ng Hydroxynorketamine: 0.25 ng" (NCT04285684)
Timeframe: 3, 6, 9, and 12 hour collections
| Intervention | ng/mL (Mean) | |||
|---|---|---|---|---|
| 3 Hours | 6 Hours | 9 Hours | 12 Hours | |
| Ketamine During Lactation | 125.0 | 48.2 | 21.6 | 18.5 |
"Quantitative analysis of the concentration of ketamine and its metabolites in breast milk (collected by pumping breast milk into containers at 24 and 30 hours post ketamine IM administration) was performed at the Clinical Medicine and Toxicology Laboratory at UCSF School of Medicine. Sample aliquots were frozen in our conventional freezer at the clinic where the sessions took place, labelled with a HIPAA compliant code which blinded the lab to all patient data.~The limits of sensitivity for the quantification of each substance were:~Ketamine: 0.25 ng Norketamine: 0.25 ng Dehydronorketamine: 0.1 ng Hydroxynorketamine: 0.25 ng" (NCT04285684)
Timeframe: 24 and 30 hour collections
| Intervention | ng/mL (Mean) | |
|---|---|---|
| 24 Hours | 30 Hours | |
| Ketamine During Lactation | 10.3 | 9.9 |
"Quantitative analysis of the concentration of ketamine and its metabolites in breast milk (collected by pumping breast milk into containers at 3, 6, 9, and 12 hours post ketamine IM administration) was performed at the Clinical Medicine and Toxicology Laboratory at UCSF School of Medicine. Sample aliquots were frozen in our conventional freezer at the clinic where the sessions took place, labelled with a HIPAA compliant code which blinded the lab to all patient data.~The limits of sensitivity for the quantification of each substance were:~Ketamine: 0.25 ng Norketamine: 0.25 ng Dehydronorketamine: 0.1 ng Hydroxynorketamine: 0.25 ng" (NCT04285684)
Timeframe: 3, 6, 9, and 12 hour collections
| Intervention | ng/mL (Mean) | |||
|---|---|---|---|---|
| 3 Hours | 6 Hours | 9 Hours | 12 Hours | |
| Ketamine During Lactation | 42.6 | 28.6 | 18.8 | 8.7 |
"Quantitative analysis of the concentration of ketamine and its metabolites in breast milk (collected by pumping breast milk into containers at 3, 6, 9, and 12 hours post ketamine IM administration) was performed at the Clinical Medicine and Toxicology Laboratory at UCSF School of Medicine. Sample aliquots were frozen in our conventional freezer at the clinic where the sessions took place, labelled with a HIPAA compliant code which blinded the lab to all patient data.~The limits of sensitivity for the quantification of each substance were:~Ketamine: 0.25 ng Norketamine: 0.25 ng Dehydronorketamine: 0.1 ng Hydroxynorketamine: 0.25 ng" (NCT04285684)
Timeframe: 3, 6, 9, and 12 hour collections
| Intervention | ng/mL (Mean) | |||
|---|---|---|---|---|
| 3 Hours | 6 Hours | 9 Hours | 12 Hours | |
| Ketamine During Lactation | 92.7 | 62.4 | 37.3 | 32.3 |
Montgomery-Asberg Depression Rating Scale, each of the ten items can be scored from 0 (absence of symptoms to 6 most severe) and has a total score range of 0-60. A lower score on a MADRS indicates a less severe depression. The primary outcome for the initial phase of the trial was the 24-h MADRS score, which included all 10 MADRS items. (NCT00419003)
Timeframe: 24 Hours
| Intervention | scores on a scale (Mean) |
|---|---|
| Riluzole Group | 24.4 |
| Placebo | 22.0 |
Change in BSI score at 24 hours following treatment as compared to baseline. Beck Scale is a 21-item self or clinician administered instrumentation used to measure the current intensity of patients' specific attitudes, behaviors and plans to commit suicide. Score range 0-42, with higher score indicating higher intensity. (NCT01507181)
Timeframe: baseline and 24 hours post infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 10.8 |
| Midazolam | 14.0 |
Change in BSI score at 48 hours following treatment as compared to baseline. Beck Scale is a 21-item self or clinician administered instrumentation used to measure the current intensity of patients' specific attitudes, behaviors and plans to commit suicide. Score range 0-42, with higher score indicating higher intensity. (NCT01507181)
Timeframe: baseline and 48 hours post infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 8.8 |
| Midazolam | 15.3 |
The PRISE assesses the presence of treatment side effects in nine organ/function systems (gastrointestinal, nervous system, heart, eyes/ears, skin, genital/urinary, sleep, sexual functioning, and other). Data reported in in Adverse Events section. (NCT01507181)
Timeframe: duration of study
| Intervention | events (Number) |
|---|---|
| Ketamine | 29 |
| Midazolam | 23 |
The MADRS-SI ranges from 0 to 6; a score of 2 corresponds to fleeting, passive SI; a score of 4 indicates that SI is frequent with at least moderate intensity but without specific plans or intention; a score of 6 corresponds to active intention and planning for suicide. (NCT01507181)
Timeframe: 24 hours post infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 1.8 |
| Midazolam | 3.3 |
The MADRS is a 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT01507181)
Timeframe: up to 7 days post infusion
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| 24 hours | 48 hours | 72 hours | 7 days | |
| Ketamine | 19.0 | 19.3 | 20.9 | 21.7 |
| Midazolam | 26.2 | 28 | 24.1 | 22.2 |
The BPRS measures psychomimetic effects with higher scores indicating more severe symptoms (scale range 7 - 49). (NCT01507181)
Timeframe: baseline, 40 minutes post infusion, and 240 minutes post infusion
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| baseline | 40 minutes post infusion | 240 minutes post infusion | |
| Ketamine | 7.7 | 9.9 | 8.1 |
| Midazolam | 7.7 | 7.9 | 7.0 |
The CADSS measures dissociation with higher scores indicating more severe symptoms (scale range 0 - 92). (NCT01507181)
Timeframe: baseline, 40 minutes post infusion and 240 minutes post infusion
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| baseline | 40 minutes post infusion | 240 minutes post infusion | |
| Ketamine | 1.1 | 17.1 | 1.2 |
| Midazolam | 4.0 | 3.3 | 1.3 |
An 11-item questionnaire, used to assess manic symptoms based on the patient's subjective report of his or her clinical condition. There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. The scores from each question are added together to form a total score ranging from 0 to 60, with higher scores indicating a greater severity of symptoms. (NCT01507181)
Timeframe: baseline, 40 minutes post infusion, 240 minutes post infusion
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| baseline | 40 minutes post infusion | 240 minutes post infusion | |
| Ketamine | 0.0 | 0.0 | 0.2 |
| Midazolam | 0.1 | 0.3 | 0.2 |
Response is defined as at least a 50% improvement in the QIDS-SR-16 scale from baseline to the End of Treatment visit. The End of Treatment visit will occur 3-5 weeks after the Baseline visit. (NCT03113968)
Timeframe: Acute Study Phase (Baseline Visit to End of Treatment Visit) - approximately 3-5 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Electroconvulsive Therapy (ECT) | 70 |
| Ketamine Infusion | 108 |
The outcome measure was the percentage of responders at the end-of-treatment visit, defined as a ≥50% decrease in MADRS score from the baseline visit (i.e., first treatment visit) to the end-of-treatment visit (within 3 days of last treatment). (NCT03113968)
Timeframe: Acute Study Phase (Baseline Visit to End of Treatment Visit) - approximately 3-5 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Electroconvulsive Therapy (ECT) | 70 |
| Ketamine Infusion | 99 |
Patients will be assessed with HAMD-28 weekly for the first 8 weeks, then every two weeks for another 8 weeks. Participants were considered as responders if there was a ⩾50% improvement on the HAM-D28. (NCT01582945)
Timeframe: Weekly for total duration of 4 months
| Intervention | participants who met response criteria (Number) |
|---|---|
| Ketamine IV | 5 |
The Clinical Global Impression Severity Subscale is an observer rated scale that measures illness severity. It has a range of responses from 1 (normal) through to 7 (among the most extremely ill patients). (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | percentage change in score (Mean) |
|---|---|
| Entire Cohort | -29.4 |
| Remission | -50.7 |
| Non-Remission | -14.3 |
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms. MADRS Factor 1 (Sadness) consisted of MADRS items 1 (Apparent Sadness) and 2 (Reported Sadness). The MADRS Factor 1 Score is derived by adding all the scores from the 2 items, meaning the lowest possible score is 0 and the highest possible is 12. (NCT02094898)
Timeframe: baseline, last acute phase observation
| Intervention | percentage change in score (Mean) |
|---|---|
| Entire Cohort | -50.3 |
| Remission | -83.6 |
| Non-Remission | -26.5 |
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms. MADRS Factor 2 (negative thoughts) consisted of MADRS items 9 (Pessimistic Thoughts) and 10 (Suicidal Thoughts). The MADRS Factor 2 Score is derived by adding all the scores from the 2 items, meaning the lowest possible score is 0 and the highest possible is 12. (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | percentage change in score (Mean) |
|---|---|
| Entire Cohort | -37.0 |
| Remission | -65.4 |
| Non-Remission | -16.7 |
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms. MADRS Factor 3 (detachment) consisted of MADRS items 6 - 8 (Concentration Difficulties, Lassitude, and Inability to Feel). The MADRS Factor 3 Score is derived by adding all the scores from the 3 items, meaning the lowest possible score is 0 and the highest possible is 18. (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | percentage change in score (Mean) |
|---|---|
| Entire Cohort | -40.2 |
| Remission | -84.3 |
| Non-Remission | -8.9 |
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms. MADRS Factor 4 (neurovegetative symptoms) consisted of MADRS items 3-5 (Inner Tension, Reduced Sleep, and Reduced Appetite). The MADRS Factor 4 Score is derived by adding all the scores from the 3 items, meaning the lowest possible score is 0 and the highest possible is 18. (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | percentage change in score (Mean) |
|---|---|
| Entire Cohort | -36.0 |
| Remission | -84.3 |
| Non-Remission | -8.4 |
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms. Item 10 scores can range from 0 to 6 (with 0 indicating enjoying life, and 6 indicating explicit plans for suicide.) (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | percentage change in score (Mean) |
|---|---|
| Entire Cohort | -26.7 |
| Remission | -50.0 |
| Non-Remission | -7.2 |
The Montgomery Asberg Depression Scale (MADRS) is a 10-item observer rating scale assessing symptoms of depression. The score ranges from 0 (no depression) to 60 (very depressed). For this study a score of less than or equal to 9 was considered clinical remission of depression. (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | percentage change in score (Mean) |
|---|---|
| Entire Cohort | -41.5 |
| Remission | -79.1 |
| Non-Remission | -14.5 |
The Clinical Global Impression Severity Subscale is an observer rated scale that measures illness severity. It has a range of responses from 1 (normal) through to 7 (among the most extremely ill patients). (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Last acute phase observation | |
| Entire Cohort | 5.6 | 3.9 |
| Non-Remission | 5.7 | 4.9 |
| Remission | 5.4 | 2.6 |
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms. MADRS Factor 1 (Sadness) consisted of MADRS items 1 (Apparent Sadness) and 2 (Reported Sadness). The MADRS Factor 1 Score is derived by adding all the scores from the 2 items, meaning the lowest possible score is 0 and the highest possible is 12. (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Last acute phase observation | |
| Entire Cohort | 7.4 | 3.5 |
| Non-Remission | 7.4 | 5.1 |
| Remission | 7.4 | 1.2 |
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms. MADRS Factor 2 (Negative Thoughts) consisted of MADRS items 9 (Pessimistic Thoughts) and 10 (Suicidal Thoughts). The MADRS Factor 2 Score is derived by adding all the scores from the 2 items, meaning the lowest possible score is 0 and the highest possible is 12. (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Last acute phase observation | |
| Entire Cohort | 6.0 | 3.4 |
| Non-Remission | 5.9 | 4.6 |
| Remission | 6.2 | 1.8 |
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms. MADRS Factor 3 (Detachment) consisted of MADRS items 6 - 8 (Concentration Difficulties, Lassitude, and Inability to Feel). The MADRS Factor 3 Score is derived by adding all the scores from the 3 items, meaning the lowest possible score is 0 and the highest possible is 18. (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Last acute phase observation | |
| Entire Cohort | 9.5 | 4.9 |
| Non-Remission | 9.3 | 7.4 |
| Remission | 9.8 | 1.4 |
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms. MADRS Factor 4 (Neurovegetative Symptoms) consisted of MADRS items 3-5 (Inner Tension, Reduced Sleep, and Reduced Appetite). The MADRS Factor 4 Score is derived by adding all the scores from the 3 items, meaning the lowest possible score is 0 and the highest possible is 18. (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Last acute phase observation | |
| Entire Cohort | 6.5 | 3.8 |
| Non-Remission | 6.9 | 5.9 |
| Remission | 6.0 | 1.0 |
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms. Item 10 scores can range from 0 to 6 (with 0 indicating enjoying life, and 6 indicating explicit plans for suicide.) (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Last acute phase observation | |
| Entire Cohort | 2.9 | 1.7 |
| Non-Remission | 2.7 | 2.2 |
| Remission | 3.2 | 1.2 |
The Montgomery Asberg Depression Scale (MADRS) is a 10-item observer rating scale assessing symptoms of depression. The score ranges from 0 (no depression) to 60 (very depressed). For this study a score of less than or equal to 9 was considered clinical remission of depression. (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Last acute phase observation | |
| Entire Cohort | 29.4 | 15.9 |
| Non-Remission | 29.4 | 23.4 |
| Remission | 29.4 | 5.4 |
"Beck's Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures attitudes and symptoms of depression. Each sentence has a rating from 0 to 3 and the sentences go from mild to fairly severe descriptions of moods. The numbers are tabulated, the lowest possible score is 0 and the highest is 63.~A score of 1-10 indicates normal ups and downs. 11-16 indicates a mild mood disturbance; 17-20, borderline clinical depression; 21-30, moderate depression; 31-40, severe depression; over 40, extreme depression" (NCT02424591)
Timeframe: Post-op Day 3
| Intervention | points (Median) |
|---|---|
| Ketamine | 8 |
| Placebo | 9 |
"McGill Short Form measures pain in different ways. The first part of the form lists 15 adjectives for pain, for which the answers can be none (0), Mild (1), Moderate (2) and Severe (3). Descriptors 1-11 represent the sensory dimension of pain experience and 12-15 represent the affective dimension. A score of 0 is good, and a score of 45 indicates extreme pain. The lower the score the less pain a subject feels (better), as the scores go up, so do the pain levels (worse).~PPI (Present Pain Intensity) asks patients to measure pain from 0 (no pain) to 5 (excruciating). Again, a lower score is ideal." (NCT02424591)
Timeframe: Post-op Day 3
| Intervention | points (Median) |
|---|---|
| Ketamine | 11 |
| Placebo | 10.5 |
Quality of Recovery 15 questions questionnaires that ask, on a scale of 0-10, with 0 always being bad and 10 always being best, how the patient is recovering. The total number is reviewed, so the highest total score possible is 150 and the lowest is 0. (NCT02424591)
Timeframe: Post-op Day 3
| Intervention | points (Median) |
|---|---|
| Ketamine | 95 |
| Placebo | 101 |
Clinician-administered structured interview measuring PTSD symptoms. frequency score - scale 0 = none of the time to 4 = most or all of the time intensity score - scale 0 = none to 4 = extreme To meet criteria for a symptom, a patient must meet criteria in both frequency and intensity score for each item. Frequency and intensity and then combined to form a single severity score. 30 questions scale, with total score ranging from 0 to 240. (NCT00749203)
Timeframe: 7 days after first infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 54 |
| Midazolam | 65.69 |
"A 22-item self-report questionnaire measuring PTSD symptoms. Items are rated on a 5-point scale ranging from 0 (not at all) to 4 (extremely). The IES-R yields a total score ranging from 0 (not at all) to 88 (extremely)" (NCT00749203)
Timeframe: 7 days after first infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 25.76 |
| Midazolam | 36.32 |
Clinician-administered questionnaire measuring depressive symptoms. The MADRS-S has 10-items which are based on mood symptoms over the past 7 days. Each items is scored 0 (normal) to 6 (severe depression) with overall score ranges from 0 (normal) to 60 (severe depression). Mean difference between baseline and 2 weeks. (NCT00749203)
Timeframe: 24 hours after first infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 12.6 |
| Midazolam | 10.1 |
Self-report questionnaire measuring depressive symptoms. Each item is rated 0 (no depression) to 3 (severe depression). The total score ranges from 0-27. (NCT00749203)
Timeframe: 24 hours after first infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 12.4 |
| Midazolam | 11.3 |
The CY-BOCS is a semi-structured measure of OCD severity with excellent inter-rater reliability, internal consistency, and test-retest reliability. It is validated in those starting at age 7 and used in studies up to age 20. The CYBOCS differs from the adult YBOCS only in its use of simpler language. The CY-BOCS consists of 10 items which are summed up to derive the total CY-BOCS score. The total score ranges from 0-40 with higher scores indicating greater severity of OCD symptoms. (NCT02422290)
Timeframe: Screening, Baseline, Day 7, Day 17, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| CY-BOCS Baseline | CY-BOCS Day 14 | |
| Ketamine Treatment Group | 29.00 | 26.20 |
The CGI-S is a clinician rated 7-point rating scale for the severity of a participant's illness relative to the clinician's experience of working with this particular population. The score ranges from 1-7 with higher scores indicating greater illness severity. (NCT02422290)
Timeframe: Screening, Baseline, Day 7, Day 17, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| CGI-S Baseline | CGI-S Day 14 | |
| Ketamine Treatment Group | 5.80 | 5.00 |
"The OCD-VAS is a one-item unipolar scale to assess OCD symptoms over a rapid time frame (No obsessions to Constant obsessions). The scale ranges from 0-10 with higher scores indicating higher presence of obsessions." (NCT02422290)
Timeframe: Screening, Baseline, Day 1-14, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| OCD-VAS Baseline | OCD-VAS Day 14 | |
| Ketamine Treatment Group | 5.00 | 5.00 |
"The Y-BOCCS is self-report scale which assesses OCD symptoms on a 5-point likert scale (None to Extreme). It consists of 10 items which are summed up to derive the total Y-BOCCS score. The total score ranges from 0-40 with higher scores indicating higher prevalence of OCD symptoms." (NCT02422290)
Timeframe: Screening, Baseline, Day 1-14, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Y-BOCCS Baseline | Y-BOCCS Day 14 | |
| Ketamine Treatment Group | 18.25 | 16.50 |
The items mostly range from a score of 0-4 but there are some questions that range from a score of 0-2. The maximum total score that can be reported is 76 and the lowest score is 0. Higher values represent a worse outcome. Items are summed together to compute the total score. Remission is defined as two consecutive Hamilton Rating Scale for Depression, 24 items (HRSD-24) scores < 10, and HRSD-24 total score does not increase > 3 points on the second consecutive HRSD-24, or remains < 6 at the last two consecutive treatments. HRSD-24 scores are used to define remission. (NCT01881763)
Timeframe: Days required to achieve remission (on average 3-4 weeks)
| Intervention | HRSD units (Mean) |
|---|---|
| Ketamine | 7.82 |
| Methohexital | 8.60 |
"The imaging experiments and analysis of subject-specific data will lead to maps corresponding to separate measures: resting state functional connectivity maps. The outcome of interest is whether ketamine reduces functional connectivity between the anterior (subgenual anterior cingulate corte, sgACC) and posterior regions (posterior cingulate cortex, PCC) of the default mode network. This is the z-score of the functional connectivity correlation.~Timepoints for Initial fMRI were: Time 1:Immediately before Infusion, Time 2: After washout (Approx. 40 min after end of infusion).~Timepoints for Depression were: Time 1: 1 Day before Infusion, Time 2: 1 Day after Infusion" (NCT02196259)
Timeframe: 8 minutes scans, acquired between 1 day and 3 days (see above)
| Intervention | z score (Mean) | |
|---|---|---|
| Before Infusion sgACC-PCC connectivity | After Infusion sgACC-PCC connectivity | |
| Depression | 0.3459 | 0.3208 |
| Initial MRI | 0.3114 | -0.4424 |
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
169 reviews available for ketamine and Depressive Disorder, Major
| Article | Year |
|---|---|
Repurposing of Drugs-The Ketamine Story.
Topics: Anesthetics, Dissociative; Animals; Antidepressive Agents; Brain; Depressive Disorder, Major; Drug R | 2020 |
Evaluating the Role of Ketamine/Esketamine in the Management of Major Depressive Disorder with Suicide Risk.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depressive Disorder, Major; Disease Mana | 2021 |
Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review.
Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, G | 2021 |
The rapid anti-suicidal ideation effect of ketamine: A systematic review.
Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine; Suicidal Ideation; Suicide, Att | 2021 |
Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effects.
Topics: Antidepressive Agents; Bipolar Disorder; Depression; Depressive Disorder, Major; Humans; Ketamine | 2021 |
Sex Differences in the Behavioral, Molecular, and Structural Effects of Ketamine Treatment in Depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Female; Humans; Ketamine; Male; Sex Characteristi | 2022 |
The Effects of Ketamine on Cognition in Unipolar and Bipolar Depression: A Systematic Review.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Bipolar Disorder; Cognition; Depressive Disord | 2022 |
Connexin 43: insights into candidate pathological mechanisms of depression and its implications in antidepressant therapy.
Topics: Animals; Antidepressive Agents; Astrocytes; Connexin 43; Connexins; Depression; Depressive Disorder, | 2022 |
Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress.
Topics: Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Meta-Analysi | 2022 |
[Practical aspects of ketamine treatment-Safety, combination treatment and comorbidities].
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicidal Idea | 2022 |
Is (R)-ketamine a potential therapeutic agent for treatment-resistant depression with less detrimental side effects? A review of molecular mechanisms underlying ketamine and its enantiomers.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, N-Methyl | 2022 |
Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how?
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Suicidal Ideation | 2022 |
Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Female; Humans; Ketamine; Male | 2022 |
Rapid treatments for depression: Endocannabinoid system as a therapeutic target.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Endocannabinoids; Humans; Ketamine | 2022 |
The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: a systematic review and meta-analysis.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; | 2022 |
Potential advantages of ketamine over electroconvulsive therapy in the treatment of nonrefractory severe depression in older patients with multiple medical comorbidities.
Topics: Aged; Clinical Deterioration; Depression; Depressive Disorder, Major; Electroconvulsive Therapy; Fem | 2023 |
Craving and addictive potential of esketamine as side effects?
Topics: Adult; Bupropion; Craving; Depressive Disorder, Major; Drug-Related Side Effects and Adverse Reactio | 2022 |
The antidepressant effect and safety of non-intranasal esketamine: A systematic review.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; | 2022 |
Ketamine for resistant depression: a scoping review.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine | 2022 |
A Systematic Review of Neurocognitive Effects of Subanesthetic Doses of Intravenous Ketamine in Major Depressive Disorder, Post-Traumatic Stress Disorder, and Healthy Population.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Recept | 2022 |
Translational control by ketamine and its implications for comorbid cognitive deficits in depressive disorders.
Topics: Antidepressive Agents; Cognition; Depression; Depressive Disorder, Major; Humans; Ketamine; Mechanis | 2023 |
Imaging synaptic density in depression.
Topics: Depression; Depressive Disorder, Major; Humans; Ketamine; Neuroimaging; Positron-Emission Tomography | 2023 |
Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression.
Topics: Adult; Aripiprazole; Depression; Depressive Disorder, Major; Humans; Ketamine; Risperidone | 2023 |
New investigational agents for the treatment of major depressive disorder.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Hallucinogens; Humans; Ketamine; Rece | 2022 |
Arketamine, a new rapid-acting antidepressant: A historical review and future directions.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatme | 2022 |
BDNF Alterations in Brain Areas and the Neurocircuitry Involved in the Antidepressant Effects of Ketamine in Animal Models, Suggest the Existence of a Primary Circuit of Depression.
Topics: Animals; Antidepressive Agents; Brain; Brain-Derived Neurotrophic Factor; Depression; Depressive Dis | 2022 |
Antidepressant Effect of Ketamine on Inflammation-Mediated Cytokine Dysregulation in Adults with Treatment-Resistant Depression: Rapid Systematic Review.
Topics: Adult; Antidepressive Agents; Biomarkers; Cytokines; Depression; Depressive Disorder, Major; Humans; | 2022 |
Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode: A Systematic Review and Meta-analysis.
Topics: Depressive Disorder, Major; Electroconvulsive Therapy; Humans; Ketamine; Randomized Controlled Trial | 2022 |
Does route of administration affect antidepressant efficacy of ketamine? A meta-analysis of double-blind randomized controlled trials comparing intravenous and intranasal administration.
Topics: Administration, Intranasal; Depressive Disorder, Major; Humans; Ketamine; Randomized Controlled Tria | 2022 |
The Downstaging Concept in Treatment-Resistant Depression: Spotlight on Ketamine.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2022 |
The Downstaging Concept in Treatment-Resistant Depression: Spotlight on Ketamine.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2022 |
The Downstaging Concept in Treatment-Resistant Depression: Spotlight on Ketamine.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2022 |
The Downstaging Concept in Treatment-Resistant Depression: Spotlight on Ketamine.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2022 |
Rapidity of Symptom Improvement With Intranasal Esketamine for Major Depressive Disorder: A Systematic Review and Meta-Analysis.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Humans; Ketamine; Randomized | 2022 |
Rapidity of Symptom Improvement With Intranasal Esketamine for Major Depressive Disorder: A Systematic Review and Meta-Analysis.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Humans; Ketamine; Randomized | 2022 |
Rapidity of Symptom Improvement With Intranasal Esketamine for Major Depressive Disorder: A Systematic Review and Meta-Analysis.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Humans; Ketamine; Randomized | 2022 |
Rapidity of Symptom Improvement With Intranasal Esketamine for Major Depressive Disorder: A Systematic Review and Meta-Analysis.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Humans; Ketamine; Randomized | 2022 |
Role of the mesolimbic dopamine pathway in the antidepressant effects of ketamine.
Topics: Antidepressive Agents; Brain; Depressive Disorder, Major; Dopamine; Humans; Ketamine; Receptors, N-M | 2023 |
Role of the mesolimbic dopamine pathway in the antidepressant effects of ketamine.
Topics: Antidepressive Agents; Brain; Depressive Disorder, Major; Dopamine; Humans; Ketamine; Receptors, N-M | 2023 |
Role of the mesolimbic dopamine pathway in the antidepressant effects of ketamine.
Topics: Antidepressive Agents; Brain; Depressive Disorder, Major; Dopamine; Humans; Ketamine; Receptors, N-M | 2023 |
Role of the mesolimbic dopamine pathway in the antidepressant effects of ketamine.
Topics: Antidepressive Agents; Brain; Depressive Disorder, Major; Dopamine; Humans; Ketamine; Receptors, N-M | 2023 |
Biomarkers of ketamine's antidepressant effect: An umbrella review.
Topics: Antidepressive Agents; Biomarkers; Depression; Depressive Disorder, Major; Humans; Ketamine | 2023 |
Biomarkers of ketamine's antidepressant effect: An umbrella review.
Topics: Antidepressive Agents; Biomarkers; Depression; Depressive Disorder, Major; Humans; Ketamine | 2023 |
Biomarkers of ketamine's antidepressant effect: An umbrella review.
Topics: Antidepressive Agents; Biomarkers; Depression; Depressive Disorder, Major; Humans; Ketamine | 2023 |
Biomarkers of ketamine's antidepressant effect: An umbrella review.
Topics: Antidepressive Agents; Biomarkers; Depression; Depressive Disorder, Major; Humans; Ketamine | 2023 |
mGlu2/3 receptor antagonists for depression: overview of underlying mechanisms and clinical development.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, Metabotr | 2023 |
Differentially regulated targets in the fast-acting antidepressant effect of (R)-ketamine: A systems biology approach.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, AMPA; Re | 2023 |
Neuroimaging-Derived Biomarkers of the Antidepressant Effects of Ketamine.
Topics: Antidepressive Agents; Biomarkers; Depressive Disorder, Major; Humans; Ketamine; Neuroimaging | 2023 |
Arketamine for cognitive impairment in psychiatric disorders.
Topics: Animals; Antidepressive Agents; Cognitive Dysfunction; Depressive Disorder, Major; Ketamine; Mice | 2023 |
Role of group II metabotropic glutamate receptors in ketamine's antidepressant actions.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; Ketamine; Receptors, Metabot | 2023 |
Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties?
Topics: Antidepressive Agents; Bipolar Disorder; Depression; Depressive Disorder, Major; Depressive Disorder | 2023 |
Efficacy and adverse effects of ketamine versus electroconvulsive therapy for major depressive disorder: A systematic review and meta-analysis.
Topics: Antidepressive Agents; Depressive Disorder, Major; Electroconvulsive Therapy; Humans; Ketamine; Myal | 2023 |
[Contribution of serotonin 5-HT
Topics: Antidepressive Agents; Depressive Disorder, Major; Hallucinations; Hallucinogens; Humans; Ketamine; | 2023 |
Ketamine vs Electroconvulsive Therapy for Major Depressive Episode: A Systematic Review and Meta-analysis.
Topics: Adult; Depressive Disorder, Major; Electroconvulsive Therapy; Humans; Ketamine | 2023 |
The role of ketamine in major depressive disorders: Effects on parvalbumin-positive interneurons in hippocampus.
Topics: Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Hippocampus; H | 2023 |
The use of esketamine in the treatment of patients with severe depression and suicidal ideation: systematic review and meta-analysis.
Topics: Depression; Depressive Disorder, Major; Humans; Ketamine; Suicidal Ideation | 2023 |
Contribution of the opioid system to depression and to the therapeutic effects of classical antidepressants and ketamine.
Topics: Analgesics, Opioid; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; | 2023 |
Molecular mechanisms of rapid-acting antidepressants: New perspectives for developing antidepressants.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Disease Models, Animal; Ketamine; Mice; | 2023 |
Storm on predictive brain: A neurocomputational account of ketamine antidepressant effect.
Topics: Antidepressive Agents; Brain; Depressive Disorder, Major; Humans; Ketamine; Receptors, N-Methyl-D-As | 2023 |
[Ketamine: a neuropsychotropic drug with an innovative mechanism of action].
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Glutamic Acid; Ketamine; N-Methylasparta | 2023 |
[Interest and mechanisms of action of ketamine in alcohol addiction- A review of clinical and preclinical studies].
Topics: Alcoholism; Antidepressive Agents; Depressive Disorder, Major; Ethanol; Female; Hallucinogens; Human | 2023 |
Rodent ketamine depression-related research: Finding patterns in a literature of variability.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; Disease Models, Animal; Huma | 2019 |
Ketamine in the Treatment of Depressive Episodes.
Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine | 2020 |
Role of copper and ketamine in major depressive disorder - an update.
Topics: Antidepressive Agents; Copper; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2019 |
Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Dis | 2020 |
Leptin, obesity, and response to ketamine.
Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine; Leptin; Obesity | 2020 |
Neurophysiologic Advance in Depressive Disorder.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine; Neuronal Plasticity | 2019 |
Adjunctive intranasal esketamine for major depressive disorder: A systematic review of randomized double-blind controlled-placebo studies.
Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine; Ran | 2020 |
An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine.
Topics: Administration, Intranasal; Antidepressive Agents; Clinical Trials as Topic; Databases, Factual; Dep | 2020 |
Ketamine: The final frontier or another depressing end?
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dopamin | 2020 |
Maintaining Rapid Antidepressant Effects Following Ketamine Infusion: A Major Unmet Need.
Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine; Randomized Controlled Trials as | 2020 |
Ketamine: Leading us into the future for development of antidepressants.
Topics: Allosteric Regulation; Animals; Antidepressive Agents; Depressive Disorder, Major; Depressive Disord | 2020 |
Safety and Tolerability of Ketamine Use in Treatment-Resistant Bipolar Depression Patients with Regard to Central Nervous System Symptomatology: Literature Review and Analysis.
Topics: Administration, Intravenous; Administration, Oral; Antidepressive Agents; Bipolar Disorder; Comorbid | 2020 |
The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Dissociative Disorders; Humans; | 2020 |
Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
Topics: Antidepressive Agents; Brain; Cholinergic Neurons; Depressive Disorder, Major; Depressive Disorder, | 2020 |
Rapid anti-depressant-like effects of ketamine and other candidates: Molecular and cellular mechanisms.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine | 2020 |
Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Ketamine; Randomized Controlled | 2020 |
Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis.
Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, | 2020 |
Ketamine as a mental health treatment: Are acute psychoactive effects associated with outcomes? A systematic review.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2020 |
Targeting Homeostatic Synaptic Plasticity for Treatment of Mood Disorders.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Treatm | 2020 |
Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment.
Topics: Administration, Intranasal; Antidepressive Agents; Antipsychotic Agents; Depressive Disorder, Major; | 2020 |
Clinical overview of NMDA-R antagonists and clinical practice.
Topics: Antidepressive Agents; Depressive Disorder, Major; Glutamic Acid; Humans; Ketamine; Practice Pattern | 2020 |
Chronic stress pathology and ketamine-induced alterations in functional connectivity in major depressive disorder: An abridged review of the clinical evidence.
Topics: Antidepressive Agents; Chronic Disease; Depressive Disorder, Major; Humans; Ketamine; Nerve Net; Str | 2020 |
Rapid acting antidepressants in the mTOR pathway: Current evidence.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Drug Administration Routes; Humans; Keta | 2020 |
Neurocognitive impact of ketamine treatment in major depressive disorder: A review on human and animal studies.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant | 2020 |
Effectiveness and Safety of Ketamine for Unipolar Depression: a Systematic Review.
Topics: Antidepressive Agents; Depressive Disorder, Major; Electroconvulsive Therapy; Humans; Ketamine; Trea | 2020 |
The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2020 |
Effects of Ketamine on Rodent Fear Memory.
Topics: Analgesics; Anesthetics, Dissociative; Animals; Depressive Disorder, Major; Drug Administration Rout | 2020 |
An Update on the Efficacy and Tolerability of Oral Ketamine for Major Depression: A Systematic Review and Meta-Analysis.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Female; Humans; Ketamine; Male | 2020 |
Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine | 2021 |
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et
Topics: Adult; Antidepressive Agents; Anxiety; Canada; Depressive Disorder, Major; Humans; Ketamine | 2021 |
The time course of psychotic symptom side effects of ketamine in the treatment of depressive disorders: a systematic review and meta-analysis.
Topics: Depressive Disorder, Major; Humans; Ketamine | 2021 |
Esketamine for treatment-resistant depression.
Topics: Adult; Aged; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Depressive | 2020 |
The Ketamine Antidepressant Story: New Insights.
Topics: Animals; Antidepressive Agents; Biomarkers; Depressive Disorder, Major; Disease Susceptibility; Huma | 2020 |
The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis.
Topics: Bipolar Disorder; Depression; Depressive Disorder, Major; Humans; Ketamine; Suicidal Ideation | 2021 |
[A review of the antidepressant properties of ketamine].
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; History, 20th Century; Histo | 2021 |
Neurobiology of the Rapid-Acting Antidepressant Effects of Ketamine: Impact and Opportunities.
Topics: Antidepressive Agents; Brain; Depressive Disorder, Major; Humans; Ketamine; Neurobiology | 2021 |
Intranasal esketamine: From origins to future implications in treatment-resistant depression.
Topics: Administration, Intranasal; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-R | 2021 |
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
Topics: Antidepressive Agents; Delivery of Health Care; Depressive Disorder, Major; Depressive Disorder, Tre | 2021 |
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
Topics: Antidepressive Agents; Delivery of Health Care; Depressive Disorder, Major; Depressive Disorder, Tre | 2021 |
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
Topics: Antidepressive Agents; Delivery of Health Care; Depressive Disorder, Major; Depressive Disorder, Tre | 2021 |
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
Topics: Antidepressive Agents; Delivery of Health Care; Depressive Disorder, Major; Depressive Disorder, Tre | 2021 |
Antisuicidal and antidepressant effects of ketamine and esketamine in patients with baseline suicidality: A systematic review.
Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine; Randomized Controlled Trials as | 2021 |
Efficacy of ketamine for major depressive episodes at 2, 4, and 6-weeks post-treatment: A meta-analysis.
Topics: Affect; Clinical Trials as Topic; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Hum | 2021 |
The anterior cingulate cortex as a key locus of ketamine's antidepressant action.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Gyrus Cinguli; Humans; Ketamine | 2021 |
Therapeutic potential of ketamine for alcohol use disorder.
Topics: Adult; Alcoholism; Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine; Receptors, N | 2021 |
Update on Ketamine.
Topics: Analgesia; Anesthesia; Depressive Disorder, Major; Humans; Ketamine | 2020 |
A translational perspective on the anti-anhedonic effect of ketamine and its neural underpinnings.
Topics: Anhedonia; Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine; Receptors, N-Methyl- | 2022 |
Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders.
Topics: Allosteric Regulation; Animals; Anxiety Disorders; Brain; Depressive Disorder, Major; Depressive Dis | 2021 |
Ketamine's effect on inflammation and kynurenine pathway in depression: A systematic review.
Topics: Animals; Anti-Inflammatory Agents; Antidepressive Agents; Bipolar Disorder; Cytokines; Depressive Di | 2021 |
Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium.
Topics: Antidepressive Agents; Antipsychotic Agents; Depressive Disorder, Major; Depressive Disorder, Treatm | 2021 |
Adjunctive ketamine in electroconvulsive therapy: updated systematic review and meta-analysis.
Topics: Combined Modality Therapy; Confusion; Depressive Disorder, Major; Electroconvulsive Therapy; Humans; | 2017 |
New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity.
Topics: Animals; Antidepressive Agents; Brain; Clinical Trials as Topic; Depressive Disorder, Major; Disease | 2017 |
Ketamine for Depression, 2: Diagnostic and Contextual Indications.
Topics: Antidepressive Agents; Bipolar Disorder; Clinical Trials as Topic; Depressive Disorder, Major; Drug | 2017 |
Ketamine for Depression, 4: In What Dose, at What Rate, by What Route, for How Long, and at What Frequency?
Topics: Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administra | 2017 |
Ketamine for Depression, 5: Potential Pharmacokinetic and Pharmacodynamic Drug Interactions.
Topics: Antidepressive Agents; Benzodiazepines; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Depressive | 2017 |
The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.
Topics: Adult; Depression; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Female; Humans; In | 2018 |
The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.
Topics: Adult; Depression; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Female; Humans; In | 2018 |
The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.
Topics: Adult; Depression; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Female; Humans; In | 2018 |
The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.
Topics: Adult; Depression; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Female; Humans; In | 2018 |
The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.
Topics: Adult; Depression; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Female; Humans; In | 2018 |
The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.
Topics: Adult; Depression; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Female; Humans; In | 2018 |
The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.
Topics: Adult; Depression; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Female; Humans; In | 2018 |
The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.
Topics: Adult; Depression; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Female; Humans; In | 2018 |
The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.
Topics: Adult; Depression; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Female; Humans; In | 2018 |
Metabotropic Glutamatergic Receptor 5 and Stress Disorders: Knowledge Gained From Receptor Imaging Studies.
Topics: Antidepressive Agents; Brain; Carbon Radioisotopes; Depression; Depressive Disorder, Major; Excitato | 2018 |
General Anesthetics to Treat Major Depressive Disorder: Clinical Relevance and Underlying Mechanisms.
Topics: Anesthesia, Intravenous; Anesthetics, General; Brain; Depressive Disorder, Major; Electroconvulsive | 2018 |
A brief history of antidepressant drug development: from tricyclics to beyond ketamine.
Topics: Animals; Antidepressive Agents, Tricyclic; Biogenic Monoamines; Brain; Depressive Disorder, Major; D | 2018 |
Comparison of the effect of intravenous anesthetics used for anesthesia during electroconvulsive therapy on the hemodynamic safety and the course of ECT.
Topics: Anesthetics; Anesthetics, Intravenous; Autonomic Nervous System; Bipolar Disorder; Depressive Disord | 2017 |
[The importance of the ketamine in depressive disorders].
Topics: Depressive Disorder, Major; Humans; Ketamine | 2018 |
Is Ketamine the Future Clozapine for Depression? A Case Series and Literature Review on Maintenance Ketamine in Treatment-resistant Depression With Suicidal Behavior.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Tre | 2018 |
Decoding the Mechanism of Action of Rapid-Acting Antidepressant Treatment Strategies: Does Gender Matter?
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Electroconvulsive Therapy; Female; Human | 2019 |
Adjunctive ketamine and electroconvulsive therapy for major depressive disorder: A meta-analysis of randomized controlled trials.
Topics: Adult; Anesthetics, Dissociative; Combined Modality Therapy; Depression; Depressive Disorder, Major; | 2019 |
Regulation of Circadian Genes by the MAPK Pathway: Implications for Rapid Antidepressant Action.
Topics: Affect; Animals; Antidepressive Agents; Circadian Rhythm; Depressive Disorder, Major; Humans; Ketami | 2020 |
Novel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System.
Topics: Depression; Depressive Disorder, Major; Excitatory Amino Acid Agents; Glutamic Acid; Humans; Ketamin | 2019 |
Role of Serotonergic System in the Antidepressant Actions of mGlu2/3 Receptor Antagonists: Similarity to Ketamine.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine; Receptors, Metabotropi | 2019 |
Neurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; Glutamic Acid; Humans; Ketam | 2019 |
Oral Ketamine for Depression: A Systematic Review.
Topics: Administration, Oral; Adolescent; Adult; Bipolar Disorder; Depressive Disorder, Major; Dose-Response | 2019 |
Scientific Issues Relevant to Improving the Diagnosis, Risk Assessment, and Treatment of Major Depression.
Topics: Antidepressive Agents; Anxiety; Biomedical Research; Depressive Disorder, Major; Diagnostic and Stat | 2019 |
Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid | 2019 |
An update on NMDA antagonists in depression.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Human | 2019 |
Evaluation of the Wistar-Kyoto rat model of depression and the role of synaptic plasticity in depression and antidepressant response.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Disease Models, Animal; Hippocampus; Ket | 2019 |
Ketamine, magnesium and major depression--from pharmacology to pathophysiology and back.
Topics: Animals; Brain; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketamine; Mag | 2013 |
Current status of ketamine and related compounds for depression.
Topics: Bipolar Disorder; Chemistry, Pharmaceutical; Depressive Disorder, Major; Humans; Ketamine | 2013 |
Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Circadian Rhythm; Depressive Diso | 2013 |
Novel therapeutic strategies in major depression: focus on RNAi and ketamine.
Topics: Animals; Antidepressive Agents; Clinical Trials as Topic; Deep Brain Stimulation; Depressive Disorde | 2014 |
Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.
Topics: Animals; Antidepressive Agents; Biomarkers, Pharmacological; Depressive Disorder, Major; Excitatory | 2014 |
Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.
Topics: Animals; Antidepressive Agents; Biomarkers, Pharmacological; Depressive Disorder, Major; Excitatory | 2014 |
Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.
Topics: Animals; Antidepressive Agents; Biomarkers, Pharmacological; Depressive Disorder, Major; Excitatory | 2014 |
Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.
Topics: Animals; Antidepressive Agents; Biomarkers, Pharmacological; Depressive Disorder, Major; Excitatory | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
Targeting of NMDA receptors in the treatment of major depression.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Drug Resistance; Humans; Ketamine; Molec | 2014 |
The role of mTOR in depression and antidepressant responses.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Human | 2014 |
[Ketamine in acute and severe major depressive disorder].
Topics: Acute Disease; Clinical Trials as Topic; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2014 |
NMDA antagonists under investigation for the treatment of major depressive disorder.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Drug Design; Drug Resistance; Excitatory | 2014 |
A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes.
Topics: Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketamine; Randomized Controll | 2015 |
A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes.
Topics: Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketamine; Randomized Controll | 2015 |
A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes.
Topics: Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketamine; Randomized Controll | 2015 |
A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes.
Topics: Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketamine; Randomized Controll | 2015 |
A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes.
Topics: Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketamine; Randomized Controll | 2015 |
A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes.
Topics: Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketamine; Randomized Controll | 2015 |
A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes.
Topics: Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketamine; Randomized Controll | 2015 |
A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes.
Topics: Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketamine; Randomized Controll | 2015 |
A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes.
Topics: Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketamine; Randomized Controll | 2015 |
A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes.
Topics: Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketamine; Randomized Controll | 2015 |
A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes.
Topics: Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketamine; Randomized Controll | 2015 |
A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes.
Topics: Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketamine; Randomized Controll | 2015 |
A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes.
Topics: Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketamine; Randomized Controll | 2015 |
A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes.
Topics: Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketamine; Randomized Controll | 2015 |
A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes.
Topics: Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketamine; Randomized Controll | 2015 |
A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes.
Topics: Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketamine; Randomized Controll | 2015 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Multistage drug effects of ketamine in the treatment of major depression.
Topics: Analgesics; Brain; Depressive Disorder, Major; Humans; Ketamine; Time Factors; Treatment Outcome | 2014 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Proceed with caution: off-label ketamine treatment for major depressive disorder.
Topics: Depressive Disorder, Major; Humans; Ketamine; Off-Label Use; Receptors, N-Methyl-D-Aspartate | 2014 |
Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.
Topics: Antidepressive Agents; Brain; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2015 |
Circadian dysregulation of clock genes: clues to rapid treatments in major depressive disorder.
Topics: Animals; Antidepressive Agents; Chronobiology Disorders; CLOCK Proteins; Depressive Disorder, Major; | 2015 |
Circadian dysregulation of clock genes: clues to rapid treatments in major depressive disorder.
Topics: Animals; Antidepressive Agents; Chronobiology Disorders; CLOCK Proteins; Depressive Disorder, Major; | 2015 |
Circadian dysregulation of clock genes: clues to rapid treatments in major depressive disorder.
Topics: Animals; Antidepressive Agents; Chronobiology Disorders; CLOCK Proteins; Depressive Disorder, Major; | 2015 |
Circadian dysregulation of clock genes: clues to rapid treatments in major depressive disorder.
Topics: Animals; Antidepressive Agents; Chronobiology Disorders; CLOCK Proteins; Depressive Disorder, Major; | 2015 |
Ketamine-an update on its clinical uses and abuses.
Topics: Analgesics; Animals; Asthma; Depressive Disorder, Major; Gastrointestinal Tract; Humans; Ketamine; P | 2014 |
How does ketamine elicit a rapid antidepressant response?
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Human | 2015 |
Ketamine and other potential glutamate antidepressants.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Glutamic Acid; Humans; Ketamine; Memanti | 2015 |
The promise of ketamine for treatment-resistant depression: current evidence and future directions.
Topics: Anhedonia; Antidepressive Agents; Cognition; Depressive Disorder, Major; Depressive Disorder, Treatm | 2015 |
The use of ketamine as an antidepressant: a systematic review and meta-analysis.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2015 |
Inflammatory biomarkers as differential predictors of antidepressant response.
Topics: Antidepressive Agents; Biomarkers; C-Reactive Protein; Cytokines; Depressive Disorder, Major; Humans | 2015 |
Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition.
Topics: Animals; Antidepressive Agents; Brain; Depressive Disorder, Major; Depressive Disorder, Treatment-Re | 2016 |
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketami | 2015 |
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketami | 2015 |
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketami | 2015 |
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketami | 2015 |
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketami | 2015 |
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketami | 2015 |
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketami | 2015 |
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketami | 2015 |
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketami | 2015 |
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketami | 2015 |
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketami | 2015 |
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketami | 2015 |
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketami | 2015 |
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketami | 2015 |
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketami | 2015 |
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketami | 2015 |
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketami | 2015 |
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketami | 2015 |
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketami | 2015 |
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketami | 2015 |
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketami | 2015 |
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketami | 2015 |
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketami | 2015 |
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketami | 2015 |
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketami | 2015 |
Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis.
Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine; Randomized Controlled Trials as | 2016 |
Strategies to mitigate dissociative and psychotomimetic effects of ketamine in the treatment of major depressive episodes: a narrative review.
Topics: Depressive Disorder, Major; Drug-Related Side Effects and Adverse Reactions; Excitatory Amino Acid A | 2017 |
A Bayesian framework systematic review and meta-analysis of anesthetic agents effectiveness/tolerability profile in electroconvulsive therapy for major depression.
Topics: Anesthetics; Bayes Theorem; Depressive Disorder, Major; Electroconvulsive Therapy; Electroencephalog | 2016 |
Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; Excitatory Amino Acid Agents | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Molecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Gene Expression Regulation; Humans; Keta | 2017 |
Ketamine for treatment-resistant depression: recent developments and clinical applications.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; | 2016 |
Ketamine for treatment-resistant depression: recent developments and clinical applications.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; | 2016 |
Ketamine for treatment-resistant depression: recent developments and clinical applications.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; | 2016 |
Ketamine for treatment-resistant depression: recent developments and clinical applications.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; | 2016 |
KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Human | 2016 |
KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Human | 2016 |
KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Human | 2016 |
KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Human | 2016 |
KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Human | 2016 |
KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Human | 2016 |
KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Human | 2016 |
KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Human | 2016 |
KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Human | 2016 |
KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment- | 2016 |
Glutamate-Based Drug Discovery for Novel Antidepressants.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Drug Design; Drug Discovery; Glutamic Ac | 2016 |
Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; gamma-Aminobutyric Acid; Glutamic Acid; | 2017 |
Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; gamma-Aminobutyric Acid; Glutamic Acid; | 2017 |
Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; gamma-Aminobutyric Acid; Glutamic Acid; | 2017 |
Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; gamma-Aminobutyric Acid; Glutamic Acid; | 2017 |
[Clinical and biological predictors of ketamine response in treatment-resistant major depression: Review].
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Gene Ex | 2017 |
Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion.
Topics: Adult; Alcohol-Related Disorders; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Majo | 2017 |
Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant.
Topics: Animals; Antidepressive Agents; Cognition Disorders; Depressive Disorder, Major; Humans; Ketamine; S | 2016 |
Investigational drugs for treating major depressive disorder.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Drug Design; Drugs, Investigational; Exc | 2017 |
Targeting glutamate signalling in depression: progress and prospects.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Drug Design; Excitatory Amino Acid Antag | 2017 |
Ketamine and the next generation of antidepressants with a rapid onset of action.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Antidepressive Agents; Depressive Disorder | 2009 |
Ketamine and the next generation of antidepressants with a rapid onset of action.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Antidepressive Agents; Depressive Disorder | 2009 |
Ketamine and the next generation of antidepressants with a rapid onset of action.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Antidepressive Agents; Depressive Disorder | 2009 |
Ketamine and the next generation of antidepressants with a rapid onset of action.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Antidepressive Agents; Depressive Disorder | 2009 |
Ketamine and the next generation of antidepressants with a rapid onset of action.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Antidepressive Agents; Depressive Disorder | 2009 |
Ketamine and the next generation of antidepressants with a rapid onset of action.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Antidepressive Agents; Depressive Disorder | 2009 |
Ketamine and the next generation of antidepressants with a rapid onset of action.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Antidepressive Agents; Depressive Disorder | 2009 |
Ketamine and the next generation of antidepressants with a rapid onset of action.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Antidepressive Agents; Depressive Disorder | 2009 |
Ketamine and the next generation of antidepressants with a rapid onset of action.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Antidepressive Agents; Depressive Disorder | 2009 |
Emerging role of glutamate in the pathophysiology of major depressive disorder.
Topics: Brain; Depressive Disorder, Major; Glutamic Acid; Humans; Ketamine; Memantine; Receptors, AMPA; Rece | 2009 |
Intravenous ketamine for treatment-resistant major depressive disorder.
Topics: Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Tr | 2012 |
mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Agents; Humans; Ke | 2013 |
Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.
Topics: Antidepressive Agents; Depressive Disorder, Major; Glutamic Acid; Humans; Ketamine; Molecular Target | 2012 |
Glutamatergic approaches in major depressive disorder: focus on ketamine, memantine and riluzole.
Topics: Animals; Antidepressive Agents; Brain; Depressive Disorder, Major; Excitatory Amino Acid Antagonists | 2012 |
Ketamine as an alternative treatment for treatment-resistant depression.
Topics: Antidepressive Agents; Bipolar Disorder; Brain; Depressive Disorder, Major; Depressive Disorder, Tre | 2013 |
The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects.
Topics: Amantadine; Depressive Disorder, Major; Dopamine Agents; Excitatory Amino Acid Antagonists; Humans; | 2007 |
141 trials available for ketamine and Depressive Disorder, Major
| Article | Year |
|---|---|
Relationships between reduction in symptoms and restoration of function and wellbeing: Outcomes of the Oral Ketamine Trial on Suicidality (OKTOS).
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine; Recovery of Function; Su | 2021 |
Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment | 2021 |
Ketamine vs midazolam: Mood improvement reduces suicidal ideation in depression.
Topics: Depression; Depressive Disorder, Major; Humans; Ketamine; Midazolam; Suicidal Ideation | 2022 |
Racemic Ketamine as an Alternative to Electroconvulsive Therapy for Unipolar Depression: A Randomized, Open-Label, Non-Inferiority Trial (KetECT).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Major; Depre | 2022 |
mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Mechanistic Target | 2022 |
Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression.
Topics: Adult; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blin | 2022 |
The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder.
Topics: Antidepressive Agents; Automobile Driving; Cross-Over Studies; Depressive Disorder, Major; Double-Bl | 2022 |
Different symptomatic improvement pattern revealed by factor analysis between placebo response and response to Esketamine in treatment resistant depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2022 |
Magnetoencephalography biomarkers of suicide attempt history and antidepressant response to ketamine in treatment-resistant major depression.
Topics: Antidepressive Agents; Biomarkers; Depression; Depressive Disorder, Major; Humans; Ketamine; Magneto | 2022 |
Association between peripheral inflammation and free-water imaging in Major Depressive Disorder before and after ketamine treatment - A pilot study.
Topics: Depressive Disorder, Major; Humans; Inflammation; Interleukin-10; Interleukin-8; Ketamine; Pilot Pro | 2022 |
Comparative study of low-dose ketamine infusion and repetitive transcranial magnetic stimulation in treatment-resistant depression: A posthoc pooled analysis of two randomized, double-blind, placebo-controlled studies.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2022 |
Baseline Plasma BDNF Levelsare Associated with Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Major Depressive Disorder.
Topics: Administration, Intravenous; Anhedonia; Brain-Derived Neurotrophic Factor; Depressive Disorder, Majo | 2023 |
Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study.
Topics: Antidepressive Agents; Benzodiazepines; Depressive Disorder, Major; Double-Blind Method; Humans; Inf | 2022 |
Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study.
Topics: Antidepressive Agents; Benzodiazepines; Depressive Disorder, Major; Double-Blind Method; Humans; Inf | 2022 |
Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study.
Topics: Antidepressive Agents; Benzodiazepines; Depressive Disorder, Major; Double-Blind Method; Humans; Inf | 2022 |
Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study.
Topics: Antidepressive Agents; Benzodiazepines; Depressive Disorder, Major; Double-Blind Method; Humans; Inf | 2022 |
Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study.
Topics: Antidepressive Agents; Benzodiazepines; Depressive Disorder, Major; Double-Blind Method; Humans; Inf | 2022 |
Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study.
Topics: Antidepressive Agents; Benzodiazepines; Depressive Disorder, Major; Double-Blind Method; Humans; Inf | 2022 |
Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study.
Topics: Antidepressive Agents; Benzodiazepines; Depressive Disorder, Major; Double-Blind Method; Humans; Inf | 2022 |
Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study.
Topics: Antidepressive Agents; Benzodiazepines; Depressive Disorder, Major; Double-Blind Method; Humans; Inf | 2022 |
Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study.
Topics: Antidepressive Agents; Benzodiazepines; Depressive Disorder, Major; Double-Blind Method; Humans; Inf | 2022 |
The efficacy and safety of esketamine in the treatment of major depressive disorder with suicidal ideation: study protocol for a randomized controlled trial.
Topics: Depressive Disorder, Major; Humans; Ketamine; Randomized Controlled Trials as Topic; Suicidal Ideati | 2022 |
The efficacy and safety of esketamine in the treatment of major depressive disorder with suicidal ideation: study protocol for a randomized controlled trial.
Topics: Depressive Disorder, Major; Humans; Ketamine; Randomized Controlled Trials as Topic; Suicidal Ideati | 2022 |
The efficacy and safety of esketamine in the treatment of major depressive disorder with suicidal ideation: study protocol for a randomized controlled trial.
Topics: Depressive Disorder, Major; Humans; Ketamine; Randomized Controlled Trials as Topic; Suicidal Ideati | 2022 |
The efficacy and safety of esketamine in the treatment of major depressive disorder with suicidal ideation: study protocol for a randomized controlled trial.
Topics: Depressive Disorder, Major; Humans; Ketamine; Randomized Controlled Trials as Topic; Suicidal Ideati | 2022 |
Spectral Changes of EEG Following a 6-Week Low-Dose Oral Ketamine Treatment in Adults With Major Depressive Disorder and Chronic Suicidality.
Topics: Adult; Depressive Disorder, Major; Electroencephalography; Humans; Ketamine; Suicidal Ideation; Suic | 2023 |
The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression.
Topics: Adolescent; Adult; Antidepressive Agents; Child; Depression; Depressive Disorder, Major; Depressive | 2023 |
A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2023 |
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.
Topics: Administration, Intravenous; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, | 2023 |
Subanesthetic Dose of Ketamine Administered Before Each Electroconvulsive Therapy Session Improves Antidepressant and Sleep Quality Outcomes: A Randomized, Controlled Trial.
Topics: Antidepressive Agents; Depressive Disorder, Major; Electroconvulsive Therapy; Humans; Ketamine; Psyc | 2023 |
Baseline cognitive function predicts full remission of suicidal symptoms among patients with treatment-resistant depression and strong suicidal ideation after low-dose ketamine infusion.
Topics: Antidepressive Agents; Cognition; Depression; Depressive Disorder, Major; Depressive Disorder, Treat | 2023 |
The efficacy of oral ketamine in severely depressed patients at high risk of suicide.
Topics: Depressive Disorder, Major; Humans; Ketamine; Prospective Studies; Suicidal Ideation; Suicide | 2023 |
Arketamine for bipolar depression: Open-label, dose-escalation, pilot study.
Topics: Antidepressive Agents; Bipolar Disorder; Depression; Depressive Disorder, Major; Double-Blind Method | 2023 |
The effects of esketamine and treatment expectation in acute major depressive disorder (Expect): study protocol for a pharmacological fMRI study using a balanced placebo design.
Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine; Magnetic Resonance Imaging; Tre | 2023 |
Role of klotho on antidepressant and antisuicidal effects of low-dose ketamine infusion among patients with treatment-resistant depression and suicidal ideation.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2023 |
The Study of Ketamine for Youth Depression (SKY-D): study protocol for a randomised controlled trial of low-dose ketamine for young people with major depressive disorder.
Topics: Adolescent; Australia; Depression; Depressive Disorder, Major; Humans; Infant; Ketamine; Randomized | 2023 |
Subcutaneous ketamine infusion in palliative patients for major depressive disorder (SKIPMDD)-Phase II single-arm open-label feasibility study.
Topics: Adolescent; Adult; Antidepressive Agents; Australia; Depressive Disorder, Major; Depressive Disorder | 2023 |
Study protocol for Ketamine as an adjunctive therapy for major depression (2): a randomised controlled trial (KARMA-Dep [2]).
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Midazolam; Q | 2023 |
Ketamine metabolite pilot study in a suicidal depression trial.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; | 2019 |
Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo-control study.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Cycloserine; Depressive Disorder, Major; Depressive | 2019 |
Ketamine Enhances Visual Sensory Evoked Potential Long-term Potentiation in Patients With Major Depressive Disorder.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Double-Blind Method; E | 2020 |
Intermittent administration of low dose ketamine can shorten the course of electroconvulsive therapy for depression and reduce complications: A randomized controlled trial.
Topics: Adult; Anesthetics, Dissociative; Combined Modality Therapy; Depressive Disorder, Major; Dose-Respon | 2019 |
Effects of ketamine on circadian rhythm and synaptic homeostasis in patients with treatment-resistant depression: A protocol for mechanistic studies of its rapid and sustained antidepressant actions in humans.
Topics: Adolescent; Adult; Aged; Brain; Circadian Rhythm; Depressive Disorder, Major; Depressive Disorder, T | 2019 |
Ketamine for acute suicidal ideation. An emergency department intervention: A randomized, double-blind, placebo-controlled, proof-of-concept trial.
Topics: Depressive Disorder, Major; Double-Blind Method; Emergency Service, Hospital; Excitatory Amino Acid | 2020 |
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial.
Topics: Administration, Oral; Adult; Antidepressive Agents; Cost-Benefit Analysis; Depressive Disorder, Majo | 2019 |
Simultaneous EEG/fMRI recorded during ketamine infusion in patients with major depressive disorder.
Topics: Adolescent; Adult; Anesthetics, Dissociative; Cross-Over Studies; Depressive Disorder, Major; Double | 2020 |
Magnetoencephalographic Correlates of Suicidal Ideation in Major Depression.
Topics: Brain; Depression; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketamine; | 2020 |
Magnetoencephalographic Correlates of Suicidal Ideation in Major Depression.
Topics: Brain; Depression; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketamine; | 2020 |
Magnetoencephalographic Correlates of Suicidal Ideation in Major Depression.
Topics: Brain; Depression; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketamine; | 2020 |
Magnetoencephalographic Correlates of Suicidal Ideation in Major Depression.
Topics: Brain; Depression; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketamine; | 2020 |
Intravenous arketamine for treatment-resistant depression: open-label pilot study.
Topics: Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resis | 2021 |
Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin.
Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine; Mechanistic Target of Rapamycin | 2020 |
Cognitive function after electroconvulsive therapy for depression: relationship to clinical response.
Topics: Analgesics; Cognition; Depressive Disorder, Major; Electroconvulsive Therapy; Female; Humans; Ketami | 2021 |
Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression.
Topics: Antidepressive Agents; Cross-Over Studies; Depression; Depressive Disorder, Major; Humans; Ketamine | 2020 |
Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data.
Topics: Administration, Intranasal; Adolescent; Adult; Aged; Algorithms; Antidepressive Agents; Clinical Tri | 2020 |
Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I).
Topics: Administration, Intranasal; Adolescent; Adult; Antidepressive Agents; Depressive Disorder, Major; Do | 2020 |
A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol.
Topics: Biomarkers; Canada; Cross-Over Studies; Depression; Depressive Disorder, Major; Electroconvulsive Th | 2020 |
The effects of ketamine on typical and atypical depressive symptoms.
Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Metho | 2020 |
Cardiovascular effects of repeated subanaesthetic ketamine infusion in depression.
Topics: Antidepressive Agents; Bipolar Disorder; Blood Pressure; Cardiovascular System; Depressive Disorder, | 2021 |
Ketamine improves short-term plasticity in depression by enhancing sensitivity to prediction errors.
Topics: Adult; Cerebral Cortex; Cross-Over Studies; Depressive Disorder, Major; Double-Blind Method; Electro | 2020 |
Assessment of Relationship of Ketamine Dose With Magnetic Resonance Spectroscopy of Glx and GABA Responses in Adults With Major Depression: A Randomized Clinical Trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Female; gamma-Aminobutyric Acid; Glutamic | 2020 |
Assessment of Relationship of Ketamine Dose With Magnetic Resonance Spectroscopy of Glx and GABA Responses in Adults With Major Depression: A Randomized Clinical Trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Female; gamma-Aminobutyric Acid; Glutamic | 2020 |
Assessment of Relationship of Ketamine Dose With Magnetic Resonance Spectroscopy of Glx and GABA Responses in Adults With Major Depression: A Randomized Clinical Trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Female; gamma-Aminobutyric Acid; Glutamic | 2020 |
Assessment of Relationship of Ketamine Dose With Magnetic Resonance Spectroscopy of Glx and GABA Responses in Adults With Major Depression: A Randomized Clinical Trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Female; gamma-Aminobutyric Acid; Glutamic | 2020 |
Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II).
Topics: Administration, Intranasal; Adolescent; Adult; Antidepressive Agents; Depressive Disorder, Major; Do | 2021 |
Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double- | 2021 |
A robust and reproducible connectome fingerprint of ketamine is highly associated with the connectomic signature of antidepressants.
Topics: Antidepressive Agents; Connectome; Depressive Disorder, Major; Humans; Ketamine; Magnetic Resonance | 2021 |
Ketamine Alters Electrophysiological Responses to Emotional Faces in Major Depressive Disorder.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Emotion | 2021 |
Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression.
Topics: Administration, Intravenous; Adult; Antidepressive Agents; Cerebral Cortex; Connectome; Depressive D | 2021 |
Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Tr
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2021 |
Working memory associated with anti-suicidal ideation effect of repeated-dose intravenous ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Cognitive Dysfunction; Depressive Disorder, Major; Excitatory Amino Ac | 2021 |
Sleep improvement is associated with the antidepressant efficacy of repeated-dose ketamine and serum BDNF levels: a post-hoc analysis.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Brain-Derived Neurotrophic Factor; Depressive Disord | 2021 |
A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions.
Topics: Anesthetics; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dissociative Diso | 2021 |
Low dose oral ketamine treatment in chronic suicidality: An open-label pilot study.
Topics: Adult; Depressive Disorder, Major; Female; Humans; Ketamine; Male; Pilot Projects; Psychiatric Statu | 2021 |
Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
Topics: Adolescent; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Depressive Disord | 2021 |
A qualitative and quantitative account of patient's experiences of ketamine and its antidepressant properties.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Double-Blind Method; F | 2021 |
Prediction of repeated-dose intravenous ketamine response in major depressive disorder using the GWAS-based machine learning approach.
Topics: Depressive Disorder, Major; Genome-Wide Association Study; Humans; Infusions, Intravenous; Ketamine; | 2021 |
Predictive value of heart rate in treatment of major depression with ketamine in two controlled trials.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Female; Heart Rate; H | 2021 |
P11 (S100A10) as a potential predictor of ketamine response in patients with SSRI-resistant depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2021 |
Study protocol for SKIPMDD: subcutaneous ketamine infusion in palliative care patients with advanced life limiting illnesses for major depressive disorder (phase II pilot feasibility study).
Topics: Adult; Australia; Clinical Trials, Phase II as Topic; Depressive Disorder, Major; Feasibility Studie | 2021 |
Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Anxiety Disorders; Depression; Depressiv | 2017 |
Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials.
Topics: Adult; Anesthetics, Dissociative; Anhedonia; Bipolar Disorder; Depression; Depressive Disorder, Majo | 2017 |
Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression.
Topics: Administration, Intravenous; Adult; Antidepressive Agents; Cognition; Cognitive Behavioral Therapy; | 2017 |
Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression.
Topics: Adult; Antidepressive Agents; Asian People; Blood Pressure; Brain-Derived Neurotrophic Factor; Depre | 2017 |
Acute ketamine administration corrects abnormal inflammatory bone markers in major depressive disorder.
Topics: Adult; Biomarkers; Bone and Bones; Bone Density; Depressive Disorder, Major; Double-Blind Method; Fe | 2018 |
The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder.
Topics: Adolescent; Adult; Aged; Amygdala; Antidepressive Agents; Atrophy; Brain-Derived Neurotrophic Factor | 2017 |
A randomized clinical trial of adjunctive ketamine anesthesia in electro-convulsive therapy for depression.
Topics: Adult; Anesthetics, Dissociative; Anesthetics, Intravenous; Antidepressive Agents; Bipolar Disorder; | 2018 |
Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial.
Topics: Adult; Behavior Rating Scale; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Infus | 2018 |
Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial.
Topics: Adult; Behavior Rating Scale; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Infus | 2018 |
Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial.
Topics: Adult; Behavior Rating Scale; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Infus | 2018 |
Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial.
Topics: Adult; Behavior Rating Scale; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Infus | 2018 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2018 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2018 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2018 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2018 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2018 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2018 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2018 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2018 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2018 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2018 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2018 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2018 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2018 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2018 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2018 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2018 |
Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bipolar Disorder; Depersonalization; Depressive Diso | 2018 |
Default Mode Connectivity in Major Depressive Disorder Measured Up to 10 Days After Ketamine Administration.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Brain Mapping; Cerebral Cortex; Cross-Over Studies; | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind M | 2018 |
Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial.
Topics: Administration, Oral; Adult; Depressive Disorder, Major; Double-Blind Method; Excitatory Amino Acid | 2018 |
Glutamatergic Signaling Drives Ketamine-Mediated Response in Depression: Evidence from Dynamic Causal Modeling.
Topics: Adolescent; Adult; Affect; Aged; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Antidepre | 2018 |
Ketamine-based anesthesia improves electroconvulsive therapy outcomes: a randomized-controlled study.
Topics: Adult; Anesthesia; Anesthetics, Dissociative; Anesthetics, Intravenous; Depressive Disorder, Major; | 2018 |
7T
Topics: Adult; Antidepressive Agents; Brain; Cross-Over Studies; Depressive Disorder, Major; Depressive Diso | 2018 |
7T
Topics: Adult; Antidepressive Agents; Brain; Cross-Over Studies; Depressive Disorder, Major; Depressive Diso | 2018 |
7T
Topics: Adult; Antidepressive Agents; Brain; Cross-Over Studies; Depressive Disorder, Major; Depressive Diso | 2018 |
7T
Topics: Adult; Antidepressive Agents; Brain; Cross-Over Studies; Depressive Disorder, Major; Depressive Diso | 2018 |
Ketamine normalizes brain activity during emotionally valenced attentional processing in depression.
Topics: Adult; Antidepressive Agents; Attention; Brain; Cross-Over Studies; Depressive Disorder, Major; Doub | 2018 |
Ketamine augmentation for major depressive disorder and suicidal ideation: Preliminary experience in an inpatient psychiatry setting.
Topics: Adult; Canada; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Excita | 2018 |
Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects.
Topics: Adult; Amino Acids, Essential; Antidepressive Agents; Biogenic Amines; Carnitine; Cross-Over Studies | 2018 |
Neurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder.
Topics: Adult; Antidepressive Agents; Biomarkers; Brain; Brain-Derived Neurotrophic Factor; Cross-Over Studi | 2019 |
Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Cognition; Depressive Disorder, Major; Depressive Di | 2018 |
Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2019 |
Disentangling the association of depression on the anti-fatigue effects of ketamine.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Depressive Disorder, T | 2019 |
Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression: An Open 4-Week Longitudinal Study.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2018 |
Ketamine Versus Midazolam for Depression Relapse Prevention Following Successful Electroconvulsive Therapy: A Randomized Controlled Pilot Trial.
Topics: Aged; Aged, 80 and over; Anesthetics, Dissociative; Anesthetics, Intravenous; Depressive Disorder, M | 2019 |
Neurocognitive performance and repeated-dose intravenous ketamine in major depressive disorder.
Topics: Adult; Antidepressive Agents; Cognition; Depressive Disorder, Major; Female; Humans; Infusions, Intr | 2019 |
Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression.
Topics: Adult; Anxiety; Anxiety Disorders; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2019 |
Association of Combined Naltrexone and Ketamine With Depressive Symptoms in a Case series of Patients With Depression and Alcohol Use Disorder.
Topics: Adult; Alcohol Drinking; Alcoholism; Craving; Depressive Disorder, Major; Drug Therapy, Combination; | 2019 |
Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder.
Topics: Antidepressive Agents; Anxiety; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant | 2019 |
Investigation of medical effect of multiple ketamine infusions on patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Depressive Disorder, Major; Drug Administration Schedule; Excitatory Amino | 2019 |
Effects of Ketamine on Brain Activity During Emotional Processing: Differential Findings in Depressed Versus Healthy Control Participants.
Topics: Adult; Antidepressive Agents; Brain; Brain Mapping; Cross-Over Studies; Depressive Disorder, Major; | 2019 |
Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2019 |
Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
Topics: Adult; Ambulatory Care; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double | 2019 |
Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
Topics: Adult; Ambulatory Care; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double | 2019 |
Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
Topics: Adult; Ambulatory Care; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double | 2019 |
Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
Topics: Adult; Ambulatory Care; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double | 2019 |
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Citalopram; Depressi | 2019 |
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Citalopram; Depressi | 2019 |
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Citalopram; Depressi | 2019 |
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Citalopram; Depressi | 2019 |
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2019 |
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2019 |
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2019 |
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2019 |
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2019 |
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2019 |
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2019 |
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2019 |
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2019 |
Serial infusions of low-dose ketamine for major depression.
Topics: Adult; Aged; Antipsychotic Agents; Depressive Disorder, Major; Drug Administration Schedule; Female; | 2013 |
Serial infusions of low-dose ketamine for major depression.
Topics: Adult; Aged; Antipsychotic Agents; Depressive Disorder, Major; Drug Administration Schedule; Female; | 2013 |
Serial infusions of low-dose ketamine for major depression.
Topics: Adult; Aged; Antipsychotic Agents; Depressive Disorder, Major; Drug Administration Schedule; Female; | 2013 |
Serial infusions of low-dose ketamine for major depression.
Topics: Adult; Aged; Antipsychotic Agents; Depressive Disorder, Major; Drug Administration Schedule; Female; | 2013 |
Serial infusions of low-dose ketamine for major depression.
Topics: Adult; Aged; Antipsychotic Agents; Depressive Disorder, Major; Drug Administration Schedule; Female; | 2013 |
Serial infusions of low-dose ketamine for major depression.
Topics: Adult; Aged; Antipsychotic Agents; Depressive Disorder, Major; Drug Administration Schedule; Female; | 2013 |
Serial infusions of low-dose ketamine for major depression.
Topics: Adult; Aged; Antipsychotic Agents; Depressive Disorder, Major; Drug Administration Schedule; Female; | 2013 |
Serial infusions of low-dose ketamine for major depression.
Topics: Adult; Aged; Antipsychotic Agents; Depressive Disorder, Major; Drug Administration Schedule; Female; | 2013 |
Serial infusions of low-dose ketamine for major depression.
Topics: Adult; Aged; Antipsychotic Agents; Depressive Disorder, Major; Drug Administration Schedule; Female; | 2013 |
Effects of S-ketamine as an anesthetic adjuvant to propofol on treatment response to electroconvulsive therapy in treatment-resistant depression: a randomized pilot study.
Topics: Adjuvants, Anesthesia; Adult; Aged; Aged, 80 and over; Anesthesia; Anesthesia Recovery Period; Anest | 2013 |
Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Double-Blind Method; F | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Comparing effects of ketamine and thiopental administration during electroconvulsive therapy in patients with major depressive disorder: a randomized, double-blind study.
Topics: Adult; Analysis of Variance; Anesthesia; Anesthetics, Dissociative; Cognition; Depressive Disorder, | 2014 |
Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.
Topics: Adult; Aged; Animals; Antidepressive Agents; Brain; Cross-Over Studies; Depressive Disorder, Major; | 2014 |
Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.
Topics: Adult; Aged; Animals; Antidepressive Agents; Brain; Cross-Over Studies; Depressive Disorder, Major; | 2014 |
Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.
Topics: Adult; Aged; Animals; Antidepressive Agents; Brain; Cross-Over Studies; Depressive Disorder, Major; | 2014 |
Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.
Topics: Adult; Aged; Animals; Antidepressive Agents; Brain; Cross-Over Studies; Depressive Disorder, Major; | 2014 |
Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.
Topics: Adult; Aged; Animals; Antidepressive Agents; Brain; Cross-Over Studies; Depressive Disorder, Major; | 2014 |
Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.
Topics: Adult; Aged; Animals; Antidepressive Agents; Brain; Cross-Over Studies; Depressive Disorder, Major; | 2014 |
Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.
Topics: Adult; Aged; Animals; Antidepressive Agents; Brain; Cross-Over Studies; Depressive Disorder, Major; | 2014 |
Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.
Topics: Adult; Aged; Animals; Antidepressive Agents; Brain; Cross-Over Studies; Depressive Disorder, Major; | 2014 |
Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.
Topics: Adult; Aged; Animals; Antidepressive Agents; Brain; Cross-Over Studies; Depressive Disorder, Major; | 2014 |
Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Diagnostic and Statistic | 2014 |
Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Diagnostic and Statistic | 2014 |
Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Diagnostic and Statistic | 2014 |
Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Diagnostic and Statistic | 2014 |
A randomized comparison of ketamine versus methohexital anesthesia in electroconvulsive therapy.
Topics: Adult; Anesthetics; Blood Pressure; Cognition; Depressive Disorder, Major; Electroconvulsive Therapy | 2014 |
Post-electroconvulsive therapy recovery and reorientation time with methohexital and ketamine: a randomized, longitudinal, crossover design trial.
Topics: Adult; Aged; Anesthesia Recovery Period; Anesthetics, Dissociative; Anesthetics, Intravenous; Cross- | 2015 |
A randomized controlled trial of intranasal ketamine in major depressive disorder.
Topics: Administration, Intranasal; Adult; Aged; Antidepressive Agents; Cross-Over Studies; Depressive Disor | 2014 |
A randomized controlled trial of intranasal ketamine in major depressive disorder.
Topics: Administration, Intranasal; Adult; Aged; Antidepressive Agents; Cross-Over Studies; Depressive Disor | 2014 |
A randomized controlled trial of intranasal ketamine in major depressive disorder.
Topics: Administration, Intranasal; Adult; Aged; Antidepressive Agents; Cross-Over Studies; Depressive Disor | 2014 |
A randomized controlled trial of intranasal ketamine in major depressive disorder.
Topics: Administration, Intranasal; Adult; Aged; Antidepressive Agents; Cross-Over Studies; Depressive Disor | 2014 |
A randomized controlled trial of intranasal ketamine in major depressive disorder.
Topics: Administration, Intranasal; Adult; Aged; Antidepressive Agents; Cross-Over Studies; Depressive Disor | 2014 |
A randomized controlled trial of intranasal ketamine in major depressive disorder.
Topics: Administration, Intranasal; Adult; Aged; Antidepressive Agents; Cross-Over Studies; Depressive Disor | 2014 |
A randomized controlled trial of intranasal ketamine in major depressive disorder.
Topics: Administration, Intranasal; Adult; Aged; Antidepressive Agents; Cross-Over Studies; Depressive Disor | 2014 |
A randomized controlled trial of intranasal ketamine in major depressive disorder.
Topics: Administration, Intranasal; Adult; Aged; Antidepressive Agents; Cross-Over Studies; Depressive Disor | 2014 |
A randomized controlled trial of intranasal ketamine in major depressive disorder.
Topics: Administration, Intranasal; Adult; Aged; Antidepressive Agents; Cross-Over Studies; Depressive Disor | 2014 |
A randomized controlled trial of intranasal ketamine in major depressive disorder.
Topics: Administration, Intranasal; Adult; Aged; Antidepressive Agents; Cross-Over Studies; Depressive Disor | 2014 |
A randomized controlled trial of intranasal ketamine in major depressive disorder.
Topics: Administration, Intranasal; Adult; Aged; Antidepressive Agents; Cross-Over Studies; Depressive Disor | 2014 |
A randomized controlled trial of intranasal ketamine in major depressive disorder.
Topics: Administration, Intranasal; Adult; Aged; Antidepressive Agents; Cross-Over Studies; Depressive Disor | 2014 |
A randomized controlled trial of intranasal ketamine in major depressive disorder.
Topics: Administration, Intranasal; Adult; Aged; Antidepressive Agents; Cross-Over Studies; Depressive Disor | 2014 |
A randomized controlled trial of intranasal ketamine in major depressive disorder.
Topics: Administration, Intranasal; Adult; Aged; Antidepressive Agents; Cross-Over Studies; Depressive Disor | 2014 |
A randomized controlled trial of intranasal ketamine in major depressive disorder.
Topics: Administration, Intranasal; Adult; Aged; Antidepressive Agents; Cross-Over Studies; Depressive Disor | 2014 |
A randomized controlled trial of intranasal ketamine in major depressive disorder.
Topics: Administration, Intranasal; Adult; Aged; Antidepressive Agents; Cross-Over Studies; Depressive Disor | 2014 |
Clinical predictors of ketamine response in treatment-resistant major depression.
Topics: Adult; Bipolar Disorder; Body Mass Index; Depressive Disorder, Major; Depressive Disorder, Treatment | 2014 |
Effects of sevoflurane or ketamine on the QTc interval during electroconvulsive therapy.
Topics: Adult; Anesthetics, Dissociative; Arterial Pressure; Depressive Disorder, Major; Double-Blind Method | 2015 |
Hippocampal volume and the rapid antidepressant effect of ketamine.
Topics: Adult; Antidepressive Agents; Biomarkers; Depressive Disorder, Major; Depressive Disorder, Treatment | 2015 |
Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
Topics: Antidepressive Agents; Anxiety Disorders; Depressive Disorder, Major; Depressive Disorder, Treatment | 2014 |
Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Major; Depressive Disord | 2015 |
Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Major; Depressive Disord | 2015 |
Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Major; Depressive Disord | 2015 |
Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Major; Depressive Disord | 2015 |
Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
Topics: Adolescent; Adult; Aged; Alcohol-Related Disorders; Antidepressive Agents; Depressive Disorder, Majo | 2014 |
Rating depression over brief time intervals with the Hamilton Depression Rating Scale: standard vs. abbreviated scales.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Depressive Disorder, Major; Double-Blind Me | 2015 |
Neural correlates of change in major depressive disorder anhedonia following open-label ketamine.
Topics: Adult; Anhedonia; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment- | 2015 |
Effect of the Addition of Ketamine to Sevoflurane Anesthesia on Seizure Duration in Electroconvulsive Therapy.
Topics: Adult; Anesthesia; Anesthesia Recovery Period; Anesthetics, Dissociative; Anesthetics, Inhalation; A | 2015 |
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Major; Double-Blind Method; Excitatory Ami | 2015 |
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Major; Double-Blind Method; Excitatory Ami | 2015 |
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Major; Double-Blind Method; Excitatory Ami | 2015 |
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Major; Double-Blind Method; Excitatory Ami | 2015 |
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Major; Double-Blind Method; Excitatory Ami | 2015 |
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Major; Double-Blind Method; Excitatory Ami | 2015 |
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Major; Double-Blind Method; Excitatory Ami | 2015 |
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Major; Double-Blind Method; Excitatory Ami | 2015 |
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Major; Double-Blind Method; Excitatory Ami | 2015 |
Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
Topics: Administration, Intravenous; Adolescent; Adult; Antidepressive Agents; China; Citalopram; Depressive | 2016 |
Study protocol for the randomised controlled trial: Ketamine augmentation of ECT to improve outcomes in depression (Ketamine-ECT study).
Topics: Adolescent; Adult; Aged; Cognition; Cognition Disorders; Combined Modality Therapy; Depressive Disor | 2015 |
The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study.
Topics: Adult; Amygdala; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-R | 2016 |
Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate.
Topics: Adolescent; Adult; Affect; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Do | 2016 |
Continuation phase intravenous ketamine in adults with treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Tre | 2016 |
Continuation phase intravenous ketamine in adults with treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Tre | 2016 |
Continuation phase intravenous ketamine in adults with treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Tre | 2016 |
Continuation phase intravenous ketamine in adults with treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Tre | 2016 |
Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Biomarkers; Bipolar Disorder; Cytokines; Depressive Disorder, Major; D | 2017 |
Effect of Low Dose of Ketamine on Learning Memory Function in Patients Undergoing Electroconvulsive Therapy-A Randomized, Double-Blind, Controlled Clinical Study.
Topics: Adolescent; Adult; Aged; Anesthesia; Anesthetics, Intravenous; Asian People; Depressive Disorder, Ma | 2017 |
The Nucleus Accumbens and Ketamine Treatment in Major Depressive Disorder.
Topics: Adult; Case-Control Studies; Cross-Sectional Studies; Depressive Disorder, Major; Female; Functional | 2017 |
Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist.
Topics: Adolescent; Adult; Aged; Alcoholism; Antidepressive Agents; Depressive Disorder, Major; Excitatory A | 2009 |
Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist.
Topics: Adult; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Double- | 2009 |
Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist.
Topics: Adult; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Double- | 2009 |
Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist.
Topics: Adult; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Double- | 2009 |
Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist.
Topics: Adult; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Double- | 2009 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Topics: Adult; Aged; Analgesics; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2010 |
A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Adm | 2011 |
A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Adm | 2011 |
A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Adm | 2011 |
A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Adm | 2011 |
A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Adm | 2011 |
A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Adm | 2011 |
A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Adm | 2011 |
A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Adm | 2011 |
A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Adm | 2011 |
A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Adm | 2011 |
A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Adm | 2011 |
A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Adm | 2011 |
A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Adm | 2011 |
A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Adm | 2011 |
A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Adm | 2011 |
A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Adm | 2011 |
Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Brain Mapping; Cerebral Cortex; Depressive Disor | 2012 |
Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder.
Topics: Anesthetics, Combined; Anesthetics, Dissociative; Anesthetics, Intravenous; Depressive Disorder, Maj | 2012 |
Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder.
Topics: Anesthetics, Combined; Anesthetics, Dissociative; Anesthetics, Intravenous; Depressive Disorder, Maj | 2012 |
Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder.
Topics: Anesthetics, Combined; Anesthetics, Dissociative; Anesthetics, Intravenous; Depressive Disorder, Maj | 2012 |
Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder.
Topics: Anesthetics, Combined; Anesthetics, Dissociative; Anesthetics, Intravenous; Depressive Disorder, Maj | 2012 |
Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder.
Topics: Anesthetics, Combined; Anesthetics, Dissociative; Anesthetics, Intravenous; Depressive Disorder, Maj | 2012 |
Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder.
Topics: Anesthetics, Combined; Anesthetics, Dissociative; Anesthetics, Intravenous; Depressive Disorder, Maj | 2012 |
Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder.
Topics: Anesthetics, Combined; Anesthetics, Dissociative; Anesthetics, Intravenous; Depressive Disorder, Maj | 2012 |
Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder.
Topics: Anesthetics, Combined; Anesthetics, Dissociative; Anesthetics, Intravenous; Depressive Disorder, Maj | 2012 |
Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder.
Topics: Anesthetics, Combined; Anesthetics, Dissociative; Anesthetics, Intravenous; Depressive Disorder, Maj | 2012 |
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.
Topics: Adult; Analysis of Variance; Brain Waves; Brain-Derived Neurotrophic Factor; Depressive Disorder, Ma | 2013 |
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.
Topics: Adult; Analysis of Variance; Brain Waves; Brain-Derived Neurotrophic Factor; Depressive Disorder, Ma | 2013 |
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.
Topics: Adult; Analysis of Variance; Brain Waves; Brain-Derived Neurotrophic Factor; Depressive Disorder, Ma | 2013 |
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.
Topics: Adult; Analysis of Variance; Brain Waves; Brain-Derived Neurotrophic Factor; Depressive Disorder, Ma | 2013 |
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.
Topics: Adult; Analysis of Variance; Brain Waves; Brain-Derived Neurotrophic Factor; Depressive Disorder, Ma | 2013 |
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.
Topics: Adult; Analysis of Variance; Brain Waves; Brain-Derived Neurotrophic Factor; Depressive Disorder, Ma | 2013 |
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.
Topics: Adult; Analysis of Variance; Brain Waves; Brain-Derived Neurotrophic Factor; Depressive Disorder, Ma | 2013 |
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.
Topics: Adult; Analysis of Variance; Brain Waves; Brain-Derived Neurotrophic Factor; Depressive Disorder, Ma | 2013 |
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.
Topics: Adult; Analysis of Variance; Brain Waves; Brain-Derived Neurotrophic Factor; Depressive Disorder, Ma | 2013 |
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.
Topics: Adult; Analysis of Variance; Brain Waves; Brain-Derived Neurotrophic Factor; Depressive Disorder, Ma | 2013 |
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.
Topics: Adult; Analysis of Variance; Brain Waves; Brain-Derived Neurotrophic Factor; Depressive Disorder, Ma | 2013 |
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.
Topics: Adult; Analysis of Variance; Brain Waves; Brain-Derived Neurotrophic Factor; Depressive Disorder, Ma | 2013 |
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.
Topics: Adult; Analysis of Variance; Brain Waves; Brain-Derived Neurotrophic Factor; Depressive Disorder, Ma | 2013 |
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.
Topics: Adult; Analysis of Variance; Brain Waves; Brain-Derived Neurotrophic Factor; Depressive Disorder, Ma | 2013 |
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.
Topics: Adult; Analysis of Variance; Brain Waves; Brain-Derived Neurotrophic Factor; Depressive Disorder, Ma | 2013 |
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.
Topics: Adult; Analysis of Variance; Brain Waves; Brain-Derived Neurotrophic Factor; Depressive Disorder, Ma | 2013 |
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.
Topics: Adult; Analysis of Variance; Brain Waves; Brain-Derived Neurotrophic Factor; Depressive Disorder, Ma | 2013 |
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.
Topics: Adult; Analysis of Variance; Brain Waves; Brain-Derived Neurotrophic Factor; Depressive Disorder, Ma | 2013 |
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.
Topics: Adult; Analysis of Variance; Brain Waves; Brain-Derived Neurotrophic Factor; Depressive Disorder, Ma | 2013 |
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.
Topics: Adult; Analysis of Variance; Brain Waves; Brain-Derived Neurotrophic Factor; Depressive Disorder, Ma | 2013 |
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.
Topics: Adult; Analysis of Variance; Brain Waves; Brain-Derived Neurotrophic Factor; Depressive Disorder, Ma | 2013 |
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.
Topics: Adult; Analysis of Variance; Brain Waves; Brain-Derived Neurotrophic Factor; Depressive Disorder, Ma | 2013 |
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.
Topics: Adult; Analysis of Variance; Brain Waves; Brain-Derived Neurotrophic Factor; Depressive Disorder, Ma | 2013 |
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.
Topics: Adult; Analysis of Variance; Brain Waves; Brain-Derived Neurotrophic Factor; Depressive Disorder, Ma | 2013 |
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.
Topics: Adult; Analysis of Variance; Brain Waves; Brain-Derived Neurotrophic Factor; Depressive Disorder, Ma | 2013 |
Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting.
Topics: Adolescent; Adult; Aged; Anesthesia; Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disor | 2012 |
Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial.
Topics: Adult; Affect; Bipolar Disorder; Cognition; Cognition Disorders; Depressive Disorder, Major; Double- | 2012 |
Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial.
Topics: Adult; Affect; Bipolar Disorder; Cognition; Cognition Disorders; Depressive Disorder, Major; Double- | 2012 |
Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial.
Topics: Adult; Affect; Bipolar Disorder; Cognition; Cognition Disorders; Depressive Disorder, Major; Double- | 2012 |
Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial.
Topics: Adult; Affect; Bipolar Disorder; Cognition; Cognition Disorders; Depressive Disorder, Major; Double- | 2012 |
Baseline delta sleep ratio predicts acute ketamine mood response in major depressive disorder.
Topics: Adolescent; Adult; Affect; Aged; Antidepressive Agents; Biomarkers; Depressive Disorder, Major; Drug | 2013 |
Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action.
Topics: Adult; Antidepressive Agents; Brain Mapping; Cross-Over Studies; Depressive Disorder, Major; Double- | 2012 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Dose-Response Relation | 2006 |
Intravenous ketamine therapy in a patient with a treatment-resistant major depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Drug Resistance; Excitatory Amino Acid Antagonist | 2007 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
Antidepressant effects of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2000 |
317 other studies available for ketamine and Depressive Disorder, Major
| Article | Year |
|---|---|
Ketamine monotherapy versus adjunctive ketamine in adults with treatment-resistant depression: Results from the Canadian Rapid Treatment Centre of Excellence.
Topics: Adult; Canada; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Hum | 2021 |
Ketamine's modulation of cerebro-cerebellar circuitry during response inhibition in major depression.
Topics: Cerebellum; Depression; Depressive Disorder, Major; Female; Humans; Ketamine; Magnetic Resonance Ima | 2021 |
Intravenous ketamine for rapid treatment of major depressive disorder in the general medical hospital.
Topics: Administration, Intravenous; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Major; D | 2021 |
Ketamine induces opposite changes in AMPA receptor calcium permeability in the ventral tegmental area and nucleus accumbens.
Topics: Animals; Calcium; Depressive Disorder, Major; Humans; Ketamine; Mice; Neurons; Nucleus Accumbens; Pe | 2021 |
TAK-653, an AMPA receptor potentiator with minimal agonistic activity, produces an antidepressant-like effect with a favorable safety profile in rats.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Depre | 2021 |
Parental Attitudes Toward Use of Ketamine in Adolescent Mood Disorders and Suicidality.
Topics: Adolescent; Attitude; Bipolar Disorder; Child; Decision Making; Depressive Disorder, Major; Female; | 2021 |
The potential pro-cognitive effects with intravenous subanesthetic ketamine in adults with treatment-resistant major depressive or bipolar disorders and suicidality.
Topics: Adult; Bipolar Disorder; Cognition; Depressive Disorder, Major; Depressive Disorder, Treatment-Resis | 2021 |
Commentary: Treatment-resistant Depression: Considerations Related to ECT and Ketamine.
Topics: Adult; Aged; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Elect | 2021 |
Ketamine abrogates sensorimotor deficits and cytokine dysregulation in a chronic unpredictable mild stress model of depression.
Topics: Animals; Antidepressive Agents; Cytokines; Depression; Depressive Disorder, Major; Disease Models, A | 2022 |
Treatment-resistant bipolar disorder managed with ketamine infusions as monotherapy.
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Infusions, Intravenous; Ketamine; Suicidal Ide | 2021 |
Oral racemic ketamine for common clinical contexts in patients with major depressive disorder: An important intervention that treatment guidelines may never include.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment- | 2022 |
Remission of functional motor symptoms following esketamine administration in a patient with treatment-resistant depression: a single-case report.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2022 |
Frequency analysis of symptomatic worsening following ketamine infusions for treatment resistant depression in a real-world sample: Results from the canadian rapid treatment center of excellence.
Topics: Adult; Canada; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Infusio | 2022 |
Comparative effectiveness of repeated ketamine infusions in treating anhedonia in bipolar and unipolar depression.
Topics: Anhedonia; Bipolar Disorder; Depressive Disorder, Major; Humans; Infusions, Intravenous; Ketamine | 2022 |
[Ketamine self-medication in a patient with autism spectrum disorder and comorbid treatment-resistant depression].
Topics: Autism Spectrum Disorder; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Res | 2021 |
Increase in thalamic cerebral blood flow is associated with antidepressant effects of ketamine in major depressive disorder.
Topics: Antidepressive Agents; Cerebrovascular Circulation; Depressive Disorder, Major; Humans; Ketamine; Sp | 2022 |
A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings.
Topics: Depression; Depressive Disorder, Major; Humans; Infusions, Intravenous; Ketamine; Retrospective Stud | 2022 |
Intravenous esketamine leads to an increase in impulsive and suicidal behaviour in a patient with recurrent major depression and borderline personality disorder.
Topics: Antidepressive Agents; Borderline Personality Disorder; Depression; Depressive Disorder, Major; Depr | 2022 |
US budget impact analysis of esketamine nasal spray in major depressive disorder with acute suicidal ideation/behavior.
Topics: Administration, Intranasal; Adult; Depressive Disorder, Major; Health Care Costs; Humans; Ketamine; | 2022 |
S-Ketamine Exerts Antidepressant Effects by Regulating Rac1 GTPase Mediated Synaptic Plasticity in the Hippocampus of Stressed Rats.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; Disease Models, Animal; GTP | 2023 |
Imaging the effect of ketamine on synaptic density (SV2A) in the living brain.
Topics: Animals; Antidepressive Agents; Brain; Depressive Disorder, Major; Humans; Ketamine; Macaca mulatta; | 2022 |
Ketamine as a Potential Transdiagnostic Treatment for Anhedonia?
Topics: Anhedonia; Depression; Depressive Disorder, Major; Humans; Ketamine; Reward | 2022 |
Ketamine for suicidal ideation: heed lessons from opiate epidemic.
Topics: Depressive Disorder, Major; Humans; Ketamine; Opioid Epidemic; Psychiatric Status Rating Scales; Sui | 2022 |
Insights for the Use of Ketamine From Randomized Controlled Trials That Compared Ketamine With Electroconvulsive Therapy in Severe Depression.
Topics: Aged; Depression; Depressive Disorder, Major; Electroconvulsive Therapy; Humans; Ketamine; Randomize | 2022 |
Prospective association of psychological pain and hopelessness with suicidal thoughts.
Topics: Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Pain; Suicid | 2022 |
Neurocognitive effects of repeated ketamine infusions in comorbid posttraumatic stress disorder and major depressive disorder.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketami | 2022 |
Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptors.
Topics: Animals; Behavior, Animal; Depressive Disorder, Major; Humans; Ketamine; Mice; Naltrexone; Receptors | 2022 |
A letter to the editor, associated with the article entitled "Efficacy and tolerability of combination treatments for major depression: Antidepressants plus second-generation antipsychotics vs esketamine vs lithium" by Vázquez et al. (
Topics: Antidepressive Agents; Antipsychotic Agents; Depression; Depressive Disorder, Major; Drug Therapy, C | 2022 |
Survey of substance use among adolescent drug offenders referred from juvenile courts in Taiwan: Clinical epidemiology of single versus multiple illicit substance use.
Topics: Adolescent; Criminals; Depressive Disorder, Major; Humans; Illicit Drugs; Ketamine; Methamphetamine; | 2022 |
Comparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administration.
Topics: Animals; Antidepressive Agents; Brain; Depressive Disorder, Major; Humans; Ketamine; Metabolomics; M | 2022 |
Allergic reaction induced by subcutaneous administration of ketamine: a case report.
Topics: Adult; Depressive Disorder, Major; Humans; Hypersensitivity; Ketamine; Male; Suicidal Ideation; Youn | 2022 |
Pharmacological Treatments for Anhedonia.
Topics: Anhedonia; Brain; Depressive Disorder, Major; Humans; Ketamine; Mood Disorders; Reward | 2022 |
Anterior default mode network and posterior insular connectivity is predictive of depressive symptom reduction following serial ketamine infusion.
Topics: Antidepressive Agents; Default Mode Network; Depression; Depressive Disorder, Major; Humans; Ketamin | 2022 |
Autophagy: A New Mechanism for Esketamine as a Depression Therapeutic.
Topics: Animals; Antidepressive Agents; Autophagy; Brain-Derived Neurotrophic Factor; Cytokines; Depression; | 2022 |
Repeated subcutaneous racemic ketamine in treatment-resistant depression: case series.
Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; | 2022 |
Topics: Adolescent; Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine; Suicidal Ideation | 2022 |
Antianhedonic effects of serial intravenous subanaesthetic ketamine in anxious versus nonanxious depression.
Topics: Antidepressive Agents; Anxiety; Depression; Depressive Disorder, Major; Depressive Disorder, Treatme | 2022 |
Occlusion of dopamine-dependent synaptic plasticity in the prefrontal cortex mediates the expression of depressive-like behavior and is modulated by ketamine.
Topics: Animals; Depressive Disorder, Major; Dopamine; Humans; Ketamine; Neuronal Plasticity; Prefrontal Cor | 2022 |
Blood miR-144-3p: a novel diagnostic and therapeutic tool for depression.
Topics: Animals; Antidepressive Agents; Biomarkers; Depressive Disorder, Major; Epigenesis, Genetic; Ketamin | 2022 |
The effect of IV ketamine in patients with major depressive disorder and elevated features of borderline personality disorder.
Topics: Adult; Antidepressive Agents; Borderline Personality Disorder; Depressive Disorder, Major; Humans; K | 2022 |
Ketamine induces rapid antidepressant effects via the autophagy-NLRP3 inflammasome pathway.
Topics: Animals; Antidepressive Agents; Autophagy; Brain-Derived Neurotrophic Factor; Depressive Disorder, M | 2022 |
Assessment of Objective and Subjective Cognitive Function in Patients With Treatment-Resistant Depression Undergoing Repeated Ketamine Infusions.
Topics: Cognition; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; | 2022 |
Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Receptors, AMPA; Re | 2022 |
Predicting Antidepressant Effects of Ketamine: the Role of the Pregenual Anterior Cingulate Cortex as a Multimodal Neuroimaging Biomarker.
Topics: Antidepressive Agents; Biomarkers; Depressive Disorder, Major; Glutamic Acid; Gyrus Cinguli; Humans; | 2022 |
A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Nonsuicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine.
Topics: Anhedonia; Data Analysis; Depression; Depressive Disorder, Major; Humans; Ketamine; Midazolam; Place | 2022 |
Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression.
Topics: Administration, Intranasal; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Dep | 2022 |
Clinical Effectiveness of Intravenous Racemic Ketamine Infusions in a Large Community Sample of Patients With Treatment-Resistant Depression, Suicidal Ideation, and Generalized Anxiety Symptoms: A Retrospective Chart Review.
Topics: Anxiety; Depression; Depressive Disorder, Major; Humans; Ketamine; Retrospective Studies; Suicidal I | 2022 |
Longitudinal Course of Adverse Events With Esketamine Nasal Spray: A Post Hoc Analysis of Pooled Data From Phase 3 Trials in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Major; | 2022 |
Longitudinal Course of Adverse Events With Esketamine Nasal Spray: A Post Hoc Analysis of Pooled Data From Phase 3 Trials in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Major; | 2022 |
Longitudinal Course of Adverse Events With Esketamine Nasal Spray: A Post Hoc Analysis of Pooled Data From Phase 3 Trials in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Major; | 2022 |
Longitudinal Course of Adverse Events With Esketamine Nasal Spray: A Post Hoc Analysis of Pooled Data From Phase 3 Trials in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Major; | 2022 |
Evaluation of Early Ketamine Effects on Belief-Updating Biases in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Bias; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment- | 2022 |
Sex differences on the response to antidepressants and psychobiotics following early life stress in rats.
Topics: Animals; Antidepressive Agents; Antioxidants; Depressive Disorder, Major; Escitalopram; Female; Keta | 2022 |
Real-world depression, anxiety and safety outcomes of intramuscular ketamine treatment: a retrospective descriptive cohort study.
Topics: Adult; Anxiety; Anxiety Disorders; Cohort Studies; Depression; Depressive Disorder, Major; Humans; K | 2022 |
Chronic lithium treatment ameliorates ketamine-induced mania-like behavior via the PI3K-AKT signaling pathway.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Ketamine; Lithium; Lithium Compounds; Ma | 2022 |
Ketamine May Exert Rapid Antidepressant Effects Through Modulation of Neuroplasticity, Autophagy, and Ferroptosis in the Habenular Nucleus.
Topics: Animals; Autophagy; Depressive Disorder, Major; Habenula; Ketamine; Rats | 2022 |
Replication of distinct trajectories of antidepressant response to intravenous ketamine.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2023 |
Association of anhedonia and suicidal ideation in patients with treatment-refractory depression after intravenous ketamine infusions.
Topics: Anhedonia; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; P | 2023 |
Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Authors' Response to Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Authors' Response to Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Authors' Response to Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Authors' Response to Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Authors' Response to Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Authors' Response to Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Authors' Response to Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Authors' Response to Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Authors' Response to Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
An Innovative Approach to Extending the Antidepressant Effects of Intravenous Ketamine in Major Depression.
Topics: Administration, Intravenous; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; | 2022 |
An Innovative Approach to Extending the Antidepressant Effects of Intravenous Ketamine in Major Depression.
Topics: Administration, Intravenous; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; | 2022 |
An Innovative Approach to Extending the Antidepressant Effects of Intravenous Ketamine in Major Depression.
Topics: Administration, Intravenous; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; | 2022 |
An Innovative Approach to Extending the Antidepressant Effects of Intravenous Ketamine in Major Depression.
Topics: Administration, Intravenous; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; | 2022 |
Intranasal racemic ketamine for patients hospitalized with treatment-resistant depression: A retrospective analysis.
Topics: Administration, Intranasal; Analgesics; Antidepressive Agents; Depression; Depressive Disorder, Majo | 2023 |
Intranasal racemic ketamine for patients hospitalized with treatment-resistant depression: A retrospective analysis.
Topics: Administration, Intranasal; Analgesics; Antidepressive Agents; Depression; Depressive Disorder, Majo | 2023 |
Intranasal racemic ketamine for patients hospitalized with treatment-resistant depression: A retrospective analysis.
Topics: Administration, Intranasal; Analgesics; Antidepressive Agents; Depression; Depressive Disorder, Majo | 2023 |
Intranasal racemic ketamine for patients hospitalized with treatment-resistant depression: A retrospective analysis.
Topics: Administration, Intranasal; Analgesics; Antidepressive Agents; Depression; Depressive Disorder, Majo | 2023 |
The Effects of Acute and Repeated Administration of Ketamine on Memory, Behavior, and Plasma Corticosterone Levels in Female Mice.
Topics: Animals; Anxiety; Behavior, Animal; Corticosterone; Depression; Depressive Disorder, Major; Female; | 2023 |
The Effects of Acute and Repeated Administration of Ketamine on Memory, Behavior, and Plasma Corticosterone Levels in Female Mice.
Topics: Animals; Anxiety; Behavior, Animal; Corticosterone; Depression; Depressive Disorder, Major; Female; | 2023 |
The Effects of Acute and Repeated Administration of Ketamine on Memory, Behavior, and Plasma Corticosterone Levels in Female Mice.
Topics: Animals; Anxiety; Behavior, Animal; Corticosterone; Depression; Depressive Disorder, Major; Female; | 2023 |
The Effects of Acute and Repeated Administration of Ketamine on Memory, Behavior, and Plasma Corticosterone Levels in Female Mice.
Topics: Animals; Anxiety; Behavior, Animal; Corticosterone; Depression; Depressive Disorder, Major; Female; | 2023 |
Association of intranasal esketamine, a novel 'standard of care' treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2022 |
Clinical experiences with intranasal esketamine for major depressive disorder resistant to treatment and with a psychiatric emergency: case presentations.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Dis | 2023 |
Comorbidity of ketamine dependence with major depressive disorder increases the vulnerability to neuroaxonal pathology.
Topics: Biomarkers; Comorbidity; Depressive Disorder, Major; Humans; Ketamine | 2023 |
Ketamine-induced hippocampal functional connectivity alterations associated with clinical remission in major depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Hippocampus; Humans; Ketamine; Magnet | 2023 |
3,4-Dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide analogs act as potential AMPA receptor potentiators with antidepressant activity.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Ketamine; Mice; Neurons; Rats; Receptors | 2023 |
The Glutamatergic System in Treatment-Resistant Depression and Comparative Effectiveness of Ketamine and Esketamine: Role of Inflammation?
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Inflammation; Ketamine | 2023 |
Clinical pharmacological innovation in the treatment of depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Hallucinogens; Humans; Ketamine | 2023 |
Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Comorbidity; Depression; Depressive Disord | 2023 |
A comparative analysis of antidepressant and anti-suicidal effects of repeated ketamine infusions in elderly and younger adults with depression.
Topics: Aged; Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment- | 2023 |
Ketamine Noninferior to Electroconvulsive Therapy for Depression.
Topics: Anesthetics, Dissociative; Anesthetics, Intravenous; Antidepressive Agents; Depression; Depressive D | 2023 |
Progress in treatment-resistant bipolar depression using repeated ketamine infusions.
Topics: Bipolar Disorder; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2023 |
Antidepressant effects of novel positive allosteric modulators of Trk-receptor mediated signaling - a potential therapeutic concept?
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Fluox | 2023 |
Ketamine Reduces the Surface Density of the Astroglial Kir4.1 Channel and Inhibits Voltage-Activated Currents in a Manner Similar to the Action of Ba
Topics: Animals; Astrocytes; Depressive Disorder, Major; Ketamine; Mice; Neurons; Rats | 2023 |
Functional and Molecular Changes in the Prefrontal Cortex of the Chronic Mild Stress Rat Model of Depression and Modulation by Acute Ketamine.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; Ketamine; Male; Prefrontal C | 2023 |
[Consider (es)ketamine for treatment-resistant depression].
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Psychotherapy | 2023 |
Repeated infusions of ketamine for treatment-resistant bipolar depression in real-world practice.
Topics: Bipolar Disorder; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2023 |
(S)-Ketamine but Not (R)-Ketamine Shows Acute Effects on Depression-Like Behavior and Sleep-Wake Architecture in Rats.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; Ketamine; Rats; Sleep | 2023 |
Effects of cannabis use on antidepressant treatment response to repetitive transcranial magnetic stimulation and ketamine.
Topics: Antidepressive Agents; Cannabis; Depressive Disorder, Major; Hallucinogens; Humans; Ketamine; Transc | 2023 |
Have Effective Antidepressants Finally Arrived? Developments in Major Depressive Disorder Therapy.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Halluci | 2023 |
Nitrous Oxide Reduced Suicidal Ideation in Treatment-Resistant Major Depression in Exploratory Analysis.
Topics: Depression; Depressive Disorder, Major; Humans; Ketamine; Nitrous Oxide; Suicidal Ideation | 2023 |
In treatment-resistant major depression, ketamine was noninferior to ECT for treatment response.
Topics: Depression; Depressive Disorder, Major; Humans; Ketamine | 2023 |
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.
Topics: Depression; Depressive Disorder, Major; Humans; Ketamine | 2023 |
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.
Topics: Depression; Depressive Disorder, Major; Humans; Ketamine | 2023 |
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. Reply.
Topics: Depression; Depressive Disorder, Major; Humans; Ketamine | 2023 |
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.
Topics: Depression; Depressive Disorder, Major; Humans; Ketamine | 2023 |
Changes in neurotrophic signaling pathways in brain areas of the chronic mild stress rat model of depression as a signature of ketamine fast antidepressant response/non-response.
Topics: Animals; Antidepressive Agents; Brain; Depression; Depressive Disorder, Major; Glycogen Synthase Kin | 2024 |
A HOPEFUL ALTERNATIVE “THERAPY WITH INTRA- NASAL ESKETAMINE IN A PATIENT WITH RESISTANT DEPRESSION”. A CASE REPORT.
Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine | 2023 |
Ketamine versus electroconvulsive therapy for major depressive disorder: A deeper dive into the data.
Topics: Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Electroconvulsive Therapy; Hum | 2024 |
Choosing Between Ketamine and Electroconvulsive Therapy for Outpatients With Treatment-Resistant Depression-Advantage Ketamine?
Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Electroconvulsive | 2023 |
National Network of Depression Centers position statement: Insurance coverage for intravenous ketamine in treatment-resistant major depressive disorder.
Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Infusions, | 2024 |
Nebulized and intraperitoneal ketamine have equivalent antidepressant-like effect in the forced swim and tail suspension tests in mice.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; Dexamethasone; Disease Model | 2023 |
[How can ketamine be used to manage suicidal risk?]
Topics: Anhedonia; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Hum | 2023 |
Ketamine as augmentation for the treatment of major depression and suicidal risk in advanced cancer: Case report.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Drug Combinations; Female; Humans; Ketamin | 2020 |
Repeated ketamine injections in synergy with antidepressants for treating refractory depression: A case showing 6-month improvement.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Sy | 2020 |
Association between depression subtypes and response to repeated-dose intravenous ketamine.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2019 |
The immunomodulatory effect of ketamine in depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2019 |
Suicidality in treatment resistant depression: perspective for ketamine use.
Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; | 2019 |
Short-term ketamine administration in treatment-resistant depression patients: focus on adverse effects on the central nervous system.
Topics: Central Nervous System; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resis | 2019 |
Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression.
Topics: Adult; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusio | 2020 |
A single coadministration of subeffective doses of ascorbic acid and ketamine reverses the depressive-like behavior induced by chronic unpredictable stress in mice.
Topics: Animals; Antidepressive Agents; Ascorbic Acid; Behavior, Animal; Depression; Depressive Disorder, Ma | 2019 |
Pro-inflammatory monocyte profile in patients with major depressive disorder and suicide behaviour and how ketamine induces anti-inflammatory M2 macrophages by NMDAR and mTOR.
Topics: Adult; Animals; Biomarkers; Cytokines; Depressive Disorder, Major; Disease Models, Animal; Female; G | 2019 |
Increasing doses of ketamine curtail antidepressant responses and suppress associated synaptic signaling pathways.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depressive Diso | 2020 |
Treatment-Resistant Depression and Ketamine Response in a Patient With Bilateral Amygdala Damage.
Topics: Adult; Amygdala; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Excitatory Am | 2019 |
Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2020 |
Ketamine and esketamine for suicidal ideation: Recent progress and practical issues.
Topics: Adult; Depressive Disorder, Major; Humans; Ketamine; Psychiatric Status Rating Scales; Suicidal Idea | 2020 |
Splenic NKG2D confers resilience versus susceptibility in mice after chronic social defeat stress: beneficial effects of (R)-ketamine.
Topics: Animals; Antidepressive Agents; Autopsy; Behavior, Animal; Depressive Disorder, Major; Disease Model | 2021 |
Ketamine normalizes subgenual cingulate cortex hyper-activity in depression.
Topics: Depression; Depressive Disorder, Major; Gyrus Cinguli; Humans; Ketamine; Magnetic Resonance Imaging | 2020 |
Evaluating global brain connectivity as an imaging marker for depression: influence of preprocessing strategies and placebo-controlled ketamine treatment.
Topics: Antidepressive Agents; Brain; Brain Mapping; Depression; Depressive Disorder, Major; Humans; Ketamin | 2020 |
Low-Dose Ketamine Improves LPS-Induced Depression-like Behavior in Rats by Activating Cholinergic Anti-inflammatory Pathways.
Topics: Animals; Depression; Depressive Disorder, Major; Ketamine; Lipopolysaccharides; Neuroimmunomodulatio | 2020 |
S-ketamine induces acute changes in the proteome of the mouse amygdala.
Topics: Amygdala; Animals; Depressive Disorder, Major; Ketamine; Mice; Proteome; Proteomics | 2020 |
Single and repeated ketamine treatment induces perfusion changes in sensory and limbic networks in major depressive disorder.
Topics: Adult; Affect; Anhedonia; Apathy; Brain Mapping; Cerebrovascular Circulation; Depressive Disorder, M | 2020 |
Modulation of amygdala reactivity following rapidly acting interventions for major depression.
Topics: Adult; Amygdala; Antidepressive Agents; Brain Mapping; Depressive Disorder, Major; Electroconvulsive | 2020 |
(2R,6R)-Hydroxynorketamine (HNK) plasma level predicts poor antidepressant response: is this the end of the HNK pipeline?
Topics: Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Depressive Disorder, Treatmen | 2020 |
Baseline insomnia as a predictor of antidepressant efficacy to repeated intravenous ketamine for unipolar and bipolar depression: A preliminary study.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Humans; Infusions, Intravenous; | 2020 |
Registered clinical trials investigating ketamine for psychiatric disorders.
Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine; Obsessive-Compulsive Disorder; | 2020 |
The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder.
Topics: Adult; Anxiety; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment-Resista | 2020 |
Response to a recently published systematic review on intranasal esketamine for major depressive disorder.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double- | 2020 |
Guanosine fast onset antidepressant-like effects in the olfactory bulbectomy mice model.
Topics: Anhedonia; Animals; Antidepressive Agents; Behavior, Animal; Depressive Disorder, Major; Disease Mod | 2020 |
Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence.
Topics: Adult; Bipolar Disorder; Canada; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2020 |
What ketamine can teach us about the opioid system in depression?
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Human | 2020 |
Ketamine metabolite (2R,6R)-hydroxynorketamine reverses behavioral despair produced by adolescent trauma.
Topics: Animals; Behavior, Animal; Depressive Disorder, Major; Female; Ketamine; Male; Mice; Mice, Inbred C5 | 2020 |
Ketamine and Ro 25-6981 Reverse Behavioral Abnormalities in Rats Subjected to Dietary Zinc Restriction.
Topics: Analgesics; Animals; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major | 2020 |
The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence.
Topics: Adult; Bipolar Disorder; Canada; Depression; Depressive Disorder, Major; Depressive Disorder, Treatm | 2020 |
Adjunctive intranasal esketamine for major depressive disorder: a systematic review of randomized double-blind controlled-placebo studies - Authors' reply.
Topics: Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; K | 2020 |
Alterations of multiple peripheral inflammatory cytokine levels after repeated ketamine infusions in major depressive disorder.
Topics: Antidepressive Agents; Cytokines; Depressive Disorder, Major; Humans; Ketamine; Treatment Outcome | 2020 |
Genome-wide association study and polygenic risk score analysis of esketamine treatment response.
Topics: Antidepressive Agents; Depressive Disorder, Major; Female; Genetic Markers; Genetic Predisposition t | 2020 |
Modulation of inhibitory control networks relate to clinical response following ketamine therapy in major depression.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment | 2020 |
Volumetric changes in subcortical structures following repeated ketamine treatment in patients with major depressive disorder: a longitudinal analysis.
Topics: Amygdala; Antidepressive Agents; Depressive Disorder, Major; Hippocampus; Humans; Ketamine; Magnetic | 2020 |
Managing dissociative symptoms following the use of esketamine nasal spray: a case report.
Topics: Administration, Intranasal; Depressive Disorder, Major; Dissociative Disorders; Female; Humans; Keta | 2021 |
Can 'floating' predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression.
Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Metho | 2020 |
Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence.
Topics: Adult; Anhedonia; Bipolar Disorder; Canada; Depressive Disorder, Major; Humans; Ketamine; Retrospect | 2020 |
Relationship between hippocampal volume and inflammatory markers following six infusions of ketamine in major depressive disorder.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Hippoca | 2020 |
Effects of Serial Ketamine Infusions on Corticolimbic Functional Connectivity in Major Depression.
Topics: Brain; Depression; Depressive Disorder, Major; Humans; Ketamine; Neural Pathways | 2021 |
Intravenous ketamine for postmenopausal women with treatment-resistant depression: Results from the Canadian Rapid Treatment Center of Excellence.
Topics: Adult; Canada; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Fem | 2021 |
A new indication for esketamine nasal spray (Spravato).
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; | 2020 |
The Antisuicidal Effect of Esketamine Should Be Further Investigated.
Topics: Depressive Disorder, Major; Double-Blind Method; Humans; Ketamine; Nasal Sprays; Suicidal Ideation | 2020 |
No evidence for the effectiveness of IV ketamine for treatment resistant mood disorders in retrospective study.
Topics: Adult; Anxiety; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment-Resista | 2020 |
The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence.
Topics: Administration, Intravenous; Adult; Anxiety; Anxiety Disorders; Bipolar Disorder; Canada; Depressive | 2021 |
Predicting therapeutic response to oral ketamine for chronic suicidal ideation: a Bayesian network for clinical decision support.
Topics: Bayes Theorem; Decision Support Systems, Clinical; Depressive Disorder, Major; Humans; Ketamine; Psy | 2020 |
Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2021 |
Copper and anti-anhedonic effect of ketamine in treatment-resistant depression.
Topics: Copper; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ke | 2020 |
Does body mass index predict response to intravenous ketamine treatment in adults with major depressive and bipolar disorder? Results from the Canadian Rapid Treatment Center of Excellence.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Body Mass Index; Canada; Depressive Disorder, Major; | 2022 |
Effectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulation.
Topics: Adult; Anhedonia; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Keta | 2022 |
Antidepressant actions of ketamine engage cell-specific translation via eIF4E.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antidepressive Agents; Cell Cycle Proteins; Depressiv | 2021 |
Subanesthetic ketamine infusions for suicide ideation in patients with bipolar and unipolar treatment refractory depression.
Topics: Adult; Analgesics; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment-Resi | 2021 |
Ketamine treatment protects against oxidative damage and the immunological response induced by electroconvulsive therapy.
Topics: Animals; Antidepressive Agents; Bupropion; Combined Modality Therapy; Depressive Disorder, Major; El | 2021 |
Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity.
Topics: Adult; Antidepressive Agents; Anxiety; Anxiety Disorders; Comorbidity; Depression; Depressive Disord | 2021 |
Chronic lithium exposure attenuates ketamine-induced mania-like behavior and c-Fos expression in the forebrain of mice.
Topics: Amygdala; Animals; Antidepressive Agents; Antimanic Agents; Behavior, Animal; Bipolar Disorder; Depr | 2021 |
Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case Series.
Topics: Aged; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Huma | 2021 |
Sex- and stress-dependent effects of a single injection of ketamine on open field and forced swim behavior.
Topics: Animals; Depression; Depressive Disorder, Major; Female; Ketamine; Male; Mice; Mice, Inbred C57BL; S | 2021 |
Comments to Drs. Bahji, Vazquez, and Zarate.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2021 |
Hypomania associated with high dose ketamine treatment.
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Mania | 2021 |
Functional connectivity between the amygdala and subgenual cingulate gyrus predicts the antidepressant effects of ketamine in patients with treatment-resistant depression.
Topics: Amygdala; Antidepressive Agents; Depression; Depressive Disorder, Major; Gyrus Cinguli; Humans; Keta | 2021 |
Ketamine specifically reduces cognitive symptoms in depressed patients: An investigation of associated neural activation patterns.
Topics: Antidepressive Agents; Brain Mapping; Cognition; Depressive Disorder, Major; Humans; Ketamine; Magne | 2021 |
Compounded intranasal racemic ketamine for major depressive disorder: A case report.
Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, | 2021 |
Moving toward a process-oriented perspective in the personalized treatment of depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine; Precision Medicine | 2021 |
Commentary on the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder.
Topics: Adult; Anxiety; Canada; Depressive Disorder, Major; Humans; Ketamine | 2021 |
Distinct trajectories of antidepressant response to intravenous ketamine.
Topics: Adult; Antidepressive Agents; Child; Depressive Disorder, Major; Depressive Disorder, Treatment-Resi | 2021 |
Neurofilament light chain as novel blood biomarker of disturbed neuroaxonal integrity in patients with ketamine dependence.
Topics: Biomarkers; Depressive Disorder, Major; Female; Humans; Intermediate Filaments; Ketamine; Male; Neur | 2021 |
Letter to the editor: Are ketamine-induced subjective bodily experiences associated with antidepressant effects? A sensation of floating and a sensation of lightness are not the same - A comment on Acevedo-Diaz et al.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2021 |
Acute cognitive effects of single-dose intravenous ketamine in major depressive and posttraumatic stress disorder.
Topics: Antidepressive Agents; Cognition; Depressive Disorder, Major; Humans; Ketamine; Stress Disorders, Po | 2021 |
The effect of repeated doses of intravenous ketamine on measures of workplace attendance and productivity in adults with major depressive and bipolar disorder: Results from the canadian rapid treatment center of excellence.
Topics: Adult; Bipolar Disorder; Canada; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2021 |
Letter to the Editor: Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis.
Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
Validation of the McIntyre And Rosenblat Rapid Response Scale (MARRRS) in Adults with Treatment-Resistant Depression Receiving Intravenous Ketamine Treatment.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment | 2021 |
The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE).
Topics: Adult; Bipolar Disorder; Canada; Cognition; Depressive Disorder, Major; Depressive Disorder, Treatme | 2021 |
Fine-tuning neural excitation/inhibition for tailored ketamine use in treatment-resistant depression.
Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Excitatory Amino A | 2021 |
Do sleep changes mediate the anti-depressive and anti-suicidal response of intravenous ketamine in treatment-resistant depression?
Topics: Adult; Depression; Depressive Disorder, Major; Humans; Ketamine; Sleep; Suicidal Ideation | 2022 |
Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression?
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resi | 2021 |
Opioid receptor system contributes to the acute and sustained antidepressant-like effects, but not the hyperactivity motor effects of ketamine in mice.
Topics: Anesthetics, Dissociative; Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; E | 2021 |
Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic.
Topics: Adult; COVID-19; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; H | 2021 |
The Resilient Phenotype Induced by Prophylactic Ketamine Exposure During Adolescence Is Mediated by the Ventral Tegmental Area-Nucleus Accumbens Pathway.
Topics: Animals; Depressive Disorder, Major; Ketamine; Male; Mice; Mice, Inbred C57BL; Nucleus Accumbens; Ph | 2021 |
Fluoroethylnormemantine, a Novel NMDA Receptor Antagonist, for the Prevention and Treatment of Stress-Induced Maladaptive Behavior.
Topics: Animals; Depressive Disorder, Major; Female; Ketamine; Male; Memantine; Mice; Receptors, N-Methyl-D- | 2021 |
Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study.
Topics: Administration, Intravenous; Adult; Aged; Antidepressive Agents; Blood Pressure; Cohort Studies; Dep | 2021 |
The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine.
Topics: Adult; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Human | 2021 |
A positron emission tomography study of the serotonin1B receptor effect of electroconvulsive therapy for severe major depressive episodes.
Topics: Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Electroconvulsive Therapy; Hum | 2021 |
Ketamine decreases neuronally released glutamate via retrograde stimulation of presynaptic adenosine A1 receptors.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Glutamic Acid; Humans; Ketamine; Recepto | 2021 |
Dissociative symptoms with intravenous ketamine in treatment-resistant depression exploratory observational study.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Anesthetics, Dissociative; Depressive Disorder | 2021 |
Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome.
Topics: Adult; Case-Control Studies; Chemokines; Cytokines; Depressive Disorder, Major; Depressive Disorder, | 2017 |
Ketamine as a Treatment for Adolescent Depression: A Case Report.
Topics: Adolescent; Depressive Disorder, Major; Humans; Ketamine; Male; Psychiatric Status Rating Scales; Tr | 2017 |
Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [
Topics: Adult; Antidepressive Agents; Brain; Carbon Radioisotopes; Case-Control Studies; Depression; Depress | 2018 |
S -ketamine compared to etomidate during electroconvulsive therapy in major depression.
Topics: Aged; Anesthetics, Intravenous; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant | 2017 |
Motor-Activity Markers of Circadian Timekeeping Are Related to Ketamine's Rapid Antidepressant Properties.
Topics: Actigraphy; Adult; Affect; Aged; Antidepressive Agents; Bipolar Disorder; Circadian Rhythm; Depressi | 2017 |
Low-dose ketamine for treatment resistant depression in an academic clinical practice setting.
Topics: Academic Medical Centers; Adult; Aged; Depressive Disorder, Major; Depressive Disorder, Treatment-Re | 2017 |
Ketamine for the Treatment of Depression-Reply.
Topics: Consensus; Depression; Depressive Disorder, Major; Humans; Ketamine; Mood Disorders | 2017 |
Agonist E-6837 and antagonist SB-271046 of 5-HT6 receptors both reverse the depressive-like effect induced in mice by subchronic ketamine administration.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Depression; Depressive Disorder, Major; Diseas | 2017 |
Efficacy of Esketamine in the Treatment of Depression With Psychotic Features: A Case Series.
Topics: Adult; Bipolar Disorder; Depressive Disorder, Major; Female; Humans; Ketamine; Male; Middle Aged; Ps | 2018 |
Alterations in amino acid levels in mouse brain regions after adjunctive treatment of brexpiprazole with fluoxetine: comparison with (R)-ketamine.
Topics: Administration, Oral; Amino Acids; Animals; Antidepressive Agents; Brain; Depressive Disorder, Major | 2017 |
Ketamine metabolites with antidepressant effects: Fast, economical, and eco-friendly enantioselective separation based on supercritical-fluid chromatography (SFC) and single quadrupole MS detection.
Topics: Antidepressive Agents; Chromatography, High Pressure Liquid; Chromatography, Supercritical Fluid; De | 2017 |
What Should be Done When Elderly Patients with Major Depression Have Failed to Respond to All Treatments?
Topics: Aged; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Keta | 2017 |
Ketamine-Induced Glutamatergic Mechanisms of Sleep and Wakefulness: Insights for Developing Novel Treatments for Disturbed Sleep and Mood.
Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine; Sleep; Wakefulness | 2019 |
Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Factor Analysis, Statistical; Female; Huma | 2018 |
Role of Ketamine in Severe Depression with suicidal ideation - Insights from a Case Study.
Topics: Aged; Anesthetics, Dissociative; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2017 |
Behavioural and computational methods reveal differential effects for how delayed and rapid onset antidepressants effect decision making in rats.
Topics: Acoustic Stimulation; Amphetamine; Analgesics; Animals; Antidepressive Agents; Association Learning; | 2017 |
Ketamine and its metabolite (2R,6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit.
Topics: Animals; Antidepressive Agents; Brain; Depression; Depressive Disorder, Major; Excitatory Amino Acid | 2018 |
The rapid-onset antidepressant effect of ketamine: More surprises?
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Drug Discovery; Humans; Ketamine; Rec | 2018 |
Acute treatment with ketamine and chronic treatment with minocycline exert antidepressant-like effects and antioxidant properties in rats subjected different stressful events.
Topics: Amitriptyline; Animals; Antidepressive Agents; Antioxidants; Brain; Chronic Disease; Depressive Diso | 2018 |
Intravenous ketamine infusion for a patient with treatment-resistant major depression: a 10-month follow-up.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; | 2018 |
Mapping the central effects of (±)-ketamine and traxoprodil using pharmacological magnetic resonance imaging in awake rats.
Topics: Animals; Antidepressive Agents; Brain; Brain Mapping; Depressive Disorder, Major; Dose-Response Rela | 2018 |
Intravenous Ketamine Relieves Pain and Depression After Traumatic Suicide Attempts: A Case Series.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Analgesics; Antidepressive Agents; Depressive | 2018 |
Parsing the heterogeneity of depression: An exploratory factor analysis across commonly used depression rating scales.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Factor Analysis, Statist | 2018 |
Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects.
Topics: Adult; Antidepressive Agents; Case-Control Studies; Cross-Over Studies; Depression; Depressive Disor | 2019 |
Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects.
Topics: Adult; Antidepressive Agents; Case-Control Studies; Cross-Over Studies; Depression; Depressive Disor | 2019 |
Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects.
Topics: Adult; Antidepressive Agents; Case-Control Studies; Cross-Over Studies; Depression; Depressive Disor | 2019 |
Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects.
Topics: Adult; Antidepressive Agents; Case-Control Studies; Cross-Over Studies; Depression; Depressive Disor | 2019 |
Ketamine: Quo Vadis?
Topics: Depression; Depressive Disorder, Major; Humans; Ketamine; Midazolam; Suicidal Ideation | 2018 |
Ketamine for Treatment-Resistant Depression: a New Advocate.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Excitat | 2018 |
[Ketamine administration in case of severe, therapy resistant depressed patient, case report].
Topics: Anesthetics, Dissociative; Antidepressive Agents; Depressive Disorder, Major; Drug Resistance; Femal | 2016 |
Translational control of depression-like behavior via phosphorylation of eukaryotic translation initiation factor 4E.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Benzofurans; Citalopram; Depression; Depr | 2018 |
[In process].
Topics: Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Huma | 2016 |
Ketamine and Electroconvulsive Therapy for Depression.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Depressive Disorder, Major; Electroconvulsive Ther | 2018 |
Characterizing the course of suicidal ideation response to ketamine.
Topics: Adult; Bipolar Disorder; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Dis | 2018 |
Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Female; Humans; Infusion | 2018 |
The novel antidepressant ketamine enhances dentate gyrus proliferation with no effects on synaptic plasticity or hippocampal function in depressive-like rats.
Topics: Animals; Dentate Gyrus; Depressive Disorder, Major; Dexamethasone; Disease Models, Animal; Drug Eval | 2019 |
NMDA Antagonists for Treatment-Resistant Depression.
Topics: Depression; Depressive Disorder, Major; Humans; Ketamine; N-Methylaspartate; Pilot Projects | 2019 |
VGF and its C-terminal peptide TLQP-62 in ventromedial prefrontal cortex regulate depression-related behaviors and the response to ketamine.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depression; Dep | 2019 |
Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: A replication study.
Topics: Adult; Anesthetics, Dissociative; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Ma | 2019 |
Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Female | 2018 |
Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Clinical Trials as Topic; Depressive Disorder, Major | 2019 |
Ketamine for suicidal ideation treatment: Available evidence remains convincing.
Topics: Depression; Depressive Disorder, Major; Humans; Ketamine; Suicidal Ideation | 2019 |
A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation.
Topics: Adult; Antidepressive Agents; Asian People; Bipolar Disorder; China; Depressive Disorder, Major; Fem | 2019 |
Increased Reactivity of the Mesolimbic Reward System after Ketamine Injection in Patients with Treatment-resistant Major Depressive Disorder.
Topics: Administration, Intravenous; Adult; Anesthetics, Dissociative; Depressive Disorder, Major; Depressiv | 2019 |
Depression and antidepressant action-from molecules to networks.
Topics: Animals; Antidepressive Agents; Biogenic Monoamines; Depressive Disorder, Major; Disease Models, Ani | 2019 |
Evolving Issues in the Treatment of Depression.
Topics: Anti-Inflammatory Agents; Antidepressive Agents; Depressive Disorder; Depressive Disorder, Major; Di | 2019 |
Successful Use of Ketamine for the Treatment of Psychotic Depression in a Teenager.
Topics: Adolescent; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketamine; Psychot | 2019 |
TAK-137, an AMPA receptor potentiator with little agonistic effect, produces antidepressant-like effect without causing psychotomimetic effects in rats.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cerebellar Cortex; Depression; De | 2019 |
Toward specific ways to combine ketamine and psychotherapy in treating depression.
Topics: Antidepressive Agents; Brain; Depressive Disorder, Major; Humans; Ketamine; Neuronal Plasticity; Psy | 2020 |
Ketamine exerts a protective role in a cell-based model of major depressive disorder via the inhibition of apoptosis and inflammation and activation of the Krebs cycle.
Topics: Adult; Animals; Apoptosis; Cell Survival; Citric Acid Cycle; Cytokines; Depressive Disorder, Major; | 2020 |
Microglial production of quinolinic acid as a target and a biomarker of the antidepressant effect of ketamine.
Topics: Animals; Antidepressive Agents; Anxiety; Anxiety Disorders; Biomarkers, Pharmacological; Depression; | 2019 |
Astrocyte Specific Remodeling of Plasmalemmal Cholesterol Composition by Ketamine Indicates a New Mechanism of Antidepressant Action.
Topics: Animals; Antidepressive Agents; Astrocytes; Cell Membrane; Cholesterol; Cyclic AMP; Depressive Disor | 2019 |
Ketamine for the treatment of depression.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment- | 2013 |
Urgent ketamine infusion rapidly eliminated suicidal ideation for a patient with major depressive disorder: a case report.
Topics: Adult; Anesthetics, Dissociative; Depressive Disorder, Major; Female; Humans; Infusions, Intravenous | 2013 |
Ketamine infusion as a treatment for major depressive disorder: a new role for anesthesiologists?
Topics: Adult; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Female; Humans; Infusions, Int | 2012 |
Case report: long-term mood response to repeat dose intramuscular ketamine in a depressed patient with advanced cancer.
Topics: Adult; Comorbidity; Depressive Disorder, Major; Female; Humans; Injections, Intramuscular; Ketamine; | 2013 |
Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder.
Topics: Adult; Anxiety; Depressive Disorder, Major; Female; Humans; Ketamine; Middle Aged; Obsessive-Compuls | 2013 |
Antidepressant effect of the first electroconvulsive therapy with ketamine and/or propofol.
Topics: Anesthetics, Dissociative; Anesthetics, Intravenous; Depressive Disorder, Major; Electroconvulsive T | 2013 |
Antidepressant effect of the first electroconvulsive therapy with ketamine and/or propofol: response.
Topics: Anesthetics, Dissociative; Anesthetics, Intravenous; Depressive Disorder, Major; Electroconvulsive T | 2013 |
Exploiting N-methyl-d-aspartate channel blockade for a rapid antidepressant response in major depressive disorder.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Excitat | 2013 |
Sustained antidepressant response to ketamine.
Topics: Adult; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Female; Huma | 2013 |
Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder: a perspective from anesthesiologists.
Topics: Anesthesia; Anesthetics, Combined; Anesthetics, Dissociative; Anesthetics, Intravenous; Cognition; D | 2013 |
Effects of ketamine on major depressive disorder in a patient with posttraumatic stress disorder.
Topics: Adult; Anesthetics, Dissociative; Depressive Disorder, Major; Humans; Infusions, Intravenous; Ketami | 2013 |
Ketamine for treatment-resistant depression: ready or not for clinical use?
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Excitat | 2013 |
Mice lacking NMDA receptors in parvalbumin neurons display normal depression-related behavior and response to antidepressant action of NMDAR antagonists.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Disease Models, Animal; Dizocilpine Male | 2014 |
Long-lasting effects of a single subcutaneous dose of ketamine for treating melancholic depression: a case report.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Female; Humans | 2014 |
A word to the wise about ketamine.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Excitat | 2014 |
Ketamine as an electroconvulsive therapy anesthetic agent.
Topics: Anesthetics, Dissociative; Depressive Disorder, Major; Electroconvulsive Therapy; Female; Humans; Ke | 2014 |
Do the dissociative side effects of ketamine mediate its antidepressant effects?
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Dissociative Disorders; | 2014 |
Do the dissociative side effects of ketamine mediate its antidepressant effects?
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Dissociative Disorders; | 2014 |
Do the dissociative side effects of ketamine mediate its antidepressant effects?
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Dissociative Disorders; | 2014 |
Do the dissociative side effects of ketamine mediate its antidepressant effects?
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Dissociative Disorders; | 2014 |
Baseline vitamin B12 and folate levels do not predict improvement in depression after a single infusion of ketamine.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Bipolar Disorder; Depressive Disorder, Major; | 2014 |
Electroconvulsive therapy is a standard treatment; ketamine is not (yet).
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Excitat | 2014 |
Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression.
Topics: Antidepressive Agents; Biomarkers, Pharmacological; Depressive Disorder, Major; Depressive Disorder, | 2015 |
A comment on Fond and colleagues' systematic review and meta-analysis of ketamine in the treatment of depressive disorders (Psychopharmacology 2014; Jul 20 [Epub ahead of print]).
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
BICC1 expression is elevated in depressed subjects and contributes to depressive behavior in rodents.
Topics: Anhedonia; Animals; Behavior, Animal; Case-Control Studies; Dentate Gyrus; Depressive Disorder, Majo | 2015 |
Intranasal ketamine treatment in an adult with autism spectrum disorder.
Topics: Administration, Intranasal; Adult; Anorexia Nervosa; Child Development Disorders, Pervasive; Depress | 2014 |
Ketamine's effectiveness in unipolar versus bipolar depression.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Speed of response to electroconvulsive therapy compared with ketamine.
Topics: Antidepressive Agents; Depressive Disorder, Major; Electroconvulsive Therapy; Excitatory Amino Acid | 2015 |
Comparison of ketamine vs. ECT in major depressive disorder: need for ECT standard dosing and duration parameters.
Topics: Antidepressive Agents; Depressive Disorder, Major; Electroconvulsive Therapy; Excitatory Amino Acid | 2015 |
Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression.
Topics: Animals; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Dose-Response | 2015 |
Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression.
Topics: Animals; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Dose-Response | 2015 |
Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression.
Topics: Animals; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Dose-Response | 2015 |
Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression.
Topics: Animals; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Dose-Response | 2015 |
Neural correlates of suicidal ideation and its reduction in depression.
Topics: Brain; Brain Mapping; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; | 2014 |
Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder.
Topics: Adult; Brain; Case-Control Studies; Caudate Nucleus; Depressive Disorder, Major; Depressive Disorder | 2015 |
Ketamine modulates TRH and TRH-like peptide turnover in brain and peripheral tissues of male rats.
Topics: Animals; Brain; Depressive Disorder, Major; Humans; Ketamine; Male; N-Methylaspartate; Peptides; Rat | 2015 |
Ribosomal protein S6 kinase 1 signaling in prefrontal cortex controls depressive behavior.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depressive Disorder, Major; Disease Models, Animal | 2015 |
Changes in cortical N-methyl-D-aspartate receptors and post-synaptic density protein 95 in schizophrenia, mood disorders and suicide.
Topics: Adult; Biomarkers; Bipolar Disorder; Depressive Disorder, Major; Disks Large Homolog 4 Protein; Fema | 2016 |
The positive effect on ketamine as a priming adjuvant in antidepressant treatment.
Topics: Animals; Antidepressive Agents; Anxiety; Aspartic Acid; Behavior, Animal; Brain; Depression; Depress | 2015 |
Sex differences in glutamate receptor gene expression in major depression and suicide.
Topics: Adult; Case-Control Studies; Depressive Disorder, Major; Female; Gene Expression; Glutamic Acid; Hum | 2015 |
Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bipolar Disorder; Clozapine; Cross-Over Studies; Dep | 2015 |
Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bipolar Disorder; Clozapine; Cross-Over Studies; Dep | 2015 |
Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bipolar Disorder; Clozapine; Cross-Over Studies; Dep | 2015 |
Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bipolar Disorder; Clozapine; Cross-Over Studies; Dep | 2015 |
The Prodrug 4-Chlorokynurenine Causes Ketamine-Like Antidepressant Effects, but Not Side Effects, by NMDA/GlycineB-Site Inhibition.
Topics: Animals; Behavior, Animal; Conditioning, Psychological; Depressive Disorder, Major; Glycine; Hindlim | 2015 |
A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder.
Topics: Adult; Amino Acids; Antidepressive Agents; Brain; Depressive Disorder, Major; Female; gamma-Aminobut | 2016 |
Structural connectivity and response to ketamine therapy in major depression: A preliminary study.
Topics: Adult; Anisotropy; Antidepressive Agents; Case-Control Studies; Corpus Callosum; Depressive Disorder | 2016 |
Time-Course of Depression Improvement With Ketamine Adjunction in Electroconvulsive Therapy.
Topics: Anesthetics, Dissociative; Depression; Depressive Disorder, Major; Electroconvulsive Therapy; Humans | 2016 |
Potential Risks of Poorly Monitored Ketamine Use in Depression Treatment.
Topics: Alcohol-Related Disorders; Analgesics; Antidepressive Agents; Depressive Disorder, Major; Depressive | 2016 |
Critical Appraisal of Existing Ketamine Trials: Existing Limitations and Limited Applicability for Treatment.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketami | 2016 |
Response to Zhang and Ho: Addressing Ketamine's Use in Depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketami | 2016 |
The role of adipokines in the rapid antidepressant effects of ketamine.
Topics: Adipokines; Adiponectin; Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; | 2017 |
Bidirectional Homeostatic Regulation of a Depression-Related Brain State by Gamma-Aminobutyric Acidergic Deficits and Ketamine Treatment.
Topics: Animals; Behavior, Animal; Depressive Disorder, Major; Down-Regulation; gamma-Aminobutyric Acid; Glu | 2016 |
Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study.
Topics: Adolescent; Adult; Aged; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose- | 2016 |
Comments on Cooper et al.'s review on strategies to mitigate dissociative and psychotomimetic effects from ketamine when used as a fast-acting antidepressant.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Humans; Ketami | 2017 |
Preliminary differences in resting state MEG functional connectivity pre- and post-ketamine in major depressive disorder.
Topics: Adult; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Functional Neuroimaging; Gyrus | 2016 |
Antidepressant-like effects of ascorbic acid and ketamine involve modulation of GABAA and GABAB receptors.
Topics: Animals; Antidepressive Agents; Ascorbic Acid; Depression; Depressive Disorder, Major; Disease Model | 2016 |
MicroRNAs as biomarkers for major depression: a role for let-7b and let-7c.
Topics: Adult; Biomarkers; Case-Control Studies; Depressive Disorder, Major; Depressive Disorder, Treatment- | 2016 |
Gene expression related to serotonergic and glutamatergic neurotransmission is altered in the flinders sensitive line rat model of depression: Effect of ketamine.
Topics: Animals; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Frontal Lobe; Hippocampus; K | 2017 |
Ketamine Treatment and Global Brain Connectivity in Major Depression.
Topics: Adult; Antidepressive Agents; Caudate Nucleus; Cerebellum; Cerebral Cortex; Connectome; Depressive D | 2017 |
Ketamine Treatment and Global Brain Connectivity in Major Depression.
Topics: Adult; Antidepressive Agents; Caudate Nucleus; Cerebellum; Cerebral Cortex; Connectome; Depressive D | 2017 |
Ketamine Treatment and Global Brain Connectivity in Major Depression.
Topics: Adult; Antidepressive Agents; Caudate Nucleus; Cerebellum; Cerebral Cortex; Connectome; Depressive D | 2017 |
Ketamine Treatment and Global Brain Connectivity in Major Depression.
Topics: Adult; Antidepressive Agents; Caudate Nucleus; Cerebellum; Cerebral Cortex; Connectome; Depressive D | 2017 |
Ketamine Treatment and Global Brain Connectivity in Major Depression.
Topics: Adult; Antidepressive Agents; Caudate Nucleus; Cerebellum; Cerebral Cortex; Connectome; Depressive D | 2017 |
Ketamine Treatment and Global Brain Connectivity in Major Depression.
Topics: Adult; Antidepressive Agents; Caudate Nucleus; Cerebellum; Cerebral Cortex; Connectome; Depressive D | 2017 |
Ketamine Treatment and Global Brain Connectivity in Major Depression.
Topics: Adult; Antidepressive Agents; Caudate Nucleus; Cerebellum; Cerebral Cortex; Connectome; Depressive D | 2017 |
Ketamine Treatment and Global Brain Connectivity in Major Depression.
Topics: Adult; Antidepressive Agents; Caudate Nucleus; Cerebellum; Cerebral Cortex; Connectome; Depressive D | 2017 |
Ketamine Treatment and Global Brain Connectivity in Major Depression.
Topics: Adult; Antidepressive Agents; Caudate Nucleus; Cerebellum; Cerebral Cortex; Connectome; Depressive D | 2017 |
Ketamine Treatment and Global Brain Connectivity in Major Depression.
Topics: Adult; Antidepressive Agents; Caudate Nucleus; Cerebellum; Cerebral Cortex; Connectome; Depressive D | 2017 |
Ketamine Treatment and Global Brain Connectivity in Major Depression.
Topics: Adult; Antidepressive Agents; Caudate Nucleus; Cerebellum; Cerebral Cortex; Connectome; Depressive D | 2017 |
Ketamine Treatment and Global Brain Connectivity in Major Depression.
Topics: Adult; Antidepressive Agents; Caudate Nucleus; Cerebellum; Cerebral Cortex; Connectome; Depressive D | 2017 |
Ketamine Treatment and Global Brain Connectivity in Major Depression.
Topics: Adult; Antidepressive Agents; Caudate Nucleus; Cerebellum; Cerebral Cortex; Connectome; Depressive D | 2017 |
Ketamine Treatment and Global Brain Connectivity in Major Depression.
Topics: Adult; Antidepressive Agents; Caudate Nucleus; Cerebellum; Cerebral Cortex; Connectome; Depressive D | 2017 |
Ketamine Treatment and Global Brain Connectivity in Major Depression.
Topics: Adult; Antidepressive Agents; Caudate Nucleus; Cerebellum; Cerebral Cortex; Connectome; Depressive D | 2017 |
Ketamine Treatment and Global Brain Connectivity in Major Depression.
Topics: Adult; Antidepressive Agents; Caudate Nucleus; Cerebellum; Cerebral Cortex; Connectome; Depressive D | 2017 |
Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants.
Topics: Adult; Arginine; Citrulline; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; E | 2016 |
Reducing the silence.
Topics: Depressive Disorder, Major; Drug Approval; Excitatory Amino Acid Antagonists; Humans; Ketamine; Rese | 2016 |
Major Depressive Disorder Induced by Chronic Ketamine Abuse: A Case Report.
Topics: Adult; Anesthetics, Dissociative; Depressive Disorder, Major; Humans; Ketamine; Male; Substance-Rela | 2016 |
How much of ketamine's antidepressant response is shared with ethanol?
Topics: Antidepressive Agents; Depressive Disorder, Major; Ethanol; Humans; Ketamine | 2016 |
Sustained Resolution of Panic Disorder, Agoraphobia, and Generalized Anxiety Disorder With a Single Ketamine Infusion: A Case Report.
Topics: Adult; Agoraphobia; Anxiety Disorders; Depressive Disorder, Major; Female; Humans; Ketamine; Panic D | 2016 |
Alcohol Use Disorder as a Possible Predictor of Electroconvulsive Therapy Response.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alcoholism; Anesthesia; Anesthetics, Dissociative; Benz | 2017 |
Intranasal Ketamine and Cognitive-Behavioral Therapy for Treatment-Refractory Obsessive-Compulsive Disorder.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Cognitive Behavioral Therapy; Combined Mod | 2017 |
Reduction in Suicidal Ideation Following Repeated Doses of Intravenous Ketamine?
Topics: Administration, Intravenous; Depression; Depressive Disorder, Major; Humans; Ketamine; Suicidal Idea | 2017 |
Electroconvulsive therapy with S-ketamine anesthesia for catatonia in coexisting depression and dementia.
Topics: Aged; Anesthesia; Catatonia; Dementia; Depressive Disorder, Major; Electroconvulsive Therapy; Female | 2017 |
The fibrinolytic system: A new target for treatment of depression with psychedelics.
Topics: Animals; Antidepressive Agents; Brain; Depressive Disorder, Major; Fibrinolysin; Fibrinolysis; Hallu | 2017 |
Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine.
Topics: Adult; Amygdala; Antidepressive Agents; Biomarkers; Cerebral Cortex; Data Interpretation, Statistica | 2009 |
Intravenous ketamine "burst" for refractory depression in a patient with advanced cancer.
Topics: Anesthetics, Dissociative; Depressive Disorder, Major; Humans; Infusions, Intravenous; Ketamine; Mal | 2008 |
Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Female; Halluc | 2009 |
Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Female; Halluc | 2009 |
Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Female; Halluc | 2009 |
Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases.
Topics: Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Female; Halluc | 2009 |
[Ketamine in melancholic depression].
Topics: Adult; Analgesics; Anesthetics, Dissociative; Depressive Disorder; Depressive Disorder, Major; Human | 2010 |
Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine.
Topics: Adult; Amygdala; Antidepressive Agents; Brain Mapping; Depressive Disorder, Major; Gyrus Cinguli; Hu | 2010 |
Research suggests new drug targets for depression. Pilot studies of ketamine intrigue scientists, but risks of this anesthetic limit its clinical use.
Topics: Anesthetics, Dissociative; Bipolar Disorder; Brain; Chronic Disease; Depressive Disorder, Major; Dou | 2010 |
The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS.
Topics: Adult; Aged; Antidepressive Agents; Blood Pressure; Depressive Disorder, Major; Dissociative Disorde | 2011 |
The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS.
Topics: Adult; Aged; Antidepressive Agents; Blood Pressure; Depressive Disorder, Major; Dissociative Disorde | 2011 |
The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS.
Topics: Adult; Aged; Antidepressive Agents; Blood Pressure; Depressive Disorder, Major; Dissociative Disorde | 2011 |
The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS.
Topics: Adult; Aged; Antidepressive Agents; Blood Pressure; Depressive Disorder, Major; Dissociative Disorde | 2011 |
The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS.
Topics: Adult; Aged; Antidepressive Agents; Blood Pressure; Depressive Disorder, Major; Dissociative Disorde | 2011 |
The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS.
Topics: Adult; Aged; Antidepressive Agents; Blood Pressure; Depressive Disorder, Major; Dissociative Disorde | 2011 |
The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS.
Topics: Adult; Aged; Antidepressive Agents; Blood Pressure; Depressive Disorder, Major; Dissociative Disorde | 2011 |
The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS.
Topics: Adult; Aged; Antidepressive Agents; Blood Pressure; Depressive Disorder, Major; Dissociative Disorde | 2011 |
The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS.
Topics: Adult; Aged; Antidepressive Agents; Blood Pressure; Depressive Disorder, Major; Dissociative Disorde | 2011 |
Clinically favourable effects of ketamine as an anaesthetic for electroconvulsive therapy: a retrospective study.
Topics: Aged; Anesthetics, Dissociative; Anesthetics, Intravenous; Antihypertensive Agents; Cognition Disord | 2011 |
Editor's note.
Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine | 2011 |
A case of sustained remission following an acute course of ketamine in treatment-resistant depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Female; Humans; Ketamine; Middle Aged; Remission | 2011 |
Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression.
Topics: Adolescent; Adult; Aged; Depressive Disorder, Major; Electroconvulsive Therapy; Excitatory Amino Aci | 2011 |
Dose- and exposure-response to ketamine in depression.
Topics: Analgesics; Depressive Disorder, Major; Female; Humans; Ketamine; Male | 2011 |
Lack of effect of ketamine on cortical glutamate and glutamine in healthy volunteers: a proton magnetic resonance spectroscopy study.
Topics: Adult; Cerebral Cortex; Depressive Disorder, Major; Female; Glutamic Acid; Glutamine; Humans; Ketami | 2012 |
Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation.
Topics: Adolescent; Animals; Antidepressive Agents; Depressive Disorder, Major; Drug Resistance; Female; Hum | 2011 |
Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex.
Topics: Alleles; Animals; Brain-Derived Neurotrophic Factor; Dendrites; Depressive Disorder, Major; Excitato | 2012 |
An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression.
Topics: Adult; Cerebral Cortex; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Female; gamma | 2012 |
Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer.
Topics: Adult; Anesthetics, Dissociative; Depressive Disorder, Major; Disease Progression; Dysthymic Disorde | 2012 |
Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression.
Topics: Adult; Aged; Antidepressive Agents; Bipolar Disorder; Chromatography, Liquid; Cytochrome P-450 Enzym | 2012 |
Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression.
Topics: Adult; Aged; Antidepressive Agents; Bipolar Disorder; Chromatography, Liquid; Cytochrome P-450 Enzym | 2012 |
Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression.
Topics: Adult; Aged; Antidepressive Agents; Bipolar Disorder; Chromatography, Liquid; Cytochrome P-450 Enzym | 2012 |
Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression.
Topics: Adult; Aged; Antidepressive Agents; Bipolar Disorder; Chromatography, Liquid; Cytochrome P-450 Enzym | 2012 |
Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression.
Topics: Adult; Aged; Antidepressive Agents; Bipolar Disorder; Chromatography, Liquid; Cytochrome P-450 Enzym | 2012 |
Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression.
Topics: Adult; Aged; Antidepressive Agents; Bipolar Disorder; Chromatography, Liquid; Cytochrome P-450 Enzym | 2012 |
Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression.
Topics: Adult; Aged; Antidepressive Agents; Bipolar Disorder; Chromatography, Liquid; Cytochrome P-450 Enzym | 2012 |
Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression.
Topics: Adult; Aged; Antidepressive Agents; Bipolar Disorder; Chromatography, Liquid; Cytochrome P-450 Enzym | 2012 |
Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression.
Topics: Adult; Aged; Antidepressive Agents; Bipolar Disorder; Chromatography, Liquid; Cytochrome P-450 Enzym | 2012 |
Rethinking restimulation: a case report.
Topics: Aged, 80 and over; Anesthesia; Anesthetics, Dissociative; Depressive Disorder, Major; Electroconvuls | 2012 |
Management of severe postictal agitation after electroconvulsive therapy with bispectrum electroencephalogram index monitoring: a case report.
Topics: Aged; Anesthesia; Anesthetics, Dissociative; Consciousness Monitors; Depressive Disorder, Major; Ele | 2012 |
The complexities of depression.
Topics: Affective Disorders, Psychotic; Antidepressive Agents; Antipsychotic Agents; Brain; Depressive Disor | 2012 |
New insights into BDNF signaling: relevance to major depression and antidepressant action.
Topics: Animals; Antidepressive Agents; Brain; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major | 2012 |
A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Rapid antidepressant effects of ketamine ignite drug discovery.
Topics: Analgesics; Antidepressive Agents; Depressive Disorder, Major; Drug Discovery; Humans; Ketamine; Rec | 2013 |
Comparison of seizure duration, ictal EEG, and cognitive effects of ketamine and methohexital anesthesia with ECT.
Topics: Aged; Aged, 80 and over; Anesthesia, Intravenous; Bipolar Disorder; Depressive Disorder, Major; Elec | 2003 |
Comparison of seizure duration, ictal EEG, and cognitive effects of ketamine and methohexital anesthesia with ECT.
Topics: Aged; Aged, 80 and over; Anesthesia, Intravenous; Bipolar Disorder; Depressive Disorder, Major; Elec | 2003 |
Comparison of seizure duration, ictal EEG, and cognitive effects of ketamine and methohexital anesthesia with ECT.
Topics: Aged; Aged, 80 and over; Anesthesia, Intravenous; Bipolar Disorder; Depressive Disorder, Major; Elec | 2003 |
Comparison of seizure duration, ictal EEG, and cognitive effects of ketamine and methohexital anesthesia with ECT.
Topics: Aged; Aged, 80 and over; Anesthesia, Intravenous; Bipolar Disorder; Depressive Disorder, Major; Elec | 2003 |
Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy.
Topics: Combined Modality Therapy; Depressive Disorder, Major; Electroconvulsive Therapy; Excitatory Amino A | 2007 |
Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Depressive Disorder, Major; Excit | 2008 |
Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Depressive Disorder, Major; Excit | 2008 |
Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Depressive Disorder, Major; Excit | 2008 |
Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Depressive Disorder, Major; Excit | 2008 |
Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Depressive Disorder, Major; Drug Administration Sc | 2009 |
Ketamine for the treatment of depression: what about the addictive potential?
Topics: Anesthetics, Dissociative; Depressive Disorder, Major; Humans; Infusions, Intravenous; Ketamine; Rec | 2007 |
Ketamine followed by memantine for the treatment of major depression.
Topics: Administration, Oral; Depressive Disorder, Major; Drug Administration Schedule; Drug Therapy, Combin | 2008 |